Alternative splicing in sodium channels: biophysical and functional effects in NaV1.1, NaV1.2 & NaV1.7 by Liavas, A
1 
 
Alternative splicing in sodium channels: 
Biophysical and functional effects in  
Nav1.1, Nav1.2 & Nav1.7. 
 
 
 
Andrianos Liavas 
 
 
A thesis submitted to University College London for the 
degree of Doctor of Philosophy 
 
 
Department of Clinical and Experimental Epilepsy 
Institute of Neurology 
Queen Square 
London 
WC1N 3BG 
2 
 
Declaration 
 
I, Andrianos Liavas, confirm that the work presented in this thesis is my original research work. 
Where contributions of others are involved, this has been clearly indicated in the thesis. 
 
 
The copyright of this thesis rests with the author and no quotation from it or information derived 
from it may be published without the prior written consent of the author. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Acknowledgements 
 
I would like to thank first of all my supervisor, Dr Stephanie Schorge, for her continuous care and 
support that went far beyond the duties of an ordinary supervisor and for which I'm truly greatful. 
 
I would also like to thank my professors and colleagues, in my lab as well as in previous labs I've 
worked in, for sharing their time, knowledge, expertise as well as their everyday life with me, 
which has ended up in great partnerships and true friendships. A special thanks to Gabriele, my lab 
brother, (I'm gonna miss working together my friend!), the whole 808 gang, with all of which we 
came really close together (and not just because of lack of office space!), the Friday night pub 
crew (and Monday and Thursday sometimes...!) and especially Elodie, for being truly special to 
me.  
 
A very big thank you also to my family, my brother Mathios and all my friends and beloved ones 
for always being there for me. It's their constant love and support through which I found the 
strength and courage to persist through the difficulties and finally reach the end of this big journey 
today.  
 
Finally, I would also like to thank my examiners, Dr Martin Stocker and Prof Richard Baines, for 
finding the time to read and correct my thesis. 
 
 
 
 
4 
 
Abstract 
 
Alternative splicing in voltage-gated sodium channels can affect pathophysiological conditions, 
including epilepsy and pain. A conserved alternative splicing event in sodium channel genes, 
including SCN1A, SCN2A and SCN9A, gives rise to the neonatal (5N) and adult (5A) isoforms. 
Differences in the ratio of 5A/5N in Nav1.1 (encoded by SCN1A) in patients may lead to different 
predisposition to epilepsy or response to antiepileptic drugs (AED). Previous HEK293T whole-cell 
voltage-clamp recordings showed that Nav1.1-5N channels recover more quickly from fast 
inactivation than 5A. However it was unknown whether this effect is conserved in Nav1.2 
(encoded by SCN2A) and Nav1.7 (SCN9A) channels, or what the functional consequences of this 
splicing event are for neurons. 
This project used whole-cell voltage-clamp recordings on heterologously expressed neonatal and 
adult channels to compare the biophysical properties of the splice isoforms for all three channel 
types and their modulation by AEDs. It also used current-clamp and dynamic-clamp recordings on 
transfected hippocampal cultured neurons to assess the effect of splicing on neuronal properties 
during epileptiform activity. 
Biophysical analysis in HEK293T cells revealed that splicing profoundly regulates fast 
inactivation and channel availability during fast, repetitive stimulation, with neonatal channels 
showing higher availability compared to adult channels and this difference was conserved among 
Nav1.1, Nav1.2 and Nav1.7. The change in inactivation imposed by splicing can be modeled as a 
modification of the stability of the inactivation statein resting channels. This change can be 
eradicated by administration of the AEDs phenytoin and carbamazepine. Current-clamp recordings 
in transfected neurons showed that the alternatively spliced variantmodifies the rising phase of 
action potentials for Nav1.1 and Nav1.2 at high firing frequencies, implying a consistent splice-
dependent modulation of channel availability. For Nav1.1 in interneurons, this translated to higher 
firing frequency for the neonatal isoform, which also conferred a higher maximal firing rate during 
epileptiform events imposed under dynamic-clamp recordings.  
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Chapter 1: Introduction 
 
 
 
1.1 Voltage-gated sodium channel structure and function 
 
1.1.1 Discovery and purification of the sodium channel protein 
 
Voltage-gated sodium channels (VGSCs) are critically important for the initiation and propagation 
of action potentials in excitable cells. As a consequence they play a central role in regulating 
neuronal and muscle fibre electrical excitability, enabling the coordination and communication of 
the body’s higher processes. 
The sodium channel protein was first discovered more than 30 years ago using neurotoxin-
labelling methods (Agnew et al., 1980; Beneski & Catterall, 1980) and was purified from rat brain 
in the early 1980s by Hartshorne and Catterall (Hartshorne & Catterall, 1981). Purification 
revealed a heterooligomeric polypeptide complex comprising of an alpha (α) (260kDa) subunit 
associated with one or two auxiliary beta (β) subunits, in this case β1 (36kDa) and β2 (33kDa), 
which will be discussed in more detail later on. Further studies on purified sodium channels 
revealed the existence of a functional pore within the channel that allows ion conduction 
(Talvenheimo et al., 1982), while fusion within a planar lipid bilayer revealed gating in response 
to voltage changes (Hartshorne et al., 1985; Furman et. al., 1986). In parallel to that, successful 
cloning of the sodium channel cDNA from the electric organ of the eel Electrophorus electricus 
(Noda et al., 1984) led to the heterologous expression and molecular manipulation of the channel. 
This, together with the parallel development of patch-clamp techniques, opened the way for more 
detailed functional and molecular analysis of the sodium channel protein, greatly expanding our 
knowledge and understanding about sodium channel structure and function. 
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1.1.2 Na+ channel structure: α-subunits 
 
The sodium channel architecture is composed of a 260kDa α-subunit in association with one or 
two regulatory β-subunits of 33 – 36kDa. Studies expressing sodium channel subunits in Xenopus 
oocytes (Noda et al., 1986) and mammalian cell lines (West et al., 1992) showed that the α-
subunit alone is necessary and sufficient to give rise to a functional channel. The 
secondarystructure of the α-subunit predicts that it is organised into four homologous domains 
(designated I – IV) connected to each other by cytoplasmic linkers, with each domain consisting of 
6 α-helical transmembrane segments (S1 – S6) (Figure 1.1A). Segments 1 to 4 serve as the voltage 
domainof the channel, with S4 acting as the voltage sensor, while S5 and S6 together with their 
interconnecting re-entrant linker, called P-loop, form the pore region, which determines the ion 
selectivity and conductance properties of the channel (Guy & Seetharamulu, 1986). The four 
domains are folded into a square array within the plasma membrane, with the S5-S6 segments and 
their interconnecting P-loop located in the centre, forming the ion conducting aqueous pore. 
Recent studies have shown that the voltage sensing domain (VSD) of one of the four subunits is in 
closest proximity with the S5 – S6 domain of the next subunit (Namadurai et al., 2015, Figure 
1.1B). 
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Figure 1.1: Three-dimensional structure of the VGSC 
A. Schematic illustration of the Na+ channel α- and β-subunit structure. The four homologous domains (I–IV) of the 
α-subunit are illustrated, with cylinders representing transmembrane α-helices ; S5 and S6 of each domain are the 
pore-lining segments of the channel and S4  acts as the voltage sensor. The β-subunit (violet, right) is a single 
transmembrane α-helix segment. β-subunits can interact with the α-subunit covalently or non-covalently, depending 
on the subtype. Figure redrawn from Meisler and Kearney, 2005. B. Putative transmembrane folding of the Nav 
channel from the bacterium Arcobacter butzeri (NavAb) α-subunit from top view (left) and side view (right). Two of 
the four P-loops between S5-S6 lining the pore of the channel at side view are shown . Figure redrawn from 
Nanmadurai et al., 2015. 
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The exact tertiary structure of sodium channels is still not fully determined. X-ray crystallography 
and Nuclear Magnetic Resonance (NMR) analysis of a distally related potassium channel (Doyle 
et al., 1998) first gave some insight into the crystal structure and especially the pore region.  Sato 
et al., (2001) later used cryo-electron microscopy to create a 19 ̊ resolution image representation 
of a sodium channel. A 3D reconstruction based on Sato et al. (2001) images revealed a bell-
shaped channel with a roughly symmetrical arrangement of the four channel domains around a 
cross-shaped central pore (Figure 1.2). More recently Payandeh et al., (2011) captured a crystal 
structure of a bacterial sodium channel (NavAb) in the closed configuration, at a resolution limit of 
2.7 ̊. This work, together with many previous studies relating structure to function in VGSCs, has 
led to a growing understanding of how different regions of the α-subunit may contribute to the 
gating, activation, permeation and inactivation of the sodium channel, which will be discussed in 
more detail later on. 
 
 
 
 
Figure 1.2: Three-dimensional structure of the sodium channel pore 
The three-dimensional structure of the Nav channel α-subunit at 19 ̊   resolution, compiled from electron 
micrograph reconstructions. Green color indicates the ion conducting pore and its connections to the intracellular 
and extracellular medium. Red color indicates gating pores, which will be discussed in more detail later on. Figure 
redrawn fromCatterall, 2010. 
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1.1.3 Sodium channel α-subunit genes: evolution and chromosomal location  
 
VGSCs are thought to be the last member among voltage-gated ion channels to have evolved, 
since they are not found in unicellular organisms, contrary to K+ and Ca2+ channels (Marban et al., 
1998; Catterall, 2009). Na+ channels are thought to have arisen from mutations in the primitive 
Ca2+ channel, which in turn evolved by gene duplication of the primordial 2TM K+ channel, KcsA. 
KcsA is the prokaryotic potassium ion channel derived from Streptomyces lividans bacteria and 
each of its four identical subunits comprising the functional tetrameric channel is composed of 
only two transmembrane segments. This is because each subunit lacks the S1-S4 voltage sensing 
domain that sodium channels contain, instead KcsA is primarily activated by changes in pH 
(Schrempf et al., 1995) The human genome contains 9 separate sodium channel genes (designated 
SCN1A – SCN5A and SCN8A – SCN11A), giving rise to an equal number of VGSC α-subunits 
(designated Nav1.1 – Nav1.9) expressed in excitable cells (Goldin et al., 2000). All family 
members are quite closely related, sharing 50 – 85% amino acid sequence identity (Figure 1.3, 
Catterall et al., 2005). This also translates to similar (yet not identical) functional properties and 
drug sensitivities for more closely related channels.  
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Figure 1.3: Amino acid sequence similarity (A) and phylogenetic relationships (B) of VG“C α-subunits 
Analysis was performed by aligning the amino acid sequences for all isoforms. Even for most distantly related 
channels, the amino acid similarity is >75%. Figure redrawn from Catterall et al., 2005. 
 
 
 
Four out of nine genes (SCN1A, SCN2A, SCN3A and SCN9A) are clustered in chromosomal 
position 2q24 in humans, while a second cluster in chromosome 3p21-24 includes SCN5A, 
SCN10A and SCN11A. SCN4A and SCN8A are isolated as single genes on chromosomal places 
17q23 and 12q13 respectively (Figure 1.4, Meisler et al., 2010). 
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Figure 1.4: Chromosomal location and arrangement of the 10 paralogous α-subunit human genes encoding the 
voltage-gated sodium channels. 
Figure redrawn from Meisler et al., 2010.  
 
 
 
1.1.4 β-subunits 
 
β-subunits are not a requirement for sodium channels to be functional, but they are important for 
modulating the α-subunit’s surface expression and biophysical properties. Hence, their expression 
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alongside with α-subunits is essential for proper channel function in vivo. β-subunits are encoded 
by four separate genes in mammals, giving rise to four different types (β1-β4). The β1-encoding 
gene is located on chromosome 19q13, whereas the β2 and β4 genes are located next to each other 
alongside on chromosome 11q22-23, and β3 is nearby at chromosome 11q24 (Catterall, 2009). β-
subunits are expressed in both excitable and non-excitable (astrocytes, radial glia, Schwann cells) 
tissues within the nervous system and heart (Patino & Isom, 2010). There has also been evidence 
of expression of β-subunits in cells without the presence of any α-subunits (Patino & Isom, 2010).  
All four β-subunits are proteins with a single transmembrane-spanning segment containing a small 
intracellular carboxy-terminal domain and a large extracellular amino-domain (Figure 1.1A, right). 
The amino-domain is thought to fold in an immunoglobulin-like manner, a typical characteristic of 
cell adhesion molecules (Isom et al., 1995). 
β-subunits can associate with α-subunits in two ways, either non-covalently in the case of β1 and 
β3 subunits, or through disulphide bonds, for β2 and β4. One α-subunit can associate with one or 
more β-subunits, usually one covalently and one non-covalently linked (Catterall et al., 2005; 
Patino & Isom, 2010). 
Co-expression of β-subunits with the α-subunit of the sodium channel has at least two 
consequences. First of all, they can strongly modulate sodium channel kinetics, as seen in 
heterologous expression systems, ranging from voltage dependence of activation and inactivation 
to sodium current density. Isom et al., (1995) reported an increase in current amplitude and 
membrane capacitance when β2 was co-expressed with neuronal α-subunits in Xenopus oocytes. 
β-subunits also shifted the voltage dependence of activation and inactivation states towards 
hyperpolarisation in Nav1.6 and Nav1.8 channels stably expressed in a HEK293 cell line, while 
they also modulated current density (Zhao et al., 2011). Overall, effects of β-subunits on sodium 
channel function appear to be variable and dependent on both the α- and β-subunit combination, as 
well as the cell type where the sodium channel is expressed (Savio-Galimberti et al., 2012).  
In addition to their role as functional modulators, β-subunits also act as cell adhesion molecules. 
They can interact with the extracellular matrix and other cell adhesion molecules as well as the 
cytoskeleton and intracellular regulatory and signalling proteins, like protein kinases and 
phosphatases (Isom, 2002; Brackenbury & Isom, 2011). Such β-subunit-dependent interactions are 
thought to mediate cell surface expression and trafficking of VGSCs, affecting both channel 
density (Isom et al., 1995) as well as appropriate sub-cellular localization (Savio-Galimberti et al., 
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2012). This can have a significant effect in cell responsiveness and has recently been suggested as 
a possible mediator affecting nociceptor excitability in vivo (Lopez-Santiago et al., 2011). Apart 
from these roles, β2 and β4 intracellular domains have recently been suggested to function as 
potential transcriptional regulators of the SCN1A α-subunit, by translocating into the nucleus and 
enhancing gene expression (Savio-Galimberti et al., 2012). Finally, there is growing evidence that 
β-subunits are involved in cellular migration and/or neurite outgrowth, linked also to cancer cell 
growth and metastasis (Eijkelkamp et al., 2012). 
The physiological importance of β-subunits becomes evident when looking at the effects of 
mutations in β-subunit genes in animals and humans or in knockout animal models. Heterozygous 
mutations in β1 have been discovered in families with Generalized Epilepsy with Febrile Seizures 
plus (GEFS+), an epilepsy syndrome with usually an early life onset (Scheffer et al., 2007). Also, 
mutations in β3 and β4-subunits leading to reduced peak sodium current in Nav1.5 have been 
linked to Sudden Infant Death Syndrome (SIDS) (Tan et al. 2010). Furthermore, whole β1 and β2 
gene deletions in knockout experiments in mice reveal impairments in the myelination process and 
axonal conduction (Chen et al., 2004), while they have also been linked to epileptic seizures, heart 
conditions, pain and premature death (Catterall, 2009; Patino & Isom, 2010). For an overview of 
mutant β-subunit-associated conditions, see table 1.1 (from Savio-Galimberti et al., 2012).   
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Table 1.1: Nav β-subunits 
Summary of the different types of β-subunits associated with the different VGSC, and the related channelopathies 
associated with the mutations in the genes that encode them (modified from Patino and Isom, 2010). 
 
 
 
1.1.5a Sodium channels subtypes have been appropriated to different locations and functions 
in neurons. 
 
The various α-subunits have distinct regional, developmental and sub-cellular expression patterns 
that differ from each other, as well as between species. This expression is a highly dynamic 
process, depending on age, activity and pathophysiology. Because of the importance of sodium 
channels, many studies using antibody staining, RNA detection or a combination of these 
approaches have sought to clarify the distribution of different subtypes. Distinct expression and 
localization patterns suggest that different α-subunit channel subtypes play specialized roles in 
body physiology. 
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Nav1.1, Nav1.2, Nav1.3 and Nav1.6 are the prevalent α-subunits expressed in adult brain neurons in 
humans (Catterall, 2000; Goldin et al., 2000; Goldin, 2001; Trimmer & Rhodes, 2004). Nav1.1 and 
Nav1.3 are primarily localized in neuronal somata, where they are believed to control neuronal 
excitability by setting the threshold for Action Potential (AP) generation in the axon initial 
segment (AIS) and further axonal propagation (Westenbroek et al., 1989; 1992; Catterall, 2009). 
Nav1.1 in particular is suggested to be preferentially expressed in the proximal part of the AIS of 
GABAergic interneurons, since it plays a predominant role in the excitability of fast-spiking 
parvalbumin-positive interneurons in the CNS (Yu et al., 2006; Ogiwara et al., 2007) and is also 
suggested to be expressed, at lower levels, in somatostatin-positive interneurons (Li et al., 2014). 
In contrast, while highly conserved at the amino acid level, Nav1.2 is primarily expressed in 
excitatory neurons, in unmyelinated or premyelinated fibres, usually early in development, before 
being replaced by Nav1.6 in mature Nodes of Ranvier in myelinated axons and dendrites (Caldwell 
et al., 2000; Jenkins & Bennett, 2001; Catterall et al., 2010, Oliva et al., 2012). Nav1.6 channels 
are also found on the axon initial segment as well as on dendrites of projection neurons 
(Mantegazza et al., 2010), while a recent study has also reported their presence at the distal part of 
the AIS in interneurons (Li et al., 2014). Nav1.2 and Nav1.6 also show strong expression in the 
granule cells of the dentate gyrus as well as the hippocampal pyramidal cell layer, whereas the 
expression of Nav1.1 and Nav1.3 in these areas if moderate to low. On the contrary, all of these 
subtypes seem to be expressed in the cerebellar granular layer and in the cortical layers III, IV and 
VI, in comparison to layers I and II, which show low expression (Wood & Baker, 2001). Nav1.3 
brain levels are quite high in rodents during embryonic life and drop sharply soon after birth, with 
Nav1.2 and Nav1.6 taking over (Gordon et al., 1987; Beckh et al., 1989; Gazina et al., 2010). In 
humans, expression of Nav1.3 remains comparatively high in the adult brain (Chen et al., 2000; 
Mantegazza et al., 2010).  
The rest of the neuronal sodium channels are Nav1.7, Nav1.8 and Nav1.9, which are predominantly 
expressed in the peripheral nervous system (Ogata & Ohishi, 2002; Savio-Galimberti et al., 2012). 
All three of these channels are suggested to play a key role in nociception. Nav1.7 is localized 
mainly in sensory neuron axons, mediating AP initiation and propagation (Catterall, 2009; Black 
et al., 2012). It is largely found in the PNS, and is particularly important for subthreshold signaling 
and nociception in small diameter neurons, which are anatomically distinct from the CNS neurons 
(Cox et al., 2006; Yang et al., 2004). Immunohistochemical analysis in rat DRG neurons showed a 
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wide Nav1.7 expression, extending from the cell’s soma to peripheral C-fibers in the skin and 
central dorsal horn up to the presynaptic terminal (Black et al., 2012).  
Nav1.8 is thought to be the major contributor of nociceptor excitability especially at lower 
temperatures, since its kinetics appear to be cold-resistant (Zimmermann et al., 2007). Nav1.9, 
which was the last VGSC subtype to have been discovered (Dib-Hajj et al., 2003), is also found in 
peripheral sensory neuron afferents. Nav1.9 has much slower kinetic properties compared to 
Nav1.7 and Nav1.8, but it is activated near resting membrane potentials (~-60mV). As a result, 
Nav1.9 acts more as a modulator of nociceptor membrane excitability rather than as a generator of 
APs in peripheral sensory neurons. 
Nav1.4 and Nav1.5 are known as the non-neuronal VGSCs. Nav1.4 is the primary VGSC in skeletal 
muscle, mediating myocyte excitability and muscle contraction. Nav1.5 is the main sodium 
channel found in the heart. Reports have also suggested that Nav1.5 is also transiently expressed in 
developing skeletal muscle, before being replaced by Nav1.4 in later development (Catterall, 
2009).  
A tenth sodium channel subtype exists, Navx (Figure 1.3B), which is evolutionarily more distant 
from the VGSCs discussed so far. The SCN7A gene, which encodes Navx, is located in the cluster 
with SCN1A, SCN2A, SCN3A and SCN9A on the human chromosome 2. It has a widespread 
expression in many organs like the circumventricular organs of the brain, the heart, the uterus, the 
dorsal root ganglia and skeletal muscle (Savio-Galimberti et al., 2012). Yet, Navx is not thought to 
work as a VGSC in the same way as the other Navs. Mouse knockout experiments have indicated 
that Navx may work as part of a mechanism sensing extracellular sodium levels in the brain and 
controlling the ionic balance (Hiyama et al., 2002; Noda, 2006). For a summary of main temporal 
and spatial expression sites of the different sodium channel subtypes, see table 1.2. 
For the purpose of this study, we focused on 3 distinct sodium channel subtypes, Nav1.1, Nav1.2 
and Nav1.7. All three channel subtypes share a conserved splicing event giving rise to two 
different splice isoforms, which are going to be compared in terms of their biophysical and 
functional properties, but are expressed in distinct types of neurons, thereby mediating different 
kinds of neuronal activity. Also, in terms of both the physiology of the neurons, and the 
macroscopic kinetics of gating, Nav1.7 channels are more distant from the two channels in the 
CNS (Dib-Hajj et al., 2013). Therefore, as part of this study it will be examined whether potential 
functional differences between splice isoforms are conserved among the three sodium channel 
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subtypes, despite their different macroscopic properties and areas of expression (described in detail 
in Chapters 6 & 7). 
 
 
 
Gene Chromosome Channel Function TTX 
sensitivity 
Splicing at 
S3-S4? 
      
SCN1A 2q24.3 Nav1.1 inhibitory CNS S Yes 
SCN2A 2q24.3 Nav1.2 excitatory CNS (early in 
development) 
S Yes 
SCN3A 2q24.3 Nav1.3 excitatory/inhibitory CNS 
(embryonic) 
S Yes 
SCN4A 17q23.3 Nav1.4 non-neuronal ‒ skeletal 
muscle 
S No 
SCN5A 3p22.2 Nav1.5 non-neuronal ‒ cardiac 
myocytes 
R Yes 
SCN8A 12q13.13 Nav1.6 excitatory CNS (later in 
development) 
S Yes 
SCN9A 2q24.3 Nav1.7 fast PNS S Yes 
SCN10A 3p22.2 Nav1.8 slow PNS R No 
SCN11A 3p22.2 Nav1.9 slow PNS R No 
SCN7A 2q24.3 Na(x) salt-sensing Unknown unknown 
 
 
Table 1.2: Nav α-subunits 
Summary of the different voltage-gated sodium channel α-subunit subtypes and general area of function. For 
tetrodotoxin (TTX) sensitivity, channels are separated to (S)ensitive and (R)esistant. Out of 10 sodium channel genes, 
6 of them show a conserved splicing event at the S3-S4 linker of Domain I. 
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1.1.5b Non-canonical distribution of sodium channels  
 
Lower levels of expression of some sodium channel subtypes in tissues beyond their major 
expression sites have also been detected. For example, transient expression of Nav1.5 has been 
seen in some brain areas (Wang et al., 2009), while the same has also been suggested for neuronal 
sodium channels, especially Nav1.1, in the heart (Dar Malhotra et al., 2001; Maier et al., 2003). 
VGSC expression has also been detected in glial cells, despite the fact that glial cells are not 
thought to normally fire APs. Yet, AP-like events mediated by VGSCs have been reported in 
astrocytes and glial precursor cells in the past (Sontheimer et al., 1996; Mantegazza, 2010). 
Moreover, an upregulation of Na-mediated currents in astrocytes has been detected in human 
tissues taken from epileptic patients, potentially linking Na-mediated glial defects to seizure spread 
(Steinhauser & Seifert, 2002). The exact roles of VGSC expression in glia are not yet fully 
understood. They have been suggested to involve regulation of cytoplasmic Na homeostasis 
(Sontheimer et al., 1996) and phagocytosis (Black et al., 2009). β-subunits also appear to have a 
regional and temporal spectrum of expression. For example, a splice variant of β1 named β1-A is 
highly expressed during embryonic development, with its levels falling sharply after birth while 
being replaced by β1 (Wood & Baker, 2001). β1 levels during early development are quite low, in 
contrast to β2, which is expressed at high levels continuously from development to adulthood 
(Isom et al., 1994). Furthermore, β2 expression is  only limited to neurons (Isom et al., 1995), 
while β1 is both expressed in neurons and muscle cells (Isom et al., 1992). 
 
 
 
1.1.6 Molecular properties of VGSCs underlying function: Overview 
 
At resting membrane potentials (-65 to -75mV) sodium channels remain in a closed conformation 
in quiescent cells. Upon membrane depolarization above threshold levels, VGSCs are activated, 
that is to say, they shift into an open conformation within microseconds allowing Na+ ions to rush 
down their concentration gradient from the extracellular side to the cell interior. Concomitant Na+ 
flux through thousands of VGSCs gives rise to the classical transient macroscopic Na+ current 
traces seen in whole-cell patch clamp experiments (Figure 1.5). This inward Na+ current accounts 
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for the depolarizing phase of the AP in most excitable cells. Within 1 to 2 milliseconds after 
opening, sodium channels convert into a non-conducting, inactivated state so that Na+ influx is 
ceased, irrespectively of prolonged depolarization.   
 
 
 
 
 
Figure 1.5: Whole-cell sodium current from a patched Nav1.1-transfected HEK293T cell upon membrane 
depolarization 
Upon depolarization from -80mV to 0mV, voltage-gated sodium channels are passing from closed to open and then 
to inactivated state.  
 
 
 
1.1.7 Voltage Dependence of activation and gating 
 
The molecular mechanism that is suggested to lead to the opening of VGSCs upon depolarization 
is the movement of the S4 segments of the four domains of the channel, which act as voltage 
sensors for activation. Each S4 segment contains a repeated motif of positively charged amino 
acids (either an Arginine (R) or Lysine (K)) followed by two hydrophobic residues, creating a 
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transmembrane α-helix with positive charges pointing outwards (Figure 1.6A). The movement of 
the S4 segment creates a measurable electronic charge, known as the gating charge or gating 
current, which can be measured experimentally (Hodgkin & Huxley, 1952). At resting states the 
positively charged residues are in close proximity and interact with negatively charged amino 
acids mainly from segments 2 and 3 forming ion pairs. In this configuration, the negative resting 
membrane potential pulls the gating charge inwards, keeping the channel locked into a closed state 
(Figure 1.6, Resting). Upon depolarization, the change in the polarity of the membrane’s electric 
field relieves the electrostatic force, so that the S4 segment is now moved outwards in a rotational 
manner, through a narrow gating pore, leading to opening of the channel since the gating charges 
are forming new pair partners with different negatively charged and polar residues than before at a 
more extracellular cluster, mainly from S1 and S2 segments (Miceli et al., 2015; Figure 1.6, 
Activated). The movement detected by Miceli et al., (2015) creates a conformational change of the 
S4 segment of 5 - 8Å relative to the membrane, and is consistent with  electrophysiological 
measurements of the gating current, through small changes in charge movement across the S4 
segment in response to voltage steps when pores are blocked. (Armstrong, 1974; Schneider, 1973; 
Ragsdale 1998). The S4 helix is suggested to slide through a narrow channel formed by segments 
1, 2 and 3 while simultaneously rotating 30 (Yarov-Yarovoy et al., 2012), pulling the S4-S5 
linker, (Catterall, 2010; Savio-Galimberti 2012) and consequently dilating the central pore of the 
channel by pivoting at its base (Payandeh et al., 2011) (Figure 1.7). This mechanism was initially 
characterized as the “sliding helix” (Catterall, 1986) or “helical screw” model (Guy & 
Seetharamulu, 1986).    
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Figure 1.6: State-dependent interactions between the gating charge-carrying arginines in the S4 segment and 
negatively charged residues in neighboring transmembrane segments 
A. amino acid orientation on the S4 segments of the sodium channel. Hydrophobic residues (in white) are flanked by 
positively charged arginine residues (in yellow) in every third position pointing outwards. Figure modified from 
Catterall, 2010. B. schematic representation of the gating model illustrating the rotational movement of the S4 
segments through narrow channels in each domain of the sodium channel protein from resting to activation stages. 
A single (one of the four) Domain is illustrated here for clarity. The positively charged arginine residues (in blue) are 
stabilized by interacting with negatively charged and polar residues from the S1, S2 and S3 segments to keep the 
sensor locked at resting position. Upon depolarization, the S4 segment slides outward in a rotational way, 
transporting the gating charges from an inner aqueous vestibule to an extracellular aqueous vestibule, shifting the 
positively charged residues in more outward positions, yet still neutralized by interactions with negative residues in 
the upper transmembrane part of the protein. Figure redrawn from Catterall, 2012). 
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Figure 1.7: Outward rotational sliding movement of S4 upon voltage changes leads to dilation and opening of the 
pore 
Cylinder representation model of the open and closed states for the bacterial sodium channel NaChBac upon voltage 
changes. Only one of the four voltage-sensing domains (S1 – S4) is shown here attached to the pore forming 
tetramer (S5 – S6) for clarity. R1 and R4 arginines on the S4 segment (in blue), negatively charged (in red), polar (in 
purple) and hydrophobic residues (in grey) on S1, S2 and S3 segments are represented as spheres. The S4 segment is 
tilted with respect to the S4-S5 linker from 100 to 60 as the pore passes from closed to open state. Figure taken 
from Yarov-Yorovoy et al., 2012. 
 
 
 
1.1.8 Ion selectivity 
 
The central pore of the VGSC is lined by the four re-entrant S5-S6 linkers (P-loops), which come 
together at the centre to form the narrowest part of the channel. Different residues in each of these 
4 loops come together to form an inner (DEKA) and outer (EEDD) ring within the folded channel. 
This confers an ion selectivity filter that makes the channel Na+-permeable upon activation (Figure 
1.8, from Catterall 2000). Changing of the inner ring residues into all glutamates (EEEE) in 
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mutagenesis experiments can shift the ion selectivity to Ca2+ (Heinemann et al., 1992; Ragsdale 
1998). This indicates that the pore loops are the major determinants of ion selectivity in VGSCs. 
 
 
 
Figure 1.8: The sodium channel pore, using the KcsA potassium channel α-helical fold (Doyle et al., 1998) as a 
model 
Light gray or blue represent S5, while darker gray or blue S6 (M1 and M2 respectively in KcsA). Residues forming the 
outer ring of the selectivity filter (EEDD) are superimposed on the KcsA structure. Residues forming the inner 
selectivity ring (DEKA) are shown in red. Figure redrawn from Catterall, 2000. 
 
 
 
1.1.9 Inactivation 
 
The change in conformation of the VGSC from an open state to a non-conducting state within only 
1-2 milliseconds from activation and upon maintained depolarization is known as inactivation. 
Inactivation is different from the closed and resting configuration of the channel. The classic, 
“fast” inactivation process involves the physical occlusion of the cytoplasmic end of the gating 
pore by the intracellular linker between domains III and IV. The main inactivation particle consists 
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of four consecutive amino acids, isoleucine, phenylalanine, methionine and threonine (IFMT) 
(Goldin, 2003; Savio-Galimberti et al., 2012). This particle is suggested to block the channel pore 
in a “hinged-lid” or “ball-and-chain” mechanism (Figure 1.9). The inactivation gate receptor is 
thought to be partly formed by the S4-S5 cytoplasmic linker of domains III and IV (McPhee et al., 
1996; Marban et al., 1998; Catterall, 2009) as well as the intracellular end of segment S6 in 
domain IV. More recent studies have also involved the C-terminus of the channel as part of the 
docking site as well (Mantegazza et al., 2001; Motoike et al., 2004). 
 
 
 
Figure 1.9: VGSC inactivation mechanism and structure 
(Top) The hinged-lid mechanism of sodium channel fast inactivation. The IFM motif on the DIII – DIV intracellular 
loop of the channel is suggested to form a hinged lid, with the phenylalanine residue (F1489) physically occluding the 
mouth of the pore during inactivation. (Bottom) 3D structure of the inactivation gate by multidimensional NMR. The 
IFM motif is illustrated in yellow. Threonine 1491, which is also involved in inactivation and serine 1506, a major 
phosphorylation site, that can also be modulated by protein kinase C are also shown. Figure redrawn from Catterall, 
2009.  
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Fast inactivation determines the refractoriness of the cell, setting a limit to how rapid repetitive 
firing it can sustain upon prolonged depolarization. Originally, Hodgkin & Huxley (1952) had 
characterized activation and inactivation as two independent processes. Following studies have 
suggested that the two processes are coupled, since inactivation derives its voltage dependence 
from the transmembrane movements of the four S4 voltage sensors, which also drive the activation 
process (Armstrong, 1981). Therefore, inactivation is suggested to be highly dependent on 
activation (Rudy & Silva, 2006). Recent studies have implicated the S4 segment of domain IV to 
play a principal role in this process (Capes et al., 2013). The outward movement of the S4 segment 
of domain IV, which is intrinsically slower compared to the other three S4 segments (Bosmans et 
al., 2008), is suggested to signal the starting of the fast inactivation process.  
In contrast to fast inactivation, slow inactivation is a distinct process that does not involve the DIII 
– DIV intracellular IFMT linker. Slow inactivation involves conformational rearrangements of the 
channel pore, which restrict ion flow (Struyk & Cannon, 2002). Slow inactivation develops after 
prolonged depolarization or high frequency repetitive firing. Currents that are slowly inactivating 
take seconds to shut down (Ptak et al., 2005). The exact mechanism and structural rearrangements 
through which slow inactivation occurs are not fully understood, yet they are thought to be 
independent of those driving fast inactivation. 
 
 
 
1.1.10 Persistent current 
 
A non-inactivating, “persistent” sodium current (INap) is a typical characteristic in many 
electrophysiological recordings from mammalian neurons. INap appears as “an intrinsic 
component of transient sodium currents” (Bean, 2007) (Figure 1.10). Its origin and mode of action 
are still not very well understood by electrophysiologists. The general notion is that it is derived 
from incomplete or defective fast inactivation. Taddese and Bean (2002) have described INap as a 
consequence of loose binding of the inactivation particle in partially activated channels, so that 
partial activation might play as much of a role as incomplete inactivation. INap accounts for 1 – 
3% of the transient sodium current (Magistretti et al., 1999; Mantegazza et al., 2010). 
Nevertheless, INap has effects on neuronal function since it is suggested to have more 
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hyperpolarized voltage dependence of activation than the associated transient sodium current. For 
example, Taddese and Bean (2002) found that the INap of isolated tuberomammilary neurons had 
an activation midpoint of -55 mV, which was considerably hyperpolarized compared to that of the 
transient current (-28 mV). This allows to the INap to operate as a modulator of neuronal 
subthreshold activity and fine-tune electrical excitability. Subthreshold persistent currents have 
been involved in facilitating repetitive firing (Mantegazza et al., 2010), driving oscillations and 
spontaneous rhythmic firing in pacemaker neurons (Taddese & Bean, 2002). Conditions that affect 
INap magnitude and/or kinetics can therefore lead to pathophysiological conditions, as seen in 
neurological disorders. Even a small increase in INap (1 – 2%) is sufficient to increase spiking 
frequency (Kuo et al., 2006) and to promote neuronal hyperexcitability, promoting setting a very 
favorable background for abnormal synchronous firing and, possibly, epileptogenesis (Scharfman, 
2007). Mutations in the SCN1A, SCN2A and SCN3A genes associated with epilepsy can lead to an 
increase in INap amplitude (Meisler & Kearney, 2005). SCN8A mutations in mice affecting INap 
can also alter proper neuronal firing, leading to ataxia (Meisler et al., 2002; 2004).  
 
 
 
 
 
Figure 1.10: The persistent sodium current 
Superimposition of a large persistent sodium current component (green trace) on top of a typical transient whole cell 
sodium current (black trace). Figure redrawn from Ragsdale, 2008.  
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Studying the persistent current properties in more depth is still a challenge for neuroscientists, 
since there is no known drug that can pharmacologically distinguish it from transient currents. As 
a result, INap cannot be studied in isolation. In addition, INap can vary considerably in different 
heterologous expression system studies, depending on the cell type and recording conditions. Its 
amplitude can be largely affected by temperature, G-protein activity and the major ion of the 
intracellular solution used (Fletcher et al., 2011). 
 
 
 
1.1.11 VGSC Pharmacology 
 
Given the integral role that VGSCs play in excitable cell physiology as well as pathophysiological 
conditions, ranging from cardiac arrhythmias and neuropathic pain to muscle myotonia and 
epilepsy, it is not surprising that VGSCs have been the subject of extensive pharmacological study. 
Neurotoxin pore blockers like tetrodotoxin (TTX), interacting with P-loop residues at the 
extracellular side of the channel, have contributed to the greater understanding of VGSC structure 
and function. Among sodium channel subtypes, Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and 
Nav1.7 are considered to be sensitive to TTX, i.e. they can be blocked by TTX in nanomolar 
concentrations, while Nav1.5, Nav1.8 and Nav1.9 are TTX-resistant. (For a summary of TTX 
sensitivity of sodium channels, see table 1.2). TTX completely blocks Na+ conductance of sensitive 
channels, and consequently is not therapeutically useful (as complete blockade of Na+ current 
conductance in vivo would be lethal).  
The mode of action of therapeutically used sodium channel blockers, such as local anesthetics, 
antiarrhythmics and antiepileptic drugs (AEDs), is through use-dependent inhibition. Such sodium 
channel blockers bind most efficiently when the channel is in an open or inactivated state. They 
are thought to have very little or no effect at rest when the channel is closed. Increased efficiency 
of drug action when the channel is open is probably a result of more efficient access to the binding 
site in the open/inactivated state. Thus, the drug will bind upon AP firing and dissociate after 
repolarization, relieving the channel from blockade (Figure 1.11). Yet, upon repetitive, high-
frequency firing, as it occurs in many neurological pathological conditions, the association rate of 
the drug to its target surmounts the rate of dissociation. This creates a cumulative blocking effect 
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and consequently increases the steady-state channel block. Therefore, frequency-dependent 
blockers will only inhibit VGSCs in high activity areas, leaving normally active channels 
minimally affected. The optimal frequency at which drug blockade is strongest is determined by 
the pharmacokinetic properties of each compound, which will be different from drug to drug.  
 
 
 
 
 
Figure 1.11: The modulated receptor model 
Voltage-dependent or frequency-dependent inhibition of VGSCs by sodium channel blockers, such as many common 
AEDs (green diamond) are explained by the modulated receptor model. According to this model, the inactivated 
channel has a higher affinity for the drug to bind than the resting channel state. Figure redrawn from Mantegazza et 
al., 2010. 
 
 
 
Separate classes of sodium channel blockers are used in different pathophysiological conditions, 
depending on the nature of the condition and how it affects normal channel physiology. Local 
anesthetics, antiarrhythmics and AEDs all have slightly different binding sites, yet they share an 
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overlapping site of action located on a specific receptor pocket site. This pocket is formed by 
residues in the intracellular surface of the S6 segments of domains I, III and IV (Ragsdale et al., 
1994; 1996; Catterall, 2000; Catterall, 2009) (Figure 1.12A). The interaction of sodium channel 
blockers with specific amino acid residues at this site occludes the channel pore, hence impeding 
Na+ conduction (Figure 1.12B). Of primary importance in determining the binding of such 
blockers is the electrostatic interaction between charged local anaesthetics and pi electrons of the 
aromatic ring of the Phe1579 residue, known as cation-pi interaction (Ahern et al., 2008). This 
electrostatic attraction facilitates the interaction between the local anaesthetic and the sodium 
channel pore, thereby contributing to tonic channel inhibition.  
 
 
  
 
 
Figure 1.12: VGSC blocker binding and interaction 
A. The IS6, IIIS6, and IVS6 transmembrane segments of the sodium channel form the Na+ channel blocker binding 
site. Here is shown the 3D orientation of the amino acid residues and binding site of the local aneasthetic etidocaine 
(in yellow) that block the channel pore of Nav1.2. Figure redrawn from Catterall, 2009. B. Illustration of a typical 
sodium channel blocker structure and interaction with the Nav1.4 sodium channel: the positively charged nitrogen 
moiety in one end of the blocker interacts strongly with Phe1579 in S6 of domain IV and less with Leu1280 in S6 of 
domain III. At the other end of the blocker, an aromatic ring interacts with Tyr1586 and Asn434 in S6 of domains IV 
and I respectively. For other sodium channel subtypes, blockers interact with the same amino acid residues at the 
equivalent positions. Figure redrawn from Mantegazza et al., 2010. A key problem with sodium channel 
blockers is that there is no or very little discrimination between different sodium channel subtypes. 
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This is mostly due to the high amino acid sequence conservation between VGSCs, which is greater 
than 85% for TTX-sensitive channels (Catterall et al., 2005). Selective blockade of Na+ channels 
could suppress specific symptoms, such as pain or epilepsy, which can be due to defects on a 
particular channel subtype, with minimal side effects on the rest of VGSC function. In addition, 
even subtype-specific channel openers may prove useful therapeutically, for example in the case of 
Nav1.1-specific openers in cases of epilepsy where these channels may be lost. 
Compounds with some selectivity have started being developed, especially for pain-related 
disorders, targeting Nav1.7 and Nav1.8. For example, Abbott labs is currently developing an oral 
derivative of A-803467 (Jarvis et al., 2007), a weakly-selective Nav1.8 blocker that shows efficacy 
in alleviating neuropathic pain in mouse models (Drizin et al., 2008). BZP (or else  N-[(R)-1-((R)-
7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-2-(2-
fluorophenyl)-ethyl]-4-fluoro-2-trifluoromethyl-benzamide ), a suggested Nav1.7-selective 
blocker, has partial selectivity conferred by poorly penetrating the brain, thereby having minimal 
CNS side-effects (McGowan et al., 2009). An alternative way proposed to produce selectivity is 
the development of polyclonal antibodies against a channel’s second and third extracellular loop 
(Chioni et al., 2005). This approach has been used to selectivity block TRP channels (Naylor et 
al., 2008) as well as in voltage-gated calcium channels (Liao et al., 2008). 
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1.2 VGSCs and Disease 
 
1.2.1 Different Na+ channels are associated with distinct diseases  
 
Mutations or other defects that can affect a channel’s structure and its biophysical properties or 
surface expression can lead to neurological disorders, known as “channelopathies”. Almost all of 
the conditions associated with sodium channel defects have an autosomal dominant mode of 
inheritance. From a clinical point of view, Na+ channels have been associated with different 
diseases that have in many cases lead to a better understanding of what roles these channels play in 
different tissues. Therefore, they have been separated depending on their principal target into four 
groups (George, 2005; Savio-Galimberti et al., 2012): skeletal muscle sodium channelopathies 
(caused by mutations in Nav1.4), cardiac sodium channelopathies (Nav1.5), brain sodium 
channelopathies (Nav1.1, Nav1.2, Nav1.3 & Nav1.6) and peripheral nerve sodium channelopathies 
(Nav1.7, Nav1.8 & Nav1.9). This project is focusing on three channels (Nav1.1, Nav1.2 & Nav1.7) 
with different macroscopic properties, areas of expression, as well as distinct clinical 
manifestations. Therefore, the results found here are going to be relevant for more than one disease 
condition. 
Hyperkalemic periodic paralysis (Ptacek et al., 1991; Rajar et al., 1991) and paramyotonia 
congenita (McClatchey et al., 1992; Placek et al., 1992) caused by mutations in the skeletal 
muscle Nav1.4 channel subtype were the first sodium channelopathies to be described. To date, 
three more hereditary sodium channelopathies affecting skeletal muscles have been identified: 
hypokalemic periodic paralysis, potassium-aggrevated myotonia and congenital myasthenic 
syndrome (Jurkat-Rott et al., 2010). Many of the mutations in the SCN4A gene show a marked 
temperature dependence (Sugiura et al., 2000; Wood & Baker, 2001). Temperature is important in 
Na+ channel function in disease as well as during electrophysiological recordings in 
heterologously expressed Na+ channels. 
Cardiac sodium channelopathies mostly involve mutations in the SCN5A gene, which is 
predominant in the heart muscle, but the SCN10A gene has also recently been found to be 
expressed in the heart (Facer et al., 2011; Verkerk et al., 2012; Yang et al., 2012). Heart 
syndromes associated with SCN5A mutations include long QT syndrome type 3 (Zimmer & 
Surber, 2008), Brugada syndrome (Kapplinger et al., 2010), Atrial Fibrillation (Darbar et al., 
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2008), progressive familial heart block type 1A (PFHB1A), familial atrial standstill, sinus node 
dysfunction (SND), sudden infant death syndrome (SIDS) and others. Most of these conditions are 
caused by gain-of-function effects on Nav1.5 channels, except Brugada syndrome, which typically 
results from loss of function effects. This loss of function occurs via different mechanisms, 
ranging from expression of a non-functional channel (Valdivia et al., 2004; Hsueh et al., 2009) 
and decreased protein expression (Kyndt et al., 2001) to defects in channel inactivation (Hsueh et 
al., 2009). Interestingly enough, a novel SCN5A mutation that was identified recently in a patient 
with idiopathic epilepsy dying from SUDEP (Sudden Unexpected Death in Epilepsy) reveals a 
possible, previously unreported link between SCN5A mutations and epilepsy (Aurlien et al., 2009). 
A possible explanation linking heart sodium channel mutations with epilepsy has come from rat 
studies, which have reported the localization of Nav1.5 channels also in the rat limbic system apart 
from the cardiac muscle (Hartmann et al., 1999).  
 
 
 
1.2.2 SCN9A – Peripheral nerve sodium channelopathies 
 
Peripheral nerve sodium channelopathies involve mutations in peripheral neuronal channel genes 
SCN9A, and to a lesser extent SCN10A and SCN11A. Such mutations are mainly associated with 
peripheral neuropathic and inflammatory related pain syndromes (Savio-Galimberti et al., 2012). 
Nav1.7, Nav1.8 and Nav1.9 are particularly important in peripheral DRG and nociceptive sensory 
neurons and, especially in the case of Nav1.7, which is of primary focus here, they are considered 
primary mediators of neuropathic peripheral pain. Gain-of-function mutations in the SCN9A gene 
lead to different pain-related hypersensitivity disorders. Inherited primary erythromelalgia (Yang 
et al., 2004) may be caused by a leftward shift in voltage dependence of activation (Cummins et 
al., 2007). Paroxysmal extreme pain disorder (PEPD, Fertleman et al., 2006) is caused by SCN9A 
mutations that slow fast inactivation in Nav1.7 and result in increased persistent currents from 
these channels (Eijkelkamp et al., 2012). In contrast, congenital insensitivity to pain (CIP), where 
pain perception is impaired in patients, is thought to be coupled with nonsense mutations in the 
SCN9A gene, leading to a truncated or non-functional channel (Cox et al., 2006; Ahmad et al., 
2007).  
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1.2.3 SCN1A & SCN2A – Brain sodium channelopathies 
 
Brain sodium channelopathies include mutations and defects in the sodium channel genes SCN1A, 
SCN2A and, to a smaller extent, SCN3A and SCN8A. For this project, focus will be given on 
SCN1A and SCN2A, which are thought to play distinct roles in the brain and are linked to different 
brain disorders. 
The gene that is most associated with brain sodium channelopathies is SCN1A, with over 700 
mutations to date giving rise to various forms of inherited and sporadic epilepsy syndromes. The 
most common of these syndromes are Generalized Epilepsy with Febrile Seizures plus (GEFS+) 
and Severe Myoclonic Epilepsy of Infancy (SMEI), also known as Dravet syndrome (Dravet et al., 
2005). Mutations in SCN1A have also been associated with autosomal dominant familial 
hemiplegic migraine type 3. Although originally this migraine syndrome was thought to be 
mediated through gain-of-function mutations (Cestele et al., 2008), heterologous expression 
studies have suggested loss-of-function effects may be important (Kahlig et al., 2008). Other types 
of epileptic disorders that have been associated with SCN1A mutations include intractable 
childhood epilepsy with generalized tonic-clonic (ICEGTC) seizures and familial febrile 
convulsions type 3A (FEB3A) (Savio-Galimberti et al., 2012), although the former is now 
included in Dravet syndrome (Mullen & Scheffer, 2009; Savio-Galimberti et al., 2012). 
 
 
 
1.2.4 Epilepsy 
 
Epilepsy is generally considered to be as a disorder of brain hyperexcitability, where parts or the 
whole of the brain undergoes abnormal excessive or synchronous neuronal activity. The basic 
hallmark of epilepsy is the occurrence of epileptic seizures, which are attacking events of 
hypersynchronous neuronal excitability. Epilepsy was actually defined as a disorder characterized 
by increased predisposition of generating seizures in the future (Fisher et al., 2005). This 
definition has recently been extended by the International League Against Epilepsy (ILAE) in a 
more practical clinical version, defining epilepsy as a brain disorder with either 1. Minimum two 
unprovoked or reflex seizures with >24 h distance between them, or 2. A single unprovoked or 
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reflex seizure but with increased recurrence risk (>60%) according to the clinician, or 3. Being 
diagnosed with an epilepsy syndrome (Fisher et al., 2014). Epilepsy affects more than 50 million 
people worldwide and people that experience an epileptic seizure at some point in their life have a 
30 – 35% chance of experiencing a second one in the future (Berg, 2008).  
The etiology of epilepsy can be a consequence of genetic abnormalities in multiple autosomal, X-
linked or mitochondrial genes (Stafstorm, 2009) in about 50% of the cases (Pal et al., 2010). 
Otherwise, epilepsy can develop as a result of head trauma or injury, or it can even arise as a 
secondary effect after, for example, a stroke or an infection. A large percentage of epilepsy events 
still remain idiopathic, i.e. of unknown origin (Berg et al., 2010). 
 
 
 
1.2.5 Epilepsy and VGSCs 
 
There are a large and constantly increasing number of brain sodium channel mutations, especially 
in SCN1A, that are linked with a spectrum of epilepsy syndromes. These Syndromes range from 
the comparatively milder Generalized Epilepsy with Febrile Seizures plus (GEFS+) (Scheffer & 
Berkovic, 1997) to the more severe Dravet syndrome (Dravet et al., 2005) (Figure 1.13). Related 
or subset epilepsy channelopathies include: borderline SMEI, Intractable Childhood Epilepsy with 
Generalized Tonic-Clonic seizures (ICE-GTC) and Severe Infantile Multifocal Epilepsy, which all 
lie along the GEFS+ – Dravet Syndrome spectrum (Singh et al., 2001; Mulley et al., 2005; Harkin 
et al., 2007; Ragsdale 2008). 
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Figure 1.13: The unified loss-of-function hypothesis for Nav1.1 genetic epilepsies. 
The increase in mutation severity of Nav1.1 loss-of-function mutations as indicated by the arrow, progressively leads 
to more severe forms of epilepsy syndromes, ranging from milder familial febrile seizures due to mild Nav1.1 
mutations to more severe GEFS+ and finally Dravet Syndrome, usually due to complete loss-of-function mutations. 
Symptoms of each epileptic syndrome are also given. Figure adapted from Catterall et al., 2010. 
 
 
 
1.2.6 Dravet Syndrome 
 
SMEI, or else Dravet syndrome, after Dr. Charlotte Dravet who first described it in 1978, is a 
severe epileptic encephalopathy that usually begins in early infancy. The first seizure starts before 
the age of 1, mostly in association with fever (febrile seizures) (Scheffer et al., 2009). With time, 
febrile seizures progress to a higher frequency and intensity. Seizure types include myoclonic 
(stiffening and jerking of muscles in arms, legs and head), complex partial and absence (fixed gaze 
with occasional eyelid flickering) seizures. Prolonged and clustered seizures may lead to status 
epilepticus (Dravet et al., 1992; Engel, 2001; Catterall et al., 2010), which can last for more than 
30 minutes. After the age of 2, children start developing comorbidities, including ataxia, 
developmental delays and cognitive and intellectual impairments that progress to adulthood 
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(Jansen et al., 2006). Post infancy seizures can usually become afebrile, occurring spontaneously 
even in the absence of fever. The etiology of Dravet has been primarily linked to mutations in the 
SCN1A gene (usually leading to a truncated or non-functional protein), but genetic mutations have 
also been found in SCN9A, SCN2B, GABRG2 (γ2 GABAA receptor subunit), as well as a growing 
number of genes which do not encode ion channels (eg. PCDH19, a protein found in the 
extracellular matrix) (Depienne et al., 2009). However, a significant number of Dravet syndrome 
cases still has no known genetic cause.  
 
 
 
1.2.7 GEFS+ 
 
GEFS+ is a milder epilepsy syndrome compared than Dravet Syndrome. Febrile seizures begin 
from the age of 6months to 6 years. In some patients seizures may persist beyond 6 years of age 
(thus the “+” in these cases) and may become afebrile, including tonic-clonic, myotonic and 
absence seizures (Ragsdale et al., 2008). Clinical symptoms are usually less severe than in Dravet 
patients, better controlled by AED treatment and with fewer or no cognitive impairments. Gene 
mutations associated with GEFS+ have been found primarily in SCN1A, but also in SCN1B, 
SCN2A, GABRG2 and GABRD. 
 
 
 
1.2.8 Epilepsy and SCN1A 
 
A large (>700) and growing number of mutations discovered in the SCN1A gene is supposed to 
result in epilepsy syndromes of variable severity, ranging from GEFS+ to Dravet, linking Nav1.1 
function to these conditions. Mutations are widely distributed in the SCN1A gene, with no obvious 
hotspots or relation to domains of the channel that are linked to specific channel functions (Figure 
1.14, Catterall 2010). 
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Figure 1.14: Mutations in Nav1.1 channel patients with epilepsy 
A. Circles indicate missense mutations while triangles represent in-frame deletions. B. Stars indicate truncation 
mutations mostly linked with Dravet Syndrome. Each epilepsy clinical type is indicated by color: GEFS+, generalized 
epilepsy with febrile seizures plus; ICEGTC, idiopathic childhood epilepsy with generalized tonic–clonic seizures; IS, 
infantile spasms; CGE, cryptogenic generalized epilepsy; CFE, cryptogenic focal epilepsy; MAE, myoclonic astatic 
epilepsy; SIGEI, severe idiopathic generalized epilepsy of infancy. Figure redrawn from Catterall et al., 2010. 
 
 
 
To understand the mechanisms through which Nav1.1 mutations promote seizures, neuroscientists 
have developed SCN1A-knockout mouse models (Yu et al., 2006) or mutant knock-in mice with 
various known GEFS+ or Dravet SCN1A mutations (Tang et al., 2009; Martin et al., 2010). In 
addition, the biophysical properties of cloned mutant channels have been extensively compared to 
their wild-type counterparts by electrophysiological recordings in heterologous expression systems 
including Xenopus oocytes and mammalian cell lines, using human channel isoforms, (Lossin et 
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al., 2002; 2003; Rhodes et al., 2004; 2005; Mantegazza et al., 2005; Ragsdale, 2008) or their rat or 
mouse orthologs (Spampanato et al., 2001; 2003; 2004; Barela et al., 2006, Ragsdale 2008). 
Since epilepsy is a disorder linked with brain hyperexcitability, the original hypothesis was that 
proepileptic mutations in sodium channels causing GEFS+ and Dravet would result in gain-of-
function effects that would increase excitability of the neurons affected. This was supported by 
several early studies. For example, Lossin et al., (2002) has characterized several Nav GEFS+ 
mutations in tsA201 cells that reduced channel inactivation and produced sustained “persistent” 
inward currents, which is consistent with a gain-of-function (hyperexcitability) effect in affected 
neurons. Similarly, a gain-of-function effect was also found by Cossette et al., (2003) for the 
D188V SCN1A mutation, which impaired slow inactivation. Yet, on the other hand not all data 
fitted with this pattern. In contrast, later studies revealed many mutations that were mostly 
associated with loss-of-channel-function effects and likely decreased neuronal excitability. For 
example, the T875M mutation in SCN1A is suggested to lead to enhanced slow inactivation 
(Spampanato et al., 2001), while the I1656M mutation caused a rightward shift in the voltage 
dependence of activation (Lossin et al., 2003). Both changes are consistent with reduced neuronal 
excitability. 
Ragsdale et al., (2008) has reviewed the functional effects of a number of GEFS+ and Dravet 
related mutations, the vast majority of which leads to reduced Na+ currents (Figure 1.15). In 
addition, in the case of Dravet, which is a more severe condition to GEFS+, the majority of 
mutations are nonsense, resulting in a truncated or a completely non-functional channel (Mulley et 
al., 2005; Ohmori et al., 2006; Harkin et al., 2007; Ragsdale 2008; De Jonghe, 2011). 
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Figure 1.15: Effects of epilepsy mutations on Nav1.1 current amplitude 
Histogram of whole-cell Na max current recordings for several GEFS+ and Dravet Syndrome mutations, obtained 
from the following studies: Lossin et al., 2002, 2003; Sugawara et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006; 
and Mantegazza et al., 2005a. Current max amplitudes were normalized to the WT current obtained from each 
study. Most GEFS+ and all Dravet mutations result in partial or complete loss of sodium current. Figure redrawn from 
Ragsdale, 2008. 
 
 
 
Another line of evidence linking epilepsy syndromes to loss-of-function mutations in SCN1A 
comes from mouse models. Homozygous SCN1A null mice, (SCN1A(-/-)), experience severe, 
prolonged spontaneous seizures and die before 3 weeks after birth (Meisler et al., 2010). 
Heterozygotes, (SCN1A(+/-)),  which had one functional and one mutant allele (similar to many 
Dravet patients), had less catastrophic effects than homozygotes, yet they also experienced 
spontaneous seizures. This indicates that the epileptic effects associated with many Dravet and 
GEFS+ cases in patients may have to do with SCN1A haploinsufficiency (Meisler & Kearney, 
2005; Kearney & Meisler, 2009). SCN1A seems to be the only VGSC α-subunit gene in mice that 
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shows haploinsufficiency, since heterozygote (+/-) knockout mice for SCN2A (Planells-Cases et 
al., 2000), SCN3A (Nassar et al., 2006) and SCN9A (Nassar et al., 2004) all have normal 
phenotypes.  
An explanation for the unexpected finding that loss-of-function in sodium channels could result in 
epilepsy was proposed by Yu et al., (2006), who used a Nav1.1 knockout mouse, to show reduced 
excitability of GABAergic inhibitory neurons in the hippocampus as a result of reduced sodium 
current. This indicated for the first time that inhibitory interneurons were disproportionately 
sensitive to the loss of SCN1A, as summarised in Table 1.2. The same also applies for cerebellar 
GABAergic Purkinje neurons, as seen in a heterozygous SCN1A(+/-) mouse model (Kalume et al., 
2007). Nav1.1 may account for a larger proportion of the total cell current in inhibitory 
interneurons than in excitatory neurons within the brain, meaning SCN1A loss-of-function 
mutations result in over-excitation, probably via reduced inhibition (Figure 1.16).  
 
 
 
 
 
Figure 1.16: Nav1.1 is mainly found in interneurons 
GABAergic inhibitory interneurons are shown in red. Upon excitation via (mainly) SCN1A channel activation, 
interneurons project to hippocampal pyramidal neurons or Purkinje neurons (light blue) to inhibit their action. Loss 
of function of GABAergic interneurons due to SCN1A defects would result in hyperexcitability of primary neurons, 
probably through a classical “inhibition of an inhibitor” mechanism.   
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The finding that SCN1A may predominate in interneurons still does not fully explain why some 
mutations that are thought to be associated with gain of sodium channel function and electrical 
hyperexcitability in heterologous expression studies may also lead to epilepsy. There can be 
multiple reasons for this discrepancy and all of them have to be taken into account when 
evaluating results from such functional studies. First of all, a number of mutations may partly or 
solely result in channel trafficking defects, changing the abundance of functional channels on the 
cell surface. The biophysical properties of these mutants may not really differ from wild-type (or 
may even be opposite in functional effect), yet epilepsy could stem from fewer channels getting to 
the cell membrane. Secondly, the functional properties of a channel seem to be cell type-dependent 
and can also differ depending on whether a channel is studied in neurons or in heterologous 
expression systems.  So, for example, Tang et al., (2009) studied the properties of a GEFS+ 
mutation in neurons taken from transgenic mice and reported a loss of function, although the same 
mutation was characterized as a gain of channel function in previous studies carried out using 
heterologous expression systems. The same study also indicated that functional effects in neurons 
where dependent on the neuronal subtype expressing the mutant channel, therefore showing a 
subtype-specific functional effect (Tang et al., 2009). Similarly, Rush et al., (2006) working on an 
SCN9A mutant linked to a pain disorder known as Inherited Erythromelalgia (IE), showed that the 
same mutation (L858H) could cause hyperexcitability in DRG neurons, while it caused the 
opposite effect (hypoexcitability) in cultured superior cervical ganglion neurons. This clearly 
demonstrates that the outcome of the functional effect and consequent neuronal excitability of a 
proepileptic mutation in VGSCs does not only depend on the α-subunit sequence, but can be 
affected by neuronal background.  
Modulation by protein kinases and phosphorylases can also play a role in the functional outcome, 
as well as association with accessory β-subunits, which have been shown to modulate the 
functional properties of VGSCs (Farmer et al., 2012). α-subunits associate with different 
combinations of β-subunits in a subtype and cell-type specific manner, so that different regulation 
of Nav1.1 by different β-subunits depending on the cell type may result in distinct functional 
properties. Also, the role of β-subunits on mediating targeted subcellular localization of the α-
subunit can affect neuronal excitability as well and this localization process can again also be cell-
type specific. Finally, channels expressed in heterologous systems are studied in isolation, whereas 
channels in neurons or from mouse ex vivo brain slices are found in a more complex cellular 
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milieu. Therefore, the functional contribution of an SCN1A mutation in a neuron will also rely on 
the balance of all the native, cell-specific currents that set the neuron’s membrane potential, AP 
threshold and firing frequency. 
A point of caution when extrapolating results of functional effects from heterologous systems to 
neurons and vice versa is possible compensatory mechanisms that neurons might exploit to 
minimize the effects of a mutation on excitability. Yu et al., (2006) reporting a reduction in 
hippocampal GABAergic neuronal excitability in SCN1A null mice due to loss of Nav1.1 channel 
expression, also reported an upregulation of Nav1.3. This may represent a compensation 
mechanism in GABAergic neurons and probably accounted for a significant proportion of the 
residual sodium current seen in SCN1A(-/-) homozygotes, yet increased expression of Nav1.3 was 
not enough to prevent seizures in mice.  SCN1A missense mutations that cause a loss of function 
due to folding defects can sometimes be rescued and present a normal cell phenotype when 
interacting with accessory proteins or VGSC blockers (Rusconi et al., 2007; 2009). Rescue could 
partly account for the phenotypic variability seen among GEFS+ patients who carry the same 
mutation. Similar variability was reported by Yu et al., (2006), who found strain-dependent 
differences in the severity of SCN1A null phenotype between two strains of mice with different 
genetic backgrounds. Similarly in humans, a high level of clinical heterogeneity can be seen 
between patients carrying mutations in the same gene, even in cases where they carry the same 
gene mutation. Depienne et al., (2010) has reported of an SCN1A mutation within a family, where 
the parent was described with a benign GEFS+ phenotype, while the severity of the phenotype on 
the child was much more neurologically devastating. This suggests that there are also other 
additional underlying factors, probably both environmental and epigenetic, that may modify the 
impact of a given mutation on clinical phenotype. Such finding may also partly account for 
population-specific differences in patients that show a wide range of GEFS+ phenotypes or 
different sensitivity to AED response, indicating that these may have an underlying genetic factor 
(Doty, 2010; Kobow et al., 2013). These may include genetic variants, either on sodium channels 
themselves or in other genes. In sodium channels, one obvious contributor to variability in channel 
function is alternative splicing and the current study is focussed on dissecting how a conserved 
splicing event may affect channel function and drug response in three sodium channel subtypes, 
Nav1.1, Nav1.2 and Nav1.7. 
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To re-evaluate, SCN1A mutations linked to epilepsy syndromes can either have a loss of channel 
function effect (in most cases) as well as gain-of-function effects. Yet, what sets the brain 
dysfunction is much more complex and multifactorial and results from widespread imbalance of 
whole brain network inhibition. 
 
 
 
1.2.9 SCN2A and Benign Familial Neonatal Infantile Seizures (BFNIS) 
 
Missense mutations in the SCN2A gene have been linked to different forms of epilepsy syndromes, 
the most common of which is benign familial neonatal infantile seizures (BFNIS). This is an 
autosomal dominant disorder that usually begins within 4 months of life in infants and is 
characterized by afebrile seizures that carry on spontaneously until about the first year, and then 
resolve without any residual neurological deficit. (Berkovic et al., 2004). Seizures usually start 
focally, yet secondary generalization is not uncommon (Steinlein, 2014), yet they usually respond 
well to antiepileptic drug treatment (Miceli et al., 2015). The temporal pattern of disease is 
consistent with the early life expression of Nav1.2 in unmyelinated axons (Westenbroek at al, 
1989), which is replaced by Nav1.6 later in postnatal development during axon myelination 
(Rasband 2010; Mantegazza et al., 2010).  
Similar to SCN1A, BFNIS mutations have been reported to have both gain and loss of function 
effects. Three BFNIS mutations in SCN2A studied by Misra et al., (2008) show reduced current 
density due to either reduced expression within the plasma membrane or a depolarizing shift in 
voltage dependence of activation for the R1319Q mutant. Other mutations leading to BFNIS are 
suggested to result in gain of channel function in studies using transfected cell lines (Scalmani et 
al., 2006; Liao et al., 2010), which is consistent with primary expression of Nav1.2 channels in 
excitatory brain nerves (Savio-Galimberti et al., 2012).  
Fewer cases of SCN2A mutations are linked to patients with GEFS+ (Sugawara et al., 2001). More 
recently, patients also suffering from Dravet have also been found to carry SCN2A mutations 
(Ogiwara et al., 2009; Shi et al., 2009; Meisler et al., 2010). In the case of Ogiwara et al., (2009) 
the two de novo mutations studied (E1211K and I1473M) probably cause a gain-of-channel-
function via a hyperpolarizing shift in voltage dependence of activation. A recent study has also 
57 
 
discovered a Nav1.2 mutation linked with a more severe phenotype than BFNIS, including 
intractable seizures and brain and muscular developmental abnormalities (Baasch et al., 2014). 
This suggests that in some cases the spectrum of epilepsies observed due to mutations in Nav1.2 
channels may overlap with that seen for Nav1.1 mutations. 
Furthermore, also in relation to the splicing event studied in this project, another missense 
mutation (L1563V at the S2 segment of DIV) specifically within the neonatal Nav1.2 isoform has 
also been associated with epilepsy. The mutation is causing a positive shift to the voltage 
dependence of activation on neonatal channels specifically, leading to a gain-of-function effect and 
hyperexcitability. This proepileptic predisposition of the neonatal variant might also partly explain 
the disappearance of seizures postnatally in BFNIS patients, as a result of the developmental 
switch ofNav1.2 channels in excitatory neurons (Liao et al., 2010). This is further supported by 
recent finding from Gazina et al. (2014), where the genetic removal of the Nav1.2 neonatal exon 
leads to a change in seizure threshold. 
 
 
 
1.2.10 Epilepsy and SCN3A and SCN8A 
 
There are very few cases of SCN3A or SCN8A mutations that are linked to epilepsy syndromes 
compared to SCN1A and SCN2A. Yet, in SCN3A, a missense (K354Q) mutation has been 
described in patients suffering from cryptogenic paediatric partial epilepsy (Eijkelkamp et al., 
2012). Study of this mutation in hippocampal neurons showed a hyperexcitability effect via 
increased persistent current and slowing of fast inactivation (Holland et al., 2008; Estacion et al., 
2010). For SCN8A, missense mutations in this gene in some mouse models and in patients cause 
cognitive impairments, which are usually linked to ataxia (Trudeau et al., 2006; Levin et al., 
2006), without any obvious association to seizures. Recently however, a de novo SCN8A mutation 
was been identified in a patient with infantile epileptic encephalopathy who died from SUDEP 
(Veermah et al., 2012) and later on two new de novo SCN8A mutations (G214D and R1872Q) and 
one dominant mutation (L1331V), inherited from a parent with somatic mosaicism in patients with 
epileptic encephalopathy were also revealed (Carvill et al., 2013). Three mouse model studies also 
suggest a role for SNC8A in epilepsy. Martin et al., (2007) showed that mice with 
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haploinsufficiency for both Nav1.1 and Nav1.6 had a less severe seizure phenotype than SCN1A-
only (+/-) heterozygotes. The mechanism suggested for this is that the Nav1.6 mutation reduces 
excitability of excitatory neurons, thus partly offsetting the loss of Nav1.1 in GABAergic 
inhibitory neurons and consequent reduced inhibition. Also, SCN8A(+/-) heterozygote mice are 
more resistant to chemically induced (Martin et al., 2007) or electrically induced (Blumenfeld et 
al., 2009) seizures, thereby indicating some possible degree of association between SCN8A and 
epilepsy. 
 
 
 
1.2.11 Pain & Epilepsy and SCN9A  
 
Due to its primary expression in the PNS rather than in the brain, SCN9A mutations are mostly 
associated with pain syndromes (Dib-Hajj et al., 2009). Nevertheless, a missense mutation 
(N641Y) in the SCN9A gene has been identified within a family with febrile seizures (Singh et al., 
2009). Furthermore, Doty (2010) has reported that some mutations in SCN9A can act as modifiers 
of epilepsy severity on top of other mutations in other sodium channel subtypes or even lead to a 
mild seizure phenotype themselves. 
Yet, most mutations on the SCN9A gene are usually associated with pain perception disorders, 
including primary erythermalgia (PE), paroxysmal extreme pain disorder (PEPD), small-fiber 
neuropathy, as well as congenital insensitivity to pain (CIP). Depending on the effect of the 
mutation, the pain spectrum can vary from extreme sensitivity to complete insensitivity. 
Paroxysmal extreme pain disorder (PEPD) is characterized by burning pain episodes, mostly in the 
rectum, eyes or jaw, often associated with skin redness, usually starting early in childhood and 
continuing throughout life (Fertleman et al., 2007). There are currently 10 known missense 
mutations on the SCN9A gene giving rise to this particular disorder (Marcovic et al., 2015), all of 
which are thought to work by affecting channel inactivation. Reduced or incomplete inactivation 
in mutant channels leads to prolonging of the AP and repetitive firing in DRG neurons (Dib-Hajj 
et al., 2008). 
On the other side of the spectrum, congenital insensitivity to pain (CIP) is a rare disorder 
characterized by the lack of any pain sensation from patients. This is mostly due to loss-of-
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function mutations in the SCN9A gene, which can lead to impairment of AP firing in DRG neurons 
as it has been seen in CIP families (Cox et al., 2006). Some of the known mutations in SCN9A 
gene leading to CIP phenotype include S459X, I767X, W897X, M899I, and M932L (Goldberg et 
al., 2007; Yuan et al., 2011; Marcovic et al., 2015). Yuan et al. (2011) also indicated that for the 
mutations M899I and M932L, there was variation in pain sensitivity in the Chinese population 
which was partly related to a single nucleotide polymorphism (SNP) at exon 16 of the SCN9A 
gene (c3312G>T). This indicates that splicing can potentially play a crucial role in the outcome of 
SCN9A disorders, the mechanism of which is part of the current project here, where the 
biophysical profile of a conserved splicing event between SCN1A, SCN2A and SCN9A genes that 
has been related to epilepsy and pain disease states is going to be examined. 
Similar to PEPD, primary erythermalgia (PE) is an autosomal dominant pain disorder 
characterized by extreme neuropathic burning pain in response to heat or movement (Marcovic et 
al., 2015). Therapy usually involves cooling of extremities at early stages, but soon becomes 
resistant to that and requires the usage of local anesthetics, such as lidocaine and mexiletine 
(Kuhnert et al., 1999; Legroux-Crespel et al., 2003), yet without much effect in many of the cases 
(Davis & Sandoroni, 2002). There are 19 mutations that are associated with PE to date, the vast 
majority of which are missense mutations leading to gain-of-function effects (Lampert et al., 2006; 
Wu et al., 2013; Marcovic et al., 2015). For example, mutations I848T and L858H found at the 
S4-S5 linker of DII are suggested to cause a hyperpolarizing shift, probably due to a change at the 
VD of activation (Cummins et al., 2004), which is linked to DRG hyperexcitability (Rush et al., 
2006). A similar biophysical effect was also found by Ahn et al. (2010) for the I234T mutant, 
which also showed slower deactivation and higher responses in current amplitude to depolarization 
stimuli due to a -18 mV shift in the voltage-dependence of activation and an accelerated time-to-
peak. Furthermore, F1449V and A853P mutations can induce bursting of sensory neurons by 
lowering the action potential (AP) triggering threshold (Dib-Hajj et al., 2005). Also, the 
substitution of serine to threonine in position 241 (S241T) is suggested to result to faster AP peak 
time, slower deactivation and increased sensitivity to lower depolarizations (Lampert et al., 2006). 
Clinical symptoms of PE start in early childhood, around 5-6 years old, yet manifestation of the 
disease is thought to be partly dependent by a gene splicing event (Choi et al., 2010) that will be 
studied in this project. This splicing event is also conserved in SCN1A and SCN2A genes andis 
also implicated in distinct disease manifestations (Kasperaviciute eta al, 2013; Kumari et al., 2013; 
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Xu et al., 2007; Gazina et al., 2014). This indicates that this conserved splicing event in three 
functionally distinct channel types (Nav1.1, Nav1.2 & Nav1.7) can modify the disease state of three 
phenotypically different disorders. Therefore, part of the current study is to reveal any potentially 
conserved biophysical mechanisms through which this splicing event is conferring different 
functional properties between the two splice isoforms of each channel type, which may account for 
the differences seen between them in distinct epilepsy and pain disease states. 
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1.3 VGSCs and use-dependent blockers 
 
1.3.1 Use-dependent blockers – AEDs 
 
As mentioned earlier, VGSCs are the targets of many kinds of drugs that can modulate their 
function in a use-dependent manner, such as local anaesthetics (Lidocaine), anticonvulsants and 
tricyclic antidepressants (Imipramine). Drugs that are mainly used in blocking the effects of 
sodium channels associated with epilepsy syndromes are called anti-epileptics or antiepileptic 
drugs (AEDs). However, these drugs have also been used for pain disorders, linked to SCN9A 
mutations, although without being able to discriminate specifically between channel subtypes (Lai 
et al., 2004; Drenth & Waxman, 2007). Phenytoin, the prototypic VGSC blocker, and 
carbamazepine are front line AEDs used throughout the world for treating epilepsy.  
 
 
1.3.2 Phenytoin 
 
Phenytoin is suggested to be an effective treatment for partial and generalized tonic-clonic seizures 
in epileptic patients as well as in animal models (Perucca &Tomson 2011). However it is not 
effective in treating absence seizures (Dreifuss 1983; Mantegazza et al., 2010). Phenytoin was the 
first antiepileptic to approach the ideal of suppressing epileptic activity, yet without affecting 
normal brain function. From very early on, Toman, (1949) doing experiments on the frog sciatic 
nerve noted that phenytoin did not have much effect on the initial AP caused by supramaximal 
current stimulation, but rather inhibited the following “rebound spike” generated (Ragsdale et al., 
1998). Intracellular microelectrode recordings from mouse spinal cord neurons by McLean & 
McDonald (1983) showed that phenytoin could prevent high frequency repetitive firing upon 
depolarizing current pulses, yet leaving spontaneous neuronal firing unaffected. The mechanism 
through which phenytoin could achieve that was still unknown, yet it was evident that phenytoin 
was selectively inhibiting high-frequency neuronal activity. 
A greater insight into phenytoin’s mode of action was achieved from studies involving voltage-
clamp recordings of VGSCs. These studies revealed that phenytoin is a very weak blocker of 
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sodium channels at hyperpolarized (less than -80 mV) membrane potentials, where sodium 
channels are suggested to be in a closed conformation. This indicated that phenytoin has a low 
affinity for VGSCs lying in resting states. However, with increased depolarization, phenytoin 
blocks VGSCs in a voltage-dependent manner, with greater blockade at progressively more 
depolarized potentials (Ragsdale et al., 1998) (Figure 1.17A). The voltage dependence of 
phenytoin follows the same pattern as voltage dependence of channel fast inactivation (Figure 
1.17B), indicating that phenytoin blocking action might be somehow related to the channel’s 
inactivation process or state. Phenytoin blockade builds up in an activity-dependent manner upon 
high-frequency rates of stimulating pulses (Figure 1.17C). 
 
 
 
Figure 1.17: VGSC blockade by phenytoin is both voltage- and activity dependent. 
A. Voltage-dependent block of phenytoin on NaV1.2-5A sodium channels: The level of inhibition on sodium currents 
from Xenopus oocytes after 100mM of phenytoin application increases at more depolarized holding potentials. Cells 
were held at -100, -70 and -40mV and currents were elicited by depolarization at 0mV.  B. Phenytoin shifts the 
voltage dependence of inactivation of sodium channels to the left, i.e. to more negative potentials (control, black 
circles; phenytoin, open circles). C. Activity-dependent block of phenytoin in sodium channels. Giving a 10Hz train of 
stimuli in the presence of 100µM of phenytoin, the drug’s blockade builds up from the 1st to the 40th pulse. Figure 
redrawn from Ragsdale et al., 1998. 
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1.3.3 The modulated receptor model  
 
As a conclusion from above, phenytoin is suggested to inhibit VGSC action in a voltage- and 
frequency-dependent manner. In order to understand this mechanism of action, the modulated 
receptor model was developed, firstly used to describe the mode of action of local anaesthetics 
(LAs), which work in a very similar mechanism to phenytoin. Site-directed mutagenesis studies 
suggest that LAs and AEDs share common or overlapping binding sites on VGSCs (Ragsdale et 
al., 1998). 
The modulated receptor model suggests that phenytoin has a low affinity for resting sodium 
channels but binds much more efficiently in the inactivated or open state. This reflects a 
modulation of the drug receptor site, which probably occurs through an allosteric mechanism as 
the channel changes conformation from a low affinity site in closed states to a high affinity site in 
inactivated or open states. Hence, the drug receptor site is in a low affinity conformation when the 
channel is resting, while converting into a high affinity state upon channel opening/inactivation. 
Given that sodium channel inactivation is more prevalent at more depolarized potentials and 
during high-frequency channel activation (Mantegazza et al., 2010), this model accounts for 
phenytoin’s voltage and activity dependence. The model also provides a mechanistic explanation 
of phenytoin’s mode of action as an AED. During times of normal brain function between seizures 
most VGSCs are in resting state, since neurons would only fire single or short bursts of APs. 
Phenytoin would be a poor blocker in this state, hence only minimally affecting neuronal (and 
cognitive) functions. On the contrary, within a seizure, neurons experience “high frequency trains 
of APs, riding on prolonged depolarizing episodes” (Ragsdale et al., 1998; Mantegazza et al., 
2010), the ideal condition for phenytoin to bind to high affinity sites in open and inactivated 
sodium channels and inhibit sodium current flow, hence suppressing seizures from developing.  
The original modulated receptor model suggested only three VGSC conformational states: open, 
closed (resting) and inactivated. Kuo & Bean, (1994) suggested a more mechanistic gating scheme 
to characterize state-dependent binding of phenytoin in VGSCs. In this model the resting sodium 
channel can pass through five different closed transition states before opening, which are 
consistent with the outward movement towards activation of the four S4 segments that constitute 
the voltage sensors of the channel (Figure 1.18). Starting with all four S4 segments in closed state 
(C1), all four have to be activated (C5) before the actual channel opening can occur (O). 
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Phenytoin, or any other similar-acting drug (indicated as B (Blocker) at the bottom row), can bind 
to any transition state in the activation scheme with a binding strength that is proportional to the 
number of voltage sensors that are in open position (Kuo & Bean, 1994). This model version does 
not differ in principle from the original modulated receptor model, since it also predicts voltage 
and activity dependence of phenytoin binding, favouring blockade at more depolarized channel 
potentials. 
 
 
 
 
 
Figure 1.18: The extended modulated receptor stochastic model.  
suggested by Kuo & Bean (1994) C1 – C5 represent closed states, free of drug blockade. C1B – C5B are closed states 
with the channel blocker bound. O and OB represent open channel states with blocker unbound and bound 
respectively. 
 
 
 
1.3.4 Molecular basis of phenytoin’s action 
 
The intracellular part of the S6 segment in domain IV is thought to be crucial for drug binding in 
VGSCs, especially in the case of LAs and AEDs. Site-directed mutagenesis studies have revealed 
specific residues in IVS6 that contribute to the drug receptor site, which, when disrupted, decrease 
the drug’s affinity for its binding site, with negligible effects in other channel functional 
properties. Two such residues of major importance for AED binding are a phenylalanine in 
position 1764 (F1764) and a tyrosine residue (Y1771) (Ragsdale et al., 1994; Fizzard et al., 2011). 
These two amino acids are thought to project towards the cytoplasmic vestibule of the VGSC pore 
to form a part of the drug binding site (Figure 1.19). 
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Figure 1.19: Molecular model of sodium channel blocker to VGSC inner pore 
Model of interaction between the sodium channel blocker (here lidocaine, in blue circle) and the phenylalanine and 
tyrosine residues on the IVS6 segment of the sodium channel (in red circles), with the drug blocking the inner 
vestibule of the pore. Figure redrawn from Fozzard et al., 2011. 
 
 
 
The close relationship between AED blockade and inactivation of the sodium channel is what 
drove scientists to also study the inactivation particle (IFM) as a potential contributor to drug 
binding or of the drug’s receptor site. After all, one of the functional effects of AEDs on VGSCs is 
to slow their recovery from fast inactivation, reducing in that way the channel availability for 
subsequent openings (Rogawski & Loscher, 2004). This happens because the rate of dissociation 
of AEDs in activated channels is much slower than their normal recovery from inactivation 
process, which occurs as the IFM linker is released from its intracellular site of binding. In search 
for such a relationship, Bennett et al., (1995) disabled the inactivation linker (IFM) particle in 
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Nav1.5 channels by substituting the three residues with glutamines (QQQ). Disruption of the 
inactivation gate greatly reduced the channel’s blocking by lidocaine, a local anaesthetic with a 
similar mode of action to phenytoin. This indicated that drug binding in VGSCs in depolarized 
states may also involve residues present in the inactivation gate, in addition to those in IVS6. 
Alternatively, disruption of the inactivation process might act indirectly, by hindering the possible 
conformational changes that would be required to form a “high affinity drug binding site” 
(Ragsdale et al., 1998). 
 
 
 
1.3.5 Carbamazepine 
 
Carbamazepine is another widely used AED, whose anticonvulsant profile is almost identical to 
phenytoin. Therefore, carbamazepine also exhibits voltage and activity-dependent inhibition of 
VGSCs, with minimal effects on normal brain function. However, compared to phenytoin, 
carbamazepine has a 3-fold lower affinity rate for depolarized channels so that it binds less 
effectively, yet its rate of binding is 5-times faster (Kuo et al., 1997; Rogawski & Loscher, 2004). 
This could probably render carbamazepine more effective than phenytoin at blocking VGSCs 
during very high frequency firing. It could also partly explain why some different epilepsy patients 
with different VGSC mutations may be more responsive to treatment with one or the other drug. 
 
Despite their wide usage as anticonvulsants, anaesthetics or pain killers, current use-dependent 
blockers, at their vast majority, cannot really discriminate between different sodium channel types. 
This limits their potential for efficiently tackling specific disease states without unwanted side-
effects due to non-specific targeting. Therefore, any modification that could provide a 
pharmacological dissection between sodium channels would be of benefit for basic science and 
potentially clinically useful. Alternative splicing is a naturally occurring process that vastly 
increases the diversity of proteins and splice variants have sometimes been shown to have different 
pharmacological properties (Bruss et al., 1999; Ryberg et al., 2005; Song et al., 2015). 
In this study we compared the effect of both phenytoin and carbamazepine on recovery from fast 
inactivation in two splice variants of a conserved splicing event in Nav1.1, Nav1.2 and Nav1.7 
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channels under conditions simulating very high, pathophysiological frequency firing. This was 
done in order to determine whether the functional effects that a conserved splicing event in VGSCs 
has can alter AED response in seizure-like conditions. Furthermore, potential differences in AED 
pharmacology between splice variants might be useful for pharmacologically discriminating 
between the different isoforms of sodium channels, which could potentially be of high clinical 
value for the development of more selective drugs. 
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1.4 VGSCs and splicing 
 
1.4.1 Splicing 
 
Alternative splicing of genes involves the processing of several possible mature mRNAs derived 
from a single gene transcript. In splicing introns (non-coding transcript regions of typically 200 – 
1000 nucleotides) are removed (or “spliced-out”) and exons (coding transcript regions of 50 – 300 
base pairs) come together in various ways (involving exon skipping, mutual exon exclusion etc.), 
resulting in subtly different final mature mRNA and protein combinations. It is an efficient way of 
increasing protein diversity from a single gene without the need of having to undergo gene 
duplication and mutation each time. Alternative splicing in neurons can therefore diversify protein 
function and widen neuronal responses within different neuronal subtypes (Bell et al., 2004) or at 
different network activity levels (Mu et al., 2003), thereby greatly expanding neuronal function 
and network structure. It is estimated that the vast majority of human genes are alternatively 
spliced, resulting in fine-tuning of physiological functions (Modrek & Lee, 2002; Pan et al., 2008), 
with most of splice variants being expressed in the brain (Xu et al., 2002).   
 
As mentioned before, among sodium channels there are 10 different subtypes, thereby greatly 
expanding the range of possible responses upon activation according to the different spatial and 
temporal localization of each of them. Alternative splicing is yet another great source of increasing 
variability among sodium channels, while also holding potential advantages over the evolution of 
even more ion channel orthologs. First of all, different splice isoforms are likely to maintain the 
same expression pattern, which would be less likely to be kept with new channel subtypes. 
Furthermore, since splicing is carried out at the post-transcriptional level, it allows for finer and 
more precise modification of the ion channel properties and also on a much faster timescale than 
what would involve switching off the transcription of one gene and turning on another (Copley, 
2004). 
 
Among the multiple splicing events occurring in sodium channels, there is one event that is 
conserved among all neuronal TTX-sensitive sodium channel α-subunit genes (namely SCN1A, 
SCN2A, SCN3A, SCN5A, SCN8A & SCN9A). This involves the alternative splicing of two 
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mutually exclusive cassette exons which encode for part of the S3 and the entire S4 
transmembrane segment of Domain I of the functioning channel (Figure 1.20C). 
  
 
 
1.4.2 Alternative splicing in the SCN1A gene 
 
The SCN1A gene has two alternately spliced variants of exon 5, denoted 5A and 5N (Figure 
1.20A). A and N stand for Adult and Neonatal respectively, as when initially characterised in rat 
brain sodium channel mRNAs by Sarao et al., 1991, the neonatal form is thought to preferentially 
be expressed in prenatal and early post-natal period and gradually being replaced by the adult form 
during development. Yet, 5N expression is still evident also in the adult brain. Amplified SCN1A 
mRNA taken from foetal brain contains >60% exon 5N, while in adult brains without a history of 
epilepsy 5N SCN1A levels were much lower (~9.5% to 30 – 40%) (Tate et al., 2005; Heinzen et 
al., 2007). Exons 5A and 5N are mutually exclusive, meaning that mature mRNAs will either 
retain one or the other exon. Despite several nucleotide differences between the two exons, 
following translation, 5A and 5N Nav1.1 channels differ from each other only by three amino acid 
changes (adult to neonatal): Y203F, D207N and V211F (Tate et al., 2005) (Figure 1.20B). When 
translated, exon 5 corresponds to the site of the channel spanning the extracellular loop between 
S3 and S4 in domain I and almost the entire S4 (Figure 1.20C). The differences between the two 
variants are all located on the S3 – S4 linker area. Since exon 5 spans a region of the channel that 
is important for voltage sensing, alternative splicing at this site was predicted to confer changes in 
channel (and consequently neuronal) behaviour.  
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Figure 1.20: Structure and conservation of splicing in Nav1.1, Nav1.2 & Nav1.7 voltage-gated sodium channels. 
A. Conserved structure of the splicing motif in the first domain of Nav1.1, Nav1.2 & Nav1.7 sodium channels. Introns 
(thin black lines) and exons (squares) are to scale. In all cases the neonatal exon (N) precedes the adult (A) exon and 
they are separated by a short intron. B. Conserved sequences encoded by the adult (top row) and neonatal versions 
(bottom 3 rows) of the conserved exons in sodium channels used in this study. The sequence encoded by the adult 
exons (Nav1.X-XA) is invariant. The sequence encoded by the neonatal exons contains conservative amino acid 
substitutions. Only the part of the exon that differs between neonatal and adult sequences is shown here for clarity, 
since the rest of the exon sequence is identical between neonatal and adult genes. The sequence of the exons is 
aligned alongside with the S3 – S4 segment of Domain I of the α-subunit (shown in red). It has been previously 
shown that the two phenylalanine (F) substitutions in Nav1.1-5N do not alter channel properties (Fletcher et al., 
2011). The boxed site indicates where splicing toggles the negatively-charged aspartate (D) in the adult exon, and a 
neutral amino acid (asparagine, N, in these channels); the conserved replacement of a single amino acid in TTX-
sensitive neuronal channels. C. Cartoon indicating the site of the single amino acid change in the short extracellular 
linker between the third and fourth transmembrane segments in domain I (DI S3-S4, arrow). The overall length of 
these channels is typically >2000 amino acids. The region outlined in black corresponds to the entire sequence 
encoded by the alternate exons, including the voltage sensor in the first domain. 
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This splicing event is conserved in all TTX-sensitive neuronal VGSCs, namely SCN2A, SCN3A 
(Sarao et al., 1991; Gustafson et al., 1993; Lu & Brown, 1998), SCN8A (Plummer et al., 1997) and 
SCN9A (Belcher et al., 1995) (Figure 1.20B). In the case of SCN2A and SCN3A it is exon 6 that is 
alternatively spliced, yet it corresponds to the same position in the channel sequence. 
While humans have functional copies of both 5A and 5N in SCN1A, rodents contain a premature 
stop codon in the 5N exon of their SCN1A gene, leading to a non-functional protein (Fletcher et 
al., 2011; Gazina et al., 2010). Therefore, rodents only express 5A Nav1.1 channels, but conserved 
alternative splicing in the other sodium channel subtypes is not affected. Studies estimating the 
relative proportions of adult and neonatal channels of different sodium channel types in rodents 
have revealed conflicting data that make the “adult” and “neonatal” nomenclature misleading in 
some cases. For example, Gazina et al., (2010) found that the Nav1.2-6N isoform was predominant 
in newborn mouse brains, but for SCN3A and SCN8A the A isoform was more abundant at the 
same time point. Higher abundance of the 5A isoform of SCN8A in newborn or early life rodent 
brains has also been found in other studies (Raymond et al., 2004; Mechaly et al., 2005). Gazina’s 
results were in accordance with Gustafson et al., (1993) for SCN2A, but not for SCN3A, with the 
latter suggesting that Nav1.3-6N levels are higher in newborn rats and get replaced by the adult 
isoform by P10. Yet, for all SCN2A, SCN3A and SCN8A, the 5N/5A ratio did gradually decrease 
with development. 
Alternative splicing of exon 5 in SCN1A is partly modulated by the activity of the splice-modifier 
protein Nova 2. Overexpression of Nova 2 increased the proportion of 5N transcripts relative to 
5A for SCN1A (Heinzen et al., 2007). Similar developmental pattern expression for SCN1A, 
SCN2A, SCN3A and SCN8A in mice has suggested that Nova 2 or other splicing factors may be 
commonly involved in alternative splicing of all four genes (Gazina et al., 2010). Nova 2 is 
thought to coordinate splicing in genes expressed in inhibitory neuronal synapses (Ule et al., 
2005), which is in line with a role of the SCN1A gene in inhibitory GABAergic interneurons. 
 
For SCN1A, the relative proportion of 5A and 5N transcripts in humans can vary significantly from 
population to population and also between individuals. A major genetic cause that can modulate 
alternative splicing in exon 5 in humans is a single nucleotide polymorphism (SNP) located in the 
sequence encoding an intron of the SCN1A gene between exons 5A and 5N (Figure 1.21). A SNP 
is a common single nucleotide variation in the DNA sequence between individuals. It is different 
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from a mutation in the sense that SNPs occur in a much higher percentage of the population than 
mutations do, i.e. >1%. The particular SNP adjacent to exon 5N in the SCN1A gene (rs3812718) is 
located in the 5’ splice donor site of the 5N exon (Figure 1.21, from Tate et al., 2005). Individuals 
can either carry the ancestral G allele or the alternative A allele. The frequency of each allele in the 
population is fairly similar, i.e. about 0.45 for G and 0.55 for the A allele (Tate et al., 2005). The 
major allele (A) is predicted to disrupt the consensus sequence of the 5N exon, thereby reducing its 
expression relative to the adult exon (5A) (Tate et al., 2005; Heinzen et al., 2007). On the other 
hand, the G allele is more “permissive”, i.e. allowing more efficient splicing of the 5N exon. 
 
 
 
 
 
 
Figure 1.21: Position of the SCN1A G>A (rs3812718) polymorphism at the intron between exons 5N and 5A. 
Genomic sequence of SCN1A between exons 5N and 5A, and exact location of the rs3812718 polymorphism at the 
consensus sequence. Amino acid changes between the Nav1.1-5N and -5A exons are indicated in boxes. In red box is 
the conserved amino acid change across different channel subtypes. Figure redrawn from Tate et al., 2005.  
 
 
 
Studies quantifying the proportion of 5N splicing among different SNP genotypes (AA, AG and 
GG) have given different and sometimes conflicting results. Tate et al., (2005) estimates 5N levels 
to be relatively low (~9.5%) in adult brains without a history of epilepsy, while there was no 
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significant difference between different genotypes. On the other hand, Heinzen et al., (2007) used 
both quantitative PCR in human brain tissues as well as minigene assays to measure the effect of 
the SNP in relative exon proportions. Brain tissues showed a 5N splicing proportion of 0.7%, 28% 
and 41% for AA, AG and GG genotypes respectively. The minigene assay gave values of similar 
magnitude (7.5%, 40% and 51% respectively). Overall, the proportion of 5N splicing between 
studies was quite different. Furthermore, one of them also showed increased 5N splicing with 
increased G retention (AA<AG<GG) (Heinzen et al., 2007), while in the other study 5N splicing 
was unaffected from genotype (Tate et al., 2005). However, Tate et al., (2005) used RT-PCR to 
determine the 5N percentage spliced, whereas Heinzen et al., (2007) used quantitative PCR, which 
is more accurate, since it gives an absolute rather than a relative value. Therefore, an incremental 
increase in %N splicing occurring with increased G allele retention on the phenotype is likely to 
reflect an accurate measure. This project seeks to clarify the molecular mechanism linking a single 
amino acid in the extracellular loop to the voltage sensitivity and AED binding, by comparing the 
biophysical characteristics of three different channels that share the alternative splicing event in 
different conditions and modelling their behaviour. 
 
 
 
1.4.3 SCN1A splicing and epilepsy 
 
About 30% of epilepsy patients are resistant to one or more AEDs (Kwan & Brodie, 2000). Since 
VGSCs are considered to be the main targets of AED action, it has been suggested that 
pharmacoresistance in some patients may in part arise from genetic variations in sodium channels, 
which in turn may result in altered electrophysiological properties between individuals. Remy et 
al., (2003) recorded sodium currents from hippocampal neurons derived from human brain tissues 
of both AED-resistant and AED-responsive patients. Neurons from AED-resistant patients showed 
loss of carbamazepine sensitivity to use-dependent block or in-vitro seizure activity, whereas 
neurons from responsive patients were sensitive to carbamazepine activity under the same 
conditions. The question that arose from this is: which mechanisms might influence a differential 
response of sodium channels between individuals? The evolutionary conserved alternative splicing 
of the voltage sensor spanning exon in VGSCs is an attractive candidate for such a mechanism. 
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This is because the voltage sensor region can affect the gating properties of the channel, as well as 
the channel’s interaction with AEDs. Further supporting this, alternative splicing at the voltage 
sensor region in the insect sodium channel altered the sensitivity of the channel to pyrethroid 
insecticides (Tan et al., 2002; Loscher et al., 2009). 
The splicing in domain I in the SCN1A gene is influenced by a G>A single nucleotide 
polymorphism (SNP) at the intron sequence between exons 5N and 5A. GG genotype individuals 
have a higher proportion of the 5N exon spliced compared to AA (Heinzen et al., 2007), therefore 
they contain a higher proportion of 5N Nav1.1 channels. A pharmacogenetic study compared 
patients’ SNP genotypes with their maximal dosage of antiepileptics phenytoin and carbamazepine 
(Tate et al., 2005). A significant association was found for people with the AA genotype correlated 
with a higher maximal dosage of carbamazepine compared to GG patients. A similar – albeit 
weaker – association was found for phenytoin. AG heterozygotes were in the middle, since they 
were prescribed with higher max doses of carbamazepine and phenytoin than GG patients and 
lower doses than AA homozygotes on average. This association was not replicated for phenytoin 
at maintenance doses in a second smaller study involving 71 Chinese patients (Tate et al., 2006). 
Yet, within that patient group they found a marginally significant association when looking at 
phenytoin serum levels. Further supporting the link between the G>A SNP and altered drug 
response, Abe et al., (2008) found, the percentage of AA genotype was significantly higher 
compared to AG and GG in a group of carbamazepine-resistant patients, while also insignificantly 
higher in (generally speaking) AED-resistant patients. More recently, a study performing 
transcranial magnetic stimulations (TMS) in healthy volunteers showed a significantly bigger 
increase in the cortical silent period (CSP) of GG compared to AA homozygous patients after 
carbamazepine administration, with no other difference at baseline (Menzler et al., 2014). That is 
the first association study indicating that the polymorphism might affect carbamazepine response 
via specifically affecting GABAergic cortical interneurons.  
However, these results should be dealt with caution, since this association has not always been 
replicated. Kwan et al., (2008) and Haerian et al., (2013) both failed to show any correlation 
between antiepileptic multidrug resistance in epilepsy and the SNP genotype. Another study 
involving 369 cases with pharmacoresistant focal epilepsy syndromes did not find a correlation 
between the genotype and carbamazepine maintenance dosage (Zimprich et al., 2008). Finally, an 
additional recent study found no association between the SNP genotype and AED responsiveness 
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(especially to carbamazepine) (Manna et al., 2011), similar to an even more recent one that failed 
to show an association with carbamazepine response in North Indian epilepsy patients (Kumari et 
al., 2013). 
 
Apart from a potential role in altered AED response, the G>A SNP has also been linked with a 
possible predisposition to epilepsy and more specifically to febrile seizures. Buchner et al., (2003) 
was the first to suggest that splicing differences and altered expression of sodium channel splice 
variants (in this case in Nav1.6) can modify both the severity of inherited disorders, such as 
epilepsy, and also influence disease susceptibility. Concerning SCN1A, a study involving a cohort 
of Austrian and German patients suffering from febrile or afebrile seizures showed a significant 
association between febrile seizure incidence and the AA genotype, while epilepsy in general did 
not correlate with the SNP genotype (Schlachter et al., 2009). However, this association was not 
replicated in a similar study in Australian patients (Petrovski et al., 2009). Yet, in support of the 
first study, a newer study by Le Gal et al., (2011) did find an association between the SNP in 
question and febrile seizures in a new cohort of patients. Statistical significance was also 
maintained when results from this study were combined with data from both previous studies, 
further supporting a correlation between the AA genotype and predisposition to febrile seizures. 
More recent studies also look in favour of an association of this polymorphism and epilepsy 
susceptibility (Kumari et al., 2013). Baum et al., (2014) has also reported a significant association 
between the G allele and decrease of epilepsy risk in Malay, Indian and Chinese patients, while 
also revealing an age component of that association, since at the Hong Kong subgroup of the study 
analysis revealed an association only in younger patients (<16 years old), but not in older ones. A 
meta-analysis done by the same group including this and previous reports still held that 
association, as also did a meta-analysis performed by Tang et al., (2014), demonstrating an 
association between the polymorphism and susceptibility to febrile seizures. Interestingly enough 
though, at the same study, an association with epilepsy without febrile seizures was only seen in 
Caucasian patients, but not in Indian or Chinese. 
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1.4.4 Possible reasons for differences between studies 
 
Taking all studies of this SNP mentioned above together, the link between the G>A SNP and 
altered AED dosage in epilepsy patients or febrile seizure predisposition remains controversial. 
Results between studies are usually mixed, even conflicting in many cases. A major issue that 
arises with AED response studies is that several of them look at the maximum or maintenance 
dosage in patients (Tate et al., 2005; Zimprich et al., 2008), but there is a number of factors that 
can affect AED pharmacokinetics/dosage other than the SNP in question. Genetic variations in 
drug-metabolizing enzymes (e.g. P450 CYP2C9, CYP2C19, CYP3A4) that are known to be 
involved in AED metabolism can affect drug pharmacokinetics, as shown in the case of phenytoin 
in multiple studies (Odani et al., 1997; Mamiya et al., 1998; Aynacioglu et al., 1999; Hung et al., 
2004). Furthermore, genetic variability in metabolizing enzymes can also affect drug dosage 
requirements, as seen for both phenytoin (Steijns et al., 2001) and carbamazepine (Tate et al., 
2005). An additional confound is the use of patients from different ethnic origins 
(Austrians/Germans, Australians, Chinese). Genetic differences between different ethnic 
backgrounds, like different polymorphisms in drug-metabolizing enzymes, might lead to 
differences in drug levels between subjects that could obscure a potential significant difference in 
AED responsiveness. Tate et al., (2006) have actually reported a significant difference in allele 
frequency of the phenytoin-metabolizing enzyme CYP2C19 between a Chinese and European 
population, which is consistent with population-specific differences in drug metabolism. In further 
support to this notion, Lakhan et al., (2009) also reported population-specific differences for the 
role of the multidrug transporter gene ABC1 in drug resistant epilepsy. Therefore, it is possible 
that observed discrepancies between association studies may be partly attributed to genetic factors 
other than the SNP in question, which can differ from population to population or even between 
individuals from the same ethnic background. In an effort to partly control for that, Tate et al., 
(2006) tried to isolate the pharmacodynamic determinant of the G>A polymorphism from the AED 
pharmacokinetic factors by looking at serum drug levels instead of maximum or maintenance AED 
dose. This approach did reveal a marginally significant association with the G>A SNP genotype 
for phenytoin dosage, when previously it had failed to show a similar association when phenytoin 
maintenance doses were used.  
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An important additional reason for mixed results in association studies is that a single SNP will 
probably have little contribution on drug response on its own. Apart from influences from other 
genes discussed before, non-genetic factors can also influence the impact of the G>A 
polymorphism and possibly mask its effects. As suggested in Loscher et al., (2009): “the inherited 
component of the response to drugs is typically polygenic”, with the G>A polymorphism having 
only a limited contribution to a polygenic inheritance. As a consequence, this makes it even harder 
for association studies to catch such correlations that do not correct also for non-genetic factors 
that may lack the power to find correlations for a weak genetic effect. For example, Tate et al., 
(2006) looking for an association between the SCN1A G>A genotype and phenytoin maximum or 
maintenance dose, did not find a significant relationship, not even a trend as in their previous study 
(i.e. AA>AG>GG, Tate et al., (2005)). Yet, when patient body mass was taken into account as an 
affecting parameter and was corrected for, a genotype trend was revealed, although it still did not 
reach statistical significance. This indicates that if the differences between genotypes are subtle 
then even small non-genetic parameters taken or not taken into account (like for e.g. body mass) 
can make a difference in revealing a trend or a significant correlation in association studies.  
Furthermore, the G>A polymorphism in SCN1A only influences a single AED target, yet AEDs 
can also work through multiple targets. AEDs act similarly on sodium channel subtypes other than 
Nav1.1. As a consequence, the contribution of an SCN1A-specific SNP on AED dosage might be 
smaller than expected and therefore more difficult to be detected in association studies. In 
addition, among other targets, carbamazepine may is also bind acetylcholine receptors (Picard et 
al., 1999). Genetic variations and mutations in the α4 and β2 subunits of acetylcholine receptor 
channels have been linked to a rare form of epilepsy called named dominant nocturnal frontal lobe 
epilepsy (ADNFLE), as well as to altered sensitivity to carbamazepine compared to the wild-type 
channels (Picard et al., 1999). This indicates that VGSCs constitute only a part of AED targets, not 
to mention that AEDs act also equally on sodium channel subtypes other than Nav1.1. As a 
consequence, the contribution of an SCN1A-specific SNP on AED dosage might be smaller than 
expected and therefore more difficult to be detected in association studies.  
Another point of caution in drug dosage association is whether AEDs are studied as one big group, 
for example in patients that receive a polytherapy treatment, or if drugs are assessed individually. 
Kwan et al., (2008), who found no association between the G>A polymorphism and AED 
response, admits to have assessed AEDs as one big group rather than individually and this was 
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also the case in the Haerian et al., (2013) study. This approach may have masked any potential 
associations between this SNP and individual drugs within these groups. In support to this 
argument, Abe et al., (2008) found a significant correlation between the AA genotype and 
carbamazepine-resistant patients, but the correlation became insignificant when compared to 
generally AED-resistant patients. This finding leaves the potential for the correlation with AED 
response to be drug-specific. This is also further supported by the more significant association 
found for carbamazepine in comparison to phenytoin in Tate et al., (2005). However, in opposition 
to that, a functional heterologous expression study on 5A and 5N Nav1.1 channels showed a 
different sensitivity of the two variant channels to phenytoin but not to carbamazepine (Thompson 
et al., 2011). This result, although it appears opposite to the previous association studies that 
suggest a higher difference between variants with carbamazepine treatment, is in principle in line 
with a drug-specific association of the SNP genotype and AED response.  
As for Zimprich et al., (2008), who failed to find an association between the SNP genotype and 
carbamazepine dosage, they used a cohort of patients that was suffering from focal epilepsy 
syndromes. Such syndromes may arise from completely different aetiology than one linked with 
the SCN1A gene and the SNP in question. Epilepsy is a heterogeneous disorder and aetiology will 
differ from patient to patient and – even more – from one group of patients to another. When 
studying a functional polymorphism on the SCN1A gene, the strongest correlations are likely those 
in epilepsy incidents and types that are influenced by one particular gene. These syndromes would 
probably include GEFS+ and SMEI, conditions that have directly been linked to SCN1A 
mutations/defects, so that an association of the G>A SNP with the severity of these disorders 
would benefit from a direct mechanistic link. This could be another important reason why some 
studies fail to show an association while some others do. Ideally, cohorts of patients should be 
chosen based on the aetiology (or at least “similarity”) of their epileptic syndromes, for example 
patients suffering from febrile seizures or SMEI patients etc. In fact, it is not too surprising that in 
the search for an association between the G>A polymorphism and seizure predisposition, it is 
primarily febrile seizure patients that show a correlation (Schlachter et al., 2009; Le Gal et al., 
2011). As Schlachter et al., (2009) states “the sodium channel gene SCN1A is arguably the most 
important gene found for Mendelian forms of febrile seizure syndromes so far”. Yet, this does not 
ignore the fact that febrile seizures can show complex inheritance beyond SCN1A, usually with a 
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polygenic basis, which may partly explain the lack of association between the G>A SNP and 
febrile seizure predisposition in Petrovski et al., (2009). 
Finally, it is worth noting that it seems unlikely for different proportions of 5A and 5N channels on 
their own, to confer febrile seizures in patients. The imposition of a proepileptic mutation on top of 
the SNP genotype might be processed differently, depending on whether this mutation is applied 
on a 5A or a 5N channel. Different SCN1A mutations may affect the channel’s biophysical 
properties and AED response to different extents, which might be splice variant-specific. Thereby, 
proepileptic mutations in the SCN1A gene may result in a different functional effect, depending on 
whether they are expressed in a 5A or 5N context. Since different patients will probably have 
suffer from different mutations in the SCN1A gene and since each mutation may have different 
effects on the two SCN1A splice variants, this might as well account for some of the differences 
found between association studies, and between patients, even those carrying the same mutations.  
 
 
 
1.4.5 5N overexpression in epilepsy 
 
A separate link between relative proportions of alternatively spliced N and A channels and 
epilepsy has come from studies suggesting that N channel levels are upregulated after seizures, not 
only in the case of Nav1.1, but also in other neuronal sodium channels where this splicing event is 
conserved. Gastaldi et al., (1997) showed a transient upregulation for about 12 hours of the 
neonatal isoform in Nav1.2 and Nav1.3 channels in hippocampal neurons of a kainite-induced rat 
epilepsy model. A much longer-lasting increase of Nav1.2-6N and Nav1.3-6N levels compared to 
their adult isoforms was also seen in the dentate gyrus of a status epilepticus rodent model 
(Aronica et al., 2001). These rodent models are not informative for SCN1A 5A/5N ratios, since 
rodents do not have a functional 5N copy (Tate et al., 2005; Gazina et al., 2010). A human study 
using brain tissues taken after surgery for refractory epilepsy showed an upregulation in Nav1.1-
5N levels in the temporal lobe relative to the hippocampus, which was significant only for patients 
with the “permissive” GG SNP genotype and not for AA or AG genotype patients (Tate et al., 
2005). A follow-up study (Heinzen et al., 2007) did not find an association between increased 
Nav1.1-5N levels and seizures in human brain tissues derived from mesial temporal lobe epilepsy 
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patients. On the contrary, neonatal transcripts showed a slight downward trend in relation to 
comparable tissues. A still unpublished human study within our lab comparing “epileptic” tissue 
samples taken out during surgery with non-age matched controls from the Parkinson’s brain bank 
showed a significant increase in N transcripts in epilepsy for all SCN1A, SCN2A and SCN8A 
genes. Therefore, although several studies suggest that neonatal channel levels are increased by 
seizures in most channels where this splicing event is conserved, results are still inconclusive. A 
study in Drosophila supports an activity-dependent regulation of this splicing event. Lin et al., 
(2012), looked at alternative splicing of exons K and L in domain III of a Drosophila Nav channel, 
at an equivalent position with the 5A/5N splicing event in domain I in humans. They found that 
increased synaptic activity promotes splicing towards exon L over exon K, which in turn may lead 
to seizure incidents. Therefore, in the same way that increased synaptic activity can bias a splicing 
decision in Drosophila Nav channels, epilepsy could similarly result in more inclusion of the N 
transcript in human and rodent neuronal sodium channel subtypes.  
 
 
 
1.4.6 Functional studies for Nav transcript variants 
 
Despite the high conservation of this splicing event among all neuronal TTX-sensitive sodium 
channel types, the importance of this splicing in neuronal functioning is still not clear. The 
conservation of this site is not only particularly striking but also uncommon. Gerstein et al., (2014) 
has recently indicated that orthologous genes rarely share the same exon-intron structure or 
alternative splicing across three different species (humans, worms, flies), suggesting that 
alternative splicing is not generally well-conserved. In fact, apart from conservation, exon 
duplication and alternative splicing of this linker region has also been suggested to have arisen in 
other clades (for eg. insects) and related ion channels (eg. Ca2+ channels) as a means of repeated 
cases of convergent evolution, rather than pre-existing in a common ancestral gene (Copley, 
2004).  
The two different variants (neonatal and adult) have been suggested to differ when examined in 
individual Na+ channel subtypes in a variety of ways under particular recording conditions in non-
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neuronal cells. In Nav1.2 channels, which are preferentially expressed in CNS excitatory neurons 
early in life, splicing affects recovery from inactivation and voltage dependence of inactivation in 
HEK293T cells (Xu et al., 2007), but that difference was not seen in another study, where β2 
subunits were co-expressed (Liao et al., 2010). In Nav1.7 channels, predominantly found in pain-
mediating neurons in the PNS, splicing can modify the channel’s association with β-subunits 
(Farmer et al., 2012), while in tsa201 cells the adult variant showed slower development of 
inactivation as well as modifications in phosphorylation (Chatelier et al., 2008). Another study 
using a different intracellular recording solution (CsCl instead of CsF) showed an increased rump 
current for the adult isoform compared to the neonatal as a result of a mutation at the inactivation 
gate (Jarecki et al., 2009). Another human mutation in Nav1.7 linked to erythromelalgia has been 
shown to differentially regulate inactivation in neurons between the two isoforms, thereby linking 
this splicing to differential disease course (Choi et al., 2010). 
In paralogue channels in other phyla, the homologous splicing event has been found to modify 
channel pharmacology in cockroaches (Tan et al., 2002) and also to reduce fast inactivation in 
Drosophila (Lin et al., 2012). 
With relation to Nav1.1 and epilepsy, the physiological purpose of a possible increase in N 
transcript levels in TTX-sensitive neuronal sodium channels is still unknown. No clear conclusion 
can still be drawn about whether this alternative splicing event leads to functional differences 
between neonatal and adult sodium channels that can make epilepsy worse, or whether it is a 
physiological response that may reduce future seizure occurrence. In order to answer this question 
and also try to understand what effect may this splicing have in epilepsy predisposition and in 
response to AEDs, the functional properties of the neonatal and adult channel variants need to be 
determined, not just for Nav1.1 but also for all sodium channel subtypes where this splicing event 
is conserved. To date, very few studies have looked at the biophysical properties of 5A and 5N 
Nav1.1 channels in order to delineate what is the effect of splicing at a functional level for this 
channel subtype. Thompson et al., (2011) looked at functional properties and the AED response of 
wild-type Nav1.1-5A and Nav1.1-5N channels, transiently transfected in HEK293T cells at room 
temperature (20 – 22°C). In these conditions, there were no differences between the two isoforms 
in voltage dependence of activation and inactivation or recovery from inactivation. However 5N 
channels showed a higher sensitivity in blockade from phenytoin and lamotrigine compared to 
Nav1.1-5A. In contrast, sensitivity to carbamazepine was the same for the two isoforms. A study 
82 
 
from our group looked at several functional features of Nav1.1-5A and Nav1.1-5N channels in 
HEK293T cells, while also comparing different recording conditions that could affect channel 
behaviour (Fletcher et al., 2011). Nav1.1 channel isoforms were compared at either room (20 - 
22°C) or physiological (~37°C) temperatures, using a caesium fluoride (CsF) or a caesium 
chloride (CsCl) based intracellular solution, while also testing the effect of β-subunit co-
transfection or G-protein activation. Results from this study revealed that recording conditions can 
significantly change the functional consequences of the two splice isoforms, with 5N channels 
appearing more sensitive than 5A to changes in temperature and major intracellular ion 
composition. The biophysical properties of the two splice variant isoforms were condition-
dependent. For example, at room temperature and using a CsF-based intracellular solution, Nav1.1-
5N channels inactivated more rapidly than Nav1.1-5A channels. On the other hand, substituting 
CsF for CsCl caused the opposite effect, with the 5N isoform channels now inactivating more 
slowly than 5A. When recording at physiological temperatures (37°C) with CsCl-based 
intracellular solution, the inactivation rate was exactly the same for both channel isoforms, as were 
their voltage dependence of activation and inactivation, current densities and proportion of 
persistent current. This finding indicates that there should be much caution when comparing 
electrophysiological data for Nav1.1 splice isoforms in different conditions, since data may be 
skewed by experimental conditions.  
Recordings at 37°C can maybe better recapitulate human body temperature conditions. Yet, these 
conditions are different to those most often used in electrophysiological recordings of 
heterologously expressed channels. Moreover, intracellular CsCl and HEK293T cells cannot 
precisely mimic the sodium channel’s native environment within a neuron. VGSC α-subunits are 
suggested to interact with β-subunits in neurons, which can affect their membrane localization 
and/or modify their functional properties (Farmer et al., 2012). Many functional studies of VGSCs 
co-transfect one or more β-subunits, usually β1 and β2, together with the α-subunit and results 
have been both condition and cell type-specific (Isom et al., 1995; Meadows et al., 2002; Qu et al., 
2001). In Fletcher et al., (2011), at physiological temperature, β1 and β2 co-expression with the α-
subunit did not reveal any differences between Nav1.1-5A and Nav1.1-5N channels. The same was 
also true for general G-protein activation within HEK293T cells using GTPγS, showing that, at 
physiological temperatures, modulation of the 5A and 5N isoforms by G-proteins is not 
significantly different.  
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Only one functional parameter was found to be significantly different between Nav1.1-5A and 
Nav1.1-5N channels under physiological temperature recording conditions with CsCl-based 
intracellular solution and that was recovery from fast inactivation. 5N channels were found to 
recover significantly more quickly from fast inactivation than their 5A counterparts (Figure 1.22, 
from Fletcher et al., 2011). This difference was most pronounced for shorter recovery time 
intervals, and was lost at longer recovery intervals (200 ms onwards). This difference in rate of 
recovery was attributed to a single amino acid change between the two splice variants, which 
replaces a negatively charged aspartate residue into a neutrally charged asparagine, D207N. The 
other two flanking residues that differ between the two splice variants of Nav1.1 do not seem to 
play a role in this recovery from inactivation difference. No difference in recovery from 
inactivation was found in Thompson et al., (2011), however in that study recordings were made at 
room temperature (20 – 22°C) and using a CsF-based intracellular solutions. Therefore, the 
different recording conditions (which are also further away from physiological temperature) might 
have masked a potential difference.  
 
 
 
Figure 1.22: Faster recovery from inactivation for Nav1.1-5N channels. 
Nav1.1-5N channels (open circles) recover more quickly from inactivation for shorter interpulse durations than 
Nav1.1-5A channels (black circles) in whole-cell patch clamp recordings in HEK293T cells at 37C. Figure modified 
from Fletcher et al., 2011. 
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As seen from Fletcher et al., (2011), electrophysiological recordings to characterize the 
biophysical properties of Nav1.1-5A and Nav1.1-5N channels and potential differences between 
them can be condition-dependent. The only difference detected in the CsCl-based intracellular 
solution andphysiological temperature recording conditions was a faster recovery rate from 
inactivation for Nav1.1-5N channels compared to 5A for shorter recovery time intervals. This 
difference was obscured under different recording conditions in another study (Thompson et al., 
2011). Since the differences between Nav1.1 channel isoforms have been found to specific to 
recording conditions, we used the difference in recovery from inactivation found in Fletcher et al., 
(2011) as a starting point in order to characterize the parameters that underlie this functional effect. 
Our aim was to illustrate how this difference between splice isoforms might be masked or 
augmented depending on recording conditions and stimulation parameters. We also aimed to 
investigate how the difference altered channel availability in conditions that mimic high-activity 
neuronal firing, for example, the kind of activity that occurs during an epileptic seizure. Any 
difference in these conditions might indicate that the biophysical properties of Nav1.1-5A and 5N 
isoforms could contribute to physiological and pathophysiological differences. Such a finding 
could provide a mechanism on a biophysical/functional level, contributing to the difference in 
epilepsy predisposition that may be seen due to different 5A/5N relative proportions in some 
epilepsy patients.  
Recovery from fast inactivation is a biophysical property of VGSCs that is directly affected by 
binding of AEDs, which make recovery significantly slower. Since Nav1.1-5A and 5N channels 
have been linked with altered drug dosage to some AEDs (Tate et al., 2005; 2006; Abe et al., 
2008; Thompson et al., 2011), and since the biophysical property that distinguishes the two 
channel isoforms is directly affected by AED usage, another aim of this study is to determine 
whether recovery from inactivation is modulated differently between Nav1.1-5A and Nav1.1-5N 
channels in the presence of two widely used AEDs, phenytoin and carbamazepine. A potential 
differential modulation of a key functional property affected by AEDs between the two splice 
isoforms could provide a mechanistic explanation for association between AED dosage and the 
SNP in SCN1A that has been suggested by several pharmacogenetic studies. 
Also, up to today and to our knowledge, no unifying functional impact of this splicing event has 
been suggested among the different sodium channel subtypes. Since the alternatively spliced linker 
region includes a voltage-sensing part of the channel, it seems possible that alternative splicing at 
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this site could have an adaptive significance, finely modulating the channel’s gating properties and 
hence modifying the physiology of the neurons that the different isoforms are expressed in. On top 
of that, the fact that this exon duplication event seems to have arisen independently through 
convergent evolution between different kingdoms as well as between different ion channels 
(including subtypes of the same channel family as in VGSCs) could indicate a possible 
evolutionary drive for also a common functional impact between the alternatively spliced variants, 
perhaps slightly adapted to the predominant area of expression of each channel subtype. Actually, 
a parallel assessment of isoform functional properties across different sodium channel subtypes 
may reveal the evolutionary drive for the convergent nature of this splicing event by unmasking a 
possible unifying functional difference. Furthermore, extrapolation of this study from heterologous 
expression systems to each channels’ native neuronal milieu might fill in the link between splicing 
in this area of the channel and effect on neuronal behavior. So, another aim is to ask whether the 
functional consequences of the conserved alternative splicing are also conserved in other neuronal 
sodium channels (in this case Nav1.2 and Nav1.7). By potentially extrapolating this effect in 
additional channels, this could provide evidence for this functional difference contributing to the 
conservation of alternative splicing in neuronal sodium channels. 
 
 
 
1.4.7 Dynamic-Clamp as a direct link to epileptiform bursts 
 
The biggest part of this study is characterizing the biophysical and functional differences between 
the neonatal and adult isoforms, initially in HEK293T cells and then in cultured neurons. Yet, 
voltage-clamp and current-clamp recordings, although quite informative as analysis tools, cannot 
feature the direct relevance of this splicing event to brain physiology and possible circuit 
pathology. The potential link of the G>A splicing event in SCN1A and possible differential 
predisposition to febrile seizures has already been discussed. In order for that association to be 
directly attributed to the activity of Nav1.1-5A and 5N variants, this would require the link of 
single cell response to a bigger brain network. Slice whole-cell or field recordings, where the 
relative expression of the two variants would be endogenously or exogenously manipulated, could 
potentially fill that gap. Yet, endogenous manipulation is impossible in rodents, since they do not 
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express the neonatal isoform, while on the other hand, exogenously transfecting the two variants in 
vivo in order to do slice recordings is an extremely difficult and challenging task. As a way to try 
to directly correlate single cell response of either Nav1.1-5A or 5N expressing cultured 
interneurons to broader network epileptic activity, dynamic-clamp recordings from single neurons 
can be used as a useful alternative. Dynamic-clamp is widely known as a way to simulate 
conductances in cells. Hence, it is also widely referred to as “conductance-clamp” (Yang et al., 
2015), since a command conductance is given initially on a cell and then the amplifier is injecting 
the appropriate current to the cell to keep the conductance steady (i.e. “clamped”) at the set value 
(Figure 1.23).  
 
 
 
Figure 1.23: An overview of dynamic-clamp principles 
A. building a dynamic clamp is based on the reciprocal interaction between the synaptic conductance command 
(gsyn), synaptic current injected (Isyn) to keep conductance clamped, and membrane potential of the cell (Vm). As 
current is injected into the cell to keep the conductance at the command value, the cell starts getting depolarized, so 
that less current is now needed to follow the gsyn. This is mostly evident when depolarization reaches threshold, so 
that an AP is fired, which vastly increases the cell’s conductance. Therefore, the Isyn needs to compensate for that 
sudden increased conductance due to the AP firing and actually inject negative current at this point in order to keep 
the gsym steady (i.e. “clamped”). B. Schematic of hardware interactions and calculation of current injected from the 
amplifier through the real-time feedback loop within the G-clamp. The amplifier is recording the Vm output of the 
cell at a user-specified rate, which is then digitized and stored in an onboard buffer at the DAQ-board. The G-clamp 
system then continually reads the Vm, looks up or calculates the command conductance value (G), calculates the 
current (I) needed to keep G steady from Ohm’s law (V=I ‘) and then this value is written to memory and converted 
to a current command signal which is fed back to the cell through the amplifier. This process is then ongoing on a 
feedback loop, with the system injecting the appropriate current to keep conductance clamped. Figure redrawn from 
Kullmann et al., 2004. 
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Dynamic-clamp can therefore be used to simulate the synaptic activity, in terms of changes in 
conductance, of a neuron’s response under an epileptic network using in-vitro models of epilepsy, 
such as the zero Mg2+ (Deshpande et al., 2007) or the 4-aminopyridine model (Gonzalez-Sulser et 
al., 2012). This simulated epileptic conductance activity, which reflects synaptic response of a 
broad epileptic network, could then be used as an activity template for either neonatal or adult 
channels in neurons in order to validate how each of them affects neuronal behavior under broader 
epileptic network conditions. 
 
 
 
1.5 Experimental aims 
 
 
Delineating the difference between Nav1.1 isoforms 
 
To measure the difference in recovery from inactivation between Nav1.1 5A and 5N channels in 
HEK293T cells during shorter interpulse durations. 
 
To assess the effect of inactivating prepulse length and voltage dependence on the difference in 
inactivation recovery between Nav1.1 5A and 5N channels. 
 
To test if this difference can impact channel availability during high frequency activity, which may 
occur during epileptic events. 
 
 
Identifying conserved differences in other channels 
 
To evaluate if this difference in inactivation recovery is also conserved in closely related Na+ 
channels bearing the same splicing event, namely Nav1.2 and Nav1.7. 
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To examine how fast inactivation recovery is affected in the presence of AEDs like phenytoin and 
carbamazepine between the two isoforms. 
 
 
Testing the significance of splicing on neuronal physiology 
 
To determine if this splicing event can affect neuronal properties when channels are expressed in 
their natural milieu (interneurons for Nav1.1, excitatory neurons for Nav1.2). 
 
To examine if different neuronal backgrounds (Nav1.1 in excitatory neurons, Nav1.2 in 
interneurons) can affect the outcome of the splicing event. 
 
To assess if the two Nav1.1 isoforms can alter the way that interneurons respond during simulated 
epileptiform activity using Dynamic-Clamp. 
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Chapter 2: General Materials and Methods 
 
 
2.1 Molecular Biology  
 
2.1.1 LB Broth, LB agar and Antibiotic solutions 
 
20g of LB Broth (Luria Bertani medium – Tryptone, 10 g; Yeast extract, 5 g; NaCl, 5 g, Sigma) 
was dissolved in 1L ddH2O, autoclaved and stored at room temperature. 17.5g of LB agar (LB 
Broth to Agar ratio: 1.67 to 1, Sigma) were dissolved in 500 ml ddH2O, autoclaved and stored at 
room temperature. For LB plate preparation, agar was melted and then cooled down below 40C 
before addition of the proper antibiotic (ampicillin or ampicillin + tetracycline, see also table 2.1). 
Agar was poured into 10cm plates (VWR International), allowed to set and either used on the day, 
or stored at 4C for up to 1 month.  
 
 
 
 
 
Antibiotic 
 
 
Stock 
concentration 
 
LB agar plate 
concentration 
 
LB Broth culture 
concentration 
 
Ampicillin 
 
 
10 mg/ml (in 
ddH2O) 
 
100 µg/ml 
 
100 µg/ml 
 
Tetracycline 
 
 
5 mg/ml (in 100% 
EtOH) 
 
5 µg/ml 
 
5 µg/ml 
 
 
Table 2.1: Antibiotic concentrations for the preparation of agar plates and bacterial culture media 
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2.1.2 DNA constructs and Cloning 
 
Human sodium channel cDNAs are notoriously difficult to maintain in bacteria (Feldman & 
Lossin, 2014), so special care was taken in the growth and propagation of our clones. Human 
SCN1A transcript variant constructs, already incorporated into the pcDM8 vector, were 
transformed into TOP10/P3 E.coli cells (Life Technologies). These bacteria contain a low copy 
number plasmid, P3, with incorporated tetracycline- and ampicillin-resistance genes. During 
normal E.coli life cycle these genes carry amber mutations (stop codons), which render them 
inactive. Upon successful transformation, the pcDM8 vector encodes the supressorF gene, which 
can nullify these amber mutations, so that antibiotic-resistance genes are switched on, thereby 
inducing bacterial resistance to these antibiotics. The SCN2A and SCN9A transcript variant 
constructs are in pcDNA3 or pcDNA3-derived vectors. SCN2A and SCN9A transformants were 
grown under ampicillin selection only in One-Shot Stbl3 Chemically Competent E.coli cells 
(Invitrogen). SCN1A-transformed P3 cells were grown in ampicillin and tetracycline. 
Even with Stbl3 cells (SCN2A and SCN9A), and low copy vectors (SCN1A), spontaneous 
mutagenesis of sodium channel gene constructs when propagated in bacterial cultures is not 
uncommon (Mantegazza et al., 2005; Thompson et al., 2011). To minimize this, the temperature 
during incubation of bacterial cultures was always kept below 30C, and confluence of liquid 
cultures was not allowed to surpass an OD600nm value of 0.35. 
 
 
 
2.1.3 Transformation of bacteria by heat shock and culture 
 
50 µl of either TOP10/P3 E.coli cells or Stbl3 cells per transformation reaction were thawed on 
ice. 50 – 100 ng of supercoiled plasmid DNA was added and cells were incubated on ice for 30 
mins. Bacteria were heat-shocked for 45 secs at 42C (30 secs for TOP10/P3 cells) and then 
immediately put back on ice for 3 mins. 250 µl of pre-warmed S.O.C. medium (20 g/L Tryptone 
5 g/L Yeast Extract, 4.8 g/L MgSO4, 3.603 g/L dextrose, 0.5g/L NaCl, 0.186 g/L KCl, Sigma) was 
added to each transformation reaction and cells were then shaken (225rpm, IKA incubating 
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shaker) for 80 mins at 25C. Bacteria were then spread on agar plates (2 plates per vial, one with 
250 µl of cells and one with 50 µl of cells) containing the appropriate antibiotic selection and 
incubated for >24 hours at room temperature. Colony growth at this temperature is slower and it 
could take up to 5 days for colonies to appear. Sometimes, colonies were visible after having 
grown rapidly overnight even at this lower temperature. Usually these colonies carried corrupted 
or re-arranged plasmid DNA which was identified after sequencing. A bias towards slower-
growing, more transparent, smaller colonies provided a higher rate for successful transformation of 
full length sodium channel cDNA constructs and a reduction in the number of false positive 
colonies selected. This is consistent with what is reported by other groups working on sodium 
channel cloning (Feldman & Lossin, 2014). It is possible that successful transformation of the Nav-
containing plasmid is toxic for bacteria, hence leading to a slow growth rate and, maybe, to a 
higher degree of damaged plasmid DNA.  
After colonies of transformed bacteria had grown on agar plates, single colonies were inoculated in 
either 5 ml (Miniprep) or 1000 ml (Maxiprep) of LB Broth, containing the appropriate antibiotic 
concentration. Cultures were shaken at <30C for >24 hours, until bacterial confluence 
(OD600nm) was near but not higher than 0.35.  
 
 
 
2.1.4 DNA purification  
 
DNAs were transformed and purified according to standard protocols (using QIAfilter Maxi 
Plasmid purification kit, Qiagen), excepting that bacteria were never incubated at higher than 30C 
or to become more dense than OD600nm = 0.35. Keeping bacterial density relatively low was also 
important for increasing the ratio of supercoiled (sc) to open circular (oc) plasmid DNA at the end 
of the purification process. It has been reported that preserving a high degree of sc plasmid DNA 
can ameliorate plasmid transfection efficacy (Sousa et al., 2009; Maucksch et al., 2009).  Since the 
purified plasmid DNA was to be used for transfection of HEK293T cells or cultured neurons, 
keeping a high degree of sc : oc plasmid DNA was important for supporting high transfection 
efficiency. Another study has also shown that to maximize the isolation of sc plasmid DNA from 
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QIAGENs purification kit, it necessary to conduct the whole process below 12°C (Carbone et al., 
2012). In contrast, performing the plasmid DNA isolation at temperatures higher than 30°C greatly 
increases the proportion of oc plasmid DNA compared to sc. Lower temperatures may markedly 
decrease the catalytic efficiency of nucleases and other enzymatic activities that can disrupt the 
DNA supercoiling, thereby introducing nicks that lead to an oc plasmid DNA secondary structure 
(Lee et al., 1989; Osheroff et al., 1983). Because all Nav transcripts were maintained in low-copy 
number plasmids and bacterial confluence was kept relatively low in order to minimize 
spontaneous mutation rate, the volume inoculated was quite high (1L) in order to obtain a 
sufficient yield of high quantity of plasmid DNA. For Maxiprep purifications, 1000ml of LB Broth 
culture is more than what is recommended for a single purification, therefore each culture was split 
into two 500ml parallel reactions that were united in the final step. Plasmid DNA samples were 
resuspended in 100 µl Tris-EDTA (10 mM Tris, pH8.0; 1 mM EDTA, TE) Bufferand stored at -
20C.  
 
 
 
2.1.5 DNA quantification 
 
Plasmid DNA concentration was measured using a spectrophotometer (Nanodrop ND-1000, 
Thermoscientific). The 260/280nm absorbance ratio was used as a quality indicator, with samples 
< 1.6 being discarded. Proper sodium channel of the whole cDNA sequence was verified for all 
constructs by DNA sequencing every time after each Maxiprep preparation. 
 
 
 
2.1.6 Mutagenesis of TTX binding site  
 
Site-directed mutagenesis was performed in SCN1A 5A & 5N cDNA sequence to introduce a 
single amino acid change (F383S) in order to confer TTX resistance according to previous studies 
(Bechi et al., 2012; Cestele et al., 2013) using the QuikChange II XL kit according to 
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manufacturer’s instructions (Stratagene, CA). For each reaction, the following was added: 5 µl of 
10x reaction buffer, 10 ng of dsDNA template, 7.5 µl of forward and 7.5 µl of reverse primer (5 
pmol/µl stock concentration), 1 µl of dNTP mix, 3 µl of QuikSolution, 1 µl of PfuUltra HF DNA 
polymerase (2.5 U/µl) and then ddH2O to a final volume of 50 µl. The thermal cycling method was 
as follows: 95°C for 1 min, then 18 cycles of 95°C for 45 sec, 55°C for 45 sec, 72°C for 15 min 
and finally 72°C for 30 min. The homologous mutation was also performed in SCN2A 6A & 6N 
cDNA sequence (F385S) (Rush et al., 2005) as well as in SCN9A 5A & 5N sequence (Y362S) 
(Choi et al., 2010). The mutagenesis primers used for SCN1A were (in red is the nucleotide that is 
different from the wild-type sequence): 
 
CTAATGACTCAGGACTCCTGGGAAAATCTTTATC (forward) and 
GATAAAGATTTTCCCAGGAGTCCTGAGTCATTAG (reverse).  
The mutagenesis primers used for SCN2A were: 
CTCATGACTCAAGACTCCTGGGAAAACCTTTATC (forward) and  
GATAAAGGTTTTCCCAGGAGTCTTGAGTCATGAG (reverse).  
In the case of SCN9A, the mutagenesis primers were: 
CTAATGACCCAAGATTCCTGGGAAAACCTTTAC (forward) and 
 GTAAAGGTTTTCCCAGGAATCTTGGGTCATTAG (reverse).  
 
All mutagenesis primers were designed and characterized using the PrimerX online software 
(http://www.bioinformatics.org/primerx/cgi-bin/DNA_1.cgi). 
Transformation of the mutated constructs was performed in TOP10/P3 E.coli cells for SCN1A and 
Stbl3 cells for SCN2A and SCN9A. Successful mutagenesis was confirmed by DNA sequencing.  
 
 
 
2.1.7 Colony PCR 
 
Due to the relatively high occurrence of false positive colonies and low success rate during both 
cloning and mutagenesis of the Nav-carrying plasmid, colony PCR followed by agarose gel 
electrophoresis was routinely used to screen a large number of colonies at once. In colony PCR 
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bacterial colonies are directly used as the DNA template using an initial denaturation step before 
the PCR reaction to lyse the bacteria and allow the primers to gain access to the cells interior and 
therefore to the plasmid DNA. This was the most efficient method to quickly screen most, if not 
all, colonies that had grown and therefore to maximize the chances of achieving a successful 
mutagenesis or cloning. It should be made clear that colony PCR was not used to directly identify 
point mutations, but rather as an initial screening method to identify whether a bacterial colony 
truly contained a sodium channel plasmid instead of empty plasmid. To do this, a specific part of 
the sodium channel cDNA was cloned using primers that were complementary to the two ends of 
that part of the channel’s cDNA sequence, which was then amplified by PCR. If the colony 
contains a sodium channel insert, then the PCR reaction gives a product that runs as a clear band 
and at a predicted length on agarose gel electrophoresis. Colonies that were positive for insert are 
then grown on LB medium, minipreped and then sequenced for verification of successful 
mutagenesis. If the colony contains just empty plasmid (e.g. sodium channel insert lost), then no 
band is seen on the agarose gel and the colony is then discarded. For colony PCR, each colony to 
be screened was picked and dissolved in 4 µl LB medium. Each PCR reaction then contained: 1 µl 
of the dissolved colony, 2 µl of forward recognition primer (5 pmol/µl), 2 µl of reverse recognition 
primer (5 pmol/µl) and 5 µl of HotStar Taq Mastermix (2x) (Qiagen). The thermal cycling reaction 
was then as follows: 95°C for 15 mins, then 24 cycles of 95°C for 30 sec, 57°C for 30 sec, 72°C 
for 1kb/min and finally 72°C for 10 min. After the PCR reaction, 2 µl of 5x gel blue loading dye 
(Qiagen) was added on each sample and then all samples were loaded on a 1% agarose gel.  
 
 
 
2.1.8 Agarose gel electrophoresis 
 
Gel electrophoresis using 1% (w/v) agarose gels was used to separate and identify DNA fragments 
of predicted size in order to select the final candidates for DNA sequencing and verification. 1g of 
Agarose (Sigma) was dissolved in 100 ml x1 TAE solution (40 mM Tris, 20 mM acetic acid, and 1 
mM EDTA) and boiled. After cooling down, 1µl of 10000x Gel Red Nucleic Acid Gel Stain 
(Biotium) was added and the mixture was poured into a gel electrophoresis tray with combs 
already loaded and was allowed to set. Before loading, the DNA samples were mixed with one 
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fifth total volume of 5x gel blue loading dye (Qiagen). The DNA amount loaded in each sample 
was 100 ng. Depending on the predicted fragment size loaded, 100 bp or 1 kb DNA ladders (NEB) 
were always loaded on the first loading chamber as molecular weight markers. Gels were usually 
run for 50 min at 90 Volts and then fragments were visualized with the use of a UV-light 
transilluminator.  
 
 
 
 
2.2 Cell culture 
 
All animal procedures were carried out according to the Animals (Scientific Procedures) Act 1986 
on PPL 70-7684 (S.Schorge). 
 
 
 
2.2.1 Neuronal cultures 
 
Neuronal cultures were isolated from P0 glutamic acid decarboxylase-green fluorescence protein 
(GAD67-GFP) mouse pups. GAD67-GFP mice selectively express enhanced green fluorescent 
protein (EGFP) at the axons, soma and dendrites of parvalbumin (Pv) calretinin (CR) and 
somatostatin (SS)-expressing interneurons (Tamamaki et al., 2003). They therefore provide a very 
useful tool for the identification and distinction of interneurons specifically, by simple 
visualization of cells under UV light. Mice that are homozygous for the GAD67-GFP transgene 
die before birth, while hemizygous mice are viable and fertile. Therefore, during crossbreeding, 
GAD-67-GFP mice were paired with wild-type mice, resulting in a 50% chance of giving a 
transgenic offspring. At any given litter, GAD67-GFP P0 pups have skulls that are transparent 
enough for the brain interneuronal fluorescence to be visible under UV-light illumination. 
Therefore, GAD67-GFP P0 pups were identified from wild-type ones by shedding UV light on 
their skull surface and monitoring fluorescent illumination by using UV goggles. 
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2.2.2 Preparation of coverslips for neuronal cultures 
 
13-mm glass coverslips (VWR) were placed in ceramic racks and incubated in concentrated nitric 
acid (65% w/w) for at least 24 hours. Coverslips were then rinsed four times for 2 hours with 
distilled water and then baked overnight at 225°C to sterilize. The next day, coverslips were placed 
into 24-well plates and 60µl of poly L-lysine (PLL, Sigma-Aldrich, P2636) solution (1 mg/ml in 
borate buffer, Sigma) were applied on each coverslip and coverslips were then incubated overnight 
at 37°C. The following day, coverslips were washed from PLL with distilled water three times, 2 
hours each. After the last wash, 1ml of Glial Medium (minimal essential medium (MEM, Sigma, 
M2279), supplemented with 0.6% (w/v) D-glucose (Sigma, G8769, 45% solution), 1% (w/v) 
Penicillin-Streptomycin (Invitrogen, 15140-122, 100x), 200 mM L-glutamine (Sigma, G7513) and 
10% (v/v) horse serum (Invitrogen, 16050-122)) was added on each well and plates were placed in 
the incubator for up to one week until ready to use. 
 
 
 
2.2.3 Preparation and expansion of cortical astroglial feeder layer 
 
Hippocampal neurons were cultured on top of a mouse astroglial monolayer, in order to provide 
neurons with the trophic support for proper neuronal growth and survival (Kaech & Banker, 2006). 
There are several protocols for culturing hippocampal neurons, with or without the use of a 
supporting glial feed layer (Kaech & Banker, 2006), the reason this one was chosen was that it is a 
standardized protocol already being used routinely in the lab for culturing mouse hippocampal 
neurons and for electrophysiological recordings. The protocol used for isolating and expanding 
cortical astroglial cells from P0 mice was exactly the same as the one used in Kaech & Banker, 
2006 for rats. Once flasks reached a 90 – 95% confluence, glial cells were plated on sterilized 
coverslips pre-treated with PLL one week before neuronal plating, with the glial medium being 
replaced every 2-3 days.  
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2.2.4 Freezing glial cells 
 
If glial cells were not used immediately for plating, they were frozen down for later use. 90 – 95% 
confluent flasks were rinsed with 10 ml CMF-HBSS (Calcium-, magnesium- and bicarbonate-free 
Hank’s balanced salt solution (HBSS, Sigma, H9394) and 10 mM HEPES buffer, pH 7.3 
(Invitrogen, 15630056)). Cells were incubated for 2 min with 2 ml of 0.05% Trypsin-EDTA (1x) 
(Gibco/Invitrogen, 25300054) and trypsin activity was stopped by adding 8 ml of Glial Medium. 
Cells were centrifuged for 5 min at 2000 rpm and then resuspended in 0.5 ml Glial Medium + 0.5 
ml 2x Cell-Freezing Medium (20% DMSO (Sigma, D2650) + 80% Fetal Bovine Serum (FBS, 
Invitrogen, 10082147) before being aliquoted in 2 ml cryotubes. These were frozen at -20°C for 2 
hours and then moved to -80°C until needed for plating. After defrosting and culturing into T75 
flasks for about one week, glial cells were treated as before freezing down. 
 
 
 
2.2.5 Hippocampal neuronal culture preparation 
 
P0 mice were decapitated and heads were washed in 3x25 ml of Wash buffer (Hank’s Balanced 
Salt Solution (HBSS, Sigma, H9394) + 5 mM HEPES (1M, pH 7.3, Invitrogen, 15630056)). The 
brain was removed and hippocampi were isolated with the use of fine tweezers. Isolated 
hippocampi were rinsed 5 times with 5 ml Wash buffer and were then digested with trypsin type 
XI (1 mg/ml; Sigma, T1005) and 1% (w/v) DNAse I (Sigma, D5025-150 KU) for 10 min at 37°C. 
Trypsinisation was stopped by adding 5 ml of Dissection solution (Wash buffer + 20% Fetal 
Bovine Serum (FBS, Invitrogen, 10082147)).  Cells were mechanically dissociated using a series 
of fine Pasteur pipettes. Dissociated neurons were plated in 24-well plates at a density of 100,000 
cells/well upon a glial feed layer in Neurobasal A culture medium (Invitrogen, 10888022) with 
B27 supplement (1x; Invitrogen, 17504044) and glutamine (25 μM; Invitrogen, 35050038) and 
cultured at 37°C and in 5% CO2. Next day, a 1 μM araC (Sigma, C6645) was added to stop further 
glial proliferation. 
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2.2.6 Transfection of HEK293T cells using Lipofectamine 
 
Heterologous expression of Nav1.1, Nav1.2 and Nav1.7 (N and A) splice variants was performed in 
HEK293T cells (Human Embryonic Kidney cells stably expressing the SV40 large T antigen, also 
known as tsA201 cells) widely used in in-vitro sodium channel function studies (Thompson et al., 
2011, Chatelier et al., 2008, Fletcher et al., 2011). HEK293T cells were grown in Dulbecco 
modified Eagle’s medium (DMEM + Glutamax, Sigma) supplemented with fetal bovine serum 
(10%) and maintained in a humidified 5% CO2 atmosphere at 37°C for up to 20 passages. 
One day before transfection, cells were plated in 4 well plates (Nunc, Denmark) at 20 – 30% 
confluence. The next day cells were transiently transfected with 0.5 µg of the sodium channel 
plasmid using 1.6 µl of Lipofectamine 2000 (Invitrogen) per well. An eGFP-containing plasmid 
was cotransfected in a 3:1 eGFP-to-sodium channel plasmid concentration ratio as a marker of 
successful transfection. 24 hours after transfection, cells were trypsinised using 0.05% Trypsin-
EDTA (1x) (Gibco/Invitrogen) and split into 35 mm petri dishes (Nunc, Denmark) containing 
sterilized 13 mm borosilicate glass coverslips (VWR International) at 20 – 30% confluence for 
electrophysiological analysis on the next day. 
 
 
 
2.2.7 Transfection of hippocampal neurons using magnetofection 
 
The pcDM8-hNav1.1 5A/5N or pcDNA3-hNav1.2 6A/6N DNA vector was co-transfected with a 
reporter Red Fluorescent Protein (RFP)-carrying plasmid under a beta-actin promoter in a 5 : 1 
molar ratio. The cultured neurons were transfected on day 4 after plating by magnetofection with 
NeuroMag according to manufacturer’s instructions (OZ biosciences).  Briefly, the cell medium 
was replaced 1 hour prior to transfection with serum-free Neurobasal A medium. Plasmid DNA 
(0.5 μg) was incubated with 1 μl of NeuroMag beads per well in 100 μl Opti-MEM for 15 minutes 
at RT and added dropwise on each well. Cells were incubated for 15 minutes at 37°C on top of the 
magnetic plate; the plate was then removed and original culture medium was restored after 45 
minutes. Recordings were performed 4-6 days after transfection to ensure maximal expression of 
the transfected gene. For interneuronal recordings, cells patched showed co-localization of both 
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green (indicating interneurons) and red (indicating successful transfection with the sodium channel 
plasmid).  
 
 
 
 
2.3 Electrophysiology 
 
2.3.1 Electrophysiological recordings 
 
Macroscopic currents from transiently transfected channels in HEK293T cells were recorded using 
voltage clamp in the whole cell patch-clamp configuration. Recordings were carried out 48 – 72 
hours after transfection. Cell-attached coverslips were placed on the chamber of a fluorescence-
inverted microscope (Olympus). Extracellular solution (in mM: 135 NaCl, 10 HEPES, 2 MgCl2, 
1.8 CaCl2, 4 KCl, pH 7.35) was continuously perfused using a gravity-driven heated perfusion 
tube system for at least 10 minutes before recordings started. All HEK293T cell recordings were 
carried out at physiological temperature (37C +/- 2C). Filamented borosilicate glass pipettes 
(GC150-F; Warner Instruments) were pulled using a model P-97 Flaming/Brown micropipette 
puller (Sutter Instrument, Novato, CA) to a final resistance of 1 – 3 MΩ. Whole-cell and pipette 
capacitance were corrected prior to recordings by using a +10 mV voltage step to integrate 
capacitive transients. The +10 mV seal test was also used to determine the access resistance of the 
pipette. Series resistance was monitored, but not compensated. At physiological temperatures 
series resistance compensation on the Axonclamp 700B would often result to the introduction of 
large transients, even at compensations <50%. Therefore, in voltage-clamp recordings 
compensation was avoided and series resistance was routinely kept <2 MΩ. Therefore, in the 
worst case scenario, a patched cell with a 2 MΩ series resistance producing a current of 5 nA 
(largest current magnitude allowed) would result in a voltage-clamp error of 10 mV. Recordings 
started within 1 min of establishment of the whole cell configuration. Cells with a capacitance >35 
pF, or a series resistance >3 MΩ were discarded from the analysis to avoid space-clamp errors. 
Recordings were acquired using a Multiclamp 700B amplifier (Molecular Devices) using in house 
100 
 
software for Labview 8.0 (D Kullmann), together with an analogue-to-digital converter (BNC-
2090A, National Instruments) for generating voltage command pulses. Data were leak-subtracted 
using a P/4 protocol and sodium currents were low-pass Bessel filtered at 10 kHz and digitized at 
50 kHz. Peak currents <600 pA were discarded from the analysis to avoid distortion by 
endogenous current. Cells that produced currents >5 nA were excluded to avoid large series 
resistance errors. 
 
 
 
2.3.2 Voltage clamp analysis 
  
The design and control of voltage protocols as well as acquisition and analysis of recorded current 
traces were performed using Labview 8.0 (National Instruments). Raw data was exported and 
subsequently analyzed (curve fitting – statistical analysis) using the Origin 8.0 software. The 
liquid junction potential for intracellular CsCl solution (in mM: 145 CsCl, 5 NaCl, 10 HEPES, 10 
EGTA, pH 7.35) was calculated to be -4.4 mV but was not corrected.  
 
 
 
2.3.3 Voltage dependence of steady-state activation/inactivation 
 
Starting from a holding potential of -80 mV, cells were stepped to a range of potentials (-120 mV 
to +60 mV) in 10mV increments for 300 ms, with 2 sec stimulus intervals between steps to allow 
full recovery of channels from the inactivated state. The four leak subtraction (-P/4) steps run after 
each stimulus pulse and before the next stimulus step. Voltage dependence of activation was 
determined as a function of relative membrane conductance against potential, using the equation G 
= I / (V – Vrev), where G is peak conductance (pSiemens), I is the peak sodium current (in pA) at 
any given membrane potential (V, in mV) and Vrev is the reversal potential of the sodium current 
calculated by the Nernst equation. The resulting conductance during each potential was normalized 
to the maximum conductance for each cell. Normalized conductance values against membrane 
potential were fitted in Origin 8.0 with a Boltzmann equation, G/Gmax = 1 / (1 + exp ((V50 - V) / 
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k)) to determine the half-maximal channel activation voltage (V50) and the slope factor (k). 
G/Gmax is the normalized conductance value at any given potential (V). 
The voltage dependence of fast inactivation was determined by measuring the peak sodium current 
during a 30 ms test pulse to -10 mV, after a 100ms prepulse between -120 to +40 mV with 10 mV 
increment in each step, starting from a holding potential of -80mV. Peak currents from each step 
were normalized to the maximum response for each cell. Normalized current-to-voltage data were 
fit with a Boltzmann equation, INa = (A + (B - A)) / (1 + exp ((V50 - V) / k)), where INa is the 
fraction of sodium current that is available at any given membrane potential (V), while A and B 
are the lower (bottom) and higher (top) values of the curve respectively. 
 
 
 
2.3.4 Recovery from fast inactivation 
 
Recovery from inactivation was analyzed using a two-pulse protocol with varying time intervals 
(0.5 ms to 2000 ms) between pulses to allow different levels of recovery. The first pulse (P1) 
occurred as a voltage step to -10 mV (from a holding membrane potential of -80 mV) lasting for 
100 ms, followed by incrementally increased interpulse gaps with each cycle (0.5 ms to 2000 ms), 
returning back to holding potential. A second pulse (P2) at -10 mV was then applied for 25 ms, 
with the sodium current generated normalized to the first current peak and then plotted against the 
interpulse time (recovery period). Several modified versions of the original protocol template were 
used throughout the study, affecting small parameters of the protocol like the holding voltage or 
the duration of the first pulse. Deviations from the original protocol are illustrated in insets in the 
results section. 
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2.3.5 Current-clamp neuronal recordings 
 
Current-clamp recordings of transfected neurons were obtained using the whole-cell patch clamp 
technique. The internal pipette solution contained (in mM): 126 K-gluconate, 4 NaCl, 1 MgSO4, 
0.02 CaCl2, 0.1 BAPTA, 15 Glucose, 5 HEPES, 3 ATP-Na2, 0.1 GTP-Na, pH 7.3. The 
extracellular (bath) solution contained (in mM): 2 CaCl2, 140 NaCl, 1 MgCl2, 10 HEPES, 4 KCl, 
10 glucose, pH 7.3. D‐(−)‐2‐amino‐5‐phosphonopentanoic acid (D‐AP5; 50 μM), 
6‐cyano‐7‐nitroquinoxaline‐2,3‐dione (CNQX; 10 μM) and picrotoxin (PTX; 30 μM) were added 
to block NMDA, non‐NMDA, and GABAA receptors, respectively. Tetrodotoxin (TTX; 1 μM) 
was also added to block all native voltage-gated sodium channels, allowing recordings only from 
the transfected TTX-resistant ones. Patch pipette resistance was between 5 and 7 MΩ. Series 
resistance was between 7 and 15 MΩ. Experiments were performed at room temperature (22-
24°C), since stability of transfected neurons at physiological temperature was too low for full-
length recordings to be performed (should more time were available, this would be a reasonable 
extension of this study). Neurons with unstable resting potential and/or bridge-balance >15 MΩ 
were discarded. The gigaohm seal and whole cell configuration were obtained in voltage-clamp 
mode and then the amplifier was switched to current-clamp. Bridge balance compensation was 
applied and the resting membrane potential was held at -70 mV. Action potential firing was 
recorded by injecting 10 ms long depolarizing current steps of increasing 20 pA amplitude. For the 
firing frequency reliability protocol, a 110% value of the neuron’s threshold current was used (i.e. 
a supra-threshold stimulus), given in 11 consecutive pulses with increasing frequency in each step 
(30 – 90 Hz). Cells were allowed to recover for 4 seconds between successive trains of pulses. 
Current-clamp recordings were acquired at 10 kHz and performed using a multiclamp 700B 
amplifier (Axon Instruments, Molecular Devices, Sunnyvale, CA, USA), a National Instruments 
digitizer (NI) and a Labview acquisition software homemade by Dimitri Kullmann. An inverted 
IX71 microscope (Olympus, Japan) equipped with a 120-watt mercury lamp (X-cite series 120, 
Exfo) that allowed visualization of red (RFP) and green (EGFP) fluorescence was used. (EGFP 
filter: Excitation, Blue; Cube, U-MWB; Excitation Filter, 450 – 480 nm; Dichroic Mirror, 500 nm; 
Barrier Filter, 515 nm ; RFP filter: Excitation, Green; Cube, U-MWG; Excitation Filter, 510 – 550 
nm; Dichroic Mirror, 570 nm; Barrier Filter, 590 nm). 
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2.3.6 Single action potential parameters 
 
The single action potential shape parameters were derived using the pClamp software (Molecular 
Devices) and analyzed with the Prism software (GraphPad Software, Inc.). A phase-plane plot of 
the first action potential elicited after sufficient depolarization with current steps was obtained for 
each cell by plotting the time derivative of voltage (dV/dt) versus the voltage. This allowed 
identification of the AP voltage threshold, peak and amplitude as well as the maximum rising and 
depolarizing slopes (Figure 2.1) (Bean, 2007). The action potential threshold was defined as being 
the voltage at which dV/dt exceeded 10 mV/ms, similar to other studies (Pozzi et al., 2013). 
 
 
 
 
 
 
Figure 2.1: A representative action potential (A) and phase plot (B) used to analyse active properties of transfected 
neurons. 
The highest and lowest points on the y axis are a measurement of the maximum rising and repolarizing slopes of the 
AP respectively. The highest x axis point (furthest at the right) is a measurement of the AP peak voltage. The AP 
threshold is the voltage at which the y axis exceeds 10mV/ms. The AP amplitude is the difference between the AP 
peak and the AP threshold voltage.  
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2.3.7 Dynamic clamp recordings 
 
For voltage-clamp spontaneous excitatory synaptic activity of the neuronal and interneuronal 
epileptic traces (4AP, 100 μM) and current-clamp recordings in dynamic clamp configuration the 
internal and the extracellular solutions were the same described before for neuronal whole cell 
patch clamp recordings. For voltage-clamp recordings, D-AP5 (50 μM) and PTX (30 μM) were 
added in the extracellular solution to block NMDA and GABAA receptors respectively. For 
current-clamp recordings TTX (1 μM), D‐AP5 (50 μM), CNQX (10 μM) and PTX (30 μM) were 
added to block endogenous sodium channels (allowing isolation of transfected TTX-resistant 
sodium currents), NMDA receptors, AMPA receptors and GABAA receptors, respectively. 
Experiments were performed at room temperature (22-24°C). For voltage-clamp recordings, 
neurons were clamped at -70 mV and cells with unstable resting potential and/or a leak current 
>100 pA were discarded. For current-clamp recordings, neurons with unstable resting potential 
and/or bridge-balance >15 MΩ were discarded. Bridge balance compensation was applied and the 
resting membrane potential was held at -70 mV. Dynamic clamp experiments were performed as 
followed: neuronal or interneuronal current traces were recorded in voltage-clamp configuration 
holding neurons at -70 mV in the presence of 4AP. The resulting current traces were then 
converted into conductance (G=I/V). Using a dynamic clamp software, the conductance traces 
were used to dynamically inject currents in Nav1.1-5A or 5N transfected neurons (in the presence 
of TTX) in current-clamp configuration, the resulting response voltages were recorded and AP 
elicited were analyzed. Dynamic clamp software in real-time read the voltage of the patched 
neurons and calculated the current to be injected from the conductance trace (I=G*V). In order to 
normalize for the conductance magnitude used in each cell and to be able to compare different 
cells, the conductance threshold of each patched neuron was calculated, before the dynamic clamp 
experiments with the epileptic conductance trace. An AMPA conductance step protocol 
(Erev=0mV; τ=1ms; ΔG=1nS) was used to find the conductance threshold that elicited an AP and 
then the epileptic conductance trace was scaled to the 15% of the conductance threshold. The 
sampling frequencies in voltage and in current clamp configurations were set at 20 kHz to 
accurately overlap the conductance traces with the software voltage reading. An event was 
selected as AP if its peak crossed 0 mV. All recordings and analysis for neurons were carried 
blinded to isoform expressed. Recordings were acquired using a Multiclamp 700A amplifier 
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(Axon Instruments, Molecular Devices, Sunnyvale, CA, USA) and Signal dynamic clamp software 
in conjunction with CED Power 1401-3 (CED, Cambridge Electronic Design Limited), filtered at 
10 kHz and digitized at 50 kHz.  
 
 
 
 
2.4 Statistical analysis and modelling  
 
Results are shown as mean +/- s.e.m., with n = sample size. Normally distributed two sample 
groups were compared by Student’s unpaired two-tailed t-test, at a significance level of P<0.05. 
Sample groups without a normal distribution were compared using Mann–Whitney's 
non‐parametric U test. For comparisons of more than two sample groups, two‐way ANOVA was 
used, followed by either the Bonferroni's or the Dunnett's test. Fitting used the Levenberg-
Marquardt algorithm to minimize the χ2 value, with the amplitudes of rates constrained to give 
positive values. To analyze cumulative frequency in dynamic clamp experiments, Mann-Whitney 
test was used instead of the Kolmogorov-Smirnov test because the events were dependent within 
groups (an AP depends on the stimulus pattern as well as the previous AP history). Statistical 
analysis was carried out using the Prism software (GraphPad Software, Inc.) or Origin 
(OriginLab). All modeling was carried out using IonChannelLab (Santiago-Castillo et al., 2010). 
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Chapter 3: Functional dissection of the impact of splicing on onset 
and stability of inactivation in Nav1.1  
 
 
 
3.1 Hypothesis and Aims 
 
A different relative proportion of 5A and 5N channels in epileptic patients has been associated 
with altered febrile seizure predisposition (Schlachter et al., 2009, Le Gal et al., 2011) as well as a 
difference in AED response (Tate et al., 2005; 2006; Abe et al., 2008) between individuals, 
although these associations have not always been replicated (Kwan et al., 2008; Manna et al., 
2011; Haerian et al., 2013). A recent functional study has partly attributed this to a difference in 
recovery from fast inactivation between the two isoforms under physiological temperature 
conditions (37C) and a CsCl-based intracellular solution, with neonatal channels recovering 
relatively faster than adult ones for shorter interpulse durations (Fletcher et al., 2011). The same 
study has also shown that recording conditions can affect channel behaviour and either mask or 
reveal differences between the two splice variants, as also indicated by another group, using 
different recording conditions (25C, CsF- based intracellular solution) (Thompson et al., 2011). 
The overall hypothesis is that splicing has a specific effect on the inactivation of Nav1.1 sodium 
channels, and this chapter describes systematic investigations of how splicing modifies the onset, 
stability and recovery from fast inactivation.  
 
Aims:  
 
1. Confirm and expand previous findings on the effect on recovery from inactivation. 
2.  Investigate time dependence of onset of the effect. 
3.  Investigate the voltage dependence of the effect. 
4.  Determine whether splicing could have an effect on channel availability during fast 
depolarization trains. 
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These findings will serve as a potential guideline to reveal what effects of splicing might be 
conserved in other sodium channels. Furthermore, detailed analysis of how splicing modifies 
inactivation, will allow a prediction of how splicing affects channel availability under conditions 
that can actually mimic interneuronal firing patterns or fast neuronal activity that occurs during a 
seizure. 
 
 
 
3.2 Results: Probing the effects of splicing on fast inactivation  
 
3.2.1 Validation of the constructs 
 
We first confirmed that both splice variants generated sodium currents that were comparable to 
earlier studies of these channels (Fletcher et al., 2011; Thompson et al., 2011). Voltage 
dependence of activation and inactivation were compared for 5A and 5N Nav1.1 channels under 
conditions used previously (CsCl-based intracellular, 37C), where both splice variants showed 
similar macroscopic kinetics (e.g. onset of inactivation, Figure 3.1A,B), and voltage dependence of 
activation and steady state inactivation (Boltzmann non-linear curve fits, P>0.05, two-way 
ANOVA, Figure 3.1C). This comes in agreement with Fletcher et al., (2011), who also did not 
find a difference between splice variants under the same conditions (Table 3.1). In the same study, 
changing the recording conditions (CsF-based intracellular, room temperature) still did not reveal 
any voltage dependence differences between splice variants, although V1/2 of activation and 
inactivation did shift between conditions (Table 3.1). The latter conditions were also used at an 
independent study (Thompson et al., 2011), which also did not reveal any difference in voltage 
dependent properties or macroscopic kinetics between the two Nav1.1 isoforms (Table 3.1). Thus, 
as with previous studies, we confirmed that splicing did not have diffused effects on multiple 
voltage dependent parameters or on the overall shape of currents in response to individual voltage 
steps. 
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Figure 3.1: Nav1.1: No difference in macroscopic properties and VD activation/inactivation between isoforms. 
A. Representative traces from HEK293T cells expressing adult (black) and neonatal (blue) isoforms evoked by a 2 ms 
step to -10 mV. B. Macroscopic properties of the currents were largely indistinguishable for an individual pulse (-80 
to -10 mV). B. Voltage Dependence of activation & inactivation – no difference is seen between 5A and 5N variants. 
Numbers of cells (5A n = 6; 5N n = 6) 
 
 
 
Table 3.1: V50 values and slopes for VD activation/inactivation of Nav1.1-5A and 5N from Fletcher et al., (2011), 
Thompson et al., (2011) and the current study in different recording conditions. 
RT refers to room temperature. At any given condition, there was no difference in VD of activation /inactivation or 
slope between Nav1.1-5A and 5N channels (P>0.05, two-way ANOVA). n number at each study is given in the table. 
 
 
 
3.2.2 Nav1.15N channels recover more quickly from fast inactivation than 5A channels 
 
The main difference between neonatal and adult Nav1.1 channels found by Fletcher et al., (2011) 
was a faster recovery rate from fast inactivation for 5N channels compared to 5A at physiological 
temperature. This experiment was repeated here under the same conditions but including 
additional interpulse time points, from 0.5ms to 2000ms, in order to improve the description of the 
time course, which in Fletcher et al., (2011) was limited to a single exponential because of the 
smaller number of time points. By increasing the number of time points describing the recovery, it 
will be possible to separate fast and slow components of the exponential time course. The 
nomenclature that will be used for this and later protocols in this chapter is given in Figure 3.2A 
for clarity. The increased resolution revealed that both neonatal and adult channels recovered from 
long inactivating prepulses (100 ms) with a bi-exponential timecourse. Similar to Fletcher et al., 
Nav1.1 variant 5A 5N 5A 5N 5A 5N 5A 5N 5A 5N
V50 activation (mV) −18.5 ± 0.9 −18.8 ± 0.8 −21.2 ± 1.7 −22.6 ± 1.2 −15.4 ± 1.1 −17.3 ± 1.3 −15.8 ± 0.8 −17.8 ± 0.6 −16.5 ± 1.4 −17.9 ± 1.9
slope 6.7 ± 0.4 6.5 ± 0.3 6.0 ± 0.4 5.4 ± 0.2 6.2 ± 0.4 5.8 ± 0.4 7.7 ± 0.1 7.8 ± 0.1 7.2 ± 0.6 8.6 ± 0.8
n 15 18 9 14 18 13 22 24 6 6
V50 inactivation (mV) −53.7 ± 1.2 −53.1 ± 1.3 −58.4 ± 1.4 −60.1 ± 0.7 −54.1 ± 1.6 −58.0 ± 2.0 −64.0 ± 0.6 −65.7 ± 0.8 −55.4 ± 1.1 −55.1 ± 2.4
slope 6.3 ± 0.3 5.9 ± 0.7 8.1 ± 0.9 6.7 ± 0.4 6.2 ± 0.5 6.9 ± 0.3 −5.9 ± 0.2 −5.9 ± 0.2 −7.4 ± 0.6 −8.2 ± 1.1
n 15 11 8 12 14 9 19 21 6 6
Fletcher et al.  (37CsCl) Fletcher et al. (RT, CsF) Fletcher et al. ( RT, CsCl) Thompson et al. (CsF, RT) Liavas (37°, CsCl)
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(2011), 5N channels recovered faster compared to 5A, but with the additional points used here, it 
was clear that this difference was most pronounced for shorter recovery intervals (Figure 3.2B,C).  
The recovery timecourse was well fit by two exponentials [Y0 + AF*(1-exp(-t/τF)) + AS*(1-exp(-
t/τS))], consistent with a fast (τF: 1.1 = 1.7 ms), and a slow (τS: 1.1 = 220 ms) component of 
recovery from inactivation. Y0 is the y-axis intercept, while AF and AS are the relative amplitudes 
of the fast and slow component respectively.
 
The τF and τS components were similar for both 
splice variants, suggesting that splicing was not altering the rate of either component, but the 
proportion of fast or slow component in the recovery. To probe this relationship, the number of 
free parameters was reduced by comparing splice variants with both rates (τF and τS) fixed and 
only the relative amplitudes of the fast (AF) and slow (As) components allowed to vary. These 
constraints allowed good fits (r2 > 0.98 for both fits with these restrictions, Table 3.2), however 
even with the rates fixed, AF and AS values did not significantly vary between the two fits. Instead, 
the main difference between the fits was the Y0 parameter, which sets the starting point of the fits 
(i.e. the theoretical ‘instantaneous availability’ after no recovery interval). Hence, by comparing 
the relative proportion of fast and slow components of recovery and a component of instantaneous 
availability, these data revealed that the major difference between the variants was a contribution 
of approximately 7.6% of 5N channels, which according to the fit have not inactivated or they 
recovered from inactivation even faster than 0.5 ms. For 5A channels, no contribution from this 
parameter was needed for the fits (i.e. 0% of 5A channels were in the ‘instantaneously available’ 
state). This initial difference in offset established the difference in availability between the two 
splice variants, which remained until obscured by much longer interpulse recovery intervals and 
was sufficient to describe the difference between the neonatal and adult Nav1.1 isoforms (Figure 
3.2 and Table 3.2).           
 
In order to exclude the possibility of bias during the data fitting, the analysis was again repeated, 
this time with all parameters free to fluctuate (Figure 3.3, green lines). The data still produced 
good fits (r2 > 0.98, Table 3.2), yet the deviation from the values obtained with fixed parameter fits 
were negligible, with all the free fit values over. Taken together, these findings are consistent with 
splicing altering an inactive state that is extremely rapid in recovery, with longer, slower 
inactivated states remaining insensitive to splicing. 
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Figure 3.2: Nav1.1: Channels containing exon 5N recover more rapidly from inactivation after short recovery 
intervals 
A. Nomenclature used for each component of the protocols used throughout the chapter. B. Raw traces for recovery 
from inactivation after 0.5, 1.0, 1.5 & 2.0 ms recovery interval for Nav1.1 neonatal (blue) and adult (black) channels. 
C. Nav1.1: Short recovery intervals at -80mV reveal a difference between splice variants with 5N recovering more 
quickly than 5A, which is lostas intervals get longer. (5A, n = 10; 5N, n = 9). Note that additional time points prior to 2 
ms confirm and extend the difference seen in Fletcher et al., (see Figure 1.22). 
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Figure 3.3: Recovery from inactivation for isoforms of each channel comparing fits with all parameters free (green 
lines) and with τF and τS fixed (red lines) 
Values and standard errors of the fit values are in table 3.1. 
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Table 3.2: Nav1.1: Parameters of bi-exponential fits to recovery from long (100 ms) inactivating pre-
pulses. 
Top panel: Optimized fitting parameters with τF and τS constrained (red lines in Figure 3.3, rates with n/a standard 
error (s.e.) were fixed). Bottom panel: Free fits with all parameters allowed to vary (green lines in Figure 3.3). R ̅2 is 
the adjusted R-square statistic used to improve comparison of fits with different degrees of freedom. 
Parameters from constrained fits (red lines in Figure 3.3) 
 Nav1.1-5N Nav1.1-5A  
 Value s.e. Value s.e.  
Y0 0.076 0.018 0 0.027  
AF 0.63 0.03 0.66 0.04  
τF (ms) 1.7 n/a 1.7 n/a  
AS 0.23 0.02 0.27 0.03  
τS (ms) 220 n/a 220 n/a  
R ̅2 0.996  0.995   
 
 
Parameters from free fits (green lines in Figure 3.3) 
 Nav1.1-5N Nav1.15A  
 Value s.e. Value s.e.   
Y0 0.044 0.040 0.003 0.036   
AF 0.65 0.04 0.67 0.36   
τF (ms) 1.5 0.2 1.9 0.2   
AS 0.23 0.03 0.25 0.03   
τS (ms) 218 69 272 95   
R ̅2 0.994  0.994    
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3.3 Results: Probing the ‘instantaneously available’ state with variable inactivating prepulses  
 
3.3.1 The difference between splice isoforms is dependent on the length of the conditioning 
depolarisations 
 
According to the previous section, the main effect of splicing in Nav1.1 is on the earliest 
component of availability after inactivation, with the difference potentially being due to a 
difference in the onset of recovery from fast inactivation. Thus, the next question asked was 
whether a briefer inactivating first pulse (i.e. shorter P1 duration), would increase the difference in 
the availability between 5A and 5N channels. Since neurons are usually depolarized for only a 
couple of milliseconds during an action potential (AP), a difference present after short 
depolarisations may be physiologically more relevant than a difference that requires prolonged 
depolarisation to develop. Reducing P1 duration from 100 ms to 20 ms did augment the difference 
between Nav1.1 5A and 5N for shorter interpulse gaps (2, 12 and 22 ms) (Figure 3.4). As a result, 
with a shorter P1 duration, 12 ms and 22 ms interpulse gaps now showed a significant difference 
in terms of inactivation recovery between 5A and 5N (P<0.001, two-way ANOVA with 
Bonferroni’s post-hoc tests, Figure 3.4B), a difference that was lostwhen a longer P1 duration was 
applied (100 ms, Figure 3.4A).  
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Figure 3.4: Nav1.1: Pilot data indicating that shortening the prepulse duration increases the difference in recovery 
from inactivation between isoforms. 
short recovery intervals at -80mV (5A n=3; 5N n=4) reveal a difference between splice variants, which is masked as 
intervals get longer (5A, 0.52  0.04, 0.73  0.06, 0.73  0.05; 5N, 0.60  0.02, 0.73  0.01, 0.77  0.03 for recovery 
intervals of 2, 12 and 22 ms respectively). B. a shorter P1 duration (20ms) (5A n=7; 5N n=6) appears to augment that 
difference (5A, 0.71  0.02, 0.88  0.01, 0.91  0.01; 5N, 0.79  0.02, 0.93  0.01, 0.95  0.01 for recovery intervals of 
2, 12 and 22 ms respectively). Error bars are included, but are obscured by symbols. 
 
 
 
In order to analyse in further detail the effect of P1 duration on inactivation recovery, a protocol 
was designed to probe channel availability after increasing P1 intervals, from very short (2 ms) to 
very long (500 ms). The interpulse gap duration was fixed to 2 ms, a value that had been shown 
from previous experiments to reveal a difference between the variants (Figure 3.2). In principle, 
the ideal P1 duration for probing a difference in Y0 would be ~0 ms (to test the instantaneous 
availability of channels), however 2 ms was the shortest P1 duration that could be reliably stepped 
in voltage clamp configuration. In these conditions, the availability for both neonatal and adult 
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isoforms were most suitably fit as a first order exponential decay [Y0 + A*exp(-t/τ)]. Initial fits 
were carried out with all parameters free to vary (Figure 3.6, green lines). In this instance, the 
confidence intervals of both Y0 and τ overlapped for the fits of the two isoforms, suggesting no 
real difference in time course and offset between neonatal and adult Nav1.1 channels. Note, 
however that because this fit is an exponential decay, Y0 is no longer the starting offset but the 
final offset (i.e. the value of predicted channel availability after a 2 ms recovery from a prepulse of 
infinite duration). In contrast, the amplitude (A) did differ significantly between the two isoforms 
(5A, 0.533  0.006; 5N, 0.662  0.004, P<0.05, two-way ANOVA). As A represents the 
proportion of channels available after the shortest possible pre-pulses, this suggests the difference 
between variants is not just in the fastest component of recovery (i.e. the instantaneously available 
from previous section) but also in the fastest component of onset of inactivation, in spite of the 
lack of difference in the rate of inactivation during the depolarising pulses (Fletcher et al., 2011).  
In order to test the hypothesis that only the amount (denoted by the amplitude, A, in the equation) 
but not the timecourse of availability after 2 ms was changed (i.e. that the difference between 
isoforms could be explained by a change in a single parameter) the data were fit with the τ and Y0 
fixed to be the same for the adult and neonatal isoforms, and only the amplitude (A) allowed to 
vary (τ: 1.1 = 159 ms; Y0 = 0.2; Figure 3.6 red line and Table 3.3). Data fits were again acceptable 
(r2 > 0.94) and almost identical to the totally free fits, keeping a significant and robust difference 
between the two isoforms concerning the amplitude. Testing 5A and 5N channels under this 
protocol revealed that shorter P1 durations increased the difference between splice variants (Figure 
3.5 & 3.6). Direct comparison of the fits of each isoform for all data points with two-way ANOVA 
indicated that neonatal Nav1.1 channels showed significantly more recovery from inactivation after 
a range of shorter pre-pulses compared to adult ones (P<0.001). The difference started waning off 
as the P1 duration got longer so that at P1 values 200 ms it was completely masked (Figure 
3.5A). The experiment was repeated just for the initial shorter P1 durations (2 – 10 ms) where the 
difference is most evident, with 5N channels significantly more available than 5A under these 
conditions (P<0.001; Figure 3.5B). Therefore, the neonatal isoform here shows significantly 
increased availability after short inactivating pre-pulses compared to the adult isoform.  
To test if this difference is dependent on temperature, we repeated the same experiment, this time 
at 25C. In spite of the fact that the recovery of both neonatal and adult channels decreased at 
lower temperature, we saw for Nav1.1 isoforms that the difference in availability persisted at room 
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temperature (P<0.001, two-way ANOVA, Figure 3.7). These findings are consistent with splicing 
altering an inactive state which is both rapid in onset and rapid in recovery, with longer, slower 
inactivated states remaining insensitive to splicing. 
 
 
 
 
Figure 3.5: Nav1.1: The neonatal isoform showed significantly more availability after a range of shorter pre-pulses 
under a brief interpulse gap duration (2ms) 
Raw traces are given for P1 duration of 2, 3, 4, 5, 6, 7, 8, 9 & 10 ms for Nav1.1 neonatal (blue) and adult (black) 
channels. Curves in A and B are fit with single exponentials as described in the text. A. P1 duration = 2 – 500ms (5A 
n=6; 5N n=6). B. P1 duration = 2 – 10ms (5A n=10; 5N n=5). The error bars in B are masked by the data points. The 
different duration of the protocol used in B means that these cells cannot be directly compared to cells in A. 
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Figure 3.6: Estimated channel availability for isoforms of each channel comparing quality of fits with all 
parameters free (green lines) and with Y0 and τ fixed (red lines, behind green lines) 
The green fits were seeded with the same values for both isoforms. Note that from the free fits only the non-
overlapping errors for parameter A are consistent with this value being different between the isoforms (see table 
3.2, bottom panel). 
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Table 3.3: Nav1.1: Parameters of single exponential fits describing channel availability after 2 ms 
recovery from pre-pulses of different durations 
Top panel: optimized fitting parameters with inactivation time constant τ and the offset (Y0) fixed. The 
parameters with n/a standard error (s.e.) were fixed at values similar to those found for free fits to both 
isoforms of the channel (as described in Figure 3.9). Bottom panel: Fits with all parameters allowed to 
vary. To better compare the goodness of fits with the different degrees of freedom the adjusted R-square 
statistic (R̅2) is given. 
 
Parameters from constrained fits (red lines in Figure 3.9) 
 Nav1.1-5N Nav1.1-5A 
 Value s.e. Value s.e. 
Y0 0.2 n/a 0.2 n/a 
A 0.662 0.004 0.533 0.006 
τ (ms) 159 n/a 159 n/a 
R ̅2 0.991  0.989  
 
 
Parameters from free fits (green lines in Figure 3.9) 
 Nav1.1-5N Nav1.1-5A 
 Value s.e. Value s.e. 
Y0 0.22 0.02 0.19 0.02 
A 0.640 0.022 0.547 0.018 
τ (ms) 155 13 164 15 
R ̅2 0.991  0.989  
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Figure 3.7: Nav1.1: The difference in channel availability is also preserved in room temperature 
The effect of splicing on channel availability after short depolarising prepulses is preserved in room temperature 
recordings. Recordings are for variants of Nav1.1 (5A n = 7; 5N n = 10). 
 
 
 
3.3.2 The difference in recovery from inactivation difference is masked by prolonged 
inactivating pre-pulses 
 
Since briefer inactivation pulses (<10 ms) increased the difference in availability between 5A and 
5N variants, it was hypothesized that longer inactivating steps, using a prolonged P1 duration, 
would have an opposite effect, i.e. eradicate the difference in the recovery rate between 5A and 5N 
variants. Therefore, the duration of the first depolarizing pulse (P1) was increased from 100 ms to 
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300 ms to induce more inactivation, and availability was assessed after variable recovery intervals. 
Data points in this situation were most appropriately fitted with a single rather than a double-
exponential, likely because the prolonged depolarizing pulse has pushed the channels more into 
slow inactivated states than before, where a fast component was much more evident. As a result of 
that prolonged inactivating pulse, recovery from inactivation was decreased for both variants. As 
expected, these longer pulses also obscured the difference between the isoforms with both the 
fitting curves as well as each time point over laying for the two isoforms (two-way ANOVA, 
P>0.05) (Figure 3.8).  
 
 
 
 
Figure 3.8: Nav1.1: inactivation protocols bearing long inactivation pulses obscure any differences between 5A and 
5N splice variants 
(5A n=7; 5N n=9). 
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3.4 Results: Probing the effects of voltage on inactivation recovery 
 
3.4.1 The holding voltage can obscure the difference in inactivation recovery 
 
Fast recovery from inactivation is dependent on voltage as well as time. This suggests that the 
difference seen here in fast inactivation recovery might be sensitive to the potential at which cells 
are held before stimulation and during the recovery interval. Different holding potentials, however, 
also may alter the distribution of channels in deactivated and inactivated states. In the case of 
neurons, the steady state amount of inactivation would be set by the resting membrane potential 
(RMP) of each cell, while in voltage-clamped HEK293T cells it is defined by the holding voltage. 
In order to examine how this voltage affects the inactivated states and consequently the difference 
between Nav1.1-5A and 5N channels, the original experiment probing recovery from inactivation 
was repeated (i.e. P1 = 100 ms, gap 0.5 – 2000 ms), this time holding the cell at -70 mV, and using 
-70 mV during the recovery gap (this is approximately -75 mV, taking into account the liquid 
junction potential, or LJP, of the CsCl internal solution, which was not corrected during 
recordings). Changing to a -75 mV holding potential completely eradicated the difference in 
recovery between the splice isoforms (P>0.05, two-way ANOVA, Figure 3.9A). Two-exponential 
fit analysis of the data points for both Nav1.1-5A and 5N indicated that the difference seen before 
at -80 mV holding voltage in the Y0 parameter (the theoretical “instantaneous availability”) was 
now eradicated, while none of the other equation parameters varied between isoforms (see values 
on Table 3.4, P>0.05, two-way ANOVA).Absolute membrane potential is a difficult parameter to 
measure, and it is possible that -75 mV is more representative of the membrane potential of 
GABAergic interneurons, which were measured at -65 mV (Lamsa et al., 2007), however the 
Allen Brain Atlas online database of cortical interneurons suggests a significantly more negative 
resting potential (-70 to -80 mV with an uncorrected -14 mV LJP, http://celltypes.brain-map.org/). 
In order to test the possibility of more negative potentials generating greater differences between 
variants, the experiment was repeated using a hyperpolarized holding potential (-100 mV, or 
approximately -105 mV after subtracting the LJP). Although both variants recovered more rapidly 
at this hyperpolarised potential, there was again no difference in recovery between variants at any 
given interpulse interval, nor in any of the parameters from the two-exponential fit analysis of the 
curves (P>0.05, two-way ANOVA, Figure 3.9B and Table 3.5). 
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Thus the difference between the variants was steeply dependent on the voltage used to maintain 
cells, however given the difficulties of comparing membrane potentials between cells held in 
different conditions, it is difficult to extrapolate from the HEK293T voltage clamp data to the 
situation in neurons. Furthermore, the resting membrane potential of an excitable cell such as a 
neuron is not constant, but fluctuates depending on the signal input that constantly receives from 
neighbour cells. In order to directly assess the impact of splicing on neuronal activity, the variants 
must be compared in neurons where current clamp recordings may allow direct comparison of the 
channel availability in more physiological conditions (see chapters 6 & 7). 
 
 
 
 
 
Figure 3.9: Nav1.1: Changes in holding voltage eradicate the difference in inactivation recovery between the 
isoforms 
Inactivation recovery protocols performed at A. more depolarized (-70 mV) (5A n=7; 5N n=8) or B. strongly 
hyperpolarized (-100 mV) potentials (5A n=5; 5N n=6) obscure any differences between 5A and 5N splice variants 
(0.5 ms – 2000 ms interpulse recovery intervals) 
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Table 3.4: Nav1.1: Parameters of bi-exponential fits to recovery from long (100 ms) inactivating pre-
pulses at -70 mV holding voltage. 
 
 NaV1.1-5N  NaV1.1-5A 
      
 Value S.E.  Value S.E. 
Y0 0.004 0.037  0 0.031 
AF 0.69 0.03  0.71 0.03 
tF (ms) 1.9 0.2  1.8 0.2 
AS 0.19 0.02  0.2 0.03 
tS (ms) 286 114  262 97 
R ̅2 0.995   0.995  
 
 
 
Table 3.5: Nav1.1: Parameters of bi-exponential fits to recovery from long (100 ms) inactivating pre-
pulses at -100 mV holding voltage. 
 
 NaV1.1-5N  NaV1.1-5A 
      
 Value S.E.  Value S.E. 
Y0 0.016 0.127  0.001 0.044 
AF 0.58 0.13  0.85 0.25 
tF (ms) 0.91 0.22  0.76 0.12 
AS 0.24 0.03  0.22 0.02 
tS (ms) 123 53  125 4 
R ̅2 0.971   0.991  
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3.5 Results: Probing the effects on rapid stimulation conditions 
 
3.5.1 Recovery from inactivation difference is augmented during “high-activity”, “seizure-
like” trains of depolarising steps  
 
Our initial data suggest the difference between the splice variants is greatest after short 
depolarising steps with short intervals for recovery. This raises the possibility that the difference 
between the variance is exacerbated in pathophysiological fast firing bursts of action potentials – 
such as seizures. The next aim was to model a situation mimicking this sort of burst like behaviour 
– a series of fast, relatively short depolarisations – to test whether these burst-like events could 
evoke different responses from the splice variants. The protocol alternated short depolarising P1 
pulses (to -10 mV for 10 ms) with even shorter recovery intervals than the previous protocol (1 
ms) and holding at -80 mV. Hippocampal interneurons have been found to fire at a physiological 
frequency range of 40 to 80Hz, with some cells reaching 100Hz during high frequency oscillations 
(Quilichini et al., 2012). The recovery gap duration between depolarisations here is shorter 
compared to physiological interpulse gaps between interneuronal spikes. Therefore, this protocol 
may mimic very fast, “pathophysiological” neuronal firing, or even the kind of activity that would 
be evident during a seizure event. 
As seen in Figure 3.10, there was a gap in channel availability that emerged after the first pulse, 
and which remained for all consecutive pulses, with the two Nav1.1 variants, as 5A and 5N peaks, 
decaying more or less in parallel through the train. Comparing the two isoform populations as a 
group, the difference between the two splice variants under these “seizure-like” or “high-activity” 
conditions was highly significant (two-way ANOVA, P<0.001) throughout the train of pulses, 
with 5N channels always more available and remaining approximately 10% more available 
compared to 5A channels (Figure 3.10). This indicated that 5N channels do have the potential to 
respond differently to 5A as far as their availability is concerned under conditions mimicking fast 
interneuronal spiking or an epileptic event. Such a distinct response at these conditions lays a 
functional biophysical basis for the differential predisposition for febrile seizures that occurs in 
patients with different 5A/5N relative proportions argued by several studies (Schlachter et al., 
2009, Le Gal et al., 2011). However, as noted above, these findings predict a difference between 
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the variants, which must be confirmed in neurons, ideally in interneurons where Nav1.1 channels 
are thought to dominate (see chapter 7). 
 
 
 
 
 
Figure 3.10: Nav1.1: Trains of pulses mimicking a “seizure-like burst” retain the difference between the splice 
variants. 
Raw traces are given on top for Nav1.1 neonatal (blue) and adult (black) channels (5A n=8; 5N n=8) 
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3.5.2 Splicing may have a specific effect on the affinity of the inactivation particle for the 
inner pore 
 
The modelling in this section was largely carried out by my supervisor, S. Schorge, using my data. 
 
HEK293T cell data suggest that splicing can change the fastest component of recovery from 
inactivation (i.e. the instantaneous recovery, section 3.2.2), without altering voltage-dependence of 
activation and inactivation or macroscopic kinetics of the channels. In order to determine if in 
principle this is biophysically possible, a recently reported model of Nav channels (Carter et al., 
2012) was fitted to Nav1.1 currents recorded in HEK293T cells. In order to match data collected in 
our conditions, the rates used to fit the base model were adjusted to match the voltage sensitivity 
of activation, possibly because Carter et al., (2012) were using neurons likely to be expressing a 
mix of Nav channels with a small amount of Nav1.1. This initial model (Figure 3.11.D) was then 
used to examine if it is possible to change the stability of inactivation without altering its voltage 
dependence, or macroscopic kinetics of currents in response to voltage steps. The model (thick 
grey line overlay) accurately predicts macroscopic currents produced by either splice isoform of 
Nav1.1. 5A (thin black line) and 5N (thin blue line) (Figure 3.11B). Macroscopic currents 
predicted by the model for both isoforms for a single step were identical, as also were the 
predicted voltage dependence of activation (right side) and inactivation (left side) of both isoforms 
of Nav1.1 model (Figure 3.11C). Because this model only includes active and fast-inactivated 
states (there are no slow inactivated states), there was a deviation from the steepness of the 
voltage-dependence of activation curve (Figure 3.11C) which is likely due to contamination by 
slow inactivated states at different potentials in HEK293T cells.  
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Figure 3.11: A model of sodium channel gating shows that modification of a single gating step may be sufficient to 
alter stability of fast inactivation without altering other parameters 
A. The scheme, as adapted from Carter et al., (2012) and used for our hNav1.1 channels in HEK293T cells at 37
oC. The 
top left position (#1) corresponds to resting, closed channels with all four voltage sensors down (de-activated) and 
the inactivation particle off (i.e. channels are not inactivated, or are de-inactivated). At rest at -80 mV 87% of 
channels are in this state, and 11% of channels have a single voltage sensor up (state #2). The only state which 
passes current is state #6 (top right), which channels briefly visit upon depolarization. The bottom row of states (#7-
12) all have the inactivation particle bound (‘on’). During a typical step to -10 mV, approximately 1 ms after the step 
>85% of channels are in state #7 (where the pore is open, but no current passes because the inactivation particle is 
bound). The two splice isoforms of Nav1.1 were modelled by changing the rate at which channels move between 
states #1 and #12 (i.e. the rate at which the inactivation particle binds to or comes off the inner pore of channels 
with all four voltage sensors in the resting, ‘down’, configuration). The transitions for adult isoforms are 0.35 times 
the rates for transitions between these states for the neonatal isoforms (exact values: Adult (1-12) = 0.01*350 s-1; 
Neonate (1-12) = 0.01*1000 s-1; Adult (12-1) = 2.5*350 s-1; Neonate (12-1) = 2.5*1000 s-1). B. The model can predict 
macroscopic currents produced by either splice isoform of Nav1.1. 5A = thin black line, 5N = thin blue line, model = 
thick grey line overlay, however, as this is a simplified model, it does not replicate all aspects of channel behaviour 
(e.g. no slow inactivation). Macroscopic currents predicted by the model for both isoforms for a single step from -80 
mV to -10 mV were identical. C. Predicted voltage dependence of activation (right side) and inactivation (left side) of 
both isoforms of Nav1.1 model. The data from 5N are behind data from 5A, but the line is thick to show complete 
overlay. D. Values used in model for 5N. The only difference for 5A was a slowing of rates between states 1 and 12 
by 0.35.  
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The scheme is composed of 12 different states where a Nav channel may be at any given time. The 
top left position (#1) corresponds to resting, closed channels with all four voltage sensors down 
(de-activated) and the inactivation particle off (i.e. channels are not-inactivated, or they are de-
inactivated). The four positions to the right of that (#2 - #5) are still in resting, de-inactivated states 
with an increasing number of S4 voltage sensors shifting to “up” positions as the channel moves to 
the right. Even channels in position #5, where all four S4 segments are in up positions, are still in a 
non-conducting state. The only state which passes current is state #6 (top right), which channels 
briefly visit upon depolarization. The states in the bottom row (#7 - #12) all have the inactivation 
particle bound (‘on’), so they are all in non-conducting states. 
At rest at -80 mV 87% of channels are in  state #1, and 11% of channels have a single voltage 
sensor up (state #2). During a typical step to -10 mV, approximately 1 ms after the step >85% of 
channels are in state #7 (where the pore is open, but no current passes because the inactivation 
particle is bound). 
It was first systematically probed whether it is possible to uncouple recovery from fast inactivation 
from other aspects of channel activity, such as production of persistent current, or voltage 
dependence. Not surprisingly, changes made to most of transition rates altered both the voltage-
dependence and the rates of onset of inactivation. However, one of the main parameters 
determining the recovery from fast inactivation is the return of the fully deactivated channel from 
the inactivated state (bottom left state #12 in Figure 3.11A), back to the state which is fully 
deactivated and non-inactivated (top left state #1 in Figure 3.11A). It was found that changing the 
rate of the transitions between these two states (by a factor of 0.35) was sufficient to change the 
rate of recovery with little or no impact on other parameters (Figure 3.12A). This change was also 
sufficient to reproduce the difference in availability during trains of short stimuli (Figure 3.12B). 
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Figure 3.12: The specific change in rates between states 12 and 1 replicates HEK293T cell findings for recovery 
from inactivation and availability 
A. Raw traces for recovery from fast inactivation after 0.5, 1, 1.5 and 2 ms for adult (black) and neonatal (blue) 
Nav1.1 channels. (B. C.) Slowing the transitions between states 12 and 1 (grey traces, faster rates 1-12 = 0.01*1000 s
-
1 ; 12-1 = 2.5*1000 s-1 black traces, slower rates, both = grey rate*0.35) is sufficient to increase the rate of recovery 
(B), and the availability of channels during a train of short steps (C), without modifying the kinetics of the currents 
during steps (both predicted currents are overlaid in the first steps of A and B). Voltage dependence of activation and 
steady state inactivation were also unchanged by this manipulation (Figure 3.11C).  
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There was one additional change in the voltage dependence of recovery from inactivation (Figure 
3.13A) that was predicted by the model, which was not seen in HEK293T cells (Figure 3.13B). 
This is a difference in how the voltage during the recovery step affected the rate of recovery, 
where the model predicted the neonatal channels to be more sensitive to hyperpolarising recovery 
intervals. The difference could be possibly attributed to the lack of slow inactivation in our model, 
as it may be that contamination by slow inactivated states in HEK293T cells obscures the 
difference between the two isoforms. 
 
 
 
 
 
Figure 3.13: Slow inactivation probably masks the predicted difference between isoforms on voltage dependence 
of inactivation recovery 
A. According to the model, changing the rate of transition between states 12 and 1 alters the voltage dependence of 
recovery from inactivation at strongly hyperpolarized potentials. B. For Nav1.1, the holding voltage during short 
(2ms) recovery intervals does not change the amount of channel availability (5A n = 13; 5N n = 17). 
 
 
 
Because this model is based on a structural scheme of the channel, these data suggest that splicing 
which affects the linker before the voltage sensor in domain I may have an impact on the affinity 
of the inactivation particle for fully de-activated channels. 
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3.5.3 No difference in inactivation recovery between variants with a simulated 
“interneuronal firing pattern” 
 
Up to now, experiments have suggested that the combination of short P1 intervals, short interpulse 
gap durations and a resting membrane potential of approximately -80 mV are the conditions that 
can hold a robust difference in recovery from inactivation between Nav1.1 5A and 5N channels, 
with 5N channels always recovering more quickly. As a simplified alternative, in order to partially 
simulate a “physiological interneuronal firing pattern”, a recovery protocol was designed with 
“interneuronal-like” parameters. Hence, the holding membrane voltage was set at -80 mV (i.e. 
approximately -85 mV after junction potential), while depolarizing pulses were given at 100Hz 
frequency, a rate consistent with published reports of a rapid, yet still physiological, interneuronal 
firing rate (Quilichini et al., 2012). Pulses went from -80 mV to +20 mV (not -10 mV as in all 
previous protocols) in order to simulate depolarization during an AP, while for the same reason 
depolarization (i.e. P1 duration) was kept as short as possible (2 ms). The firing rate here was 
lower than the frequency rate used in the previous “seizure-like” protocol (e.g. 10 ms step, 1 ms 
recovery). 
Under these conditions, no difference was seen between the 5A and 5N variants, as they recovered 
from inactivation at exactly the same rate throughout the pulse train (two-way ANOVA, P>0.05; 
Figure 3.14A). Pushing the system further in order to again try and mimic a pathophysiological, 
“seizure-like” firing rate, the firing frequency was doubled to 200Hz by reducing the interpulse 
gap duration. Again, 5A and 5N variants appeared to recover from inactivation in an identical way 
under these conditions (two-way ANOVA, P>0.05; Figure 3.14B). 
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Figure 3.14: Nav1.1: Simulation of an interneuronal firing pattern at -80mV does not reveal a difference between 
5A and 5N splice variants 
neither at A. 100Hz firing frequency (5A n=11; 5N n=6), nor at B. 200Hz firing frequency (5A n=6; 5N n=3). 
 
 
One possibility is that the relative lack of inactivation (in the 100Hz train only ~10% of channels 
inactivate) obscures any differences between the variants. To test whether slightly depolarising the 
resting membrane potential could reveal a difference between the two isoforms, the experiments 
were repeated with a holding potential of -70 mV. In these conditions the splice variants again 
remained indistinguishable, at 100Hz (two-way ANOVA, P>0.05; Figure 3.15A), and at 200Hz 
firing frequency (two-way ANOVA, P>0.05; Figure 3.15B). It may be that the stronger 
depolarisation in the steps was sufficient to obscure the difference between the variants, or that the 
relatively small amount of inactivation (~ 20%) meant that the differences were not big enough to 
be seen. Thus, while much of our data indicate that splicing will change channel availability, to 
test the physiological significance, it is necessary to confirm that conditions in neurons are within 
the range that generates the difference.  
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Figure 3.15: Nav1.1: Simulation of an interneuronal firing pattern at -70mV holding voltsge does not reveal a 
difference between 5A and 5N splice variants 
neither at A. 100Hz firing frequency (5A n=11; 5N n=14), nor at B. 200Hz firing frequency (5A n=6; 5N n=8) 
 
 
 
3.6 Discussion:  
 
3.6.1 Splicing affects a fast onset, short lived form of inactivation 
 
Results here indicate that the difference between the two isoforms is strongest for short-lived 
inactivated states, achieved by brief depolarisations. Such states also tend to be rapid in onset 
(Ulbricht, 2005), therefore the original relatively long prepulse (100 ms) used may mask a 
difference of availability between isoforms by shifting channels out of the short lived inactivated 
states and into slow inactivated states. This is likely to be the case in Figure 3.8, where the 
prolonged depolarization pulse (300 ms) has probably shifted cells much more towards slower 
inactivation, a state that does not appear to be affected by the splicing difference, as was seen in 
135 
 
the analysis before. Shifting towards a slower inactivated state is also suggested by the loss of the 
double exponential recovery relationship, indicative of a fast and a slow component of inactivation 
as seen before for a P1 duration of 100 ms (Figures 3.2 & 3.3) and satisfactory fitting of the data 
with a single exponential, thereby implying that a single, slower inactivated state almost 
exclusively determines the recovery of the channels after prolonged depolarisations. The shortest 
P1 durations (2 – 10 ms, Figure 3.5) prevented cells from entering into slow inactivated states and 
allowed for the difference in availability between the two isoforms to be revealed under a fixed 
short (2 ms) recovery interval. At longer time points slow inactivation is now probably 
determining the recovery rate and therefore availability and becomes the rate limiting step at that 
time and masks the effect of the splicing on channel availability. Therefore, it is a matter of further 
study to investigate how the distribution of channels in different inactivated states prior to 
activation might affect their availability at recovery. This initial distribution is going to be heavily 
dependent on the original holding voltage where cells are held and how changing voltage may 
affect splice variant behaviour is described in results section 3.4.  
Briefer pre-pulses that favour short-lived inactivated states are also suggested to be more 
representative of action potentials (AP) firing in neurons, when depolarisation lasts usually for  1, 
or at most only a few, milliseconds and prolonged depolarisations are not likely physiological. 
Therefore, the ability of the splice isoforms to respond differently after short depolarisations may 
mean splicing changes the ability of sodium channels to open repeatedly during trains of fast 
stimuli, such as bursts of action potentials. This would also be in line with this splicing event 
playing a potential role in epilepsy, where neurons are suggested to undergo very rapid burst 
firings. Therefore, another major matter of study was to assess isoform availability under 
conditions of repetitive short depolarisations, mimicking AP bursts in neurons during high-
frequency, “seizure-like” stimulations (Results section 3.5). 
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3.6.2 The difference between variants is steeply dependent on voltage 
 
The difference in fast inactivation recovery between Nav1.1 5A and 5N channels is confined to a 
specific membrane holding potentialof -80 mV, while it is lost at more depolarized (-70 mV) or 
more hyperpolarized (-100 mV) potentials. It is not clear what membrane potential in HEK293T 
cells is most relevant to neurons. One report may suggest -60 to -65 mV as a physiological resting 
potential seen in brain interneurons (Lamsa et al., 2007), which are the principal areas of 
expression of Nav1.1 channels (Yu et al., 2006). In comparison, the recently published online 
database of cells from the Allen brain atlas predicts a more negative potential between -70 and -80 
mV for most interneurons (http://celltypes.brain-map.org/).  However, the absolute potential 
depends on the liquid junction potentials, and recording setup (e.g. ground connection), which 
makes direct comparison between recordings carried out with different solutions or equipment 
notoriously unreliable. The most direct approach is to test whether the behaviour of the variants in 
neurons reflects the difference in availability as predicted in HEK293T cells.  According to the 
results here, the balance of channel inactivation states set by the holding voltage, can obscure the 
difference in inactivation recovery seen between the two Nav1.1 channel isoforms, however, in 
HEK293T cells it is not clear how the holding voltage interacts with the fast inactivation recovery 
process in Navs. Hence, in order to determine if the biophysical differences observed between 
variants may have physiological relevance, variants will need to be compared in neurons, using 
protocols designed to probe the differences seen here (see chapters 6 & 7). 
 
 
 
3.6.3 A special role for the S4 in Domain 1 in stability of inactivation? 
 
At the molecular level, the modelling suggests that inclusion of a negatively charged amino acid 
(in the adult exon) in the D1S3-S4 linker stabilizes the inactivation particle in the inner side of the 
channel pore when all four S4 sensors are down. In crystal studies of voltage-gated channels the 
S3-S4 linkers are notably disorganized compared to the helices (Payandeh et al., 2011), and 
consequently at this time the exact position of the conserved amino acid change is not known. 
Previous studies of gating currents have suggested that the voltage sensor in the fourth domain 
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(D4S4) is most important for limiting the rate of onset of inactivation (Capes et al., 2013), and this 
S3-S4 linker is already implicated in drug binding (Yang et al., 2009). Here, it is proposed that the 
S4 segment in the first domain (D1S4) may have a relatively more important role in release from 
inactivation. A possible mechanistic explanation is that, while the S4 in the fourth domain is the 
last to activate and to initiate inactivation (Capes et al., 2013; Chanda and Bezanilla, 2002), the S4 
in DI may be the last to dissociate from the inactivation particle, thereby being the rate limiting 
step in recovery from fast inactivation. 
The model used here, which is adapted from Carter et al. (2012), is designed to only contain the 
fast inactivated states. One reason for this is that the physical basis of slow inactivated states, 
although important for some types of drugs, is not well characterized (Karoly et al., 2010). 
 
 
 
3.6.4 Could the difference between the variants be physiologically relevant? HEK293T cells 
show a potential for a difference – moving to neurons 
 
It has already been previously reported that, under physiological temperature conditions using a 
CsCl-based intracellular solution, neonatal SCN1A channels show faster inactivation recovery 
compared to adults for shorter, but not for longer recovery intervals after long depolarization steps 
(P1=100 ms) (Fletcher et al., 2011). By widening the number and range of recovery interval data 
points gathered in our study –  hence allowing appropriate data fit and analysis – as well as 
manipulating the different parameters that can affect the inactivation recovery relation, has 
revealed new insights about the relationship between this splicing event and sodium channel 
biophysics and behaviour. 
Our data in Figures 3.2 & 3.3 show increased recovery of neonatal channels from fast inactivation 
for recovery intervals ≤ 10 ms, which comes in line with the main findings in Fletcher et al., 2011. 
A double exponential relationship such as the one that best fits the data here usually implies the 
existence of two distinct molecular events occurring. With the significant difference in inactivation 
recovery between splice variants being confined at the initial part of the curve while being lost on 
the second part, it could be argued that the molecular component that confers this difference 
between 5A and 5N channels occurs on a very rapid scale. This component gets masked by a 
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second molecular event occurring later on in the inactivation recovery process, which may act as a 
rate-limiting step making the two channels behaving similarly from that point and on. Therefore, 
these findings are consistent with splicing altering an inactive state that is both rapid in onset and 
rapid in recovery, with longer, slower inactivated states remaining insensitive to splicing. 
All components of the equation characterizing the two fits were comparable, irrespectively of the 
level of constraint of the constants (red VS green lines), apart from the Y0 parameter, which 
defined each fit’s starting point. In this case, Y0 represents a very fast, almost instantaneous 
component of inactivation that was established even before the first interpulse gap time point of 
0.5ms measured here. Therefore, Y0 defined the difference between the two fits throughout the fast 
and slow components of recovery from inactivation described by the double exponential decay 
equation, until convergence of the fits at later time points, most probably due to a common rate 
limiting step. To experimentally validate whether Y0 constitutes an inactivation component that 
occurred even earlier than the first 0.5ms recovery interval examined here, even shorter time 
points should be taken. This though is next to impossible, given the limitations of the equipment 
and the time constant of the cell membrane itself.  Our model predicts that after 0.10 ms 3% of 
neonatal channels have returned to the top row of states (de-inactivated) while for adult channels at 
this (very fast) time point 2% will have left the inactivated states. By 0.50 ms, the neonatal 
channels have 20% de-inactivated (18% in state #1 and 2% in state #2), while adult have only 14% 
(12% in state #1 and 2% in state #2). Thus the model predicts that the difference in variants would 
occur as soon as 100 microseconds after returning to -80 mV, and clearly outside the time points 
accessible to experimental whole cell voltage clamp. This is because the charging time constant of 
the cell is a function of its capacitance times the access resistance. Given that the average access 
resistance that was achieved during voltage clamp recordings was about 1.5 – 2 MΩ and the 
average HEK293T cell capacitance was around 16 – 20 pF, this gives an average charging time 
constant of around 240 – 400 µs, therefore any voltage change below that timeframe is impossible 
to be accurately clamped. 
From the experimental data, we could not exclude the possibility that the Y0 difference between 
the two fits is due to a bigger percentage of neonatal channels compared to adult ones having 
remained at the closed, non-inactivated state during the initial depolarisation phase (#5). This 
would imply that upon shortest repolarizations after P1 and consequent very fast re-depolarisation 
there is a bigger pool of neonatal channels at the closed non-inactivated (#5) state that can transit 
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into the open state compared to adult channels at these shortest recovery intervals, where the vast 
majority of channels still did not have enough time to recover from inactivation and reactivate. 
Yet, according to the channel modelling, there are no channels for either isoform remaining at that 
stage during the P1 depolarization at -10 mV in order to support that notion. Actually, from the 
very first microseconds of repolarization to -80 mV they pass extremely fast to the bottom left 
states, without any vertical transactions to the top, non-inactivated states (including #5). The only 
vertical transaction that occurs in the model is from state #12 to #1, which is where it is suggested 
here that the difference between the two splice variants lies. Therefore, according to the model, the 
difference in Y0 cannot actually occur due to a different proportion of neonatal channels compared 
to adults in state #5 immediately after repolarisation, but instead is due to the different rate at 
which channels return from state 12 to 1. 
As a conclusion of this analysis, the distinct neonatal and adult Y0 values found here are defining 
the difference between the two fits right from their origin, so that after that they run distinctively 
and in parallel, at least until a common rate limiting component makes them converge at longer 
recovery interval time points. This distinct, parallel movement between the isoforms during fast 
recovery is in line with the short train depolarization data in Figure 3.11, where the difference in 
channel availability is defined from the very first depolarization and then the two lines run in 
parallel.  
 
HEK293T expression is an oversimplified simulated system and not a real neuron firing APs. 
Neuronal firing involves many other voltage-gated channels from sodium channels, and after-
hyperpolarization events not taken into account here as well as different depolarization rates, 
especially during trains of APs, which may alter the response of the sodium channels. Therefore, 
extensive additional characterisation of parameters in HEK293T cells may not be the most 
informative way forward, as this may not reflect the impact on neuronal activity. Furthermore, the 
inactivation recovery when cells were held at -80 mV and together with the recording conditions 
that were set, might had been too close to 1 (i.e. full recovery) for recovery curves to have enough 
space potential to be separated. It cannot be ruled out that under more appropriate physiological 
conditions (β-subunit co-expression, channel phosphorylation etc.) inactivation recovery might 
had been less complete, thereby allowing potential differences between 5A and 5N channels to be 
better revealed.  
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Therefore, HEK293T cells have been used here as a means to reveal that the two isoforms have 
indeed the potential to respond differently under fast stimulating conditions, and to make 
predictions for how splicing may alter neuronal behaviour. Yet, in order to explore the neuronal 
effect of the two isoforms in their native environment, it is important to move to a more 
physiologically relevant system than HEK293T cells. Two lines forward might be useful for 
determining what aspects of splicing are physiologically important. Firstly, what differences are 
conserved in other channels (see chapter 4) and secondly, what differences are imposed on 
neuronal behaviour when splicing is manipulated (see chapter 6 & 7). 
 
 
 
3.7 Summary 
 
Summarizing the results for Nav1.1 5A and 5N splice variants and their difference in recovery 
from fast inactivation, it has been suggested here that the difference between splice variants seems 
to be most robust at a resting membrane potential of approximatly -80 mV (or -85 mV corrected 
for LJP), with short P1 intervals, and short interpulse gap durations (≤ 2 ms). Interestingly enough, 
the difference between splice variants is completely masked by prolonged depolarizing P1 steps, 
resting membrane potentials other than -80 mV and by recovery intervals longer than 20 ms. 
Finally, the difference is robust in consecutive rapid pulse protocols that are consistent with the 
sort of fast neuronal activity that might occur during epileptic events. This indicates that splicing 
may have its biggest impact on inactivation in conditions that could mimic interneuronal firing 
patterns or fast activity during a seizure. Given the sensitivity of splice variants to changes in 
voltage and duration of stimuli, it is important to confirm the difference observed can translate to 
effects which can have physiological relevance. The remaining chapters explore this by addressing 
some further questions: Does splicing have conserved effects on other channels? (Chapter 4) Can 
manipulating splice variants change the firing of neurons? (Chapter 6) Does splicing have the 
potential to change how neurons respond during epileptiform events? (Chapter 7) 
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Chapter 4: Conservation of a functional impact of alternative splicing 
in domain 1 of Nav1.1 channels in neuronal sodium channels Nav1.2 
and Nav1.7 
 
 
 
4.1 Hypothesis and aims 
 
The alternative splicing motif in domain 1 of Nav1.1 channels is conserved in all five TTX-
sensitive neuronal Na+ channels: Nav1.1, Nav1.2, Nav1.3, Nav1.6 and Nav1.7. The conservation of 
this site is particularly striking given recent data suggesting that alternative splicing is not, in 
general, well-conserved (Gerstein et al., 2014). In Nav1.1, channels containing exon 5N recover 
more quickly from fast inactivation in several stimulation paradigms explored here already. 
Fletcher et al., (2011) attributed the functional difference to a single amino acid change between 
the Nav1.1 5A and 5N exons (D207 to N). This change is conserved in Nav1.1, Nav1.2, Nav1.6 and 
Nav1.7 channels. This observation prompts the question whether there is a conserved functional 
impact imposed by alternative splicing in neuronal sodium channels, which may indicate an 
evolutionary drive that supports its molecular conservation (Copley, 2004). Up to now, there has 
been no functional study comparing adult and neonatal transcript variants that compares multiple 
related sodium channel subtypes bearing the same splicing event. Therefore, this study asked 
whether a molecular conservation of splicing in different channel subtypes could lead to a 
conserved functional change. Does the difference in inactivation recovery between variants found 
in Nav1.1 channels also occur in closely (Nav1.2) and more distally related (Nav1.7) sodium 
channel subtypes? Of all sodium channels Nav1.2 has the closest sequence similarity to Nav1.1, 
while Nav1.7 although still quite similar in sequence is more distantly related, (Catterall, 2005). An 
additional difference is that Nav1.7 is largely found in peripheral neurons, and is particularly 
important for subthreshold signaling and nociception in small diameter neurons, while Nav1.1 and 
Nav1.2 are preferentially expressed in the central nervous system. Nav1.1 plays a predominant role 
in the excitability of fast-spiking parvalbumin-positive interneurons in the CNS (Yu et al., 2006). 
In contrast, Nav1.2 is primarily expressed in excitatory neurons, and is particularly important early 
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in development (Oliva et al., 2012). In terms of both the physiology of the neurons, and the 
macroscopic kinetics of gating, Nav1.7 channels are more distant from the two channels in the 
CNS (Dib-Hajj et al., 2013). Nevertheless the site of splicing is conserved across all three 
channels.  
Both Nav1.2 and Nav1.7 neonatal variants have the conserved asparagine residue at an equivalent 
position to N207 in Nav1.1 5N, which was sufficient and necessary to confer a higher rate of 
inactivation recovery compared to the adult isoform (Fletcher et al., 2011). As a result it was 
hypothesized that the same splicing event in Nav1.2 and Nav1.7 channels will confer a conserved 
functional difference in fast inactivation recovery as for Nav1.1, in spite of the different functional 
roles and spatial distributions of the channels. 
 
 
 
4.2 Results: Comparing the functional properties of splice variants for Nav1.2 and Nav1.7 
 
4.2.1 As in Nav1.1, voltage dependence of activation/inactivation in Nav1.2 & Nav1.7 remains 
unaffected 
 
The first step in the study of Nav1.2 and Nav1.7 channels was to compare voltage dependence 
properties between the adult and neonatal isoforms. Voltage dependencies of activation and 
inactivation did not differ between variants for Nav1.2 (Figure 4.1, A & B) or Nav1.7 (Figure 4.2, 
A & B) (Boltzmann non-linear curve fits, P>0.05, two-way ANOVA). Consistent with other 
publications, Nav1.7 channels showed a -17 mV more hyperpolarized V1/2 of inactivation compared 
to Nav1.1 and around -10 mV more hyperpolarized V1/2 of inactivation compared to 
Nav1.2(Chatelier et al., 2008; Farmer et. al, 2012). However, as for Nav1.1, in these recording 
conditions, there were no differences in voltage dependence properties between transcript variants 
for Nav1.2 and Nav1.7 channels (see Figure 4.1 & 4.2). 
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   6A: V1/2activation = -21.5 +/-3.7 mV                                             6A: V1/2inactivation = -61.3 +/-1.4 mV 
 
   6N: V1/2activation = -21.2 +/-1.6 mV                                             6N: V1/2inactivation = -62.9 +/-2.4 mV 
 
Figure 4.1: Nav1.2: No difference in macroscopic properties and VD activation/inactivation between isoforms. 
A. Representative traces from HEK293T cells expressing adult (black) and neonatal (blue) isoforms evoked by a 2 ms 
step to -10 mV. Macroscopic properties of the currents were largely indistinguishable for individual pulses. B. 
Voltage Dependence of activation & inactivation – no difference is seen between 6A and 6N variants (6A n = 9; 6N n 
= 7). 
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   5A: V1/2activation = -15.9 +/-2.5 mV                                             5A: V1/2inactivation = -71.8 +/-3.6 mV 
 
   5N: V1/2activation = -16.2 +/-3.0 mV                                             5N: V1/2inactivation = -74.3 +/-3.9 mV 
 
Figure 4.2: Nav1.7: No difference in macroscopic properties and VD activation/inactivation between isoforms. 
A. Representative traces from HEK293T cells expressing adult (black) and neonatal (blue) isoforms evoked by a 2 ms 
step to -10 mV. Macroscopic properties of the currents were largely indistinguishable for individual pulses. B. 
Voltage Dependence of activation & inactivation – no difference is seen between 5A and 5N variants (5A n = 6; 5N n 
= 7). 
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4.2.2 Preliminary investigation of recovery from fast inactivation in Nav1.2 & Nav1.7 
 
Using the original inactivation recovery stimulating parameters described in Fletcher et al., (2011), 
Nav1.7 showed a difference in fast inactivation recovery rate between 5A and 5N splice variants 
(Figure 4.3). As for Nav1.1, the data were fit with a double-exponential decay (Y0 + AF*(1-exp(-
t/τF)) + AS*(1-exp(-t/τS)), consistent with a fast (τF), and a slow (τS) component of recovery from 
inactivation. Parameters were allowed to both freely fluctuate (Figure 4.4, green line fits) or rate 
constants were fixed (τF: 1.7 = 9.2 ms; τS: 1.7 = 312 ms), thus allowing only the relative 
amplitudes of the fast (AF) and slow (AS) components to vary (Figure 4.4, red line fits). Both 
conditions allowed good fits (r2 > 0.99 for all fits; Table 4.1) with negligible difference between 
the two levels of constraint (green vs red lines). Fits revealed a difference between neonatal and 
adult isoforms. This difference was similar to the one previously seen for Nav1.1, with 5N 
channels recovering more than 5A after shorter recovery intervals, indicated also by a significant 
difference on the Y0 parameter between Nav1.7-5A and 5N (0.079 vs 0.012 for free fits, P<0.05, 
two-way ANOVA), which was in accordance to what was seen for Nav1.1 isoforms. Similar to 
Nav1.1, the difference started attenuating at longer interpulse time intervals. Therefore, Nav1.7 
appears to behave in a similar way to Nav1.1, as far as the inactivation recovery rate of its 
transcript variants is concerned. The difference might even be more robust for Nav1.7 channels, 
since 5N channels recover more quickly than 5A for longer interpulse gap durations for Nav1.7 
than for Nav1.1. 
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Figure 4.3: Nav1.7: Channels containing exon 5N recover more rapidly from inactivation after short recovery 
intervals 
Short recovery intervals at -80mV reveal a difference between splice variants with 5N recovering more quickly than 
5A, which is masked as intervals get longer, similar to Nav1.1 (shown in inset). (5A n=5; 5N n=8). 
 
 
 
Figure 4.4: Recovery from inactivation for Nav1.7 neonatal and adult isoforms, comparing fits with all parameters 
free (green lines) and with τF and τS fixed (red lines)   
Values and standard errors of the fit values are in table 4.1. 
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Table 4.1: Nav1.7: Parameters of bi-exponential fits to recovery from long (100 ms) inactivating pre-
pulses. 
Top panel: Optimized fitting parameters with τF and τS constrained (red lines in Figure 4.4, rates with n/a 
standard error (s.e.) were fixed). Bottom panel: Free fits with all parameters allowed to vary (green lines in 
Figure 4.4). R̅2 is the adjusted R-square statistic used to improve comparison of fits with different degrees 
of freedom. Compare to values for Nav1.1 given in Table 3.2. 
 
Parameters from constrained fits (red lines in Figure 4.4) 
 Nav1.7-5N Nav1.7-5A 
 Value s.e. Value s.e. 
Y0 0.084 0.004 0.015 0.005 
AF 0.79 0.01 0.80 0.01 
τF (ms) 9.2 n/a 9.2 n/a 
AS 0.06 0.01 0.11 0.01 
τS (ms) 312 n/a 312 n/a 
R̅
2
 0.999  0.999  
 
Parameters from free fits (green lines in Figure 4.4) 
 Nav1.7-5N Nav1.7-5A 
 Value s.e. Value s.e. 
Y0 0.079 0.007 0.012 0.009 
AF 0.78 0.01 0.79 0.02 
τF (ms) 8.7 0.4 8.9 0.6 
AS 0.07 0.01 0.12 0.02 
τS (ms) 273 139 265 100 
R̅
2
 0.999  0.999  
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When the same protocol was applied to Nav1.2 6A and 6N channels, short recovery intervals failed 
to reveal a difference between splice variants, despite showing a small trend for 6N channels to 
recover more quickly (Figure 4.5).  The recovery timecourse for Nav1.2 channel isoforms was 
again well fit by two exponentials ( Y0 + AF*(1-exp(-t/τF)) + AS*(1-exp(-t/τS))), consistent with a 
fast ( τF Nav1.2 = 1.1 ms), and a slow ( τS Nav1.2 = 406 ms) component of recovery from 
inactivation. Contrary to what was seen for Nav1.1 and Nav1.7 variants, the instantaneous 
availability of both Nav1.2-6A and 6N channels (Y0 parameter) was similar (0 for both isoforms). 
To compare splice variants we fixed both rate constants (τF and τS) and only allowed the relative 
amplitudes of the fast (AF) and slow (AS) components to vary (r2 > 0.98 for fits with these 
restrictions, Table 4.2), similar to what was done for Nav1.1 and Nav1.7 isoforms (Figure 4.5 & 
4.6; Table 4.2). The lack of difference in Nav1.2 was unexpected, especially considering that the 
more distally related Nav1.7 channel did show a conserved functional change similar to Nav1.1. 
Yet, since differences found under these conditions are quite subtle, even for Nav1.1 and Nav1.7, it 
is possible that differences for Nav1.2 here are masked (note that only a relatively small proportion 
of Nav1.2 channels have recovered after 2 – 10 ms at -80 mV) and can be revealed under the 
protocols used to maximise the difference between Nav1.1 variants, and which reduce the amount 
of slow inactivation.  
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Figure 4.5: Nav1.2: Short recovery intervals at -80mV do not reveal a difference between splice variants as in 
Nav1.1 (shown in inset) and Nav1.7 
(6A n=7; 6N n=6). 
 
 
Figure 4.6: Recovery from inactivation for Nav1.2 neonatal and adult isoforms, comparing fits with all parameters 
free (green lines) and with τF and τS fixed (red lines) 
Values and standard errors of the fit values are in table 4.2. 
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Table 4.2: Nav1.2: Parameters of bi-exponential fits to recovery from long (100 ms) inactivating pre-
pulses. 
Top panel: Optimized fitting parameters with τF and τS constrained (red lines in Figure 4.6, rates with n/a 
standard error (s.e.) were fixed). Bottom panel: Free fits with all parameters allowed to vary (green lines in 
Figure 4.6). Note that for the constrained fits, all rates for Nav1.2-6N and Nav1.2-6A were fit as a group as 
there were no differences between the data from individual fits. R ̅2 is the adjusted R-square statistic used 
to improve comparison of fits with different degrees of freedom. 
Parameters from constrained fits (red lines in Figure 4.6) 
 Nav1.2-6N Nav1.2-6A 
 Value s.e. Value s.e. 
Y0   0.000 0.049 
AF   0.72 0.05 
τF (ms)   1.1 0.1 
AS   0.20 0.03 
τS (ms)   406 219 
R̅
2
 n/a  0.981  
 
Parameters from free fits (green lines in Figure 4.6) 
 Nav1.2-6N Nav1.2-6A 
 Value s.e. Value s.e. 
Y0 0 0.081 0 0.069 
AF 0.73 0.08 0.71 0.06 
τF (ms) 1.1 0.2 1.0 0.2 
AS 0.20 0.04 0.20 0.04 
τS (ms) 315 202 541 559 
R̅
2
 0.978  0.981  
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4.2.3 Recovery from fast inactivation difference is augmented in Nav1.2 and Nav1.7 with 
shorter depolarization conditions 
 
Because action potentials and depolarizations due to EPSCs in neurons are typically much shorter 
than the 100 ms depolarizing steps used in the protocol above, the difference in response to shorter 
pre-pulses seen for Nav1.1 isoforms in Chapter 3 is likely to be more relevant to physiological 
temperature conditions. Furthermore, an inactivation recovery protocol using variable P1 durations 
for Nav1.1-5A and 5N channels previously revealed that shorter P1 durations allowed 5N channels 
to recover considerably more than 5A, with the difference gradually attenuating as P1 intervals 
increased in duration. Applying the same protocol on Nav1.2-6A and 6N channels this time 
revealed a difference in inactivation recovery between the two splice variants in the same direction 
and of a similar magnitude as for Nav1.1 under these conditions (P<0.001, two-way ANOVA; 
Figure 4.7A). As seen in an independent experiment in Figure 4.7B, it is the shortest P1 durations 
that generate the biggest difference in availability for Nav1.2-6A and 6N variants. Results here also 
partly explain why a significant difference was not seen for Nav1.2 6A and 6N channels using the 
original recovery from inactivation protocol (Figure 4.5), since using a P1 duration over ~50 ms in 
Nav1.2 channels is sufficient to mask the difference between the 6A and 6N variants. 
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Figure 4.7: Nav1.2: The neonatal isoform showed significantly more availability after a range of shorter pre-pulses 
under a brief interpulse gap duration (2ms) 
Curves are fit with single exponentials as described in the text.. A. P1 duration = 2 – 500ms (6A n=10; 6N n=9). B. P1 
duration = 2 – 10ms (6A n=6; 6N n=6) 
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Figure 4.8: Nav1.2: Estimated channel availability for isoforms of each channel comparing quality of fits with all 
parameters free (green lines) and with Y0 and τ fixed (red lines, behind green lines) 
The green fits were seeded with the same values for both isoforms. Note that from the free fits only the non-
overlapping errors for parameter A are consistent with this value being different between the isoforms (see table 
4.3, bottom panel). 
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Table 4.3: Nav1.2: Parameters of single exponential fits describing channel availability after 2 ms 
recovery from pre-pulses of different durations 
Top panel: optimized fitting parameters with inactivation time constant τ and the offset (Y0) fixed. The 
parameters with n/a standard error (s.e.) were fixed at values similar to those found for free fits to both 
isoforms of that channel (as described in Figure 4.8). Bottom panel: Fits with all parameters allowed to 
vary. To better compare the goodness of fits with the different degrees of freedom the adjusted R-square 
statistic (R̅2) is given. 
Parameters from constrained fits (red lines in Figure 4.8) 
 Nav1.2-6N Nav1.2-6A 
 Value s.e. Value s.e. 
Y0 0.13 n/a 0.13 n/a 
A 0.775 0.004 0.684 0.006 
τ (ms) 108 n/a 108 n/a 
R̅
2
 0.993  0.994  
 
Parameters from free fits (green lines in Figure 4.8) 
 Nav1.2-6N Nav1.2-6A 
 Value s.e. Value s.e. 
Y0 0.13 0.02 0.13 0.01 
A 0.764 0.012 0.689 0.014 
τ (ms) 111 10 106 8 
R̅
2
 0.992  0.993  
 
 
 
155 
 
In the case of Nav1.7, using the same variable P1 duration protocol, the difference in recovery 
between 5A and 5N variants was once again repeated (Figure 4.9A). Similar to both Nav1.1 and 
Nav1.2, the difference was most robust at earlier time points (note the overall increase in 
inactivation for Nav1.7 variants compared to the CNS channels; Figure 4.9B). Nav1.7 5N channels 
maintained their increased availability compared to 5A even at longer P1 durations (up to 300 ms). 
Data for the neonatal and adult isoforms for both channel subtypes were fit as a first order 
exponential decay [Y0 + A*exp(-t/τ)]. When all parameters were free to vary (Figures 4.8 & 4.10, 
green lines and tables 4.3 & 4.4 for Nav1.2 and Nav1.7 respectively) the difference between the 
two isoforms was once again mostly described by the amplitude (A).  As for Nav1.1, in order to 
test the hypothesis that the amount of availability changed, but not the timecourse of onset was 
changed by splicing, the data were fit with the τ fixed to be the same for the adult and neonatal 
isoforms, and only the amplitude (A) was allowed to vary (τ: Nav1.2 = 108 ms; 1.7 = 95 ms; r2 > 
0.94 for both fits; Figures 4.8 & 4.10, red lines and tables 4.3 & 4.4 respectively). For both Nav1.2 
and Nav1.7, direct comparison of either free or fixed fits of the two isoforms for all data points 
with two-way ANOVA indicated that neonatal channels showed significantly more availability 
after a range of shorter pre-pulses compared to adult ones (P<0.001). The difference started 
waning off as the P1 duration got longer so that at longest P1 values it was completely masked. 
Therefore, the neonatal isoform here shows significantly increased availability after short 
inactivating pre-pulses compared to the adult one for all three channels: Nav1.2, Nav1.7, as well as 
Nav1.1. 
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Figure 4.9: Nav1.7: The neonatal isoform showed significantly more availability after a range of shorter pre-pulses 
under a brief interpulse gap duration (2ms) 
Curves are fit with single exponentials as described in the text. A. P1 duration = 2 – 500ms (5A n=7; 5N n=10). B. P1 
duration = 2 – 10ms (5A n=5; 5N n=5) 
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Figure 4.10: Estimated channel availability for Nav1.7 isoforms of each channel comparing quality of fits with all 
parameters free (green lines) and with Y0 and τ fixed (red lines, behind green lines) 
The green fits were seeded with the same values for both isoforms. Note that from the free fits only the non-
overlapping errors for parameter A are consistent with this value being different between the isoforms (see table 
4.4, bottom panel). 
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Table 4.4: Nav1.7: Parameters of single exponential fits describing channel availability after 2 ms 
recovery from pre-pulses of different durations 
Top panel: optimized fitting parameters with inactivation time constant τ and the offset (Y0) fixed. The 
parameters with n/a standard error (s.e.) were fixed at values similar to those found for free fits to both 
isoforms of that channel (as described in Figure 4.10). Bottom panel: Fits with all parameters allowed to 
vary. To better compare the goodness of fits with the different degrees of freedom the adjusted R-square 
statistic (R̅2) is given. 
 
Parameters from constrained fits (red lines in Figure 4.10) 
 Nav1.7-5N Nav1.7-5A 
 Value s.e. Value s.e. 
Y0 0.16 n/a 0.16 n/a 
A 0.351 0.008 0.208 0.009 
τ (ms) 95 n/a 95 n/a 
R̅
2
 0.967  0.942  
 
 
Parameters from free fits (green lines in Figure 4.10) 
 Nav1.7-5N Nav1.7-5A 
 Value s.e. Value s.e. 
Y0 0.18 0.01 0.14 0.01 
A 0.323 0.012 0.243 0.010 
τ (ms) 98 10 92 9 
R̅
2
 0.977  0.972  
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4.2.4 “High-activity, seizure-like” parameters maintain the difference between adult and 
neonatal channels for Nav1.2 & Nav1.7 
 
Protocols mimicking “high-activity” or “seizure-like” conditions, which combine parameters used 
to assess the difference in inactivation recovery between Nav1.1 5A and 5N channels, were applied 
to both Nav1.2 and Nav1.7 adult and neonatal channels. Therefore, we delivered trains of short (10 
ms) depolarizing steps and compared channel availability between isoforms of Nav1.2 in 
HEK293T cells, as it was done for Nav1.1 channel isoforms before (Figure 4.11). Under these 
conditions, the difference between availability of splice isoforms was evident (P<0.001, two-way 
ANOVA) after the first step and was sustained for the entire train, with the adult isoforms 
remaining approximately 10% less available than the neonatal isoform. We repeated experiments 
with Nav1.7, which exhibits relatively more inactivation after short steps (Figure 4.12). Trains with 
1 ms recovery between steps produced complete inactivation in both isoforms of Nav1.7 (data not 
shown) and consequently to allow these channels to produce measurable currents we used a 2 ms 
recovery period between steps (Figure 4.12). In these conditions the Nav1.7 isoforms replicated the 
differences seen in Nav1.1 and 1.2 with an immediate onset and sustained increase in availability 
of the neonatal isoform throughout the train duration (P<0.001, two-way ANOVA). Therefore, 
under these conditions, adult and neonatal transcript variants from three different sodium channel 
genes are behaving in a biophysically consistent manner with the same functional difference across 
all three channel subtypes. 
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Figure 4.11: Nav1.2: Trains of pulses mimicking a “seizure-like burst” retain the difference between the splice 
variants 
similar to Nav1.1 (6A n=11; 6N n=9). 
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Figure 4.12: Nav1.7: Trains of pulses mimicking a “seizure-like burst” retain the difference between the splice 
variants 
similar to Nav1.1 and Nav1.2, but with a slightly different protocol (2 ms gap between steps, 5A n=6; 5N n=8). 
 
 
 
4.3 Summary of investigation of conservation 
 
This chapter has demonstrated that a conserved molecular splicing event between sodium channel 
subtypes can lead to a conserved functional change in channel availability. After shorter 
depolarisations that favour fast inactivated states the neonatal isoforms for all three sodium 
channel subtypes, Nav1.1, Nav1.2 and Nav1.7, show more availability than their adult counterparts. 
This is true using identical recording conditions (physiological temperature, CsCl-based 
intracellular, no β-subunits), and identical, or in one case similar voltage protocols (short P1 
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intervals, short interpulse gap durations, RMP of -80 mV). Therefore it appears that the intrinsic 
effect of this alternative splicing event on early recovery from inactivation is evolutionarily 
conserved across these three distinct sodium channel subtypes. This suggests this feature may be 
imposing an evolutionarily important effect on channel activity. 
The evolutionary conservation of alternative splicing in sodium channels is especially striking 
because the different channel types support divergent functions. Nav1.1 plays a predominant role 
in the excitability of fast-spiking parvalbumin-positive interneurons in the CNS (Yu et al., 2006). 
In contrast, while highly conserved at the amino acid level, Nav1.2 is primarily expressed in 
excitatory neurons, and is particularly important early in development (Oliva et al., 2012). Nav1.7 
is largely found in peripheral neurons, and is particularly important for subthreshold signaling and 
nociception in small diameter neurons, which are anatomically distinct from the CNS neurons 
where Nav1.1 and Nav1.2 predominate (Cox et al., 2006; Yang et al., 2004). In terms of both the 
physiology of the neurons, and the macroscopic kinetics of gating, Nav1.7 channels are more 
distant from the two channels in the CNS (Dib-Hajj et al., 2013). Nevertheless the site of splicing 
is conserved across all three channels and, furthermore, it has been implicated in disease states for 
all three subtypes.  
One of the most direct indications that this splicing may be important in human disease comes 
from studies of Nav1.2 where mutations within the neonatal exon are associated with epilepsy (Xu 
et al., 2007), and where genetic removal of the neonatal exon leads to a change in seizure 
threshold (Gazina et al., 2014). In the case of Nav1.2, development of seizures is associated with a 
gain-of-function effect of the channel, and may be due to a developmental change in excitatory 
neurons (Liao et al., 2010; Gazina et al., 2014). In Nav1.7, a mutation associated with adult-onset 
inherited erythromelalgia (erythermalgia) was shown to modify the inactivation of the adult 
isoform only, consistent with delayed onset of symptoms (Choi et al., 2010). For SCN1A, the G>A 
polymorphism disrupts the inclusion of the neonatal exon in Nav1.1 channels and has been 
associated with altered dosage of AEDs in people with epilepsy (Tate et al., 2005; Zhou et al., 
2012) as well as possibly modifying the likelihood of developing epilepsy (Abe et al., 2008; 
Kumari et al., 2013), but this finding also has not been replicated universally (Manna et al., 2011). 
These different findings are consistent with the polymorphism interacting with other genetic 
differences that may differ among different populations. Results shown here in HEK293T cell 
recordings provide a conserved functional effect between neonatal and adult isoforms across 
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channel types that may contribute to the development of disease state linked with this splicing 
event for each channel type. 
We have focused on identifying conserved effects of splicing on channel activity; however 
splicing may also act by changing how isoforms interact with other proteins, and this may 
contribute to the different effects in different neuronal backgrounds. In Nav1.7, splicing has been 
shown to modify phosphorylation (Chatelier et al., 2008) as well as how these channels associate 
with β-subunits (Farmer et al., 2012). Additional insight into the conserved impact of splicing, 
includes studies showing that in flies a homologous splicing event in the third domain, which 
appears to have arrived through convergent evolution, hyperpolarizes  voltage dependence of 
activation and creates a persistent current (Lin et al., 2009), which has pronounced effects on 
neuronal excitability (Lin et al., 2012). This splicing event, giving rise to exons K or L, is also 
linked to epilepsy occurrence in Drosophila (Lin et al., 2012), since its manipulation can lead to 
seizure suppression (Lin et al., 2015), which is reminiscent of how the homologous event in 
human Nav1.1 is associated with epilepsy predisposition. Another major correlation between the 
two homologous splicing events is that splicing of the L exon in Drosophila is activity-dependent 
and is promoted by increased synaptic activity, which may, in turn, promote seizures (Lin et al., 
2012). In parallel to that, epilepsy in humans has been shown to promote splicing towards the 
neonatal variant (Heizen et al., 2007, Fletcher et al., 2011), possibly as a result of increased 
neuronal activity. In addition, increased inclusion of exon L in Drosophila is regulated by the 
RNA-binding protein Pasilla (Lin et al., 2012), whose mammalian homologues are Nova1 and 
Nova2 and these splicing factors have been involved in regulating the mammalian Nav1.1 splicing 
event (Heinzen et al., 2007; Gazina et al., 2010). Finally, in cockroaches a similar splicing motif 
has been shown to modify channel pharmacology (Tan et al., 2002). A link between this splicing 
event in human Nav1.1 and altered anti-epileptic drug response has been also suggested before 
(Tate et al., 2005; 2006; Abe et al., 2008; Zhou et al., 2012; Menzler et al., 2014) and is examined 
in more detail in Chapter 5. 
Our data demonstrate that after brief depolarizations, a conserved site of alternative splicing 
imparts a conserved impact on channel availability in HEK293T cells, most likely by manipulating 
inactivation recovery. To our knowledge this is the first time a site of alternative splicing has been 
shown to have conserved function on three separate ion channels.  
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At a physical level the data from the model indicate that the inclusion of a negatively charged 
amino acid (in the adult exon) in the D1S3-S4 segment is sufficient to stabilize the inactivation 
particle in the inner side of the channel pore. As the neonatal exon does not contain a charged 
amino acid at that position, it is tempting to speculate that the interaction of the charged arginine 
with the potential across the membrane is sufficient to alter the ‘down’ position of the attached 
voltage-sensor. Data found here are consistent with the splicing in the first domain destabilizing 
the inactivation particle after all four voltage sensors have returned to the ‘down’ position. It is 
proposed here that the S4 segment in the first domain may have a predominantly important role in 
stabilizing inactivation, and this is why splicing in DI has specific effects on this parameter. 
Consistent with this link between the S4 targeted by splicing and the biophysical effect, a 
paralogous splicing motif in DIII of Drosophila has been shown to have robust effects on the 
amount of persistent current produced by channels (Lin et al., 2009; 2012; 2015), a property that is 
also linked with the inactivation process and the motility of the inactivation particle. This is 
consistent with splicing in the S3-S4 linker affecting the motility of the inactivation particle in a 
way that is determined by which domain the splicing event occurs. In Drosophila such splicing in 
DIII results in generation of a persistent current possibly as a result of altered binding of the 
inactivation particle leading to incomplete inactivation (Stafstrom, 2007; Kiss, 2008). In the 
human paralog, we show here that splicing in the first domain affects channel availability by 
having an effect on release from inactivation, as it is modelled in Chapter 3. This reinforces the 
notion that even across different species, the conservation of splicing at the S3-S4 linker, even if in 
different domains, has specific effects on the inactivation particle and can be linked with seizure 
occurrence both in humans and flies.         
However, as all this work was carried out in HEK293T cells, we still cannot rule out other roles 
for this splicing in regulating interactions with other proteins, or contributing to neuronal 
functions. Future work exploring these possibilities, ideally in neuronal backgrounds will be 
necessary to test those possibilities. A first look of the two splice isoforms in their native neuronal 
milieu is further explored in Chapter 6. 
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Chapter 5: Differential modulation of VGSC variants by the anti-
epileptic drugs phenytoin and carbamazepine 
 
 
 
5.1 Hypothesis and aims 
 
Previous reports have suggested that splicing in Nav1.1 may contribute to an altered maximum or 
maintenance dosage of AEDs prescribed in epileptic patients (Tate et al., 2005; 2006; Abe et al., 
2008; Zhou et al., 2012; Kasperaviciute et al., 2013) or alter pharmacoresponse to AEDs such as 
carbamazepine (Menzler et al., 2014), however these findings are not always reproduced (Kwan et 
al., 2008; Manna et al., 2011; Haerian et al., 2013; Kumari et al., 2013). It has been shown here 
and elsewhere (Fletcher et al., 2011) that Nav1.1-5A and 5N variants have an innate difference in 
their early inactivation recovery rates, a property that is directly affected by AED action. 
Preliminary work in that report had indicated that phenytoin, a first line AED, might obscure the 
difference between Nav1.1-5A and 5N channels, but these preliminary data did not explicitly 
measure differences between the variants. In addition Thompson et al., (2011) previously reported 
a differential modulation of Nav1.1-5A and 5N recovery rates with phenytoin and lamotrigine, but 
not with carbamazepine. However, this study was carried out in conditions where the intrinsic 
difference in inactivation was obscured, and did not investigate the impact of the drugs on the 
functional difference which has been identified here as being conserved among channels. As yet, 
no study has investigated the impact of AEDs on splice variants of multiple sodium channels. 
Association studies between the SCN1A genotype and drug dosage – primarily phenytoin and 
carbamazepine – give mixed conclusions for both anti-epileptics. Results become even more 
dubious since some of these studies treat AEDs as one unit (Kwan et al., 2008; Haerian et al., 
2013), ignoring potential differences between AEDs. In order to clarify the relationship between 
splicing and AED inhibition, we compared channel availability using the same high-frequency 
stimulation conditions that produced robust differences between the variants from all three 
channels, this time in the presence of either phenytoin or carbamazepine, in order to to allow the 
development of a use-dependent block. Results were extended to both Nav1.2 and Nav1.7 adult and 
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neonatal transcript variants, in order to see whether a functional conservation between sodium 
channel subtypes also applies for AED pharmacology of the adult and neonatal isoforms. 
 
 
 
5.2 Results: Comparing splice variant drug responses for Nav1.1, Nav1.2 & Nav1.7 
 
5.2.1 Addition of AEDs negates the inactivation recovery difference between Nav1.1 5A and 
5N variants.  
 
Recovery from inactivation under “seizure-like” stimulation trains allows a higher recovery rate 
for neonatal over adult channels throughout the protocol in the absence of any AED (Figure 5.1, 
pale blue and grey). Repeating the same protocol for Nav1.1 transcript variants in the presence of 
phenytoin (50 µM in DMSO, 1 : 1000 dilution, 0.1% DMSO concentration in the extracellular 
solution) reduced the amount availability for both 5A and 5N channels (Figure 5.1A). This 
reduction became more evident with increased pulse numbers in comparison to the drug-free 
protocol. In addition, the 5N channels underwent a greater relative reduction in recovery, so that 
the difference between the two channel variants was obscured (P>0.05, two-way ANOVA). So, 
the effect of phenytoin on the neonatal isoform was strong enough to reduce the availability to a 
level similar to that of the adult isoform, and the difference between the isoforms was eradicated 
for the duration of the train. Similarly, the difference between Nav1.1 5A and 5N channels were 
also obscured in the presence of 50 µM carbamazepine (in DMSO, 1 : 1000 dilution, 0.1% DMSO 
concentration in the extracellular solution) (P>0.05, two-way ANOVA; Figure 5.1B). It has been 
shown before that DMSO concentrations of 0.1% and below in the external solution has no 
measurable effect on INa (Ilyin et al., 2005), therefore any effect seen in the presence of either 
phenytoin or carbamazepine is suggested to be a result of the drugs activity and not due to the 
DMSO. It should also be noted that reversibility of the effect by washing out either phenytoin or 
carbamazepine was not performed, due to high variability of current rundown after prolonged 
recordings, which made current measurements unreliable. However, both splice variants were 
compared under the same conditions. 
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Figure 5.1: Nav1.1: Phenytoin and carbamazepine negate the inactivation recovery difference between neonatal 
and adult isoforms 
Addition of AEDs (phenytoin & carbamazepine) reduces channel availability after the first step, and obscures the 
difference between Nav1.1 neonatal and adult isoforms during a series of fast pulses (two-way ANOVA p>0.05). The 
increased inhibition of the neonatal isoform means that the presence of either drug entirely removes the difference 
between the isoforms during the series of pulses. A. +50µM phenytoin (5A n=10, 5N n=7). B. +50µM carbamazepine 
(5A n=7, 5N n=5). Pale blue and grey data are from using the same protocol in the absence of drugs, dark blue and 
black data indicate the presence of drugs. Drug concentrations approximate half maximal inhibition in RT recordings 
(Thompson et al., 2011).  
 
 
5.2.2 Conservation of AED differences in Nav1.2 and Nav1.7 subtype isoforms 
 
Experiments done in the presence of phenytoin or carbamazepine for Nav1.1 transcript variants 
were now repeated for Nav1.2 and Nav1.7 channel subtypes. This would indicate whether the 
pharmacological difference between adult and neonatal isoforms is conserved across different 
channel types, in the same way as the intrinsic differences in inactivation. Indeed, similar to 
Nav1.1, addition of either phenytoin (Figure 5.2A) or carbamazepine (Figure 5.2B) obscured the 
difference between Nav1.2-6A and 6N channel variants, so that their initial difference under drug-
free conditions (P>0.05, two-way ANOVA; Figure 5.2 pale blue and grey) was now lost.  
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Figure 5.2: Nav1.2: Phenytoin and carbamazepine negate the inactivation recovery difference between neonatal 
and adult isoforms 
Similar to Nav1.1, addition of AEDs (phenytoin & carbamazepine) reduces channel availability after the first step, and 
obscures the difference between Nav1.2 neonatal and adult isoforms during a series of fast pulses (two-way ANOVA 
p>0.05). The increased inhibition of the neonatal isoform means that the presence of either drug entirely removes 
the difference between the isoforms during the series of pulses. A. +50µM phenytoin (6A n=7, 6N n=6). B. +50µM 
carbamazepine (6A n=15, 6N n=15). Pale blue and grey data are from using the same protocol in the absence of 
drugs, dark blue and black data indicate the presence of drugs. Drug concentrations approximate half maximal 
inhibition in RT recordings (Thompson et al., 2011). 
 
 
 
 
The slightly adapted protocol that allowed 2 ms recovery (to allow channels to produce 
measureable currents) was used to reveal the same situation applied for the more distally related 
Nav1.7 channel subtype, both in the presence of phenytoin (Figure 5.3A) as well as carbamazepine 
(Figure 5.3B). Therefore, the addition of either phenytoin or carbamazepine negates any difference 
in channel availability between adult and neonatal transcript variants that was previously evident 
in drug-free conditions (P>0.05, two-way ANOVA; Figure 5.3 pale blue and grey), and this effect 
is conserved across at least three sodium channels.  
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Figure 5.3: Nav1.7: Phenytoin and carbamazepine negate the inactivation recovery difference between neonatal 
and adult isoforms 
Similar to both Nav1.1 and Nav1.2, addition of AEDs (phenytoin & carbamazepine) reduces channel availability after 
the first step, and obscures the difference between Nav1.7 neonatal and adult isoforms during a series of fast pulses 
(two-way ANOVA p>0.05). The increased inhibition of the neonatal isoform means that the presence of either drug 
entirely removes the difference between the isoforms during the series of pulses. A. +50µM phenytoin (5A n=12, 5N 
n=11). B. +50µM carbamazepine (5A n=7, 5N n=8). Pale blue and grey data are from using the same protocol in the 
absence of drugs, dark blue and black data indicate the presence of drugs. Drug concentrations approximate half 
maximal inhibition in RT recordings (Thompson et al., 2011). 
 
 
 
5.3 Summary and discussion  
 
In Nav1.1, the rs3812718 polymorphism that alters splicing of the neonatal isoform in humans, and 
was initially associated with altered dosage of phenytoin and carbamazepine in patients (Tate et 
al., 2005). These drugs are thought to work by binding to and stabilizing the inactivated states 
(Kuo and Bean, 1994), which our data in Chapter 3 have indicated may be specifically targeted by 
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splicing. From the results here, it can be concluded that in the presence of phenytoin or 
carbamazepine, adult and neonatal transcript variants show comparable activity, and this change is 
conserved also in Nav1.2 and Nav1.7 channel subtypes. This highlights the similarity in mechanism 
between the drugs, and indicates that treatment may have distinct effects on different splice 
isoforms of different types of channels beyond Nav1.1, and that any neurological disorder that 
alters splicing at this site in a neuronal channel may alter the mechanism of drug response.  
On a first glance, the difference between isoforms found here could be attributed to a different 
binding of the drug between the two channel isoforms, such that the neonatal variant has a higher 
affinity, making it more sensitive to the action of the AEDs since this variant shows a higher 
relative change in inactivation recovery compared to adult channels. Yet, the possibility cannot be 
excluded that the binding of either AED upon neonatal or adult channels could be similar and the 
AED may simply be slowing down the rate of inactivation recovery to levels where a different – 
probably common – molecular event acts as a rate limiting step that defines the recovery rate. In 
that case, the action of either AED may be masking the difference between splice variants in the 
same way that long interpulse intervals or prolonged P1 durations do in the protocols described in 
chapter 3, essentially by driving the channels into slow inactivated states, or states where the first, 
fastest recovery is no longer the limit for re-opening.  
The conserved differences in response to AEDs may provide more insight into how these drugs 
work. One key challenge is that the drugs are likely to have increased effects on neonatal isoforms 
of multiple sodium channels in different types of neurons. This could be particularly relevant to 
epilepsy, as several studies have suggested that the inclusion of the neonatal exon in different 
sodium channels is increased in models of epilepsy (Gastaldi et al., 1997), or in patients with 
epilepsy (Heinzen et al., 2007; Tate et al., 2005). Thus, splicing may alter the efficacy of drugs on 
both excitatory and inhibitory neurons, and the effects in non-epileptic tissue may be different than 
in epileptic tissue, where increased neonatal exon inclusion may increase the impact of AEDs on 
recovery from inactivation. Our results highlight the importance of the same parameter that is 
sensitive to splicing in the response to antiepileptic drugs. 
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Chapter 6: Altered sodium channel availability between neonatal and 
adult channels in neurons and  effects on spike reliability in 
interneurons 
 
 
 
6.1 Hypothesis and Aims 
 
Results from the previous chapters have revealed up to now that under our conditions (37°C, CsCl-
based intracellular solution) Nav1.1 neonatal channels are able to recover more quickly from fast 
inactivation than adults – and hence are more available to be activated during a following 
stimulation – specifically under conditions of high-frequency, repetitive stimulation. Moreover, 
this effect was also conserved among other sodium channels bearing this spicing event, namely in 
this study Nav1.2 and Nav1.7 splice variants.  
A major limitation of this study up to now, as well as most studies on these splice variant 
properties (Xu et al., 2012, Fletcher et al., 2011, Thompson et al., 2011, Farmer et al., 2012), is 
that characterization is performed on heterologous expression systems (mostly HEK293T cells). 
Cell lines typically used to express these channels for voltage-clamp recordings and consequent 
characterization of their biophysical properties, cannot recapitulate the whole anatomy of sodium 
channels or their regulation. Differences in accessory β-subunits, G-proteins and subcellular 
localization of channels may modify the impact of splicing on neuronal behavior (Fletcher et al., 
2011; Farmer et al., 2012), especially since different sodium channel types are expressed on 
different types of neurons. This calls for the need to investigate sodium channel variants under 
their native physiological neuronal context, to evaluate their behavior and see how they may 
modify actual neuronal firing and properties. In the cases of Nav1.1 and Nav1.2, these channel 
types are suggested to primarily be expressed in interneurons and excitatory neurons respectively, 
in the CNS (Yu et al., 2006; Oliva et al., 2012). Therefore, the aim here was to investigate how 
splice variants of either Nav1.1 or Nav1.2 affect neuronal frequency firing and neuronal properties 
in interneurons and excitatory neurons respectively. Furthermore, this also allows direct 
assessment of whether potential differences found between neonatal and adult variants in their 
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physiological context are altered when these are expressed on a different neuronal background, by 
evaluating neonatal and adult Nav1.1 properties in excitatory hippocampal neurons as well as 
inhibitory neurons.  
 
 
 
6.2 TTX resistance and transient expression of 5N and 5A constructs in interneuronal 
hippocampal cultures 
 
The most direct approach to current-clamp studies of Nav1.1 neonatal and adult variants in neurons 
involves the manipulation of splice variant levels in mice by using variant-specific shRNAs to 
lower neonatal or adult expression and evaluate the effects on neuronal firing. However, this 
approach was not possible, since rodents have lost the ability to express the neonatal variant and 
only express adult Nav1.1 channels (Fletcher et al., 2011, Gazina et al., 2010). Furthermore, this 
would not allow us to study the channel’s effect in isolation, since the currents from the Nav1.1 
isoform would be blended with the contribution of all the native sodium channel types that are also 
expressed in these neurons.  
To address these issues, site-directed mutagenesis was used on the SCN1A-5A & 5N constructs to 
introduce the F383S mutation. The phenylalanine residue at this position is integral for the binding 
of tetrodotoxin (TTX) on the outer mouth of the channel, thereby blocking sodium conductance 
through the pore (Heinemann et al., 1992). The F383S mutation modifies the binding pocket of 
TTX on the channel so that it can no longer bind, thereby conferring TTX resistance, as also seen 
in previous studies (Bechi et al., 2012; Cestele et al., 2013). The homologous mutation was also 
performed on the SCN2A 6A & 6N cDNA constructs (Rush et al., 2005).  
After conferring TTX resistance transient transfections were attempted in hippocampal neuronal 
cultures from P0 mice as a means to express the neonatal Nav1.1 variant in neurons. This approach 
is difficult, especially due to the very low transfection efficiency rate of most neuronal transfection 
reagents, which is usually about 1 – 5% (Wanisch et al., 2013). Many different lipid-based 
transfection reagents were tested for efficiency of transient transfection in neurons with either the 
neonatal or adult construct. All of these reagents resulted into either very poor transfection 
efficiencies (1% for Lipofectamine 2000, Effectene, calcium phosphate) or too high cell toxicity 
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and cell death (poly-jetPEI). Eventually, a transfection technique called magnetofection was 
tested, using the Neuromag reagent (OZ Biosciences), which is reported to have specific high 
efficiency for transfecting neurons. Magnetofection is based on the mixture and pair formation of 
the nucleic acid with magnetic beads, which are introduced in the neuronal cell medium and then 
dragged into the neurons with the use of a magnetic plate that is placed underneath the cultures.  
In order to discriminate interneurons from excitatory neurons in the cultures, the GAD67-GFP 
mouse strain was used (Tamamaki et al., 2003). In this strain the GFP protein is expressed under 
the GAD67 promoter, so that it is only present in interneurons. In this way, interneurons can be 
identified by the emission of green light under fluorescence. The percentage of interneurons on 
every coverslip was around 10 – 15%. As a marker of successful transfection, a red fluorescent 
protein (RFP) under the β-actin promoter was co-transfected together with either the neonatal or 
adult sodium channel construct. Transfection efficiency with magnetofection usually reached 
around 10%, which resulted on average in 1 – 1.5% of neurons in the culture being interneurons 
successfully transfected. These could now be selected by the concurrent expression of GFP and 
RFP for current-clamp recordings. Excitatory neurons were selected by the absence of GFP 
expression (GFP negative). Current-clamp recordings were performed in the presence of 1 µM 
TTX in order to block the native sodium channel current and to measure the firing of purely adult- 
or neonatal-driven activity. 
 
 
 
6.3 Results:  
 
6.3.1 Single AP parameters of Nav1.1 neonatal and adult channels are similar in interneurons 
 
The effect of splicing in Nav1.1 channels was examined first in interneurons. Interneurons 
expressing either isoform of Nav1.1 were able to elicit APs upon brief depolarizing current steps of 
10 ms (Figure 6.1A). Both 5A- and 5N-transfected interneurons showed similar passive membrane 
properties (resting membrane potential, input resistance, Figure 6.2A), as well as similar threshold 
current (i.e. amount of current injected to reach threshold – Figure 6.2C). Phase plot analysis of 
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single APs elicited by Nav1.1-5A and 5N channels was used to analyze the active properties of 
transfected interneurons (Figure 6.2B). No significant difference was found between channel 
variants in terms of threshold voltage, maximum rising and repolarizing slopes, AP amplitude or 
50% AP width (P>0.05, unpaired two-tailed Student’s T test; Figure 6.2C). So, at the single AP 
level, Nav1.1-5A and 5N channels appeared to have similar properties in interneurons.  
 
 
 
Figure 6.1: Stimulation conditions for establishing single AP parameters and firing frequency ability of transfected 
hippocampal neurons 
A. A 10ms depolarizing current pulse was given at increasing amplitudes up to the threshold current where an AP 
fired. B. Prolonged depolarization (500ms) often generated just a single spike for both neonatal and adult isoforms. 
C. Firing frequency reliability was assessed by giving a 110% of the threshold current in (A) – i.e. a suprethreshold 
stimulus – in successive pulses, with intervals between pulses getting shorter with each step to increase the firing 
frequency (33 – 90Hz). 
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Figure 6.2: Intrinsic properties of interneurons expressing TTX-resistant splice isoforms of Nav1.1 
A. Neither resting membrane potential (RMP, left, 5A, -57.8  1.8; 5N, -56.7  1.8) nor input resistance (5A, 146.2  
27.8; 5N, 131.0  15.6) was affected by changing the splice isoform of Nav1.1. B. A representative action potential 
(left) and phase plot used to analyse active properties of transfected neurons. C. Parameters describing individual 
action potentials were not altered by changing the splice isoform of Nav1.1. V Threshold: 5A, -25.5  1.2; 5N, -24.4  
1.3, Current Threshold: 5A, 0.380  0.067; 5N, 0.312  0.055, Max Rising slope: 5A, 82.8  9.3; 5N, 94.1  10.0, AP 
Amplitude: 5A, 37.0  3.0; 5N, 39.5  3.2, Max Repolarizing slope: 5A, -47.4  3.0; 5N, -51.2  2.3.(5A n=14; 5N n=13, 
cells were patched from three independent transfection preparatins on three separate days). 
 
 
6.3.2 Nav1.1 splicing controls spike reliability in interneurons 
 
In order to test the firing frequency of transfected interneurons, a prolonged depolarizing current of 
500 ms was initially used. However, prolonged depolarization frequently evoked just a single AP 
(Figure 6.1B), while in the cases it evoked trains of APs, firing rates seemed to be dependent more 
on transfection efficiency (channel density) rather than on the use-dependence properties of the 
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two variants. In order to test the impact of splicing on repetitive firing in a controlled and 
normalized manner, interneurons were depolarized using trains of short, successive 10 ms current 
steps at increasing frequencies (33 – 90 Hz), with a magnitude of 110% of the threshold current 
that was required to elicit a single AP in 10 ms, i.e. meaning a supra-threshold stimulus (Figure 
6.1C). This protocol, therefore, was used to assess firing reliability of each variant channel by 
evaluating at which level and at what frequency each variant would fail to fire, despite being given 
a supra-threshold stimulus. Furthermore, this protocol is thought to be better than prolonged 
depolarizing steps for reflecting the intermittent nature of excitatory inputs in vivo and also allows 
the controlled assessment of the frequency limits of AP firing.  
 
Recordings in interneurons revealed that the neonatal Nav1.1 isoform was able to support a higher 
fidelity of APs than adult channels in response to faster trains of current injections of 60 Hz and on 
(P<0.001, two-way ANOVA; Figure 6.3A,B). At lower frequencies the two variants could elicit 
APs equally reliably, with no failures in firing reliability for any variant. Yet, adult-driven 
interneurons start showing AP failures at lower frequencies compared to “neonatal” interneurons. 
The average frequency of 50% reliability for 5N-expressing interneurons (83 Hz) was 
significantly higher than the equivalent for adult-driven interneurons (69 Hz; P<0.001, unpaired 
two-tailed Student’s T test), while there is no difference of the AP decay rate as the stimulation 
frequency increases between the two variants (P>0.05, unpaired two-tailed Student’s T test) 
(Figure 6.3C). Therefore, this indicates that at a high frequency rate, interneurons can sustain AP 
firing more reliably when expressing all neonatal than when expressing all adult channels.  
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Figure 6.3: Splicing in Nav1.1 is sufficient to alter spike reliability of interneurons during rapid trains 
A. Representative traces from interneurons transfected with Nav1.1-5A (top, black) and Nav1.1-5N (bottom, blue) 
showing reduced ability of the adult isoform to support action potentials at higher frequencies. Neurons were 
subjected to trains of 10 ms depolarizing current steps at 110% of their threshold currents in the presence of 1µM 
TTX to block endogenous channels. Neurons were cultured from GAD67-GFP mice, and interneurons were identified 
by co-localization of GFP and RFP. B,C. Interneurons expressing the neonatal isoform of Nav1.1 are able to sustain 
significantly higher rates of firing. The rate at which neurons fired action potentials at 50% of stimuli (dashed red 
line) was significantly higher for neurons expressing neonatal channels (5N 82.55 ± 2.27, n = 12; 5A 69.27 ± 2.33, n = 
12; ***p = 0.0005, unpaired two-tailed Student`s T test). Recordings and analysis of failure rates were carried out 
while investigator was blinded to isoform expressed. C. The slope of the AP decay rate with increased stimulation 
frequency was similar between Nav1.1-5A and 5N-driven interneurons. 
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6.3.3 Splicing in Nav1.1 can modify sodium channel availability in interneurons during rapid 
trains 
 
Potential differences in neonatal and adult channel availability, which were suggested to occur also 
in HEK293T cell recordings at higher frequency stimulations as seen in Chapter 3, may possibly 
account for the difference in firing frequency reliability found between neonatal- and adult-
transfected interneurons. In order to test this, the rising slope of APs was used as an indicator of 
sodium channel availability, by monitoring how this slowed during repetitive firing. The slowing 
of the AP rising slope is consistent with reduced sodium channel availability, as suggested by 
Scott et al. (2014), where a decrease in sodium channel activation in hippocampal slices is 
reflected by a decay in the AP rising phase during repetitive firing.  
As a first test, a frequency of 44 Hz was taken, at which all pulses still generate an AP in both 
variants, so, phenotypically, there is no difference between the variants in terms of their firing 
reliability. The rising slope of each successive pulse was then normalized to the initial AP to 
monitor how it slows with successive pulses (Figure 6.4A). At this frequency, rising slopes of APs 
supported by the “adult” isoform of Nav1.1 showed marked slowing as trains of stimuli 
progressed, while for neonatal-driven interneurons the rising slope decay rate was less profound 
and significantly higher than the adult at the later part of the train stimulation (Figure 6.4B). So, 
even at frequencies without AP failures, and therefore no firing differences between the variants 
(44 Hz), the neonatal isoform of Nav1.1 was associated with a more constant AP rising slope 
during the train compared to the adult, with the difference AP rising slopes broadening during the 
train and becoming significant from the 7th stimulus on (P<0.05, two-way ANOVA). If the 
stimulation frequency was increased to 56 and 67 Hz (i.e. frequencies at which the neonatal-driven 
interneurons start firing more reliably than adult ones), the difference in rising slope was evident 
after a single AP and increased even further as the stimulation frequency increased (P<0.001, two-
way ANOVA; Figure 6.4C). This suggests that for a stimuli arriving in rapid succession, splicing 
may change sodium channel availability after a single AP.  
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Figure 6.4: The increased failure rate in interneurons expressing the adult isoform is correlated with a slowing of 
the rise time of the action potentials during the series of depolarizing steps 
A. Representative AP traces at 44 Hz frequency stimulation (top panel) and first derivativesof the action potentials 
(bottom panel) evoked by a series of steps from an interneuron expressing Nav1.1-5A (left, black), and Nav1.1-5N 
(right, blue). The height of the peak, as indicated by the dotted lines, corresponds to the steepest part of the rising 
slope (i.e. where the change in voltage per unit time is largest). Traces from a stimuli of 44 Hz is the fastest rate of 
stimuli where interneurons expressing adult isoforms were able to support action potentials for all steps. B. Adult 
isoforms show reduced ability compared to neonatal isoforms to maintain fast rising slopes of action potentials 
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during trains of stimuli. As the series of steps progressed, in cells expressing Nav1.1-5A there was a marked slowing 
of the rising phase (the peak of the first derivative as in A), consistent with decreasing availability of these channels. 
There was no correlating decrease in rate of uptick of action potentials carried by Nav1.1-5N, indicating that unlike 
adult isoforms the availability of neonatal channels was not reduced during trains of action potentials. By the end of 
the series the action potentials supported by the adult isoforms were significantly slower than those supported by 
neonatal isoforms (*p<0.05; two-way ANOVA followed by Bonferroni correction for multiple comparisons, 5A n=12; 
5N n = 13). C. At higher rates of firing the reduction in rising slope for adult isoforms is evident after a single action 
potential. Data show the change in rising slope as measured from the first derivative for those interneurons that 
fired in response to both the first and second stimuli at higher frequencies. Cells which failed to fire action potentials 
were excluded (5A n = 12; 5N n = 13). At 66 Hz the difference became strongly significant (p<0.001; two-way ANOVA 
followed by Bonferroni correction for multiple comparisons).  
 
 
 
6.3.4 Splicing in Nav1.2 does not alter firing frequency fidelity in excitatory neurons  
 
To test whether splicing in Nav1.2 shared a conserved effect on neuronal behavior with splicing in 
Nav1.1, we compared APs supported by isoforms of Nav1.2 in excitatory (i.e. GFP negative) 
neurons and asked whether there were similar effects on rise time. Similar to what was seen for 
Nav1.1, there were no real differences in the passive properties of neurons transfected with either 
Nav1.2-6A or 6N or on most single AP parameters (P>0.05, unpaired two-tailed Student’s T test; 
Figure 6.5A,B). A small difference was only found at the 50% half-width of the single AP 
(P<0.05, unpaired two-tailed Student’s T test; Figure 6.5C), with the Nav1.2-6A channels 
generating APs with shorter half-widths. This effect was not seen in Nav1.1 isoforms, but was in 
accordance to what was found recently in more immature neurons expressing only Nav1.2-6A or 
6N in slice recordings (Gazina et al., 2014). 
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Figure 6.5: Intrinsic properties of excitatory neurons transfected with splice isoforms of Nav1.2 
A. Passive properties of neurons and B. of most single action potentials are not altered by transfection of different 
splice isoforms of Nav1.2. RMP = resting membrane potential. C. Expression of the adult isoform of Nav1.2 reduces 
the half width of APs in excitatory neurons. The mean half width was shorter for neurons expressing Nav1.2-6A (0.86 
± 0.02 ms) compared to Nav1.2-6N (0.99 ± 0.04 ms; *p=0.01; unpaired two-tailed “tudent’s T test).  
 
 
 
In terms of firing reliability at higher stimulation frequency, the two Nav1.2 channel variants  
showed equal reliability, since the difference in frequency at which 50% of APs failed was not 
significantly different between neonatal and adult isoforms (P>0.05, two-way ANOVA; Figure 
6.6A,B). There was a trend for the neonatal isoform to support firing more reliably at higher 
frequency rates, but this did not reach significance.  
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Figure 6.6: Splicing in Nav1.2 does not alter spike reliability in excitatory neurons during rapid trains, with 
neonatal-driven cells showing a non-significant trend to fire more at higher frequencies 
A. Representative traces from excitatory neurons transfected with Nav1.2-6A (top, black) and Nav1.2-6N (bottom, 
green). Recordings were carried out in 1µM TTX to block endogenous channels. B. Excitatory neurons expressing the 
neonatal isoform of Nav1.2 are able to sustain slightly, but not significantly, higher rates of firing than those 
expressing the adult isoform. The rate at which excitatory neurons fired action potentials for 50% of stimuli, as 
calculated by average of exponential fits to individual cells, was not different (p >0.05). Recordings and analysis of 
failure rates were carried out while investigator was blinded to isoform expressed. 
 
 
 
6.3.5 Splicing in Nav1.2 has conserved effects on AP rise time in excitatory neurons 
 
Comparing the decay of the rising slope  during AP trains for the two isoforms as done before for 
Nav1.1 at 44 Hz, both neonatal and adult isoforms of Nav1.2 showed a similar, pronounced 
slowing of AP rise times during trains (P>0.05, two-way ANOVA; Figure 6.7A,B). This indicated 
that in excitatory neurons, inactivation accumulated for both Nav1.2-6A and 6N channels to a 
similar degree, and this degree was more similar to that of the adult Nav1.1 channels in 
interneurons, than the neonatal (Figure 6.4A). When neurons were pushed to fire at higher firing 
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frequencies (56 and 67 Hz), the neonatal isoform supported faster rise times for APs even after a 
single firing during shorter inter-stimulus intervals (P<0.05, two-way ANOVA; Figure 6.7C), 
similar to what was seen for Nav1.1-5A and 5N constructs in interneurons. This suggests that, 
again, at higher stimulation frequencies, the availability of the neonatal Nav1.2 channel is higher 
compared to the adult, although, in this case, this does not directly translate to a significantly 
higher firing fidelity in excitatory neurons. Thus, for depolarizations in rapid trains, splicing in 
both SCN1A and SCN2A genes in their natural milieu has conserved effects on the AP rising phase 
after a single action potential in two different cell types.  
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Figure 6.7: Expression of Nav1.2 in excitatory neurons reveals conserved effect of splicing on rising phase of action 
potentials during fast trains 
A. The second differential of the action potentials evoked by representative series of steps from an excitatory 
neuron expressing Nav1.2-6A (left, black), and Nav1.2-6N (right, green), showing marked drop in the speed of the 
rising slope for both isoforms. Traces are from stimuli at 44 Hz. B. During trains of stimuli neither isoform is able to 
maintain rapid rising phases of action potentials in excitatory neurons. As with Nav1.1, both isoforms show similar 
slowing during the trains. C. At higher rates of firing the reduction in rising slope for adult isoforms is evident after a 
single action potential. Despite the smaller intrinsic differences in isoforms of Nav1.2 compared to Nav1.1, the Nav1.2 
isoforms confirm that for short interpulse intervals, the neonatal channels are more able to support fast rising 
phases. Data show the change in rising slope as measured from the second derivative for those excitatory neurons 
that fired in response to both the first and second stimuli. Cells which failed to fire action potentials were excluded 
(6A n =10; 6N n=9). At 67 Hz the difference was significant (p<0.05; two-way ANOVA followed by Bonferroni`s 
multiple comparisons test).  
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6.3.6 Effect of splicing on AP rise time is also conserved for Nav1.1 isoforms in excitatory 
neurons 
 
To further explore the conservation of the splicing effect on neuronal behavior, it is important to 
validate whether the same channel isoforms have conserved effects on different types of neurons. 
This could give an indication of whether channel isoforms may behave differently when expressed 
in a neuronal environment other than their native one and validate whether the differences they 
produce are cell type-specific. Therefore, it was asked whether neonatal isoforms of Nav1.1 were 
also able to support increased channel availability, this time in excitatory neurons, as opposed to 
interneurons as seen before. Interneurons have different membrane dynamics, frequently 
supporting faster trains of APs than pyramidal neurons. It is unknown whether Nav1.1 expression 
in excitatory neurons would confer a firing frequency high enough for any potential difference 
between the isoforms in reliability to be revealed, yet channel availability will be a more robust 
index of functional conservation of the splicing event in this neuronal milieu.  
Nav1.1-5A and 5N channels expressed in excitatory neurons did not confer any different passive 
properties in the cells in terms of their RMP, input resistance or cell capacitance, or on their 
current threshold (P>0.05, unpaired two-tailed Student’s T test; Figure 6.8A). As for single AP 
properties, neonatal and adult Nav1.1 channels showed similar properties for threshold voltage, 
max rising and repolarizing slopes, AP amplitude and 50% AP width, similar to interneurons 
(P>0.05, unpaired two-tailed Student’s T test; Figure 6.8B).  
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Figure 6.8: Intrinsic properties of excitatory neurons transfected with splice isoforms of Nav1.1 did not differ 
between neonatal and adult 
A. Passive properties of neurons and B. of single action potentials are not altered by transfection of different splice 
isoforms of Nav1.1. RMP = resting membrane potential.  
 
 
In terms of firing frequency, neonatal and adult-driven neurons fired equally reliably during the 
whole range of stimulation frequencies tested (33 – 90 Hz, P>0.05, two-way ANOVA; Figure 
6.9A,B). In excitatory neurons the recombinant neonatal isoform of Nav1.1 did not confer 
interneuron-like fast firing, indicating that membrane properties other than sodium channel 
availability set the maximal firing rate in these cells. In contrast to interneurons, the rising phase of 
APs carried by both isoforms slowed to a similar extent during trains of APs at 44 Hz (P>0.05, 
two-way ANOVA; Figure 6.10A,B), and again this was similar to the decay seen for adult 
channels in interneurons. However, similar to the case in interneurons as well as  Nav1.2 in 
excitatory neurons, when pushed to higher frequencies splicing did impose a significant difference 
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in rise time after a single AP at the highest (67 Hz) firing frequency tested (P<0.05, two-way 
ANOVA; Figure 6.10C).  
 
 
 
 
 
 
 
Figure 6.9: In excitatory neurons the neonatal isoform of Nav1.1 does not confer greater spike reliability at higher 
firing frequency compared to the adult as in interneurons 
A. Representative traces from excitatory neurons transfected with Nav1.1-5A (top, black) and Nav1.1-5N (bottom, 
red). Recordings were carried out in 1µM TTX to block endogenous channels. B. Transfected excitatory neurons are 
not able to sustain high rates of firing with either isoform of Nav1.1. The rate at which neurons fired action potentials 
at 50% of stimuli, as calculated by the average of exponential fits to individual cells, were not different. Recordings 
and analysis of failure rates were carried out while investigator was blinded to isoform expressed. 
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Figure 6.10: An effect of splicing on rising phase of action potentials during fast trains is also conserved when 
Nav1.1 channel isoforms are expressed in excitatory neurons 
A. The second differentials of action potentials evoked by a representative series of steps from an excitatory neuron 
expressing Nav1.1-5A (left, black), and Nav1.1-5N (right, red). Traces are from stimuli at 44 Hz, which is the fastest 
rate of stimuli where excitatory neurons were able to support action potentials for all steps. B. During trains of 
stimuli both adult and neonatal isoforms show marked slowing of the rising phases of the action potentials. In 
contrast to interneurons, where neonatal isoforms maintained rapid rising slopes, excitatory neurons showed 
slowing for both isoforms, indicating trains of action potentials reduced the availability of these channels. Adult and 
neonatal rising slopes were similar throughout the trains. C. At high firing frequencies the adult isoforms show 
reduced rising slope after a single AP. The difference is consistent with that seen for interneurons expressing the 
same isoforms. Data show the change in rising slope as measured from the second derivative for excitatory neurons 
that fired in response to both the first and second stimuli. Cells which failed to fire action potentials were excluded 
(Adult n = 10; Neonate n = 6). At 67 Hz the difference was significant (p<0.05; two-way ANOVA followed by 
Bonferroni`s multiple comparisons test). 
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Therefore, in excitatory cells, splicing in SCN1A can still modify sodium channel availability in 
response to stimuli arriving with short inter-stimuli intervals, such as bursts of APs, similar to the 
situation in interneurons or Nav1.2 isoforms in excitatory neurons as well. 
 
 
 
6.4 Discussion 
 
Recordings in transfected neurons reveal that alternative splicing in sodium channels affects the 
fidelity of action potentials during trains of stimuli in interneurons, most likely by altering the 
stability of the fast component of inactivation. While the effects of splicing are most pronounced 
in interneurons, consistent effects are seen in excitatory neurons where the adult isoforms appear 
to reduce channel availability after a single action potential. This effect is conferred by isoforms of 
at least two different channels (Nav1.1 and Nav1.2), and is consistent with a conserved effect of 
splicing on the inactivation of TTX-sensitive sodium channels, as it was seen before in HEK293T 
cell recordings (Chapter 3). Although Nav1.1 channels are most associated with interneurons that 
can fire rapid trains, in excitatory cells these channels had a trend towards firing less reliably than 
Nav1.2, which highlights the importance of cellular background in determining the firing 
parameters. Both Nav1.1 and Nav1.2 isoform pairs showed a difference in channel availability after 
high stimulation frequency, irrespectively of the cellular background, hence revealing a conserved 
functional effect of the splicing event. Yet, it is only in interneurons, where this is translated into a 
change in firing reliability for the Nav1.1 isoforms, indicating that the native neuronal background 
of Nav1.1 channels is permissive to maximizing the functional difference between variants.    
Our finding that splicing is able to impose conserved functional consequences in different channels 
with different distributions in the nervous system, suggests that the impact of splicing on 
inactivation may be the key functional consequence that has led to the conservation of this 
molecular event. However we cannot rule out other roles for this splicing in regulating interactions 
with other proteins, or contributing to distinct functions in different neuronal populations or during 
development of the nervous system. 
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6.4.1 Splicing in Nav1.1 sets the maximal firing rate in interneurons 
 
Changing the splice isoform of Nav1.1 was sufficient to change the ability of interneurons to fire 
action potentials in response to fast trains of depolarizing current steps. The slowing of the rising 
phase of the action potentials conveyed by the adult isoform strongly suggests that the reduced 
ability to fire rapidly is due to a steady reduction in availability of channels during longer trains, 
likely due to their sequestration in the fast inactivated states. Similarly, the effects of splicing in 
both Nav1.1 and Nav1.2 in excitatory neurons indicate that reliance on the adult isoform can reduce 
the availability of channels after a single action potential. These data are consistent with splicing 
having a relatively modest effect on neuronal behavior, imposing a small reduction in channel 
availability when the adult exon is included. Recently accumulation of sodium channel 
inactivation was shown to be important for setting spike timing (Scott et al., 2014), thus splicing 
may have a role in detecting synchronous inputs. However, further work in preparations with 
intact synaptic inputs would be necessary to determine whether individual EPSPs are sufficient to 
reduce adult isoform availability relative to neonatal availability during bursts of synaptic activity.  
 
 
 
6.4.2 Molecular conservation suggests strong selection against neonatal Nav1.1 in mammals 
 
Despite the fact that the functional effect of this splicing event in sodium channel availability is 
conserved among Nav1.1 and Nav1.2 isoforms in two different kinds of neurons, it is only for 
Nav1.1 in interneurons that this is translated to a difference in firing ability. Therefore, Nav1.1 
isoforms expressed in their physiological milieu can set a difference in interneuron firing at high 
frequencies, which are considered physiological for an interneuron (60 – 90 Hz). On the contrary, 
Nav1.2 isoforms in excitatory neurons do not support that difference. Even at higher frequencies, 
where there is a trend for neonatal Nav1.2 channels to confer higher reliability, this stimulation 
frequency is beyond the typical physiological firing range of excitatory neurons. This means that, 
even though the effect on sodium channel availability is conserved, it is only the Nav1.1 isoforms 
that can have a phenotypic effect in neurons under physiological conditions, at least with the 
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stimulation protocol used here. Although such an effect of the neonatal isoform could be 
considered as a positive consequence in epileptic conditions (also partly supported by association 
studies, e.g. Schlachter et al., 2009; Le Gal et al., 2011; Kumari et al., 2013; Tang et al., 2014), its 
overall effects in normal brain physiology as well as pathophysiology remain unclear. It has been 
noted before (Fletcher et al., 2011; Gazina et al., 2010) that along evolution the rodent copy of 
exon 5N in SCN1A has acquired stop codons that render it non-functional. In humans, the single 
nucleotide polymorphism (SNP) rs3812718 significantly reduces the expression of this exon 
during early development (Heinzen et al., 2007). Interestingly, this SNP occurs with a roughly 
50% prevalence in human chromosomes, suggestive of an ongoing evolutionary selection for a 
SNP that reduces levels of exon 5N.This selective pressure to reduce 5N in SCN1A may not be 
specific to rodents and humans. Analysis of 22 mammalian genomes where exon 5N could be 
identified in SCN1A using the location of this gene in the conserved cluster of five sodium channel 
genes (Figure 6.11A) showed frameshifts and stop codons in seven copies of 5N (Figure 6.11D,E, 
in red), and removal of positively charged arginines from the S4 segment in a further seven copies 
(Figure 6.11C,E in purple), a substitution likely to be damaging for channel function. As an 
example of damage, rabbit 5N harbors 11 amino acid substitutions out of 30 possible in this 
normally highly-conserved voltage-sensing module (Figure 6.11C, Oc, in yellow). Altogether, 
looking down at the single base pair level, only 8 of the 22 copies of SCN1A identified did not 
contain likely deleterious amino acid substitutions (Figure 6.11C). Further evidence for negative 
selection of 5N comes from the finding that a splice site polymorphism homologous with 
rs3812718 has apparently independently arisen in giant panda (Ailuropoda melanoleuca; in light 
blue, Figure 6.11E).  
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 E 
 
SCN1A 
 
Cj  GTTTGTAACAGAATTTGTAAACCTAGGCAAGTTTTCAGCTCTCCACACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Mml GTTTGTAACAGAATTTGTAAACCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Nl  GTTTGTAACAGAATTTGTAAGCCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Og  GTATTTAACCGAATTTGTAAACCTAG-CAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Pp  GTTTGTAACAGAATTTGTAAACCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Pt  GTTTGTAACAGAATTTGTAAACCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Pan GTTTGTAACAGAATTTGTAAACCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGTTTTGAAAACTATT-CTGTAATTCCAGGTAAG 
Pab GTTTGTAACAGAATTTGTAAACCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Sb  GTTTGTAACAGAATTTGTAAACCTAGGCAAATTTTCAGCTCTTCACACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Hs  GTTTGTAACAGAATTTGTAAACCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCGGTAATTCCAGGTAAA 
Am  GTATGTAAAAGAATTTGTAAGCCTAGGCAATTTTTCAGCTCTTCAAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAA 
Bt  GTATGTAACAGAATTTGTAAGCCTAGGCAATTTTTCAGCTGTTCACACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Cl  GTATGTAACAGAATTTGTAAGCCTAGGCAATTTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Ec  GTATGTAACAGAATTTGTAAGCCTAGGCAATTTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAACCTATTTCTGTAATTCCAGGTAAG 
Fc  GTATGTAACAGAATTTGTAAGCCTAGGCAATTTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAACTCCAGGTAAG 
Oc  GGATGTTACAGAATTTGTAAAATTAGGCAGTTTTTCAACTGTTCGCATTTACAGAGTCTTGAGAACTTTGGAAACTATTTCTATAGTTCCAGGTAAG 
Oa  GTATGTAACAGAATTTGTAAGCCTAGGCAATTTTTCAGCTGTTCACACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
La  GAATGCATACTCTATGAAGTTTACATCTAGATAAC-GGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATCTTTGTAATCCCAGGTAAG 
Cp  GATACATAACAGAATGTGTAAGCTAGGCACTTTTT-AGTTCTTTGCAATCTCATATTTTCCAGAATTTTGACAACTACTTACATAACCCAGAGTAAG 
Cg  GCCCATGGCTT-ATTTACCCCTTAATT-AATTTT-CAGCTTTTGGATTTTTT-GAGCATTGAG---TCTAAACACTATTTCATCAATTCTAGATAAG 
Mms GTAAGTAACAAAGTTTGTATACCTAGGTAATTTTT-AGCTATTCACACATTTAGAGGATTGAG---TCTAAAGACCATT-CCCACATTTCTAATTAG 
Rn  GTAAGTACCAGAATTTGTAAACCTGGGTAATTTTT-AGCTCTTGGCTCATATAGAGCATTGAG---TCTAAAGACGGTTTCCACAATTCTAGCTATA 
 
 
SCN2A 
 
Cj  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Mml GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Nl  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Og  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Pp  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Pt  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Pan GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Pab GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGCACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Sb  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Hs  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG 
Cp  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Cg  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Mms GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Rn  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Am  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Bt  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Cl  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Ec  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Fc  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
Oc  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Oa  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
La  GTATGTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG   
 
 
SCN9A 
 
Cj  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Mml GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Nl  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Og  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Pp  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Pt  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Pan GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Pab GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Sb  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Hs  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Cp  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Cg  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Mms GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Rn  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Am  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Bt  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTGTTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Cl  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Ec  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Fc  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTGTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
Oc  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTCTTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGTAAG  
Oa  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTGTTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
La  GTATTTAACAGAATTTGTAAACCTAGGCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATTCCAGGTAAG  
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Figure 6.11: Molecular conservation of sodium channel splicing in domain 1. The neonatal exon has been 
destroyed in multiple mammalian copies of SCN1A 
A. The conserved cluster of sodium channel genes on human chromosome 2 as oriented by UCSC Genome Browser 
Feb 2009 assembly. G3 is the GALNT3 gene which occupies a conserved position between the two pairs of sodium 
channels, and could be used for distinguishing SCN2A from SCN1A in genomes where the notation was incomplete. 
In several cases of published mammalian genomes SCN2A was best distinguished by the reversed orientation with 
respect to SCN3A. B. The invariant amino acid sequences of the neonatal exons in SCN2A (1.2, top) and SCN9A (1.7 
bottom). The sequences were identical for all genomes screened. C,D.  Amino acid sequences encoded by exon 5N in 
Nav1.1 for species where this exon could be un-ambiguously identified, with full length sequences aligned (B), and 
truncated exons not aligned (C). The aligned sequences have changes highlighted according to likelihood of 
functional damage: conservative (green), not conserved (yellow), loss of an S4 arginine (R) or lysine (K) (purple), and 
the non-aligned copies with nonsense (*) at the bottom (C). In some cases (Oc, Og, Cp, Cg, Mm, Rn) the exon could 
not be identified using standard megaBLAST parameters and the location of exon 5N was ascertained using its 
proximity to exon 5A in SCN1A. The identity of SCN1A was confirmed in each of these cases by the location of this 
gene compared to SCN3A, SCN2A and SCN9A in the cluster. E. Alignments of the nucleotide sequences of the 
neonatal exons and flanking 3’splice sequence for all the different mammalian species where exon 5N could be 
found in SCN1A.  Yellow highlights in SCN1A correspond to frameshifts or nonsense mutations. Purple changes in 
SCN1A indicate the site of the human polymorphism rs3812718, which appears to have emerged independently in 
Panda (Am). Highlighted (green) nucleotides in alignments of SCN2A and SCN9A are all synonymous changes. 
Species: Cj Callithrix jacchus; Hs Homo sapiens; Mml Macaca mulatta; Nl Nomascus leucogenys; Og Otolemur 
garnettii; Pp Pan paniscus; Pt Pan troglodytes; Pan Papio anubis; Pab Pongo abelii; Sb Saimiri boliviensis; Cp Cavia 
porcellus; Cg Cricetulus griseus; Mms Mus musculus; Rn Rattus norvegicus; Am Ailuropoda melanoleuca; Bt Bos 
taurus; Cl Canis lupus; Ec Equus caballus; Fc Felis cattus; Oc Oryctolagus cuniculus; Oa Ovis aries; La Loxodonta 
Africana. 
 
 
 
This variability in exon 5N of SCN1A does not appear to reflect a general flexibility in the 
sequences of neonatal isoforms of neuronal sodium channels. Neonatal exons in SCN2A (6N) and 
SCN9A (5N) in the same 22 mammalian species were also identified to see whether a similar 
degree of variation occurred. Neither SCN2A nor SCN9A contained a single amino acid 
substitution in any species (Figure 6.11B). Even at the nucleotide level there was a high level of 
conservation with infrequent silent substitutions (Figure 6.11E). This represents a highly 
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significant difference in rate of damage (p (SCN1A=SCN2A or SCN9A) < 0.0001; Fisher’s exact 
test, with a correction for multiple tests: P < 0.0002). Comparison of the rate of non-synonymous 
(Ka) to Synonymous (Ks) changes has been used as a proxy for detecting genes under rapid 
selection (Liberles & Wayne, 2002). A Ka/Ks ratio greater than 1 is indicative that a gene may be 
under strong selection, because this indicates mutations that change amino acids are more frequent 
that expected compared to silent mutations. Using a consensus ‘neonatal exon’ sequence 
containing all the observed nucleotide substitutions, a comparison was carried out with respect to 
presumed ancestral ‘neonatal’ sequence. This comparison yields a Ka/Ks = 2.4424 for SCN1A 
exon 5N, and indicates that this exon is under strong negative selective pressure in mammals 
(Liberles & Wayne, 2002). In contrast, neither SCN2A nor SCN9A contain a single non-
synonymous mutation (Ka/Ks = 0).  
Therefore, the 5N version of Nav1.1 which is associated with the highest fidelity of firing in 
interneurons appears to be under positive selection for removal from mammalian genomes. The 
selective pressure removing exon 5N from Nav1.1 is unknown, but highly specific to this gene, and 
may be associated with determining the maximal firing rates of interneurons.  
 
 
 
6.5 Summary 
 
To summarize, the change in rising slope after a single action potential was used here as an 
indicator of sodium channel availability (as suggested previously by Scott et al., 2014), which is in 
turn indicative of the ability of the channels to recover from fast inactivation. A higher relative 
rising slope value for neonatal channels compared to adult ones at higher frequencies across 
Nav1.1 and Nav1.2 channels in different neuronal types suggests that there are relatively more 
neonatal channels available during faster stimulation, possibly as a result of increased recovery 
from inactivation. This is in accordance with HEK293T cell data (Chapters 3 & 4) and it is 
consistent with this property that is allowing Nav1.1 neonatal-driven interneurons to fire more 
reliably at higher frequencies. Therefore, here we have managed to extrapolate a difference that 
was found in fast inactivation between neonatal and adult channels in HEK293T cells to a 
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difference in high frequency firing in neurons based on this mechanism, as it is supported by the 
rising slope decay data (Figure 6.12). 
 
 
 
Figure 6.12: The difference in Nav1.1 channel availability between isoforms in HEK293T cells is translated to a 
difference in firing frequency fidelity in interneurons 
The data from interneurons are consistent with the data from HEK293T cells showing a difference in recovery from 
fast inactivation. Data suggest that neurons expressing more 5N could have shorter absolute refractory periods 
allowing shorter inter-spike intervals and higher firing frequency reliability in interneurons for Nav1.1 isoforms. 
 
 
 
The selective loss of neonatal Nav1.1 suggests that although the functional impact of this splicing 
is conserved across channels, the consequences of that conserved function may not be equally 
advantageous in different channels. While there appears to have been high pressure to conserve the 
neonatal forms of Nav1.2 and 1.7, neonatal 1.1 has been removed from multiple mammalian 
genomes. It is possible that the different expression pattern of sodium channels is linked to 
different impacts. The selective loss of the neonatal exon in Nav1.1 may indicate that while the 
more subtle effects on channel availability are conserved, the ability of splicing to control firing 
rate may be deleterious, and the combination of rapid hyperpolarisation, thought to be 
predominantly set by expression of voltage-sensitive potassium channels (Bean, 2007), and fast 
recovering sodium channels may exceed the tolerability limit of even fast spiking interneurons.  
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Chapter 7: Effects of Nav1.1 splicing on single cell response to 
network epileptic activity by Dynamic-Clamp 
 
 
 
7.1 Hypothesis and Aims 
 
Experiments up to now have shown that alternative splicing of exon 5 in sodium channels can 
confer higher availability for neonatal channels in HEK293T cells through increased recovery 
from fast inactivation during trains of fast depolarizations. Extending that to neurons, neonatal 
Nav1.1 channels were able to confer higher reliability at fast firing frequency in cultured 
interneurons, which was consistent with higher availability of neonatal channels at higher 
frequencies. As has been mentioned before, an ambiguous association exists between a common 
polymorphism in SCN1A that disrupts the inclusion of the neonatal exon in Nav1.1 channels (Tate 
et al., 2005) and an increased likelihood of developing seizures (Abe et al., 2008; Kumari et al., 
2013), but this has not been replicated in some studies (Manna et al., 2011). Results shown here 
for interneurons might provide a functional (mechanistic) explanation in favor of this association, 
since the more reliable firing of neonatal interneurons at higher frequencies may better mitigate 
pyramidal cell discharges during epileptic events.  
However, in order to be able to assess the link between seizure predisposition and neuronal 
properties conferred by Nav1.1-5A or 5N channels, there is a need for a more direct assessment of 
how splicing is relevant to circuit pathology, particularly to neuronal activity during epileptiform 
events. To address this, we used dynamic clamp recordings as a tool for simulating epileptic 
synaptic activity to Nav1.1-5A or 5N-transfected neurons in cultures. Dynamic clamp recordings 
have mostly been used to reintroduce a single isolated conductance in a cell to study its properties 
(Pavlov et al., 2014; Milescu et al., 2008). We decided to use the dynamic clamp approach in a 
different way, by introducing a recorded template of network epileptic activity in isolated neurons 
in order to understand the physiological/pathological implications of Nav1.1 splicing under 
epileptic conditions. 
198 
 
This was performed by first recording the synaptic activity – in terms of changes in conductance – 
experienced by a neuron in an acutely provoked epileptiform event and then “feeding” that pattern 
of epileptic synaptic input conductances to cultured hippocampal neurons transfected with either 
Nav1.1 5A or 5N to examine their firing pattern in response. This approach, therefore, directly 
compared how neonatal and adult channels supported neuronal firing under conditions simulating 
epileptic synaptic activity.  
Dynamic clamp recordings in this chapter were performed by Dr. Gabriele Lignani, while voltage-
clamp neuronal recordings, neuronal cultures and transfections as well as data analysis were 
performed by the writer in collaboration with Dr. Lignani. 
 
 
 
7.2 Setup of a neuronal and interneuronal epileptic trace template 
 
The first step before any dynamic clamp recordings was to record epileptic traces for both 
excitatory neurons and interneurons. These traces would then be used as templates of epileptic 
activity for the dynamic clamp recordings. In order to obtain traces of epileptiform synaptic inputs, 
GAD67-GFP P0 mouse hippocampal neurons were plated and cultured for 21 days, to allow them 
to form robust synaptic connections with each other. An excitatory neuron (GFP negative) and 
after that an inhibitory neuron (GFP positive) were voltage-clamped at -70 mV and their 
spontaneous synaptic currents (AMPA current) were recorded in the presence of the convulsant 4-
Aminopyridine (4-AP, 100 μM) to mimic epileptic network activity, as used in published studies 
(Pozzi et al., 2013) (Figure 7.1A1). The current traces recorded for both excitatory and inhibitory 
neurons were converted into conductance (G=I/V) (Figure 7.1A2) and could then be given as the 
command conductance to the dynamic clamp software, which dynamically injects current in 
patched neurons in current-clamp configuration (Figure 7.1A3). The software reads the voltage of 
patched neurons in real time and calculates how much current to be injected from the conductance 
template (I=G*V), allowing patched neurons to fire APs in response to the command conductance 
(Figure 7.1A). 
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Figure 7.1: Dynamic clamp experimental procedure 
A. After excitatory neuron or interneuron recordings in voltage clamp in the presence of 4AP (1), the resulting 
current is converted in conductance (2). Then, neurons expressing the neonatal or the adult isoform of Nav1.1 were 
recorded in current clamp in presence of TTX and fed with the previous conductance trace generating dynamic 
current injections (3 & 4).  
 
 
 
7.3 Magnitude of Gth – the conductance threshold     
 
Conductance levels can vary between cells, since they depend on neuronal properties (e.g. 
membrane resistance) as well as – in case of transfected neurons – on the level of transfection 
efficiency of each individual neuron. Therefore, the conductance trace should be scaled for each 
neuron to a reference point, as a means of normalizing the conductance magnitude that was going 
to be used for each patched neuron. As a reference point, we used the conductance threshold (Gth) 
of each individual cell (i.e. the minimum conductance required to elicit an AP) (Figure 7.2A). The 
excitatory and inhibitory conductance traces were then scaled to different Gth fractions (0% – 25%) 
for untransfected excitatory and inhibitory neurons respectively, in order to evaluate the optimal 
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scale magnitude that would be used for the dynamic clamp recordings of transfected neurons 
(Figure 7.2 B & C). Analyzing the percent of the conductance threshold with respect to the APs 
elicited in current clamp and to their maximal intra-event frequency, a 15% of conductance 
threshold (max number of events and frequency before a plateau) was selected for all further 
experiments in both excitatory and inhibitory transfected neurons. 
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Figure 7.2: Calculation of the conductance magnitude used for both excitatory and inhibitory neurons and dynamic 
clamp experiments to set the magnitude of conductance threshold. 
A.  Representative protocol of dynamic clamp producing AMPA conductance steps (Erev=0mV; τ=1ms; ΔG=1nS). The 
red circle is the conductance threshold in this specific experiment (repeated 10 times for each neuron recorded. B. & 
C. Number of events and intra-event maximal frequency in excitatory (B) and in inhibitory (C) neurons, against the 
percent of conductance threshold. The red squares represent the percent of conductance threshold used for all the 
dynamic clamp experiments in neurons expressing 5N or 5A splicing isoforms of Nav1.1 
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7.4 Results 
 
7.4.1 In interneurons Nav1.1-5N channels confer higher firing ability under epileptic 
conditions  
 
Nav1.1 5A and 5N were transfected in primary neurons from GAD67-GFP mice and during the 
dynamic clamp recordings TTX was used to block innate sodium channel activity, similar to 
previous recordings (Chapter 6). GFP positive neurons (interneurons) successfully transfected with 
Nav1.1-5A or 5N (i.e.  RFP positive cells) were patched in current clamp configuration. After the 
conductance threshold for each neuron was found, the conductance trace (scaled to 15% of the 
threshold) was used to dynamically inject current in the patched neuron in order to trigger APs in a 
virtual epileptic synaptic barrage. The number of APs triggered by dynamic clamp current 
injection and their inter spike intervals were analyzed (Figure 7.3A). Frequency analysis showed 
that significantly fewer cells expressing the 5A isoform reached an instantaneous firing frequency 
of 50 Hz than cells expressing the 5N isoform (7/14 vs 15/17; P = 0.019, Fisher’s exact test, two-
tails, Figure 7.3B), indicating that neonatal-driven interneurons were able to attain higher firing 
rates than adults during the same epileptiform inputs. This difference in frequency was associated 
with an increased numbers of events for neonatal interneurons (Figure 7.3A, C, 5N 401.2 ± 48.72, 
n = 19; 5A 315 ± 48.38, n = 14), but due to the wide distribution of event numbers between cells 
this difference did not reach statistical significance (P = 0.1, Mann Whitney U test). However, in 
terms of firing frequency, a cumulative frequency histogram of instantaneous firing rate showed a 
highly significant difference between the frequency distributions of the splice variants (Figure 
7.3D; P=0.009, Mann-Whitney U test), with the most pronounced differences between 33 and 90.9 
Hz (same frequencies used in previous current clamp experiments in Chapter 6). This was 
accompanied by a slower AP rising slope for cells expressing the adult splice variant (Figure 7.3E; 
P<0.001, Mann-Whitney U test). However, the presence of a small number of fast-firing cells had 
a disproportionate effect on the number of action potentials with very fast rising slopes. 
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Figure 7.3: Dynamic clamp experiments demonstrate that splicing in Nav1.1 is sufficient to alter interneuron 
activity during epileptiform bursts 
A. Representative voltage traces of the Nav1.1 isoforms resulting from dynamic current injection of the conductance 
trace (left) and zoomed representative traces of Nav1.1 isoforms from the dotted box in A with red arrowheads 
indicating additional events in the cell expressing 5N compared to 5A during the series. B. A smaller percentage of 
interneurons expressing the 5A isoform reached an instantaneous firing frequency of 50 Hz (50%, black, top) than 
cells expressing the 5N isoform (88%, blue, bottom). C. Total number of APs recorded during dynamic current 
injection. Note the spread of points consistent with a small population of fast firing interneurons, and a cluster of 
interneurons firing at a slower rate for each splice variant. Number of events (5N 401.2 ± 48.72, n = 19; 5A 315 ± 
48.38, n = 14; p = 0.1, Mann Whitney U test) is shown as mean ± s.e.m. D. Intra-spike frequency cumulative 
frequency analysis between 33 and 90.9 Hz (frequencies mapped to those tested in Figure 6.3) showed that the 
neonatal Nav1.1 isoform have more high frequency activity during the epileptic barrage compared to the adult 
isoform (5A n=841; 5N n=2165; **p=0.009 Mann Whitney U test). E. Rising slope frequency distribution underline 
the differences between the splicing variants (5A n=4211; 5N n=7620; *** p<0.001 Mann Whitney U test). 
204 
 
Labelled interneurons in GAD-67-GFP mouse cultures cannot be distinguished in terms of 
different interneuronal types, therefore cells patched potentially include both fast and slow-spiking 
interneurons. Concurrent comparison between all three parameters analyzed before (number of 
events, max frequency, and maximal rising slope) showed two distinct clusters of neuronal 
response to the same epileptic activity for both neonatal and adult-driven interneurons (Figure 
7.4A). This distribution is likely due to the presence of a small number of fast spiking interneurons 
in the cultures and is consistent with a cluster of cells that innately fire more rapidly than other 
cells (i.e. most likely parvalbumin-positive interneurons; Figure 7.4B, in white circles). Exclusion 
of this cell group from analysis for both splice isoforms allowed a normalized distribution of event 
data (Figure 7.4C) and also now revealed a highly significant difference in event number, with 
neonatal-driven interneurons firing more APs under epileptic activity conditions than adults 
(Figure 7.4D, P = 0.007, unpaired two-tailed Student’s t-test). Removal of the putative fast spiking 
neurons also expanded the difference between isoforms in inter-spike frequency and rising slope 
frequency distribution (P<0.001 Mann-Whitney test, Figure 7.4 E,F).  
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Figure 7.4: Dynamic clamp experiments in inhibitory neurons showed two clusters of neuronal response to the 
same epileptic activity 
A. Clusters predicted by K-Means clustering for cells expressing 5A (left) and 5N (right) based on the same three 
parameters (number of events, max frequency, and maximal rising slope). For cells expressing 5N only frequency and 
events were significantly different for the two clusters, but for 5A all three parameters distinguished between the 
clusters. B. The number of events for all cells (as in Figure 7.3C), showing the cells clustering as ‘fast-spiking’ as open 
circles and removed from further analysis in D-E of this figure. C. A histogram of binned number of events shows the 
different distributions for 5N and 5A. D. Number of events with fast spiking cluster removed (5N 334.4 ± 30.16, n = 
16; 5A 214.4 ± 17.14, n = 10; **p = 0.007, unpaired two-tailed Student’s T test) Lines indicate mean ± s.e.m.  E. Inter-
spike frequency between 33 and 90.9 Hz with fast spiking neurons removed (5A n=53; 5N n=829; ***p<0.001 Mann-
Whitney test). F. Rising slope frequency distribution with fast spiking neurons removed (5A n= 1943; 5N n=5147; 
***p<0.001 Mann-Whitney test).  
206 
 
Splicing in Nav1.1 is thus sufficient to alter how interneurons fire during epileptiform bursts, in 
particular allowing more cells to support bursts of higher frequency (>50 Hz) activity in response 
to simulated epileptic synaptic barrages. Also, the fact that Nav1.1-5N-driven APs showed on 
average a higher rising slope is indicative of increased availability of this channel isoform at 
higher stimulations (Scott et al., 2014) and is again in agreement to what was seen in current-
clamp recordings for interneurons at Chapter 6.  
 
 
 
7.4.2 Nav1.1-5N channels also support higher availability during epileptic conditions in 
excitatory neurons  
 
To test whether the effect of the neonatal isoform to confer higher firing ability under epileptic 
conditions was confined to interneurons only, dynamic clamp recordings were also performed in 
excitatory (GFP negative) neurons transfected either with Nav1.1-5A or 5N (Figure 7.5A & B). 
Analysis revealed that there was no real difference in terms of how many neurons attained rapid 
bursts of > 50 Hz (5A: 6/7 vs 5N: 5/8; P = 0.569, Fisher’s exact test, two-tails), AP events (Figure 
7.5C, P>0.05, unpaired two-tailed Student’s t-test) as well as in firing frequency (Figure 7.5D, 
P>0.05, Mann-Whitney U test) between isoforms in excitatory neurons. However, neonatal 
channels still elicited APs that had on average higher rising slopes (Figure 7.5E, P=0.004 Mann-
Whitney U test), similar to what was seen before for the two isoforms in interneurons, and in 
current clamp recordings (Chapter 6). Therefore, it appears that the availability of the neonatal 
isoform is higher than the adult isoform during epileptic conditions, irrespective of the neuronal 
type in which it is expressed. Moreover, similar to what was seen in current-clamp firing reliability 
recordings in Chapter 6, it is only in interneurons where this difference in Nav1.1 availability is 
translated into significant differences in neuronal firing rates.  
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Figure 7.5: Dynamic clamp experiments in excitatory neurons demonstrate that splicing in Nav1.1 is sufficient to 
alter only rising slope during epileptic activity 
A. Representative voltage traces of the Nav1.1 isoforms resulting from dynamic current injection of the epileptiform 
conductance trace template. B. Zoomed representative traces of Nav1.1 isoforms from the dotted box in A. C. Total 
number of APs recorded during dynamic current injection showed no significant differences between Nav1.1 splicing 
isoforms. Lines indicate mean ± s.e.m. (5A n= 7; 5N n=8). D. Inter-spike frequency indicates similar firing frequencies 
were supported by 5A and 5N between 33 and 90.9 Hz (5A n=60; 5N n=35). E. Rising slope frequency distribution 
shows a significant difference between 5A and 5N (5A n=1011; 5N n=2452; p=0.004 Mann-Whitney test).  
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7.5 Discussion and summary of the results 
 
Dynamic clamp data indicate that inclusion of the neonatal exon is able to increase the number of 
high frequency bursts fired by interneurons in response to epileptiform synaptic inputs. Neonatal 
Nav1.1 channels more reliably supported bursts of higher frequency (>50 Hz) and can sustain high 
frequency stimulation during epileptiform events better than adult channels for frequencies 
between 33 Hz and 90 Hz. This is in line with current-clamp data for interneurons in Chapter 6, 
where, at the same frequency range, neonatal-Nav1.1 transfected interneurons showed a 
significantly higher firing reliability compared to neurons transfected with their adult counterparts.  
In terms of APs fired during the epileptic trace, neonatal interneurons did fire a higher number 
with respect to adults, which reached significance when cluster analysis was used to discriminate 
between slow and fast-spiking interneurons. This raises the question whether the two channel 
isoforms have a different effect depending on which interneuronal subtype expressing them. 
Dissection of different types of interneurons, by using for example Cre-parvalbumin or Cre-
somatostatin mouse strains, to specify the effects of each sodium channel isoform on each 
particular kind of interneuron would have been the next step if more time was available in order to 
answer this question. However, even this approach would be limited by the late onset of 
parvalbumin and somatostatin promoter activation (i.e. the promoter of these genes is not generally 
active during culture timeframes). A different effect of splicing depending on the interneuronal 
cell type would not be surprising, since such a cell type-specific effect has already been shown 
between excitatory and inhibitory neurons both in current-clamp (Chapter 6) and dynamic-clamp 
recordings. 
The slowing of the rising phase of the action potentials conveyed by the adult isoform strongly 
suggests that the reduced ability to fire rapidly is due to a steady reduction in availability of 
channels during longer trains, as also suggested by Scott et al. (2014). This is likely due to their 
sequestration in the fast inactivated states and these data are consistent with splicing having a 
relatively modest effect on neuronal behavior by imposing a small reduction in channel availability 
when the adult exon is included. They are also in line with current-clamp data in Chapter 6, where 
neonatal channels showed significantly slower decay in rising slope after repetitive firing 
compared to adults in interneurons and this effect was also conserved in excitatory neurons, 
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despite the fact that this was not translated into a change in firing reliability for these cells. The 
same difference in maximal rising slope between neonatal and adult channels in excitatory neurons 
was also seen in dynamic-clamp recordings here, yet again this was not extended to differences in 
the epileptiform activity supported by the two isoforms in excitatory neurons. Therefore, 
comparison of activity in excitatory and inhibitory neurons in both current-clamp and dynamic-
clamp recordings indicates that the functional difference between the two Nav1.1 isoforms is most 
clear in interneurons. It also suggests that the biophysics of Nav1.1 isoforms are particularly 
optimised for specifically modulating interneuronal activity. Finally, this change in interneuronal 
firing may be linked to the genetic association seen between variants that alter splicing of this exon 
and different types of epilepsy (Le Gal et al., 2011; Kasperaviciute et al., 2013; Kumari et al., 
2013, Tang et al., 2014). 
All together, these results reinforce the previous data on the increase AP reliability in interneurons 
expressing the 5N splicing isoform respect to the 5A isoform, but also draw the attention to the 
possible therapeutic implication of Nav1.1 5N as a means of decreasing epileptic seizures by 
increasing firing reliability in the inhibitory neurons.  
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Overview 
 
This study has used four complementary approaches (voltage-clamp, current-clamp, dynamic-
clamp and modelling) to study the biophysical and functional properties of neonatal and adult 
sodium channel isoforms in HEK293T cells and cultured neurons. It has shown that alternative 
splicing has a conserved functional effect in channel availability on three different genes within 
the sodium channel family (SCN1A, SCN2A and SCN9A). Because the study has deliberately 
compared channels with distinct distributions and roles, these results indicate a role for the 
neonatal exon that has been conserved while the genes have diverged. The data also reveal how the 
neonatal isoform of Nav1.1 supports higher firing fidelity and more rapid firing during 
epileptiform events in interneurons and may also be subjected to selective pressure for removal 
among mammals. Apart from the conserved nature of the effects reported on channel availability, 
it cannot be ruled out that other roles for this splicing may exist, in regulating interactions with 
other proteins or in contributing to distinct functions in different neuronal populations, or to 
different roles during development of the nervous system.  
As discussed in section 4.3, splicing at this site is associated with altered clinical outcomes. In 
animal models, and cells the function has also been explored by other groups. In the case of 
Nav1.2, development of seizures is associated with a gain-of-function, and may be due to a 
developmental change in excitatory neurons (Gazina et al., 2014; Liao et al., 2010). In Nav1.7, a 
similar strategy of expressing TTX-resistant variants was used to demonstrate that splicing in 
Nav1.7 on its own did not change the excitability of DRG neurons, however the study was focused 
on the impact of a mutation on the variants and did not explore the impact of splicing on channel 
availability (Choi et al., 2010). In SCN1A the lack of exon 5N in rodents has reduced the ability to 
model this behavior in neurons. However, since more rapid firing of interneurons at higher 
frequencies may better mitigate pyramidal cell discharges during potential epileptic events, 
expression of the neonatal exon in Nav1.1, as in Nav1.2 (Gazina et al., 2014), may be protective 
against seizure activity, albeit by a distinct mechanism. The loss of exon 5N from SCN1A suggests 
that although the neonatal exon may be associated with reduced seizures, this is not supporting a 
drive to keep this exon, instead the evidence from published genomes indicates this exon is having 
an unknown negative effect on survival, leading to its loss in many mammalian genomes. 
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In conclusion, data here provide a roadmap for investigating how alternative splicing may produce 
conserved effects in different genes, and in different cell backgrounds. In particular, we show that 
in spite of divergence in gene function, a conserved splicing event in VGSCs can have similar 
functional and pharmacological consequences on different channels. Finally, results in neuronal 
cultures highlight the effect that splicing can have in neuronal behavior both under physiological 
and pathophysiological conditions and reveal a previously unknown potential mechanistic link 
between this splicing event in SCN1A and epilepsy.Future work to identify the biological 
importance and potential therapeutic value of manipulating alternative splicing in sodium channels 
will likely involve regulated genetic modifications in rodent models, an approach already being 
persued by Gazina et al., (2014). These tests will allow in vivo identification of roles played by 
these channel splice variants in diseased and healthy behavior. 
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Appendix I: cDNA and amino acid sequence of all (TTX-sensitive and 
TTX-resistant) sodium channel splice variants used  
 
 
The base pairs and amino acids that differ between isoforms are indicated in red, while the base and 
amino acid that is changed to confer TTX resistance is indicated in yellow. 
 
 
SCN1A-5A cDNA sequence: 
 
ATGGAGCAAACAGTGCTTGTACCACCAGGACCTGACAGCTTCAACTTCTTCACCAGAGAATCTCTTGCGGCTATTGAA
AGACGCATTGCAGAAGAAAAGGCAAAGAATCCCAAACCAGACAAAAAAGATGACGACGAAAATGGCCCAAAGCCA
AATAGTGACTTGGAAGCTGGAAAGAACCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGAGCCCCT
GGAGGACCTGGACCCCTACTATATCAATAAGAAAACTTTTATAGTATTGAATAAAGGGAAGGCCATCTTCCGGTTCA
GTGCCACCTCTGCCCTGTACATTTTAACTCCCTTCAATCCTCTTAGGAAAATAGCTATTAAGATTTTGGTACATTCATTA
TTCAGCATGCTAATTATGTGCACTATTTTGACAAACTGTGTGTTTATGACAATGAGTAACCCTCCTGATTGGACAAAG
AATGTAGAATACACCTTCACAGGAATATATACTTTTGAATCACTTATAAAAATTATTGCAAGGGGATTCTGTTTAGAA
GATTTTACTTTCCTTCGGGATCCATGGAACTGGCTCGATTTCACTGTCATTACATTTGCGTACGTCACAGAGTTTGTGG
ACCTGGGCAATGTCTCGGCATTGAGAACATTCAGAGTTCTCCGAGCATTGAAGACGATTTCAGTCATTCCAGGCCTG
AAAACCATTGTGGGAGCCCTGATCCAGTCTGTGAAGAAGCTCTCAGATGTAATGATCCTGACTGTGTTCTGTCTGAG
CGTATTTGCTCTAATTGGGCTGCAGCTGTTCATGGGCAACCTGAGGAATAAATGTATACAATGGCCTCCCACCAATG
CTTCCTTGGAGGAACATAGTATAGAAAAGAATATAACTGTGAATTATAATGGTACACTTATAAATGAAACTGTCTTTG
AGTTTGACTGGAAGTCATATATTCAAGATTCAAGATATCATTATTTCCTGGAGGGTTTTTTAGATGCACTACTATGTG
GAAATAGCTCTGATGCAGGCCAATGTCCAGAGGGATATATGTGTGTGAAAGCTGGTAGAAATCCCAATTATGGCTA
CACAAGCTTTGATACCTTCAGTTGGGCTTTTTTGTCCTTGTTTCGCCTAATGACTCAGGACTTCTGGGAAAATCTTTAT
CAACTGACATTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGTTGGTCATTTTCcTaGGCTCATTCTACCTAA
TAAATTTGATCCTGGCTGTGGTGGCCATGGCCTACGAGGAACAGAATCAGGCCACCTTGGAAGAAGCAGAACAGAA
AGAGGCCGAATTTCAGCAGATGATTGAACAGCTTAAAAAGCAACAGGAGGCAGCTCAGCAGGCAGCAACGGCAAC
TGCCTCAGAACATTCCAGAGAGCCCAGTGCAGCAGGCAGGCTCTCAGACAGCTCATCTGAAGCCTCTAAGTTGAGTT
CCAAGAGTGCTAAGGAAAGAAGAAATCGGAGGAAGAAAAGAAAACAGAAAGAGCAGTCTGGTGGGGAAGAGAAA
GATGAGGATGAATTCCAAAAATCTGAATCTGAGGACAGCATCAGGAGGAAAGGTTTTCGCTTCTCCATTGAAGGGA
ACCGATTGACATATGAAAAGAGGTACTCCTCCCCACACCAGTCTTTGTTGAGCATCCGTGGCTCCCTATTTTCACCAA
GGCGAAATAGCAGAACAAGCCTTTTCAGCTTTAGAGGGCGAGCAAAGGATGTGGGATCTGAGAACGACTTCGCAG
ATGATGAGCACAGCACCTTTGAGGATAACGAGAGCCGTAGAGATTCCTTGTTTGTGCCCCGACGACACGGAGAGAG
ACGCAACAGCAACCTGAGTCAGACCAGTAGGTCATCCCGGATGCTGGCAGTGTTTCCAGCGAATGGGAAGATGCAC
AGCACTGTGGATTGCAATGGTGAGGTTTCCTTGGTTGGTGGACCTTCAGTTCCTACATCGCCTGTTGGACAGCTTCTG
251 
 
CCAGAGGGAACAACCACTGAAACTGAAATGAGAAAGAGAAGGTCAAGTTCTTTCCACGTTTCCATGGACTTTCTAGA
AGATCCTTCCCAAAGGCAACGAGCAATGAGTATAGCCAGCATTCTAACAAATACAGTAGAAGAACTTGAAGAATCCA
GGCAGAAATGCCCACCCTGTTGGTATAAATTTTCCAACATATTCTTAATCTGGGACTGTTCTCCATATTGGTTAAAAGT
GAAACATGTTGTCAACCTGGTCGTGATGGACCCATTTGTTGACCTGGCCATCACCATCTGTATTGTCTTAAATACTCTT
TTCATGGCCATGGAGCACTATCCAATGACGGACCATTTCAATAATGTGCTTACAGTAGGAAACTTGGTTTTCACTGGG
ATCTTTACAGCAGAAATGTTTCTGAAAATTATTGCCATGGATCCTTACTATTATTTCCAAGAAGGCTGGAATATCTTTG
ACGGTTTTATTGTGACGCTTAGCCTGGTAGAACTTGGACTCGCCAATGTGGAAGGATTATCTGTTCTCCGTTCATTTC
GATTGCTGCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACGTTAAATATGCTAATAAAGATCATCGGCAATTCCGTG
GGGGCTCTGGGAAATTTAACCCTCGTCTTGGCCATCATCGTCTTCATTTTTGCCGTGGTCGGCATGCAGCTCTTTGGT
AAAAGCTACAAAGATTGTGTCTGCAAGATCGCCAGTGATTGTCAACTCCCACGCTGGCACATGAATGACTTCTTCCAC
TCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGGGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTTGCTGGTCA
AGCCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAACCTAGTGGTCCTGAATCTCTTTCTGGCCTTGCTT
CTGAGCTCATTTAGTGCAGACAACCTTGCAGCCACTGATGATGATAATGAAATGAATAATCTCCAAATTGCTGTGGAT
AGGATGCACAAAGGAGTAGCTTATGTGAAAAGAAAAATATATGAATTTATTCAACAGTCCTTCATTAGGAAACAAAA
GATTTTAGATGAAATTAAACCACTTGATGATCTAAACAACAAGAAAGACAGTTGTATGTCCAATCATACAGCAGAAA
TTGGGAAAGATCTTGACTATCTTAAAGATGTAAATGGAACTACAAGTGGTATAGGAACTGGCAGCAGTGTTGAAAA
ATACATTATTGATGAAAGTGATTACATGTCATTCATAAACAACCCCAGTCTTACTGTGACTGTACCAATTGCTGTAGG
AGAATCTGACTTTGAAAATTTAAACACGGAAGACTTTAGTAGTGAATCGGATCTGGAAGAAAGCAAAGAGAAACTG
AATGAAAGCAGTAGCTCATCAGAAGGTAGCACTGTGGACATCGGCGCACCTGTAGAAGAACAGCCCGTAGTGGAAC
CTGAAGAAACTCTTGAACCAGAAGCTTGTTTCACTGAAGGCTGTGTACAAAGATTCAAGTGTTGTCAAATCAATGTG
GAAGAAGGCAGAGGAAAACAATGGTGGAACCTGAGAAGGACGTGTTTCCGAATAGTTGAACATAACTGGTTTGAG
ACCTTCATTGTTTTCATGATTCTCCTTAGTAGTGGTGCTCTGGCATTTGAAGATATATATATTGATCAGCGAAAGACG
ATTAAGACGATGTTGGAATATGCTGACAAGGTTTTCACTTACATTTTCATTCTGGAAATGCTTCTAAAATGGGTGGCA
TATGGCTATCAAACATATTTCACCAATGCCTGGTGTTGGCTGGACTTCTTAATTGTTGATGTTTCATTGGTCAGTTTAA
CAGCAAATGCCTTGGGTTACTCAGAACTTGGAGCCATCAAATCTCTCAGGACACTAAGAGCTCTGAGACCTCTAAGA
GCCTTATCTCGATTTGAAGGGATGAGGGTGGTTGTGAATGCCCTTTTAGGAGCAATTCCATCCATCATGAATGTGCTT
CTGGTTTGTCTTATATTCTGGCTAATTTTCAGCATCATGGGCGTAAATTTGTTTGCTGGCAAATTCTACCACTGTATTA
ACACCACAACTGGTGACAGGTTTGACATCGAAGACGTGAATAATCATACTGATTGCCTAAAACTAATAGAAAGAAAT
GAGACTGCTCGATGGAAAAATGTGAAAGTAAACTTTGATAATGTAGGATTTGGGTATCTCTCTTTGCTTCAAGTTGCC
ACATTCAAAGGATGGATGGATATAATGTATGCAGCAGTTGATTCCAGAAATGTGGAACTCCAGCCTAAGTATGAAG
AAAGTCTGTACATGTATCTTTACTTTGTTATTTTCATCATCTTTGGGTCCTTCTTCACCTTGAACCTGTTTATTGGTGTC
ATCATAGATAATTTCAACCAGCAGAAAAAGAAGTTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGAAAT
ACTATAATGCAATGAAAAAATTAGGATCGAAAAAACCGCAAAAGCCTATACCTCGACCAGGAAACAAATTTCAAGG
AATGGTCTTTGACTTCGTAACCAGACAAGTTTTTGACATAAGCATCATGATTCTCATCTGTCTTAACATGGTCACAATG
ATGGTGGAAACAGATGACCAGAGTGAATATGTGACTACCATTTTGTCACGCATCAATCTGGTGTTCATTGTGCTATTT
ACTGGAGAGTGTGTACTGAAACTCATCTCTCTACGCCATTATTATTTTACCATTGGATGGAATATTTTTGATTTTGTGG
TTGTCATTCTCTCCATTGTAGGTATGTTTCTTGCCGAGCTGATAGAAAAGTATTTCGTGTCCCCTACCCTGTTCCGAGT
GATCCGTCTTGCTAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTGCTT
TGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTACTCTTCCTAGTCATGTTCATCTACGCCATCTTTGGGATG
TCCAACTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCATGAT
CTGCCTATTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCCATTCTCAACAGTAAGCCACCCGACTG
TGACCCTAATAAAGTTAACCCTGGAAGCTCAGTTAAGGGAGACTGTGGGAACCCATCTGTTGGAATTTTCTTTTTTGT
252 
 
CAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGCTAC
TGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCGAT
GCAACTCAGTTCATGGAATTTGAAAAATTATCTCAGTTTGCAGCTGCGCTTGAACCGCCTCTCAATCTGCCACAACCA
AACAAACTCCAGCTCATTGCCATGGATTTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGATATCTTATTTGCT
TTTACAAAGCGGGTTCTAGGAGAGAGTGGAGAGATGGATGCTCTACGAATACAGATGGAAGAGCGATTCATGGCTT
CCAATCCTTCCAAGGTCTCCTATCAGCCAATCACTACTACTTTAAAACGAAAACAAGAGGAAGTATCTGCTGTCATTA
TTCAGCGTGCTTACAGACGCCACCTTTTAAAGCGAACTGTAAAACAAGCTTCCTTTACGTACAATAAAAACAAAATCA
AAGGTGGGGCTAATCTTCTTATAAAAGAAGACATGATAATTGACAGAATAAATGAAAACTCTATTACAGAAAAAACT
GATCTGACCATGTCCACTTCAGCTTGTCCACCTTCCTATGACCGGGTGACAAAGCCAATTGTGGAAAAACATGAGCA
AGAAGGCAAAGATGAAAAAGCCAAAGGGAAATAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
253 
 
SCN1A-5A amino acid sequence: 
 
Met E Q T V L V P P G P D S F N F F T R E S L A A I E R R I A E E K A K N P K P D K K D D D E N G P K P N S D L E 
A G K N L P F I Y G D I P P E Met V S E P L E D L D P Y Y I N K K T F I V L N K G K A I F R F S A T S A L Y I L T P F 
N P L R K I A I K I L V H S L F S Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I I A R G F C L E D F T F L R D P W N W L D F T V I T F A Y V T E F V D L G N V S A L R T F R V L R A L K T 
I S V I P G L K T I V G A L I Q S V K K L S D VMet I L T V F C L S V F A L I G L Q L F Met G N L R N K C I Q W P P T 
N A S L E E H S I E K N I T V N Y N G T L I N E T V F E F D W K S Y I Q D S R Y H Y F L E G F L D A L L C G N S S D 
A G Q C P E G Y Met C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D F W E N L Y Q L T L R A 
A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q Q Met I 
E Q L K K Q Q E A A Q Q A A T A T A S E H S R E P S A A G R L S D S S S E A S K L S S K S A K E R R N R R K K R K 
Q K E Q S G G E E K D E D E F Q K S E S E D S I R R K G F R F S I E G N R L T Y E K R Y S S P H Q S L L S I R G S L F 
S P R R N S R T S L F S F R G R A K D V G S E N D F A D D E H S T F E D N E S R R D S L F V P R R H G E R R N S N 
L S Q T S R S S R Met L A V F P A N G K Met H S T V D C N G E V S L V G G P S V P T S P V G Q L L P E G T T T E 
T E Met R K R R S S S F H V S Met D F L E D P S Q R Q R A Met S I A S I L T N T V E E L E E S R Q K C P P C W Y 
K F S N I F L I W D C S P Y W L K V K H V V N L V V Met D P F V D L A I T I C I V L N T L F Met A Met E H Y 
P Met T D H F N N V L T V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N I F D G F I V T L S L 
V E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F 
I F A V V G Met Q L F G K S Y K D C V C K I A S D C Q L P R W H Met N D F F H S F L I V F R V L C G E W I E 
T Met W D C Met E V A G Q A Met C L T V F Met Met V Met V I G N L V V L N L F L A L L L S S F S A D N L A A 
T D D D N E Met N N L Q I A V D R Met H K G V A Y V K R K I Y E F I Q Q S F I R K Q K I L D E I K P L D D L N N K 
K D S C Met S N H T A E I G K D L D Y L K D V N G T T S G I G T G S S V E K Y I I D E S D YMet S F I N N P S L T V 
T V P I A V G E S D F E N L N T E D F S S E S D L E E S K E K L N E S S S S S E G S T V D I G A P V E E Q P V V E P E 
E T L E P E A C F T E G C V Q R F K C C Q I N V E E G R G K Q W W N L R R T C F R I V E H N W F E T F I V 
F Met I L L S S G A L A F E D I Y I D Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G Y Q T Y F 
T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E G Met R V V 
V N A L L G A I P S IMet N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N T T T G D R F D I E D V N N 
H T D C L K L I E R N E T A R W K N V K V N F D N V G F G Y L S L L Q V A T F K G W Met D I Met Y A A V D S R 
N V E L Q P K Y E E S L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N Q Q K K K F G G Q D I F Met T E 
E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K F Q G Met V F D F V T R Q V F D I S I Met I L I C L 
N Met V T Met Met V E T D D Q S E Y V T T I L S R I N L V F I V L F T G E C V L K L I S L R H Y Y F T I G W N I F D 
F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I K G A K G I R T L L F A 
L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D D Met F N F E T F G N 
S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P N K V N P G S S V K G D C G N P S V G I F F F V S 
Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W E K F D P D A T Q 
F Met E F E K L S Q F A A A L E P P L N L P Q P N K L Q L I A Met D L P Met V S G D R I H C L D I L F A F T K R V 
L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y Q P I T T T L K R K Q E E V S A V I I Q R A Y R R H 
L L K R T V K Q A S F T Y N K N K I K G G A N L L I K E D Met I I D R I N E N S I T E K T D L T Met S T S A C P P S 
Y D R V T K P I V E K H E Q E G K D E K A K G K Stop 
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SCN1A-5N cDNA sequence: 
 
ATGGAGCAAACAGTGCTTGTACCACCAGGACCTGACAGCTTCAACTTCTTCACCAGAGAATCTCTTGCGGCTATTGAA
AGACGCATTGCAGAAGAAAAGGCAAAGAATCCCAAACCAGACAAAAAAGATGACGACGAAAATGGCCCAAAGCCA
AATAGTGACTTGGAAGCTGGAAAGAACCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGAGCCCCT
GGAGGACCTGGACCCCTACTATATCAATAAGAAAACTTTTATAGTATTGAATAAAGGGAAGGCCATCTTCCGGTTCA
GTGCCACCTCTGCCCTGTACATTTTAACTCCCTTCAATCCTCTTAGGAAAATAGCTATTAAGATTTTGGTACATTCATTA
TTCAGCATGCTAATTATGTGCACTATTTTGACAAACTGTGTGTTTATGACAATGAGTAACCCTCCTGATTGGACAAAG
AATGTAGAATACACCTTCACAGGAATATATACTTTTGAATCACTTATAAAAATTATTGCAAGGGGATTCTGTTTAGAA
GATTTTACTTTCCTTCGGGATCCATGGAACTGGCTCGATTTCACTGTCATTACATTTGCGTTCGTCACAGAGTTTGTGA
ACCTGGGCAATTTCTCGGCATTGAGAACATTCAGAGTTCTCCGAGCATTGAAGACGATTTCAGTCATTCCAGGCCTG
AAAACCATTGTGGGAGCCCTGATCCAGTCTGTGAAGAAGCTCTCAGATGTAATGATCCTGACTGTGTTCTGTCTGAG
CGTATTTGCTCTAATTGGGCTGCAGCTGTTCATGGGCAACCTGAGGAATAAATGTATACAATGGCCTCCCACCAATG
CTTCCTTGGAGGAACATAGTATAGAAAAGAATATAACTGTGAATTATAATGGTACACTTATAAATGAAACTGTCTTTG
AGTTTGACTGGAAGTCATATATTCAAGATTCAAGATATCATTATTTCCTGGAGGGTTTTTTAGATGCACTACTATGTG
GAAATAGCTCTGATGCAGGCCAATGTCCAGAGGGATATATGTGTGTGAAAGCTGGTAGAAATCCCAATTATGGCTA
CACAAGCTTTGATACCTTCAGTTGGGCTTTTTTGTCCTTGTTTCGCCTAATGACTCAGGACTTCTGGGAAAATCTTTAT
CAACTGACATTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGTTGGTCATTTTCcTaGGCTCATTCTACCTAA
TAAATTTGATCCTGGCTGTGGTGGCCATGGCCTACGAGGAACAGAATCAGGCCACCTTGGAAGAAGCAGAACAGAA
AGAGGCCGAATTTCAGCAGATGATTGAACAGCTTAAAAAGCAACAGGAGGCAGCTCAGCAGGCAGCAACGGCAAC
TGCCTCAGAACATTCCAGAGAGCCCAGTGCAGCAGGCAGGCTCTCAGACAGCTCATCTGAAGCCTCTAAGTTGAGTT
CCAAGAGTGCTAAGGAAAGAAGAAATCGGAGGAAGAAAAGAAAACAGAAAGAGCAGTCTGGTGGGGAAGAGAAA
GATGAGGATGAATTCCAAAAATCTGAATCTGAGGACAGCATCAGGAGGAAAGGTTTTCGCTTCTCCATTGAAGGGA
ACCGATTGACATATGAAAAGAGGTACTCCTCCCCACACCAGTCTTTGTTGAGCATCCGTGGCTCCCTATTTTCACCAA
GGCGAAATAGCAGAACAAGCCTTTTCAGCTTTAGAGGGCGAGCAAAGGATGTGGGATCTGAGAACGACTTCGCAG
ATGATGAGCACAGCACCTTTGAGGATAACGAGAGCCGTAGAGATTCCTTGTTTGTGCCCCGACGACACGGAGAGAG
ACGCAACAGCAACCTGAGTCAGACCAGTAGGTCATCCCGGATGCTGGCAGTGTTTCCAGCGAATGGGAAGATGCAC
AGCACTGTGGATTGCAATGGTGAGGTTTCCTTGGTTGGTGGACCTTCAGTTCCTACATCGCCTGTTGGACAGCTTCTG
CCAGAGGGAACAACCACTGAAACTGAAATGAGAAAGAGAAGGTCAAGTTCTTTCCACGTTTCCATGGACTTTCTAGA
AGATCCTTCCCAAAGGCAACGAGCAATGAGTATAGCCAGCATTCTAACAAATACAGTAGAAGAACTTGAAGAATCCA
GGCAGAAATGCCCACCCTGTTGGTATAAATTTTCCAACATATTCTTAATCTGGGACTGTTCTCCATATTGGTTAAAAGT
GAAACATGTTGTCAACCTGGTCGTGATGGACCCATTTGTTGACCTGGCCATCACCATCTGTATTGTCTTAAATACTCTT
TTCATGGCCATGGAGCACTATCCAATGACGGACCATTTCAATAATGTGCTTACAGTAGGAAACTTGGTTTTCACTGGG
ATCTTTACAGCAGAAATGTTTCTGAAAATTATTGCCATGGATCCTTACTATTATTTCCAAGAAGGCTGGAATATCTTTG
ACGGTTTTATTGTGACGCTTAGCCTGGTAGAACTTGGACTCGCCAATGTGGAAGGATTATCTGTTCTCCGTTCATTTC
GATTGCTGCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACGTTAAATATGCTAATAAAGATCATCGGCAATTCCGTG
GGGGCTCTGGGAAATTTAACCCTCGTCTTGGCCATCATCGTCTTCATTTTTGCCGTGGTCGGCATGCAGCTCTTTGGT
AAAAGCTACAAAGATTGTGTCTGCAAGATCGCCAGTGATTGTCAACTCCCACGCTGGCACATGAATGACTTCTTCCAC
TCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGGGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTTGCTGGTCA
AGCCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAACCTAGTGGTCCTGAATCTCTTTCTGGCCTTGCTT
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CTGAGCTCATTTAGTGCAGACAACCTTGCAGCCACTGATGATGATAATGAAATGAATAATCTCCAAATTGCTGTGGAT
AGGATGCACAAAGGAGTAGCTTATGTGAAAAGAAAAATATATGAATTTATTCAACAGTCCTTCATTAGGAAACAAAA
GATTTTAGATGAAATTAAACCACTTGATGATCTAAACAACAAGAAAGACAGTTGTATGTCCAATCATACAGCAGAAA
TTGGGAAAGATCTTGACTATCTTAAAGATGTAAATGGAACTACAAGTGGTATAGGAACTGGCAGCAGTGTTGAAAA
ATACATTATTGATGAAAGTGATTACATGTCATTCATAAACAACCCCAGTCTTACTGTGACTGTACCAATTGCTGTAGG
AGAATCTGACTTTGAAAATTTAAACACGGAAGACTTTAGTAGTGAATCGGATCTGGAAGAAAGCAAAGAGAAACTG
AATGAAAGCAGTAGCTCATCAGAAGGTAGCACTGTGGACATCGGCGCACCTGTAGAAGAACAGCCCGTAGTGGAAC
CTGAAGAAACTCTTGAACCAGAAGCTTGTTTCACTGAAGGCTGTGTACAAAGATTCAAGTGTTGTCAAATCAATGTG
GAAGAAGGCAGAGGAAAACAATGGTGGAACCTGAGAAGGACGTGTTTCCGAATAGTTGAACATAACTGGTTTGAG
ACCTTCATTGTTTTCATGATTCTCCTTAGTAGTGGTGCTCTGGCATTTGAAGATATATATATTGATCAGCGAAAGACG
ATTAAGACGATGTTGGAATATGCTGACAAGGTTTTCACTTACATTTTCATTCTGGAAATGCTTCTAAAATGGGTGGCA
TATGGCTATCAAACATATTTCACCAATGCCTGGTGTTGGCTGGACTTCTTAATTGTTGATGTTTCATTGGTCAGTTTAA
CAGCAAATGCCTTGGGTTACTCAGAACTTGGAGCCATCAAATCTCTCAGGACACTAAGAGCTCTGAGACCTCTAAGA
GCCTTATCTCGATTTGAAGGGATGAGGGTGGTTGTGAATGCCCTTTTAGGAGCAATTCCATCCATCATGAATGTGCTT
CTGGTTTGTCTTATATTCTGGCTAATTTTCAGCATCATGGGCGTAAATTTGTTTGCTGGCAAATTCTACCACTGTATTA
ACACCACAACTGGTGACAGGTTTGACATCGAAGACGTGAATAATCATACTGATTGCCTAAAACTAATAGAAAGAAAT
GAGACTGCTCGATGGAAAAATGTGAAAGTAAACTTTGATAATGTAGGATTTGGGTATCTCTCTTTGCTTCAAGTTGCC
ACATTCAAAGGATGGATGGATATAATGTATGCAGCAGTTGATTCCAGAAATGTGGAACTCCAGCCTAAGTATGAAG
AAAGTCTGTACATGTATCTTTACTTTGTTATTTTCATCATCTTTGGGTCCTTCTTCACCTTGAACCTGTTTATTGGTGTC
ATCATAGATAATTTCAACCAGCAGAAAAAGAAGTTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGAAAT
ACTATAATGCAATGAAAAAATTAGGATCGAAAAAACCGCAAAAGCCTATACCTCGACCAGGAAACAAATTTCAAGG
AATGGTCTTTGACTTCGTAACCAGACAAGTTTTTGACATAAGCATCATGATTCTCATCTGTCTTAACATGGTCACAATG
ATGGTGGAAACAGATGACCAGAGTGAATATGTGACTACCATTTTGTCACGCATCAATCTGGTGTTCATTGTGCTATTT
ACTGGAGAGTGTGTACTGAAACTCATCTCTCTACGCCATTATTATTTTACCATTGGATGGAATATTTTTGATTTTGTGG
TTGTCATTCTCTCCATTGTAGGTATGTTTCTTGCCGAGCTGATAGAAAAGTATTTCGTGTCCCCTACCCTGTTCCGAGT
GATCCGTCTTGCTAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTGCTT
TGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTACTCTTCCTAGTCATGTTCATCTACGCCATCTTTGGGATG
TCCAACTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCATGAT
CTGCCTATTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCCATTCTCAACAGTAAGCCACCCGACTG
TGACCCTAATAAAGTTAACCCTGGAAGCTCAGTTAAGGGAGACTGTGGGAACCCATCTGTTGGAATTTTCTTTTTTGT
CAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGCTAC
TGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCGAT
GCAACTCAGTTCATGGAATTTGAAAAATTATCTCAGTTTGCAGCTGCGCTTGAACCGCCTCTCAATCTGCCACAACCA
AACAAACTCCAGCTCATTGCCATGGATTTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGATATCTTATTTGCT
TTTACAAAGCGGGTTCTAGGAGAGAGTGGAGAGATGGATGCTCTACGAATACAGATGGAAGAGCGATTCATGGCTT
CCAATCCTTCCAAGGTCTCCTATCAGCCAATCACTACTACTTTAAAACGAAAACAAGAGGAAGTATCTGCTGTCATTA
TTCAGCGTGCTTACAGACGCCACCTTTTAAAGCGAACTGTAAAACAAGCTTCCTTTACGTACAATAAAAACAAAATCA
AAGGTGGGGCTAATCTTCTTATAAAAGAAGACATGATAATTGACAGAATAAATGAAAACTCTATTACAGAAAAAACT
GATCTGACCATGTCCACTTCAGCTTGTCCACCTTCCTATGACCGGGTGACAAAGCCAATTGTGGAAAAACATGAGCA
AGAAGGCAAAGATGAAAAAGCCAAAGGGAAATAA 
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SNC1A-5N amino acid sequence: 
 
Met E Q T V L V P P G P D S F N F F T R E S L A A I E R R I A E E K A K N P K P D K K D D D E N G P K P N S D L E 
A G K N L P F I Y G D I P P E Met V S E P L E D L D P Y Y I N K K T F I V L N K G K A I F R F S A T S A L Y I L T P F 
N P L R K I A I K I L V H S L F S Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I I A R G F C L E D F T F L R D P W N W L D F T V I T F A F V T E F V N L G N F S A L R T F R V L R A L K T 
I S V I P G L K T I V G A L I Q S V K K L S D VMet I L T V F C L S V F A L I G L Q L F Met G N L R N K C I Q W P P T 
N A S L E E H S I E K N I T V N Y N G T L I N E T V F E F D W K S Y I Q D S R Y H Y F L E G F L D A L L C G N S S D 
A G Q C P E G Y Met C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D F W E N L Y Q L T L R A 
A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q Q Met I 
E Q L K K Q Q E A A Q Q A A T A T A S E H S R E P S A A G R L S D S S S E A S K L S S K S A K E R R N R R K K R K 
Q K E Q S G G E E K D E D E F Q K S E S E D S I R R K G F R F S I E G N R L T Y E K R Y S S P H Q S L L S I R G S L F 
S P R R N S R T S L F S F R G R A K D V G S E N D F A D D E H S T F E D N E S R R D S L F V P R R H G E R R N S N 
L S Q T S R S S R Met L A V F P A N G K Met H S T V D C N G E V S L V G G P S V P T S P V G Q L L P E G T T T E 
T E Met R K R R S S S F H V S Met D F L E D P S Q R Q R A Met S I A S I L T N T V E E L E E S R Q K C P P C W Y 
K F S N I F L I W D C S P Y W L K V K H V V N L V V Met D P F V D L A I T I C I V L N T L F Met A Met E H Y 
P Met T D H F N N V L T V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N I F D G F I V T L S L 
V E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F 
I F A V V G Met Q L F G K S Y K D C V C K I A S D C Q L P R W H Met N D F F H S F L I V F R V L C G E W I E 
T Met W D C Met E V A G Q A Met C L T V F Met Met V Met V I G N L V V L N L F L A L L L S S F S A D N L A A 
T D D D N E Met N N L Q I A V D R Met H K G V A Y V K R K I Y E F I Q Q S F I R K Q K I L D E I K P L D D L N N K 
K D S C Met S N H T A E I G K D L D Y L K D V N G T T S G I G T G S S V E K Y I I D E S D YMet S F I N N P S L T V 
T V P I A V G E S D F E N L N T E D F S S E S D L E E S K E K L N E S S S S S E G S T V D I G A P V E E Q P V V E P E 
E T L E P E A C F T E G C V Q R F K C C Q I N V E E G R G K Q W W N L R R T C F R I V E H N W F E T F I V 
F Met I L L S S G A L A F E D I Y I D Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G Y Q T Y F 
T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E G Met R V V 
V N A L L G A I P S IMet N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N T T T G D R F D I E D V N N 
H T D C L K L I E R N E T A R W K N V K V N F D N V G F G Y L S L L Q V A T F K G W Met D I Met Y A A V D S R 
N V E L Q P K Y E E S L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N Q Q K K K F G G Q D I F Met T E 
E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K F Q G Met V F D F V T R Q V F D I S I Met I L I C L 
N Met V T Met Met V E T D D Q S E Y V T T I L S R I N L V F I V L F T G E C V L K L I S L R H Y Y F T I G W N I F D 
F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I K G A K G I R T L L F A 
L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D D Met F N F E T F G N 
S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P N K V N P G S S V K G D C G N P S V G I F F F V S 
Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W E K F D P D A T Q 
F Met E F E K L S Q F A A A L E P P L N L P Q P N K L Q L I A Met D L P Met V S G D R I H C L D I L F A F T K R V 
L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y Q P I T T T L K R K Q E E V S A V I I Q R A Y R R H 
L L K R T V K Q A S F T Y N K N K I K G G A N L L I K E D Met I I D R I N E N S I T E K T D L T Met S T S A C P P S 
Y D R V T K P I V E K H E Q E G K D E K A K G K Stop 
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SCN2A-6A cDNA sequence: 
 
ATGGCACAGTCAGTGCTGGTACCGCCAGGACCTGACAGCTTCCGCTTCTTTACCAGGGAATCCCTTGCTGCTATTGAA
CAACGCATTGCAGAAGAGAAAGCTAAGAGACCCAAACAGGAACGCAAGGATGAGGATGATGAAAATGGCCCAAAG
CCAAACAGTGACTTGGAAGCAGGAAAATCTCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGTGCCC
CTGGAGGATCTGGACCCCTACTATATCAATAAGAAAACGTTTATAGTATTGAATAAAGGGAAAGCAATCTCTCGATT
CAGTGCCACCCCTGCCCTTTACATTTTAACTCCCTTCAACCCTATTAGAAAATTAGCTATTAAGATTTTGGTACATTCTT
TATTCAATATGCTCATTATGTGCACGATTCTTACCAACTGTGTATTTATGACCATGAGTAACCCTCCAGACTGGACAAA
GAATGTGGAGTATACCTTTACAGGAATTTATACTTTTGAATCACTTATTAAAATACTTGCAAGGGGCTTTTGTTTAGA
AGATTTCACATTTTTACGGGATCCATGGAATTGGTTGGATTTCACAGTCATTACTTTTGCATATGTGACAGAGTTTGT
GGACCTGGGCAATGTCTCAGCGTTGAGAACATTCAGAGTTCTCCGAGCATTGAAAACAATTTCAGTCATTCCAGGCC
TGAAGACCATTGTGGGGGCCCTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCTTGACTGTGTTCTGTCTAA
GCGTGTTTGCGCTAATAGGATTGCAGTTGTTCATGGGCAACCTACGAAATAAATGTTTGCAATGGCCTCCAGATAAT
TCTTCCTTTGAAATAAATATCACTTCCTTCTTTAACAATTCATTGGATGGGAATGGTACTACTTTCAATAGGACAGTGA
GCATATTTAACTGGGATGAATATATTGAGGATAAAAGTCACTTTTATTTTTTAGAGGGGCAAAATGATGCTCTGCTTT
GTGGCAACAGCTCAGATGCAGGCCAGTGTCCTGAAGGATACATCTGTGTGAAGGCTGGTAGAAACCCCAACTATGG
CTACACGAGCTTTGACACCTTTAGTTGGGCCTTTTTGTCCTTATTTCGTCTCATGACTCAAGACTTCTGGGAAAACCTT
TATCAACTGACACTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGCTGGTCATTTTCTTGGGCTCATTCTATC
TAATAAATTTGATCTTGGCTGTGGTGGCCATGGCCTATGAGGAACAGAATCAGGCCACATTGGAAGAGGCTGAACA
GAAGGAAGCTGAATTTCAGCAGATGCTCGAACAGTTGAAAAAGCAACAAGAAGAGGCTCAGGCGGCAGCTGCAGC
CGCATCTGCTGAATCAAGAGACTTCAGTGGTGCTGGTGGGATAGGAGTTTTTTCAGAGAGTTCTTCAGTAGCATCTA
AGTTGAGCTCCAAAAGTGAAAAAGAGCTGAAAAACAGAAGAAAGAAAAAGAAACAGAAAGAACAGTCTGGAGAA
GAAGAGAAAAATGACAGAGTCCGAAAATCGGAATCTGAAGACAGCATAAGAAGAAAAGGTTTCCGTTTTTCCTTGG
AAGGAAGTAGGCTGACATATGAAAAGAGATTTTCTTCTCCACACCAGTCCTTACTGAGCATCCGTGGCTCCCTTTTCT
CTCCAAGACGCAACAGTAGGGCGAGCCTTTTCAGCTTCAGAGGTCGAGCAAAGGACATTGGCTCTGAGAATGACTTT
GCTGATGATGAGCACAGCACCTTTGAGGACAATGACAGCCGAAGAGACTCTCTGTTCGTGCCGCACAGACATGGAG
AACGGCGCCACAGCAATGTCAGCCAGGCCAGCCGTGCCTCCAGGGTGCTCCCCATCCTGCCCATGAATGGGAAGAT
GCATAGCGCTGTGGACTGCAATGGTGTGGTCTCCCTGGTCGGGGGCCCTTCTACCCTCACATCTGCTGGGCAGCTCC
TACCAGAGGGCACAACTACTGAAACAGAAATAAGAAAGAGACGGTCCAGTTCTTATCATGTTTCCATGGATTTATTG
GAAGATCCTACATCAAGGCAAAGAGCAATGAGTATAGCCAGTATTTTGACCAACACCATGGAAGAACTTGAAGAAT
CCAGACAGAAATGCCCACCATGCTGGTATAAATTTGCTAATATGTGTTTGATTTGGGACTGTTGTAAACCATGGTTAA
AGGTGAAACACCTTGTCAACCTGGTTGTAATGGACCCATTTGTTGACCTGGCCATCACCATCTGCATTGTCTTAAATA
CACTCTTCATGGCTATGGAGCACTATCCCATGACGGAGCAGTTCAGCAGTGTACTGTCTGTTGGAAACCTGGTCTTCA
CAGGGATCTTCACAGCAGAAATGTTTCTCAAGATAATTGCCATGGATCCATATTATTACTTTCAAGAAGGCTGGAATA
TTTTTGATGGTTTTATTGTGAGCCTTAGTTTAATGGAACTTGGTTTGGCAAATGTGGAAGGATTGTCAGTTCTCCGAT
CATTCCGGCTGCTCCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACTCTAAATATGCTAATTAAGATCATTGGCAATT
CTGTGGGGGCTCTAGGAAACCTCACCTTGGTATTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCT
TTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATTTCCAATGATTGTGAACTCCCACGCTGGCACATGCATGACTTTT
TCCACTCCTTCCTGATCGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTCGCT
GGCCAAACCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAATCTAGTGGTTCTGAACCTCTTCTTGGCC
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TTGCTTTTGAGTTCCTTCAGTTCTGACAATCTTGCTGCCACTGATGATGATAACGAAATGAATAATCTCCAGATTGCTG
TGGGAAGGATGCAGAAAGGAATCGATTTTGTTAAAAGAAAAATACGTGAATTTATTCAGAAAGCCTTTGTTAGGAA
GCAGAAAGCTTTAGATGAAATTAAACCGCTTGAAGATCTAAATAATAAAAAAGACAGCTGTATTTCCAACCATACCA
CCATAGAAATAGGCAAAGACCTCAATTATCTCAAAGACGGAAATGGAACTACTAGTGGCATAGGCAGCAGTGTAGA
AAAATATGTCGTGGATGAAAGTGATTACATGTCATTTATAAACAACCCTAGCCTCACTGTGACAGTACCAATTGCTGT
TGGAGAATCTGACTTTGAAAATTTAAATACTGAAGAATTCAGCAGCGAGTCAGATATGGAGGAAAGCAAAGAGAAG
CTAAATGCAACTAGTTCATCTGAAGGCAGCACGGTTGATATTGGAGCTCCCGCCGAGGGAGAACAGCCTGAGGTTG
AACCTGAGGAATCCCTTGAACCTGAAGCCTGTTTTACAGAAGACTGTGTACGGAAGTTCAAGTGTTGTCAGATAAGC
ATAGAAGAAGGCAAAGGGAAACTCTGGTGGAATTTGAGGAAAACATGCTATAAGATAGTGGAGCACAATTGGTTC
GAAACCTTCATTGTCTTCATGATTCTGCTGAGCAGTGGGGCTCTGGCCTTTGAAGATATATACATTGAGCAGCGAAA
AACCATTAAGACCATGTTAGAATATGCTGACAAGGTTTTCACTTACATATTCATTCTGGAAATGCTGCTAAAGTGGGT
TGCATATGGTTTTCAAGTGTATTTTACCAATGCCTGGTGCTGGCTAGACTTCCTGATTGTTGATGTCTCACTGGTTAGC
TTAACTGCAAATGCCTTGGGTTACTCAGAACTTGGTGCCATCAAATCCCTCAGAACACTAAGAGCTCTGAGGCCACTG
AGAGCTTTGTCCCGGTTTGAAGGAATGAGGGTTGTTGTAAATGCTCTTTTAGGAGCCATTCCATCTATCATGAATGTA
CTTCTGGTTTGTCTGATCTTTTGGCTAATATTCAGTATCATGGGAGTGAATCTCTTTGCTGGCAAGTTTTACCATTGTA
TTAATTACACCACTGGAGAGATGTTTGATGTAAGCGTGGTCAACAACTACAGTGAGTGCAAAGCTCTCATTGAGAGC
AATCAAACTGCCAGGTGGAAAAATGTGAAAGTAAACTTTGATAACGTAGGACTTGGATATCTGTCTCTACTTCAAGT
AGCCACGTTTAAGGGATGGATGGATATTATGTATGCAGCTGTTGATTCACGAAATGTAGAATTACAACCCAAGTATG
AAGACAACCTGTACATGTATCTTTATTTTGTCATCTTTATTATTTTTGGTTCATTCTTTACCTTGAATCTTTTCATTGGTG
TCATCATAGATAACTTCAACCAACAGAAAAAGAAGTTTGGAGGTCAAGACATTTTTATGACAGAAGAACAGAAGAA
ATACTACAATGCAATGAAAAAACTGGGTTCAAAGAAACCACAAAAACCCATACCTCGACCTGCTAACAAATTCCAAG
GAATGGTCTTTGATTTTGTAACCAAACAAGTCTTTGATATCAGCATCATGATCCTCATCTGCCTTAACATGGTCACCAT
GATGGTGGAAACCGATGACCAGAGTCAAGAAATGACAAACATTCTGTACTGGATTAATCTGGTGTTTATTGTTCTGT
TCACTGGAGAATGTGTGCTGAAACTGATCTCTCTTCGTTACTACTATTTCACTATTGGATGGAATATTTTTGATTTTGT
GGTGGTCATTCTCTCCATTGTAGGAATGTTTCTGGCTGAACTGATAGAAAAGTATTTTGTGTCCCCTACCCTGTTCCG
AGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTG
CTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTTCTTTTCCTGGTCATGTTCATCTACGCCATCTTTGGG
ATGTCCAATTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCAT
GATCTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAATAGTGGACCTCCAGA
CTGTGACCCTGACAAAGATCACCCTGGAAGCTCAGTTAAAGGAGACTGTGGGAACCCATCTGTTGGGATTTTCTTTTT
TGTCAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGC
TACTGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCC
GATGCGACCCAGTTTATAGAGTTTGCCAAACTTTCTGATTTTGCAGATGCCCTGGATCCTCCTCTTCTCATAGCAAAAC
CCAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGACATCTTATTTG
CTTTTACAAAGCGTGTTTTGGGTGAGAGTGGAGAGATGGATGCCCTTCGAATACAGATGGAAGAGCGATTCATGGC
ATCAAACCCCTCCAAAGTCTCTTATGAGCCCATTACGACCACGTTGAAACGCAAACAAGAGGAGGTGTCTGCTATTAT
TATCCAGAGGGCTTACAGACGCTACCTCTTGAAGCAAAAAGTTAAAAAGGTATCAAGTATATACAAGAAAGACAAA
GGCAAAGAATGTGATGGAACACCCATCAAAGAAGATACTCTCATTGATAAACTGAATGAGAATTCAACTCCAGAGA
AAACCGATATGACGCCTTCCACCACGTCTCCACCCTCGTATGATAGTGTGACCAAACCAGAAAAAGAAAAATTTGAA
AAAGACAAATCAGAAAAGGAAGACAAAGGGAAAGATATCAGGGAAAGTAAAAAGTAA 
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SCN2A-6A amino acid sequence: 
 
Met A Q S V L V P P G P D S F R F F T R E S L A A I E Q R I A E E K A K R P K Q E R K D E D D E N G P K P N S D L 
E A G K S L P F I Y G D I P P E Met V S V P L E D L D P Y Y I N K K T F I V L N K G K A I S R F S A T P A L Y I L T P F 
N P I R K L A I K I L V H S L F N Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I L A R G F C L E D F T F L R D P W N W L D F T V I T F A Y V T E F V D L G N V S A L R T F R V L R A L K 
T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L R N K C L Q W P 
P D N S S F E I N I T S F F N N S L D G N G T T F N R T V S I F N W D E Y I E D K S H F Y F L E G Q N D A L L C G N 
S S D A G Q C P E G Y I C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D F W E N L Y Q L T L R 
A A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q 
Q Met L E Q L K K Q Q E E A Q A A A A A A S A E S R D F S G A G G I G V F S E S S S V A S K L S S K S E K E L K N 
R R K K K K Q K E Q S G E E E K N D R V R K S E S E D S I R R K G F R F S L E G S R L T Y E K R F S S P H Q S L L S I 
R G S L F S P R R N S R A S L F S F R G R A K D I G S E N D F A D D E H S T F E D N D S R R D S L F V P H R H G E 
R R H S N V S Q A S R A S R V L P I L P Met N G K Met H S A V D C N G V V S L V G G P S T L T S A G Q L L P E G 
T T T E T E I R K R R S S S Y H V S Met D L L E D P T S R Q R A Met S I A S I L T N T Met E E L E E S R Q K C P P 
C W Y K F A N Met C L I W D C C K P W L K V K H L V N L V V Met D P F V D L A I T I C I V L N T L 
F Met A Met E H Y P Met T E Q F S S V L S V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N 
I F D G F I V S L S L Met E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A 
L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V C K I S N D C E L P R W H Met H D F F H S F L I V F 
R V L C G E W I E T Met W D C Met E V A G Q T Met C L T V F Met Met VMet V I G N L V V L N L F L A L L L S 
S F S S D N L A A T D D D N E Met N N L Q I A V G R Met Q K G I D F V K R K I R E F I Q K A F V R K Q K A L D E 
I K P L E D L N N K K D S C I S N H T T I E I G K D L N Y L K D G N G T T S G I G S S V E K Y V V D E S D Y Met S F 
I N N P S L T V T V P I A V G E S D F E N L N T E E F S S E S D Met E E S K E K L N A T S S S E G S T V D I G A P A 
E G E Q P E V E P E E S L E P E A C F T E D C V R K F K C C Q I S I E E G K G K L W W N L R K T C Y K I V E H N W 
F E T F I V F Met I L L S S G A L A F E D I Y I E Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G 
F Q V Y F T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E 
G Met R V V V N A L L G A I P S I Met N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N Y T T G 
E Met F D V S V V N N Y S E C K A L I E S N Q T A R W K N V K V N F D N V G L G Y L S L L Q V A T F K G 
W Met D I Met Y A A V D S R N V E L Q P K Y E D N L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N 
Q Q K K K F G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P A N K F Q G Met V F D F V T 
K Q V F D I S I Met I L I C L N Met V T Met Met V E T D D Q S Q E Met T N I L Y W I N L V F I V L F T G E C V L 
K L I S L R Y Y Y F T I G W N I F D F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I 
K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D 
D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S G P P D C D P D K D H P G S S V K G D C 
G N P S V G I F F F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W 
E K F D P D A T Q F I E F A K L S D F A D A L D P P L L I A K P N K V Q L I A Met D L P Met V S G D R I H C L D I L 
F A F T K R V L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y E P I T T T L K R K Q E E V S A I I I Q 
R A Y R R Y L L K Q K V K K V S S I Y K K D K G K E C D G T P I K E D T L I D K L N E N S T P E K T D Met T P S T T 
S P P S Y D S V T K P E K E K F E K D K S E K E D K G K D I R E S K K Stop 
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SCN2A-5N cDNA sequence: 
 
ATGGCACAGTCAGTGCTGGTACCGCCAGGACCTGACAGCTTCCGCTTCTTTACCAGGGAATCCCTTGCTGCTATTGAA
CAACGCATTGCAGAAGAGAAAGCTAAGAGACCCAAACAGGAACGCAAGGATGAGGATGATGAAAATGGCCCAAAG
CCAAACAGTGACTTGGAAGCAGGAAAATCTCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGTGCCC
CTGGAGGATCTGGACCCCTACTATATCAATAAGAAAACGTTTATAGTATTGAATAAAGGGAAAGCAATCTCTCGATT
CAGTGCCACCCCTGCCCTTTACATTTTAACTCCCTTCAACCCTATTAGAAAATTAGCTATTAAGATTTTGGTACATTCTT
TATTCAATATGCTCATTATGTGCACGATTCTTACCAACTGTGTATTTATGACCATGAGTAACCCTCCAGACTGGACAAA
GAATGTGGAGTATACCTTTACAGGAATTTATACTTTTGAATCACTTATTAAAATACTTGCAAGGGGCTTTTGTTTAGA
AGATTTCACATTTTTACGGGATCCATGGAATTGGTTGGATTTCACAGTCATTACTTTTGCATATGTGACAGAGTTTGT
GAACCTGGGCAATGTCTCAGCGTTGAGAACATTCAGAGTTCTCCGAGCATTGAAAACAATTTCAGTCATTCCAGGCC
TGAAGACCATTGTGGGGGCCCTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCTTGACTGTGTTCTGTCTAA
GCGTGTTTGCGCTAATAGGATTGCAGTTGTTCATGGGCAACCTACGAAATAAATGTTTGCAATGGCCTCCAGATAAT
TCTTCCTTTGAAATAAATATCACTTCCTTCTTTAACAATTCATTGGATGGGAATGGTACTACTTTCAATAGGACAGTGA
GCATATTTAACTGGGATGAATATATTGAGGATAAAAGTCACTTTTATTTTTTAGAGGGGCAAAATGATGCTCTGCTTT
GTGGCAACAGCTCAGATGCAGGCCAGTGTCCTGAAGGATACATCTGTGTGAAGGCTGGTAGAAACCCCAACTATGG
CTACACGAGCTTTGACACCTTTAGTTGGGCCTTTTTGTCCTTATTTCGTCTCATGACTCAAGACTTCTGGGAAAACCTT
TATCAACTGACACTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGCTGGTCATTTTCTTGGGCTCATTCTATC
TAATAAATTTGATCTTGGCTGTGGTGGCCATGGCCTATGAGGAACAGAATCAGGCCACATTGGAAGAGGCTGAACA
GAAGGAAGCTGAATTTCAGCAGATGCTCGAACAGTTGAAAAAGCAACAAGAAGAGGCTCAGGCGGCAGCTGCAGC
CGCATCTGCTGAATCAAGAGACTTCAGTGGTGCTGGTGGGATAGGAGTTTTTTCAGAGAGTTCTTCAGTAGCATCTA
AGTTGAGCTCCAAAAGTGAAAAAGAGCTGAAAAACAGAAGAAAGAAAAAGAAACAGAAAGAACAGTCTGGAGAA
GAAGAGAAAAATGACAGAGTCCGAAAATCGGAATCTGAAGACAGCATAAGAAGAAAAGGTTTCCGTTTTTCCTTGG
AAGGAAGTAGGCTGACATATGAAAAGAGATTTTCTTCTCCACACCAGTCCTTACTGAGCATCCGTGGCTCCCTTTTCT
CTCCAAGACGCAACAGTAGGGCGAGCCTTTTCAGCTTCAGAGGTCGAGCAAAGGACATTGGCTCTGAGAATGACTTT
GCTGATGATGAGCACAGCACCTTTGAGGACAATGACAGCCGAAGAGACTCTCTGTTCGTGCCGCACAGACATGGAG
AACGGCGCCACAGCAATGTCAGCCAGGCCAGCCGTGCCTCCAGGGTGCTCCCCATCCTGCCCATGAATGGGAAGAT
GCATAGCGCTGTGGACTGCAATGGTGTGGTCTCCCTGGTCGGGGGCCCTTCTACCCTCACATCTGCTGGGCAGCTCC
TACCAGAGGGCACAACTACTGAAACAGAAATAAGAAAGAGACGGTCCAGTTCTTATCATGTTTCCATGGATTTATTG
GAAGATCCTACATCAAGGCAAAGAGCAATGAGTATAGCCAGTATTTTGACCAACACCATGGAAGAACTTGAAGAAT
CCAGACAGAAATGCCCACCATGCTGGTATAAATTTGCTAATATGTGTTTGATTTGGGACTGTTGTAAACCATGGTTAA
AGGTGAAACACCTTGTCAACCTGGTTGTAATGGACCCATTTGTTGACCTGGCCATCACCATCTGCATTGTCTTAAATA
CACTCTTCATGGCTATGGAGCACTATCCCATGACGGAGCAGTTCAGCAGTGTACTGTCTGTTGGAAACCTGGTCTTCA
CAGGGATCTTCACAGCAGAAATGTTTCTCAAGATAATTGCCATGGATCCATATTATTACTTTCAAGAAGGCTGGAATA
TTTTTGATGGTTTTATTGTGAGCCTTAGTTTAATGGAACTTGGTTTGGCAAATGTGGAAGGATTGTCAGTTCTCCGAT
CATTCCGGCTGCTCCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACTCTAAATATGCTAATTAAGATCATTGGCAATT
CTGTGGGGGCTCTAGGAAACCTCACCTTGGTATTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCT
TTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATTTCCAATGATTGTGAACTCCCACGCTGGCACATGCATGACTTTT
TCCACTCCTTCCTGATCGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTCGCT
GGCCAAACCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAATCTAGTGGTTCTGAACCTCTTCTTGGCC
261 
 
TTGCTTTTGAGTTCCTTCAGTTCTGACAATCTTGCTGCCACTGATGATGATAACGAAATGAATAATCTCCAGATTGCTG
TGGGAAGGATGCAGAAAGGAATCGATTTTGTTAAAAGAAAAATACGTGAATTTATTCAGAAAGCCTTTGTTAGGAA
GCAGAAAGCTTTAGATGAAATTAAACCGCTTGAAGATCTAAATAATAAAAAAGACAGCTGTATTTCCAACCATACCA
CCATAGAAATAGGCAAAGACCTCAATTATCTCAAAGACGGAAATGGAACTACTAGTGGCATAGGCAGCAGTGTAGA
AAAATATGTCGTGGATGAAAGTGATTACATGTCATTTATAAACAACCCTAGCCTCACTGTGACAGTACCAATTGCTGT
TGGAGAATCTGACTTTGAAAATTTAAATACTGAAGAATTCAGCAGCGAGTCAGATATGGAGGAAAGCAAAGAGAAG
CTAAATGCAACTAGTTCATCTGAAGGCAGCACGGTTGATATTGGAGCTCCCGCCGAGGGAGAACAGCCTGAGGTTG
AACCTGAGGAATCCCTTGAACCTGAAGCCTGTTTTACAGAAGACTGTGTACGGAAGTTCAAGTGTTGTCAGATAAGC
ATAGAAGAAGGCAAAGGGAAACTCTGGTGGAATTTGAGGAAAACATGCTATAAGATAGTGGAGCACAATTGGTTC
GAAACCTTCATTGTCTTCATGATTCTGCTGAGCAGTGGGGCTCTGGCCTTTGAAGATATATACATTGAGCAGCGAAA
AACCATTAAGACCATGTTAGAATATGCTGACAAGGTTTTCACTTACATATTCATTCTGGAAATGCTGCTAAAGTGGGT
TGCATATGGTTTTCAAGTGTATTTTACCAATGCCTGGTGCTGGCTAGACTTCCTGATTGTTGATGTCTCACTGGTTAGC
TTAACTGCAAATGCCTTGGGTTACTCAGAACTTGGTGCCATCAAATCCCTCAGAACACTAAGAGCTCTGAGGCCACTG
AGAGCTTTGTCCCGGTTTGAAGGAATGAGGGTTGTTGTAAATGCTCTTTTAGGAGCCATTCCATCTATCATGAATGTA
CTTCTGGTTTGTCTGATCTTTTGGCTAATATTCAGTATCATGGGAGTGAATCTCTTTGCTGGCAAGTTTTACCATTGTA
TTAATTACACCACTGGAGAGATGTTTGATGTAAGCGTGGTCAACAACTACAGTGAGTGCAAAGCTCTCATTGAGAGC
AATCAAACTGCCAGGTGGAAAAATGTGAAAGTAAACTTTGATAACGTAGGACTTGGATATCTGTCTCTACTTCAAGT
AGCCACGTTTAAGGGATGGATGGATATTATGTATGCAGCTGTTGATTCACGAAATGTAGAATTACAACCCAAGTATG
AAGACAACCTGTACATGTATCTTTATTTTGTCATCTTTATTATTTTTGGTTCATTCTTTACCTTGAATCTTTTCATTGGTG
TCATCATAGATAACTTCAACCAACAGAAAAAGAAGTTTGGAGGTCAAGACATTTTTATGACAGAAGAACAGAAGAA
ATACTACAATGCAATGAAAAAACTGGGTTCAAAGAAACCACAAAAACCCATACCTCGACCTGCTAACAAATTCCAAG
GAATGGTCTTTGATTTTGTAACCAAACAAGTCTTTGATATCAGCATCATGATCCTCATCTGCCTTAACATGGTCACCAT
GATGGTGGAAACCGATGACCAGAGTCAAGAAATGACAAACATTCTGTACTGGATTAATCTGGTGTTTATTGTTCTGT
TCACTGGAGAATGTGTGCTGAAACTGATCTCTCTTCGTTACTACTATTTCACTATTGGATGGAATATTTTTGATTTTGT
GGTGGTCATTCTCTCCATTGTAGGAATGTTTCTGGCTGAACTGATAGAAAAGTATTTTGTGTCCCCTACCCTGTTCCG
AGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTG
CTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTTCTTTTCCTGGTCATGTTCATCTACGCCATCTTTGGG
ATGTCCAATTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCAT
GATCTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAATAGTGGACCTCCAGA
CTGTGACCCTGACAAAGATCACCCTGGAAGCTCAGTTAAAGGAGACTGTGGGAACCCATCTGTTGGGATTTTCTTTTT
TGTCAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGC
TACTGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCC
GATGCGACCCAGTTTATAGAGTTTGCCAAACTTTCTGATTTTGCAGATGCCCTGGATCCTCCTCTTCTCATAGCAAAAC
CCAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGACATCTTATTTG
CTTTTACAAAGCGTGTTTTGGGTGAGAGTGGAGAGATGGATGCCCTTCGAATACAGATGGAAGAGCGATTCATGGC
ATCAAACCCCTCCAAAGTCTCTTATGAGCCCATTACGACCACGTTGAAACGCAAACAAGAGGAGGTGTCTGCTATTAT
TATCCAGAGGGCTTACAGACGCTACCTCTTGAAGCAAAAAGTTAAAAAGGTATCAAGTATATACAAGAAAGACAAA
GGCAAAGAATGTGATGGAACACCCATCAAAGAAGATACTCTCATTGATAAACTGAATGAGAATTCAACTCCAGAGA
AAACCGATATGACGCCTTCCACCACGTCTCCACCCTCGTATGATAGTGTGACCAAACCAGAAAAAGAAAAATTTGAA
AAAGACAAATCAGAAAAGGAAGACAAAGGGAAAGATATCAGGGAAAGTAAAAAGTAA 
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SCN2A-5N amino acid sequence: 
 
Met A Q S V L V P P G P D S F R F F T R E S L A A I E Q R I A E E K A K R P K Q E R K D E D D E N G P K P N S D L 
E A G K S L P F I Y G D I P P E Met V S V P L E D L D P Y Y I N K K T F I V L N K G K A I S R F S A T P A L Y I L T P F 
N P I R K L A I K I L V H S L F N Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I L A R G F C L E D F T F L R D P W N W L D F T V I T F A Y V T E F V N L G N V S A L R T F R V L R A L K 
T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L R N K C L Q W P 
P D N S S F E I N I T S F F N N S L D G N G T T F N R T V S I F N W D E Y I E D K S H F Y F L E G Q N D A L L C G N 
S S D A G Q C P E G Y I C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D F W E N L Y Q L T L R 
A A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q 
Q Met L E Q L K K Q Q E E A Q A A A A A A S A E S R D F S G A G G I G V F S E S S S V A S K L S S K S E K E L K N 
R R K K K K Q K E Q S G E E E K N D R V R K S E S E D S I R R K G F R F S L E G S R L T Y E K R F S S P H Q S L L S I 
R G S L F S P R R N S R A S L F S F R G R A K D I G S E N D F A D D E H S T F E D N D S R R D S L F V P H R H G E 
R R H S N V S Q A S R A S R V L P I L P Met N G K Met H S A V D C N G V V S L V G G P S T L T S A G Q L L P E G 
T T T E T E I R K R R S S S Y H V S Met D L L E D P T S R Q R A Met S I A S I L T N T Met E E L E E S R Q K C P P 
C W Y K F A N Met C L I W D C C K P W L K V K H L V N L V V Met D P F V D L A I T I C I V L N T L 
F Met A Met E H Y P Met T E Q F S S V L S V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N 
I F D G F I V S L S L Met E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A 
L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V C K I S N D C E L P R W H Met H D F F H S F L I V F 
R V L C G E W I E T Met W D C Met E V A G Q T Met C L T V F Met Met VMet V I G N L V V L N L F L A L L L S 
S F S S D N L A A T D D D N E Met N N L Q I A V G R Met Q K G I D F V K R K I R E F I Q K A F V R K Q K A L D E 
I K P L E D L N N K K D S C I S N H T T I E I G K D L N Y L K D G N G T T S G I G S S V E K Y V V D E S D Y Met S F 
I N N P S L T V T V P I A V G E S D F E N L N T E E F S S E S D Met E E S K E K L N A T S S S E G S T V D I G A P A 
E G E Q P E V E P E E S L E P E A C F T E D C V R K F K C C Q I S I E E G K G K L W W N L R K T C Y K I V E H N W 
F E T F I V F Met I L L S S G A L A F E D I Y I E Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G 
F Q V Y F T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E 
G Met R V V V N A L L G A I P S I Met N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N Y T T G 
E Met F D V S V V N N Y S E C K A L I E S N Q T A R W K N V K V N F D N V G L G Y L S L L Q V A T F K G 
W Met D I Met Y A A V D S R N V E L Q P K Y E D N L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N 
Q Q K K K F G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P A N K F Q G Met V F D F V T 
K Q V F D I S I Met I L I C L N Met V T Met Met V E T D D Q S Q E Met T N I L Y W I N L V F I V L F T G E C V L 
K L I S L R Y Y Y F T I G W N I F D F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I 
K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D 
D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S G P P D C D P D K D H P G S S V K G D C 
G N P S V G I F F F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W 
E K F D P D A T Q F I E F A K L S D F A D A L D P P L L I A K P N K V Q L I A Met D L P Met V S G D R I H C L D I L 
F A F T K R V L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y E P I T T T L K R K Q E E V S A I I I Q 
R A Y R R Y L L K Q K V K K V S S I Y K K D K G K E C D G T P I K E D T L I D K L N E N S T P E K T D Met T P S T T 
S P P S Y D S V T K P E K E K F E K D K S E K E D K G K D I R E S K K Stop 
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SNC9A-5A cDNA sequence: 
 
ATGGCAATGTTGCCTCCCCCAGGACCTCAGAGCTTTGTCCATTTCACAAAACAGTCTCTTGCCCTCATTGAACAACGC
ATTGCTGAAAGAAAATCAAAGGAACCCAAAGAAGAAAAGAAAGATGATGATGAAGAAGCCCCAAAGCCAAGCAGT
GACTTGGAAGCTGGCAAACAACTGCCCTTCATCTATGGGGACATTCCTCCCGGCATGGTGTCAGAGCCCCTGGAGGA
CTTGGACCCCTACTATGCAGACAAAAAGACTTTCATAGTATTGAACAAAGGGAAAACAATCTTCCGTTTCAATGCCAC
ACCTGCTTTATATATGCTTTCTCCTTTCAGTCCTCTAAGAAGAATATCTATTAAGATTTTAGTACACTCCTTATTCAGCA
TGCTCATCATGTGCACTATTCTGACAAACTGCATATTTATGACCATGAATAACCCGCCGGACTGGACCAAAAATGTCG
AGTACACTTTTACTGGAATATATACTTTTGAATCACTTGTAAAAATCCTTGCAAGAGGCTTCTGTGTAGGAGAATTCA
CTTTTCTTCGTGACCCGTGGAACTGGCTGGATTTTGTCGTCATTGTTTTTGCGTATGTGACAGAATTTGTAGACCTAG
GCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGCCTGAAGACAA
TTGTAGGGGCTTTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCCTGACTGTGTTCTGTCTGAGTGTGTTTG
CACTAATTGGACTACAGCTGTTCATGGGAAACCTGAAGCATAAATGTTTTCGAAATTCACTTGAAAATAATGAAACAT
TAGAAAGCATAATGAATACCCTAGAGAGTGAAGAAGACTTTAGAAAATATTTTTATTACTTGGAAGGATCCAAAGAT
GCTCTCCTTTGTGGTTTCAGCACAGATTCAGGTCAGTGTCCAGAGGGGTACACCTGTGTGAAAATTGGCAGAAACCC
TGATTATGGCTACACGAGCTTTGACACTTTCAGCTGGGCCTTCTTAGCCTTGTTTAGGCTAATGACCCAAGATTACTG
GGAAAACCTTTACCAACAGACGCTGCGTGCTGCTGGCAAAACCTACATGATCTTCTTTGTCGTAGTGATTTTCCTGGG
CTCCTTTTATCTAATAAACTTGATCCTGGCTGTGGTTGCCATGGCATATGAAGAACAGAACCAGGCAAACATTGAAG
AAGCTAAACAGAAAGAATTAGAATTTCAACAGATGTTAGACCGTCTTAAAAAAGAGCAAGAAGAAGCTGAGGCAAT
TGCAGCGGCAGCGGCTGAATATACAAGTATTAGGAGAAGCAGAATTATGGGCCTCTCAGAGAGTTCTTCTGAAACA
TCCAAACTGAGCTCTAAAAGTGCTAAAGAAAGAAGAAACAGAAGAAAGAAAAAGAATCAAAAGAAGCTCTCCAGT
GGAGAGGAAAAGGGAGATGCTGAGAAATTGTCGAAATCAGAATCAGAGGACAGCATCAGAAGAAAAAGTTTCCAC
CTTGGTGTCGAAGGGCATAGGCGAGCACATGAAAAGAGGTTGTCTACCCCCAATCAGTCACCACTCAGCATTCGTGG
CTCCTTGTTTTCTGCAAGGCGAAGCAGCAGAACAAGTCTTTTTAGTTTCAAAGGCAGAGGAAGAGATATAGGATCTG
AGACTGAATTTGCCGATGATGAGCACAGCATTTTTGGAGACAATGAGAGCAGAAGGGGCTCACTGTTTGTGCCCCA
CAGACCCCAGGAGCGACGCAGCAGTAACATCAGCCAAGCCAGTAGGTCCCCACCAATGCTGCCGGTGAACGGGAA
AATGCACAGTGCTGTGGACTGCAACGGTGTGGTCTCCCTGGTTGATGGACGCTCAGCCCTCATGCTCCCCAATGGAC
AGCTTCTGCCAGAGGGCACGACCAATCAAATACACAAGAAAAGGCGTTGTAGTTCCTATCTCCTTTCAGAGGATATG
CTGAATGATCCCAACCTCAGACAGAGAGCAATGAGTAGAGCAAGCATATTAACAAACACTGTGGAAGAACTTGAAG
AGTCCAGACAAAAATGTCCACCTTGGTGGTACAGATTTGCACACAAATTCTTGATCTGGAATTGCTCTCCATATTGGA
TAAAATTCAAAAAGTGTATCTATTTTATTGTAATGGATCCTTTTGTAGATCTTGCAATTACCATTTGCATAGTTTTAAAC
ACATTATTTATGGCTATGGAACACCACCCAATGACTGAGGAATTCAAAAATGTACTTGCTATAGGAAATTTGGTCTTT
ACTGGAATCTTTGCAGCTGAAATGGTATTAAAACTGATTGCCATGGATCCATATGAGTATTTCCAAGTAGGCTGGAA
TATTTTTGACAGCCTTATTGTGACTTTAAGTTTAGTGGAGCTCTTTCTAGCAGATGTGGAAGGATTGTCAGTTCTGCG
ATCATTCAGACTGCTCCGAGTCTTCAAGTTGGCAAAATCCTGGCCAACATTGAACATGCTGATTAAGATCATTGGTAA
CTCAGTAGGGGCTCTAGGTAACCTCACCTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCT
CTTTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACATGAACGACT
TCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTC
GCTGGTCAAGCTATGTGCCTTATTGTTTACATGATGGTCATGGTCATTGGAAACCTGGTGGTCCTAAACCTATTTCTG
GCCTTATTATTGAGCTCATTTAGTTCAGACAATCTTACAGCAATTGAAGAAGACCCTGATGCAAACAACCTCCAGATT
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GCAGTGACTAGAATTAAAAAGGGAATAAATTATGTGAAACAAACCTTACGTGAATTTATTCTAAAAGCATTTTCCAA
AAAGCCAAAGATTTCCAGGGAGATAAGACAAGCAGAAGATCTGAATACTAAGAAGGAAAACTATATTTCTAACCAT
ACACTTGCTGAAATGAGCAAAGGTCACAATTTCCTCAAGGAAAAAGATAAAATCAGTGGTTTTGGAAGCAGCGTGG
ACAAACACTTGATGGAAGACAGTGATGGTCAATCATTTATTCACAATCCCAGCCTCACAGTGACAGTGCCAATTGCA
CCTGGGGAATCCGATTTGGAAAATATGAATGCTGAGGAACTTAGCAGTGATTCGGATAGTGAATACAGCAAAGTGA
GATTAAACCGGTCAAGCTCCTCAGAGTGCAGCACAGTTGATAACCCTTTGCCTGGAGAAGGAGAAGAAGCAGAGGC
TGAACCTATGAATTCCGATGAGCCAGAGGCCTGTTTCACAGATGGTTGTGTACGGAGGTTCTCATGCTGCCAAGTTA
ACATAGAGTCAGGGAAAGGAAAAATCTGGTGGAACATCAGGAAAACCTGCTACAAGATTGTTGAACACAGTTGGTT
TGAAAGCTTCATTGTCCTCATGATCCTGCTCAGCAGTGGTGCCCTGGCTTTTGAAGATATTTATATTGAAAGGAAAAA
GACCATTAAGATTATCCTGGAGTATGCAGACAAGATCTTCACTTACATCTTCATTCTGGAAATGCTTCTAAAATGGAT
AGCATATGGTTATAAAACATATTTCACCAATGCCTGGTGTTGGCTGGATTTCCTAATTGTTGATGTTTCTTTGGTTACT
TTAGTGGCAAACACTCTTGGCTACTCAGATCTTGGCCCCATTAAATCCCTTCGGACACTGAGAGCTTTAAGACCTCTA
AGAGCCTTATCTAGATTTGAAGGAATGAGGGTCGTTGTGAATGCACTCATAGGAGCAATTCCTTCCATCATGAATGT
GCTACTTGTGTGTCTTATATTCTGGCTGATATTCAGCATCATGGGAGTAAATTTGTTTGCTGGCAAGTTCTATGAGTG
TATTAACACCACAGATGGGTCACGGTTTCCTGCAAGTCAAGTTCCAAATCGTTCCGAATGTTTTGCCCTTATGAATGT
TAGTCAAAATGTGCGATGGAAAAACCTGAAAGTGAACTTTGATAATGTCGGACTTGGTTACCTATCTCTGCTTCAAGT
TGCAACTTTTAAGGGATGGACGATTATTATGTATGCAGCAGTGGATTCTGTTAATGTAGACAAGCAGCCCAAATATG
AATATAGCCTCTACATGTATATTTATTTTGTCGTCTTTATCATCTTTGGGTCATTCTTCACTTTGAACTTGTTCATTGGT
GTCATCATAGATAATTTCAACCAACAGAAAAAGAAGCTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGA
AATACTATAATGCAATGAAAAAGCTGGGGTCCAAGAAGCCACAAAAGCCAATTCCTCGACCAGGGAACAAAATCCA
AGGATGTATATTTGACCTAGTGACAAATCAAGCCTTTGATATTAGTATCATGGTTCTTATCTGTCTCAACATGGTAACC
ATGATGGTAGAAAAGGAGGGTCAAAGTCAACATATGACTGAAGTTTTATATTGGATAAATGTGGTTTTTATAATCCT
TTTCACTGGAGAATGTGTGCTAAAACTGATCTCCCTCAGACACTACTACTTCACTGTAGGATGGAATATTTTTGATTTT
GTGGTTGTGATTATCTCCATTGTAGGTATGTTTCTAGCTGATTTGATTGAAACGTATTTTGTGTCCCCTACCCTGTTCC
GAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTT
GCTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGG
AATGTCCAACTTTGCCTATGTTAAAAAGGAAGATGGAATTAATGACATGTTCAATTTTGAGACCTTTGGCAACAGTAT
GATTTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAACAGTAAGCCACCCGA
CTGTGACCCAAAAAAAGTTCATCCTGGAAGTTCAGTTGAAGGAGACTGTGGTAACCCATCTGTTGGAATATTCTACTT
TGTTAGTTATATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATTGCAGTCATACTGGAGAATTTTAGTGTTGCC
ACTGAAGAAAGTACTGAACCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCG
ATGCGACCCAGTTTATAGAGTTCTCTAAACTCTCTGATTTTGCAGCTGCCCTGGATCCTCCTCTTCTCATAGCAAAACC
CAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTTAGTGGTGACCGGATCCATTGTCTTGACATCTTATTTGC
TTTTACAAAGCGTGTTTTGGGTGAGAGTGGGGAGATGGATTCTCTTCGTTCACAGATGGAAGAAAGGTTCATGTCTG
CAAATCCTTCCAAAGTGTCCTATGAACCCATCACAACCACACTAAAACGGAAACAAGAGGATGTGTCTGCTACTGTC
ATTCAGCGTGCTTATAGACGTTACCGCTTAAGGCAAAATGTCAAAAATATATCAAGTATATACATAAAAGATGGAGA
CAGAGATGATGATTTACTCAATAAAAAAGATATGGCTTTTGATAATGTTAATGAGAACTCAAGTCCAGAAAAAACAG
ATGCCACTTCATCCACCACCTCTCCACCTTCATATGATAGTGTAACAAAGCCAGACAAAGAGAAATATGAACAAGACA
GAACAGAAAAGGAAGACAAAGGGAAAGACAGCAAGGAAAGCAAAAAATAG 
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SCN9A-5A amino acid sequence: 
 
Met A Met L P P P G P Q S F V H F T K Q S L A L I E Q R I A E R K S K E P K E E K K D D D E E A P K P S S D L E A 
G K Q L P F I Y G D I P P G Met V S E P L E D L D P Y Y A D K K T F I V L N K G K T I F R F N A T P A L Y Met L S P 
F S P L R R I S I K I L V H S L F S Met L I Met C T I L T N C I F Met T Met N N P P D W T K N V E Y T F T G I Y T F 
E S L V K I L A R G F C V G E F T F L R D P W N W L D F V V I V F A Y V T E F V D L G N V S A L R T F R V L R A L 
K T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L K H K C F R N S 
L E N N E T L E S I Met N T L E S E E D F R K Y F Y Y L E G S K D A L L C G F S T D S G Q C P E G Y T C V K I G R N 
P D Y G Y T S F D T F S W A F L A L F R L Met T Q D Y W E N L Y Q Q T L R A A G K T Y Met I F F V V V I F L G S 
F Y L I N L I L A V V A Met A Y E E Q N Q A N I E E A K Q K E L E F Q Q Met L D R L K K E Q E E A E A I A A A A A 
E Y T S I R R S R I Met G L S E S S S E T S K L S S K S A K E R R N R R K K K N Q K K L S S G E E K G D A E K L S K S 
E S E D S I R R K S F H L G V E G H R R A H E K R L S T P N Q S P L S I R G S L F S A R R S S R T S L F S F K G R G R 
D I G S E T E F A D D E H S I F G D N E S R R G S L F V P H R P Q E R R S S N I S Q A S R S P PMet L P V N G 
K Met H S A V D C N G V V S L V D G R S A L Met L P N G Q L L P E G T T N Q I H K K R R C S S Y L L S E 
D Met L N D P N L R Q R A Met S R A S I L T N T V E E L E E S R Q K C P P W W Y R F A H K F L I W N C S P Y W 
I K F K K C I Y F I V Met D P F V D L A I T I C I V L N T L F Met A Met E H H P Met T E E F K N V L A I G N L V F T 
G I F A A E Met V L K L I A Met D P Y E Y F Q V G W N I F D S L I V T L S L V E L F L A D V E G L S V L R S F R L L 
R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V 
C K I N D D C T L P R W H Met N D F F H S F L I V F R V L C G E W I E T Met W D C Met E V A G Q A Met C L I 
V Y Met Met V Met V I G N L V V L N L F L A L L L S S F S S D N L T A I E E D P D A N N L Q I A V T R I K K G I N 
Y V K Q T L R E F I L K A F S K K P K I S R E I R Q A E D L N T K K E N Y I S N H T L A E Met S K G H N F L K E K D 
K I S G F G S S V D K H L Met E D S D G Q S F I H N P S L T V T V P I A P G E S D L E N MetN A E E L S S D S D S 
E Y S K V R L N R S S S S E C S T V D N P L P G E G E E A E A E P Met N S D E P E A C F T D G C V R R F S C C Q V 
N I E S G K G K I W W N I R K T C Y K I V E H S W F E S F I V L Met I L L S S G A L A F E D I Y I E R K K T I K I I L E 
Y A D K I F T Y I F I L E Met L L K W I A Y G Y K T Y F T N A W C W L D F L I V D V S L V T L V A N T L G Y S D L G 
P I K S L R T L R A L R P L R A L S R F E G Met R V V V N A L I G A I P S I Met N V L L V C L I F W L I F S I Met G 
V N L F A G K F Y E C I N T T D G S R F P A S Q V P N R S E C F A L Met N V S Q N V R W K N L K V N F D N V G 
L G Y L S L L Q V A T F K G W T I I Met Y A A V D S V N V D K Q P K Y E Y S L Y Met Y I Y F V V F I I F G S F F T L 
N L F I G V I I D N F N Q Q K K K L G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K I 
Q G C I F D L V T N Q A F D I S I Met V L I C L N Met V T Met Met V E K E G Q S Q H Met T E V L Y W I N V V F 
I I L F T G E C V L K L I S L R H Y Y F T V G W N I F D F V V V I I S I V GMet F L A D L I E T Y F V S P T L F R V I R L 
A R I G R I L R L V K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y 
V K K E D G I N D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P K K V H P 
G S S V E G D C G N P S V G I F Y F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S T E P L S E D D F 
E Met F Y E V W E K F D P D A T Q F I E F S K L S D F A A A L D P P L L I A K P N K V Q L I A Met D L P Met V S 
G D R I H C L D I L F A F T K R V L G E S G E Met D S L R S Q Met E E R F Met S A N P S K V S Y E P I T T T L K R 
K Q E D V S A T V I Q R A Y R R Y R L R Q N V K N I S S I Y I K D G D R D D D L L N K K D Met A F D N V N E N S 
S P E K T D A T S S T T S P P S Y D S V T K P D K E K Y E Q D R T E K E D K G K D S K E S K K Stop 
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SNC9A-5N cDNA sequence: 
 
ATGGCAATGTTGCCTCCCCCAGGACCTCAGAGCTTTGTCCATTTCACAAAACAGTCTCTTGCCCTCATTGAACAACGC
ATTGCTGAAAGAAAATCAAAGGAACCCAAAGAAGAAAAGAAAGATGATGATGAAGAAGCCCCAAAGCCAAGCAGT
GACTTGGAAGCTGGCAAACAACTGCCCTTCATCTATGGGGACATTCCTCCCGGCATGGTGTCAGAGCCCCTGGAGGA
CTTGGACCCCTACTATGCAGACAAAAAGACTTTCATAGTATTGAACAAAGGGAAAACAATCTTCCGTTTCAATGCCAC
ACCTGCTTTATATATGCTTTCTCCTTTCAGTCCTCTAAGAAGAATATCTATTAAGATTTTAGTACACTCCTTATTCAGCA
TGCTCATCATGTGCACTATTCTGACAAACTGCATATTTATGACCATGAATAACCCGCCGGACTGGACCAAAAATGTCG
AGTACACTTTTACTGGAATATATACTTTTGAATCACTTGTAAAAATCCTTGCAAGAGGCTTCTGTGTAGGAGAATTCA
CTTTTCTTCGTGACCCGTGGAACTGGCTGGATTTTGTCGTCATTGTTTTTGCGTATTTAACAGAATTTGTAAACCTAGG
CAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGCCTGAAGACAAT
TGTAGGGGCTTTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCCTGACTGTGTTCTGTCTGAGTGTGTTTGC
ACTAATTGGACTACAGCTGTTCATGGGAAACCTGAAGCATAAATGTTTTCGAAATTCACTTGAAAATAATGAAACATT
AGAAAGCATAATGAATACCCTAGAGAGTGAAGAAGACTTTAGAAAATATTTTTATTACTTGGAAGGATCCAAAGATG
CTCTCCTTTGTGGTTTCAGCACAGATTCAGGTCAGTGTCCAGAGGGGTACACCTGTGTGAAAATTGGCAGAAACCCT
GATTATGGCTACACGAGCTTTGACACTTTCAGCTGGGCCTTCTTAGCCTTGTTTAGGCTAATGACCCAAGATTACTGG
GAAAACCTTTACCAACAGACGCTGCGTGCTGCTGGCAAAACCTACATGATCTTCTTTGTCGTAGTGATTTTCCTGGGC
TCCTTTTATCTAATAAACTTGATCCTGGCTGTGGTTGCCATGGCATATGAAGAACAGAACCAGGCAAACATTGAAGA
AGCTAAACAGAAAGAATTAGAATTTCAACAGATGTTAGACCGTCTTAAAAAAGAGCAAGAAGAAGCTGAGGCAATT
GCAGCGGCAGCGGCTGAATATACAAGTATTAGGAGAAGCAGAATTATGGGCCTCTCAGAGAGTTCTTCTGAAACAT
CCAAACTGAGCTCTAAAAGTGCTAAAGAAAGAAGAAACAGAAGAAAGAAAAAGAATCAAAAGAAGCTCTCCAGTG
GAGAGGAAAAGGGAGATGCTGAGAAATTGTCGAAATCAGAATCAGAGGACAGCATCAGAAGAAAAAGTTTCCACC
TTGGTGTCGAAGGGCATAGGCGAGCACATGAAAAGAGGTTGTCTACCCCCAATCAGTCACCACTCAGCATTCGTGGC
TCCTTGTTTTCTGCAAGGCGAAGCAGCAGAACAAGTCTTTTTAGTTTCAAAGGCAGAGGAAGAGATATAGGATCTGA
GACTGAATTTGCCGATGATGAGCACAGCATTTTTGGAGACAATGAGAGCAGAAGGGGCTCACTGTTTGTGCCCCAC
AGACCCCAGGAGCGACGCAGCAGTAACATCAGCCAAGCCAGTAGGTCCCCACCAATGCTGCCGGTGAACGGGAAA
ATGCACAGTGCTGTGGACTGCAACGGTGTGGTCTCCCTGGTTGATGGACGCTCAGCCCTCATGCTCCCCAATGGACA
GCTTCTGCCAGAGGGCACGACCAATCAAATACACAAGAAAAGGCGTTGTAGTTCCTATCTCCTTTCAGAGGATATGC
TGAATGATCCCAACCTCAGACAGAGAGCAATGAGTAGAGCAAGCATATTAACAAACACTGTGGAAGAACTTGAAGA
GTCCAGACAAAAATGTCCACCTTGGTGGTACAGATTTGCACACAAATTCTTGATCTGGAATTGCTCTCCATATTGGAT
AAAATTCAAAAAGTGTATCTATTTTATTGTAATGGATCCTTTTGTAGATCTTGCAATTACCATTTGCATAGTTTTAAAC
ACATTATTTATGGCTATGGAACACCACCCAATGACTGAGGAATTCAAAAATGTACTTGCTATAGGAAATTTGGTCTTT
ACTGGAATCTTTGCAGCTGAAATGGTATTAAAACTGATTGCCATGGATCCATATGAGTATTTCCAAGTAGGCTGGAA
TATTTTTGACAGCCTTATTGTGACTTTAAGTTTAGTGGAGCTCTTTCTAGCAGATGTGGAAGGATTGTCAGTTCTGCG
ATCATTCAGACTGCTCCGAGTCTTCAAGTTGGCAAAATCCTGGCCAACATTGAACATGCTGATTAAGATCATTGGTAA
CTCAGTAGGGGCTCTAGGTAACCTCACCTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCT
CTTTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACATGAACGACT
TCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTC
GCTGGTCAAGCTATGTGCCTTATTGTTTACATGATGGTCATGGTCATTGGAAACCTGGTGGTCCTAAACCTATTTCTG
GCCTTATTATTGAGCTCATTTAGTTCAGACAATCTTACAGCAATTGAAGAAGACCCTGATGCAAACAACCTCCAGATT
267 
 
GCAGTGACTAGAATTAAAAAGGGAATAAATTATGTGAAACAAACCTTACGTGAATTTATTCTAAAAGCATTTTCCAA
AAAGCCAAAGATTTCCAGGGAGATAAGACAAGCAGAAGATCTGAATACTAAGAAGGAAAACTATATTTCTAACCAT
ACACTTGCTGAAATGAGCAAAGGTCACAATTTCCTCAAGGAAAAAGATAAAATCAGTGGTTTTGGAAGCAGCGTGG
ACAAACACTTGATGGAAGACAGTGATGGTCAATCATTTATTCACAATCCCAGCCTCACAGTGACAGTGCCAATTGCA
CCTGGGGAATCCGATTTGGAAAATATGAATGCTGAGGAACTTAGCAGTGATTCGGATAGTGAATACAGCAAAGTGA
GATTAAACCGGTCAAGCTCCTCAGAGTGCAGCACAGTTGATAACCCTTTGCCTGGAGAAGGAGAAGAAGCAGAGGC
TGAACCTATGAATTCCGATGAGCCAGAGGCCTGTTTCACAGATGGTTGTGTACGGAGGTTCTCATGCTGCCAAGTTA
ACATAGAGTCAGGGAAAGGAAAAATCTGGTGGAACATCAGGAAAACCTGCTACAAGATTGTTGAACACAGTTGGTT
TGAAAGCTTCATTGTCCTCATGATCCTGCTCAGCAGTGGTGCCCTGGCTTTTGAAGATATTTATATTGAAAGGAAAAA
GACCATTAAGATTATCCTGGAGTATGCAGACAAGATCTTCACTTACATCTTCATTCTGGAAATGCTTCTAAAATGGAT
AGCATATGGTTATAAAACATATTTCACCAATGCCTGGTGTTGGCTGGATTTCCTAATTGTTGATGTTTCTTTGGTTACT
TTAGTGGCAAACACTCTTGGCTACTCAGATCTTGGCCCCATTAAATCCCTTCGGACACTGAGAGCTTTAAGACCTCTA
AGAGCCTTATCTAGATTTGAAGGAATGAGGGTCGTTGTGAATGCACTCATAGGAGCAATTCCTTCCATCATGAATGT
GCTACTTGTGTGTCTTATATTCTGGCTGATATTCAGCATCATGGGAGTAAATTTGTTTGCTGGCAAGTTCTATGAGTG
TATTAACACCACAGATGGGTCACGGTTTCCTGCAAGTCAAGTTCCAAATCGTTCCGAATGTTTTGCCCTTATGAATGT
TAGTCAAAATGTGCGATGGAAAAACCTGAAAGTGAACTTTGATAATGTCGGACTTGGTTACCTATCTCTGCTTCAAGT
TGCAACTTTTAAGGGATGGACGATTATTATGTATGCAGCAGTGGATTCTGTTAATGTAGACAAGCAGCCCAAATATG
AATATAGCCTCTACATGTATATTTATTTTGTCGTCTTTATCATCTTTGGGTCATTCTTCACTTTGAACTTGTTCATTGGT
GTCATCATAGATAATTTCAACCAACAGAAAAAGAAGCTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGA
AATACTATAATGCAATGAAAAAGCTGGGGTCCAAGAAGCCACAAAAGCCAATTCCTCGACCAGGGAACAAAATCCA
AGGATGTATATTTGACCTAGTGACAAATCAAGCCTTTGATATTAGTATCATGGTTCTTATCTGTCTCAACATGGTAACC
ATGATGGTAGAAAAGGAGGGTCAAAGTCAACATATGACTGAAGTTTTATATTGGATAAATGTGGTTTTTATAATCCT
TTTCACTGGAGAATGTGTGCTAAAACTGATCTCCCTCAGACACTACTACTTCACTGTAGGATGGAATATTTTTGATTTT
GTGGTTGTGATTATCTCCATTGTAGGTATGTTTCTAGCTGATTTGATTGAAACGTATTTTGTGTCCCCTACCCTGTTCC
GAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTT
GCTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGG
AATGTCCAACTTTGCCTATGTTAAAAAGGAAGATGGAATTAATGACATGTTCAATTTTGAGACCTTTGGCAACAGTAT
GATTTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAACAGTAAGCCACCCGA
CTGTGACCCAAAAAAAGTTCATCCTGGAAGTTCAGTTGAAGGAGACTGTGGTAACCCATCTGTTGGAATATTCTACTT
TGTTAGTTATATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATTGCAGTCATACTGGAGAATTTTAGTGTTGCC
ACTGAAGAAAGTACTGAACCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCG
ATGCGACCCAGTTTATAGAGTTCTCTAAACTCTCTGATTTTGCAGCTGCCCTGGATCCTCCTCTTCTCATAGCAAAACC
CAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTTAGTGGTGACCGGATCCATTGTCTTGACATCTTATTTGC
TTTTACAAAGCGTGTTTTGGGTGAGAGTGGGGAGATGGATTCTCTTCGTTCACAGATGGAAGAAAGGTTCATGTCTG
CAAATCCTTCCAAAGTGTCCTATGAACCCATCACAACCACACTAAAACGGAAACAAGAGGATGTGTCTGCTACTGTC
ATTCAGCGTGCTTATAGACGTTACCGCTTAAGGCAAAATGTCAAAAATATATCAAGTATATACATAAAAGATGGAGA
CAGAGATGATGATTTACTCAATAAAAAAGATATGGCTTTTGATAATGTTAATGAGAACTCAAGTCCAGAAAAAACAG
ATGCCACTTCATCCACCACCTCTCCACCTTCATATGATAGTGTAACAAAGCCAGACAAAGAGAAATATGAACAAGACA
GAACAGAAAAGGAAGACAAAGGGAAAGACAGCAAGGAAAGCAAAAAATAG 
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SCN9A-5N amino acid sequence: 
 
Met A Met L P P P G P Q S F V H F T K Q S L A L I E Q R I A E R K S K E P K E E K K D D D E E A P K P S S D L E A 
G K Q L P F I Y G D I P P G Met V S E P L E D L D P Y Y A D K K T F I V L N K G K T I F R F N A T P A L Y Met L S P 
F S P L R R I S I K I L V H S L F S Met L I Met C T I L T N C I F Met T Met N N P P D W T K N V E Y T F T G I Y T F 
E S L V K I L A R G F C V G E F T F L R D P W N W L D F V V I V F A Y L T E F V N L G N V S A L R T F R V L R A L K 
T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L K H K C F R N S L 
E N N E T L E S I Met N T L E S E E D F R K Y F Y Y L E G S K D A L L C G F S T D S G Q C P E G Y T C V K I G R N P 
D Y G Y T S F D T F S W A F L A L F R L Met T Q D Y W E N L Y Q Q T L R A A G K T Y Met I F F V V V I F L G S F 
Y L I N L I L A V V A Met A Y E E Q N Q A N I E E A K Q K E L E F Q Q Met L D R L K K E Q E E A E A I A A A A A E 
Y T S I R R S R I Met G L S E S S S E T S K L S S K S A K E R R N R R K K K N Q K K L S S G E E K G D A E K L S K S E 
S E D S I R R K S F H L G V E G H R R A H E K R L S T P N Q S P L S I R G S L F S A R R S S R T S L F S F K G R G R 
D I G S E T E F A D D E H S I F G D N E S R R G S L F V P H R P Q E R R S S N I S Q A S R S P PMet L P V N G 
K Met H S A V D C N G V V S L V D G R S A L Met L P N G Q L L P E G T T N Q I H K K R R C S S Y L L S E 
D Met L N D P N L R Q R A Met S R A S I L T N T V E E L E E S R Q K C P P W W Y R F A H K F L I W N C S P Y W 
I K F K K C I Y F I V Met D P F V D L A I T I C I V L N T L F Met A Met E H H P Met T E E F K N V L A I G N L V F T 
G I F A A E Met V L K L I A Met D P Y E Y F Q V G W N I F D S L I V T L S L V E L F L A D V E G L S V L R S F R L L 
R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V 
C K I N D D C T L P R W H Met N D F F H S F L I V F R V L C G E W I E T Met W D C Met E V A G Q A Met C L I 
V Y Met Met V Met V I G N L V V L N L F L A L L L S S F S S D N L T A I E E D P D A N N L Q I A V T R I K K G I N 
Y V K Q T L R E F I L K A F S K K P K I S R E I R Q A E D L N T K K E N Y I S N H T L A E Met S K G H N F L K E K D 
K I S G F G S S V D K H L Met E D S D G Q S F I H N P S L T V T V P I A P G E S D L E N MetN A E E L S S D S D S 
E Y S K V R L N R S S S S E C S T V D N P L P G E G E E A E A E P Met N S D E P E A C F T D G C V R R F S C C Q V 
N I E S G K G K I W W N I R K T C Y K I V E H S W F E S F I V L Met I L L S S G A L A F E D I Y I E R K K T I K I I L E 
Y A D K I F T Y I F I L E Met L L K W I A Y G Y K T Y F T N A W C W L D F L I V D V S L V T L V A N T L G Y S D L G 
P I K S L R T L R A L R P L R A L S R F E G Met R V V V N A L I G A I P S I Met N V L L V C L I F W L I F S I Met G 
V N L F A G K F Y E C I N T T D G S R F P A S Q V P N R S E C F A L Met N V S Q N V R W K N L K V N F D N V G 
L G Y L S L L Q V A T F K G W T I I Met Y A A V D S V N V D K Q P K Y E Y S L Y Met Y I Y F V V F I I F G S F F T L 
N L F I G V I I D N F N Q Q K K K L G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K I 
Q G C I F D L V T N Q A F D I S I Met V L I C L N Met V T Met Met V E K E G Q S Q H Met T E V L Y W I N V V F 
I I L F T G E C V L K L I S L R H Y Y F T V G W N I F D F V V V I I S I V GMet F L A D L I E T Y F V S P T L F R V I R L 
A R I G R I L R L V K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y 
V K K E D G I N D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P K K V H P 
G S S V E G D C G N P S V G I F Y F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S T E P L S E D D F 
E Met F Y E V W E K F D P D A T Q F I E F S K L S D F A A A L D P P L L I A K P N K V Q L I A Met D L P Met V S 
G D R I H C L D I L F A F T K R V L G E S G E Met D S L R S Q Met E E R F Met S A N P S K V S Y E P I T T T L K R 
K Q E D V S A T V I Q R A Y R R Y R L R Q N V K N I S S I Y I K D G D R D D D L L N K K D Met A F D N V N E N S 
S P E K T D A T S S T T S P P S Y D S V T K P D K E K Y E Q D R T E K E D K G K D S K E S K K Stop 
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SCN1A-5A TTX-Resistant cDNA sequence: 
 
ATGGAGCAAACAGTGCTTGTACCACCAGGACCTGACAGCTTCAACTTCTTCACCAGAGAATCTCTTGCGGCTATTGAA
AGACGCATTGCAGAAGAAAAGGCAAAGAATCCCAAACCAGACAAAAAAGATGACGACGAAAATGGCCCAAAGCCA
AATAGTGACTTGGAAGCTGGAAAGAACCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGAGCCCCT
GGAGGACCTGGACCCCTACTATATCAATAAGAAAACTTTTATAGTATTGAATAAAGGGAAGGCCATCTTCCGGTTCA
GTGCCACCTCTGCCCTGTACATTTTAACTCCCTTCAATCCTCTTAGGAAAATAGCTATTAAGATTTTGGTACATTCATTA
TTCAGCATGCTAATTATGTGCACTATTTTGACAAACTGTGTGTTTATGACAATGAGTAACCCTCCTGATTGGACAAAG
AATGTAGAATACACCTTCACAGGAATATATACTTTTGAATCACTTATAAAAATTATTGCAAGGGGATTCTGTTTAGAA
GATTTTACTTTCCTTCGGGATCCATGGAACTGGCTCGATTTCACTGTCATTACATTTGCGTACGTCACAGAGTTTGTGG
ACCTGGGCAATGTCTCGGCATTGAGAACATTCAGAGTTCTCCGAGCATTGAAGACGATTTCAGTCATTCCAGGCCTG
AAAACCATTGTGGGAGCCCTGATCCAGTCTGTGAAGAAGCTCTCAGATGTAATGATCCTGACTGTGTTCTGTCTGAG
CGTATTTGCTCTAATTGGGCTGCAGCTGTTCATGGGCAACCTGAGGAATAAATGTATACAATGGCCTCCCACCAATG
CTTCCTTGGAGGAACATAGTATAGAAAAGAATATAACTGTGAATTATAATGGTACACTTATAAATGAAACTGTCTTTG
AGTTTGACTGGAAGTCATATATTCAAGATTCAAGATATCATTATTTCCTGGAGGGTTTTTTAGATGCACTACTATGTG
GAAATAGCTCTGATGCAGGCCAATGTCCAGAGGGATATATGTGTGTGAAAGCTGGTAGAAATCCCAATTATGGCTA
CACAAGCTTTGATACCTTCAGTTGGGCTTTTTTGTCCTTGTTTCGCCTAATGACTCAGGACTCCTGGGAAAATCTTTAT
CAACTGACATTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGTTGGTCATTTTCcTaGGCTCATTCTACCTAA
TAAATTTGATCCTGGCTGTGGTGGCCATGGCCTACGAGGAACAGAATCAGGCCACCTTGGAAGAAGCAGAACAGAA
AGAGGCCGAATTTCAGCAGATGATTGAACAGCTTAAAAAGCAACAGGAGGCAGCTCAGCAGGCAGCAACGGCAAC
TGCCTCAGAACATTCCAGAGAGCCCAGTGCAGCAGGCAGGCTCTCAGACAGCTCATCTGAAGCCTCTAAGTTGAGTT
CCAAGAGTGCTAAGGAAAGAAGAAATCGGAGGAAGAAAAGAAAACAGAAAGAGCAGTCTGGTGGGGAAGAGAAA
GATGAGGATGAATTCCAAAAATCTGAATCTGAGGACAGCATCAGGAGGAAAGGTTTTCGCTTCTCCATTGAAGGGA
ACCGATTGACATATGAAAAGAGGTACTCCTCCCCACACCAGTCTTTGTTGAGCATCCGTGGCTCCCTATTTTCACCAA
GGCGAAATAGCAGAACAAGCCTTTTCAGCTTTAGAGGGCGAGCAAAGGATGTGGGATCTGAGAACGACTTCGCAG
ATGATGAGCACAGCACCTTTGAGGATAACGAGAGCCGTAGAGATTCCTTGTTTGTGCCCCGACGACACGGAGAGAG
ACGCAACAGCAACCTGAGTCAGACCAGTAGGTCATCCCGGATGCTGGCAGTGTTTCCAGCGAATGGGAAGATGCAC
AGCACTGTGGATTGCAATGGTGAGGTTTCCTTGGTTGGTGGACCTTCAGTTCCTACATCGCCTGTTGGACAGCTTCTG
CCAGAGGGAACAACCACTGAAACTGAAATGAGAAAGAGAAGGTCAAGTTCTTTCCACGTTTCCATGGACTTTCTAGA
AGATCCTTCCCAAAGGCAACGAGCAATGAGTATAGCCAGCATTCTAACAAATACAGTAGAAGAACTTGAAGAATCCA
GGCAGAAATGCCCACCCTGTTGGTATAAATTTTCCAACATATTCTTAATCTGGGACTGTTCTCCATATTGGTTAAAAGT
GAAACATGTTGTCAACCTGGTCGTGATGGACCCATTTGTTGACCTGGCCATCACCATCTGTATTGTCTTAAATACTCTT
TTCATGGCCATGGAGCACTATCCAATGACGGACCATTTCAATAATGTGCTTACAGTAGGAAACTTGGTTTTCACTGGG
ATCTTTACAGCAGAAATGTTTCTGAAAATTATTGCCATGGATCCTTACTATTATTTCCAAGAAGGCTGGAATATCTTTG
ACGGTTTTATTGTGACGCTTAGCCTGGTAGAACTTGGACTCGCCAATGTGGAAGGATTATCTGTTCTCCGTTCATTTC
GATTGCTGCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACGTTAAATATGCTAATAAAGATCATCGGCAATTCCGTG
GGGGCTCTGGGAAATTTAACCCTCGTCTTGGCCATCATCGTCTTCATTTTTGCCGTGGTCGGCATGCAGCTCTTTGGT
AAAAGCTACAAAGATTGTGTCTGCAAGATCGCCAGTGATTGTCAACTCCCACGCTGGCACATGAATGACTTCTTCCAC
TCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGGGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTTGCTGGTCA
AGCCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAACCTAGTGGTCCTGAATCTCTTTCTGGCCTTGCTT
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CTGAGCTCATTTAGTGCAGACAACCTTGCAGCCACTGATGATGATAATGAAATGAATAATCTCCAAATTGCTGTGGAT
AGGATGCACAAAGGAGTAGCTTATGTGAAAAGAAAAATATATGAATTTATTCAACAGTCCTTCATTAGGAAACAAAA
GATTTTAGATGAAATTAAACCACTTGATGATCTAAACAACAAGAAAGACAGTTGTATGTCCAATCATACAGCAGAAA
TTGGGAAAGATCTTGACTATCTTAAAGATGTAAATGGAACTACAAGTGGTATAGGAACTGGCAGCAGTGTTGAAAA
ATACATTATTGATGAAAGTGATTACATGTCATTCATAAACAACCCCAGTCTTACTGTGACTGTACCAATTGCTGTAGG
AGAATCTGACTTTGAAAATTTAAACACGGAAGACTTTAGTAGTGAATCGGATCTGGAAGAAAGCAAAGAGAAACTG
AATGAAAGCAGTAGCTCATCAGAAGGTAGCACTGTGGACATCGGCGCACCTGTAGAAGAACAGCCCGTAGTGGAAC
CTGAAGAAACTCTTGAACCAGAAGCTTGTTTCACTGAAGGCTGTGTACAAAGATTCAAGTGTTGTCAAATCAATGTG
GAAGAAGGCAGAGGAAAACAATGGTGGAACCTGAGAAGGACGTGTTTCCGAATAGTTGAACATAACTGGTTTGAG
ACCTTCATTGTTTTCATGATTCTCCTTAGTAGTGGTGCTCTGGCATTTGAAGATATATATATTGATCAGCGAAAGACG
ATTAAGACGATGTTGGAATATGCTGACAAGGTTTTCACTTACATTTTCATTCTGGAAATGCTTCTAAAATGGGTGGCA
TATGGCTATCAAACATATTTCACCAATGCCTGGTGTTGGCTGGACTTCTTAATTGTTGATGTTTCATTGGTCAGTTTAA
CAGCAAATGCCTTGGGTTACTCAGAACTTGGAGCCATCAAATCTCTCAGGACACTAAGAGCTCTGAGACCTCTAAGA
GCCTTATCTCGATTTGAAGGGATGAGGGTGGTTGTGAATGCCCTTTTAGGAGCAATTCCATCCATCATGAATGTGCTT
CTGGTTTGTCTTATATTCTGGCTAATTTTCAGCATCATGGGCGTAAATTTGTTTGCTGGCAAATTCTACCACTGTATTA
ACACCACAACTGGTGACAGGTTTGACATCGAAGACGTGAATAATCATACTGATTGCCTAAAACTAATAGAAAGAAAT
GAGACTGCTCGATGGAAAAATGTGAAAGTAAACTTTGATAATGTAGGATTTGGGTATCTCTCTTTGCTTCAAGTTGCC
ACATTCAAAGGATGGATGGATATAATGTATGCAGCAGTTGATTCCAGAAATGTGGAACTCCAGCCTAAGTATGAAG
AAAGTCTGTACATGTATCTTTACTTTGTTATTTTCATCATCTTTGGGTCCTTCTTCACCTTGAACCTGTTTATTGGTGTC
ATCATAGATAATTTCAACCAGCAGAAAAAGAAGTTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGAAAT
ACTATAATGCAATGAAAAAATTAGGATCGAAAAAACCGCAAAAGCCTATACCTCGACCAGGAAACAAATTTCAAGG
AATGGTCTTTGACTTCGTAACCAGACAAGTTTTTGACATAAGCATCATGATTCTCATCTGTCTTAACATGGTCACAATG
ATGGTGGAAACAGATGACCAGAGTGAATATGTGACTACCATTTTGTCACGCATCAATCTGGTGTTCATTGTGCTATTT
ACTGGAGAGTGTGTACTGAAACTCATCTCTCTACGCCATTATTATTTTACCATTGGATGGAATATTTTTGATTTTGTGG
TTGTCATTCTCTCCATTGTAGGTATGTTTCTTGCCGAGCTGATAGAAAAGTATTTCGTGTCCCCTACCCTGTTCCGAGT
GATCCGTCTTGCTAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTGCTT
TGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTACTCTTCCTAGTCATGTTCATCTACGCCATCTTTGGGATG
TCCAACTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCATGAT
CTGCCTATTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCCATTCTCAACAGTAAGCCACCCGACTG
TGACCCTAATAAAGTTAACCCTGGAAGCTCAGTTAAGGGAGACTGTGGGAACCCATCTGTTGGAATTTTCTTTTTTGT
CAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGCTAC
TGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCGAT
GCAACTCAGTTCATGGAATTTGAAAAATTATCTCAGTTTGCAGCTGCGCTTGAACCGCCTCTCAATCTGCCACAACCA
AACAAACTCCAGCTCATTGCCATGGATTTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGATATCTTATTTGCT
TTTACAAAGCGGGTTCTAGGAGAGAGTGGAGAGATGGATGCTCTACGAATACAGATGGAAGAGCGATTCATGGCTT
CCAATCCTTCCAAGGTCTCCTATCAGCCAATCACTACTACTTTAAAACGAAAACAAGAGGAAGTATCTGCTGTCATTA
TTCAGCGTGCTTACAGACGCCACCTTTTAAAGCGAACTGTAAAACAAGCTTCCTTTACGTACAATAAAAACAAAATCA
AAGGTGGGGCTAATCTTCTTATAAAAGAAGACATGATAATTGACAGAATAAATGAAAACTCTATTACAGAAAAAACT
GATCTGACCATGTCCACTTCAGCTTGTCCACCTTCCTATGACCGGGTGACAAAGCCAATTGTGGAAAAACATGAGCA
AGAAGGCAAAGATGAAAAAGCCAAAGGGAAATAA 
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SCN1A-5A TTX-Resistant amino acid sequence: 
 
Met E Q T V L V P P G P D S F N F F T R E S L A A I E R R I A E E K A K N P K P D K K D D D E N G P K P N S D L E 
A G K N L P F I Y G D I P P E Met V S E P L E D L D P Y Y I N K K T F I V L N K G K A I F R F S A T S A L Y I L T P F 
N P L R K I A I K I L V H S L F S Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I I A R G F C L E D F T F L R D P W N W L D F T V I T F A Y V T E F V D L G N V S A L R T F R V L R A L K T 
I S V I P G L K T I V G A L I Q S V K K L S D VMet I L T V F C L S V F A L I G L Q L F Met G N L R N K C I Q W P P T 
N A S L E E H S I E K N I T V N Y N G T L I N E T V F E F D W K S Y I Q D S R Y H Y F L E G F L D A L L C G N S S D 
A G Q C P E G Y Met C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D S W E N L Y Q L T L R A 
A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q Q Met I 
E Q L K K Q Q E A A Q Q A A T A T A S E H S R E P S A A G R L S D S S S E A S K L S S K S A K E R R N R R K K R K 
Q K E Q S G G E E K D E D E F Q K S E S E D S I R R K G F R F S I E G N R L T Y E K R Y S S P H Q S L L S I R G S L F 
S P R R N S R T S L F S F R G R A K D V G S E N D F A D D E H S T F E D N E S R R D S L F V P R R H G E R R N S N 
L S Q T S R S S R Met L A V F P A N G K Met H S T V D C N G E V S L V G G P S V P T S P V G Q L L P E G T T T E 
T E Met R K R R S S S F H V S Met D F L E D P S Q R Q R A Met S I A S I L T N T V E E L E E S R Q K C P P C W Y 
K F S N I F L I W D C S P Y W L K V K H V V N L V V Met D P F V D L A I T I C I V L N T L F Met A Met E H Y 
P Met T D H F N N V L T V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N I F D G F I V T L S L 
V E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F 
I F A V V G Met Q L F G K S Y K D C V C K I A S D C Q L P R W H Met N D F F H S F L I V F R V L C G E W I E 
T Met W D C Met E V A G Q A Met C L T V F Met Met V Met V I G N L V V L N L F L A L L L S S F S A D N L A A 
T D D D N E Met N N L Q I A V D R Met H K G V A Y V K R K I Y E F I Q Q S F I R K Q K I L D E I K P L D D L N N K 
K D S C Met S N H T A E I G K D L D Y L K D V N G T T S G I G T G S S V E K Y I I D E S D YMet S F I N N P S L T V 
T V P I A V G E S D F E N L N T E D F S S E S D L E E S K E K L N E S S S S S E G S T V D I G A P V E E Q P V V E P E 
E T L E P E A C F T E G C V Q R F K C C Q I N V E E G R G K Q W W N L R R T C F R I V E H N W F E T F I V 
F Met I L L S S G A L A F E D I Y I D Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G Y Q T Y F 
T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E G Met R V V 
V N A L L G A I P S IMet N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N T T T G D R F D I E D V N N 
H T D C L K L I E R N E T A R W K N V K V N F D N V G F G Y L S L L Q V A T F K G W Met D I Met Y A A V D S R 
N V E L Q P K Y E E S L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N Q Q K K K F G G Q D I F Met T E 
E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K F Q G Met V F D F V T R Q V F D I S I Met I L I C L 
N Met V T Met Met V E T D D Q S E Y V T T I L S R I N L V F I V L F T G E C V L K L I S L R H Y Y F T I G W N I F D 
F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I K G A K G I R T L L F A 
L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D D Met F N F E T F G N 
S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P N K V N P G S S V K G D C G N P S V G I F F F V S 
Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W E K F D P D A T Q 
F Met E F E K L S Q F A A A L E P P L N L P Q P N K L Q L I A Met D L P Met V S G D R I H C L D I L F A F T K R V 
L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y Q P I T T T L K R K Q E E V S A V I I Q R A Y R R H 
L L K R T V K Q A S F T Y N K N K I K G G A N L L I K E D Met I I D R I N E N S I T E K T D L T Met S T S A C P P S 
Y D R V T K P I V E K H E Q E G K D E K A K G K Stop 
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SCN1A-5N TTX-Resistant cDNA sequence: 
 
ATGGAGCAAACAGTGCTTGTACCACCAGGACCTGACAGCTTCAACTTCTTCACCAGAGAATCTCTTGCGGCTATTGAA
AGACGCATTGCAGAAGAAAAGGCAAAGAATCCCAAACCAGACAAAAAAGATGACGACGAAAATGGCCCAAAGCCA
AATAGTGACTTGGAAGCTGGAAAGAACCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGAGCCCCT
GGAGGACCTGGACCCCTACTATATCAATAAGAAAACTTTTATAGTATTGAATAAAGGGAAGGCCATCTTCCGGTTCA
GTGCCACCTCTGCCCTGTACATTTTAACTCCCTTCAATCCTCTTAGGAAAATAGCTATTAAGATTTTGGTACATTCATTA
TTCAGCATGCTAATTATGTGCACTATTTTGACAAACTGTGTGTTTATGACAATGAGTAACCCTCCTGATTGGACAAAG
AATGTAGAATACACCTTCACAGGAATATATACTTTTGAATCACTTATAAAAATTATTGCAAGGGGATTCTGTTTAGAA
GATTTTACTTTCCTTCGGGATCCATGGAACTGGCTCGATTTCACTGTCATTACATTTGCGTTCGTCACAGAGTTTGTGA
ACCTGGGCAATTTCTCGGCATTGAGAACATTCAGAGTTCTCCGAGCATTGAAGACGATTTCAGTCATTCCAGGCCTG
AAAACCATTGTGGGAGCCCTGATCCAGTCTGTGAAGAAGCTCTCAGATGTAATGATCCTGACTGTGTTCTGTCTGAG
CGTATTTGCTCTAATTGGGCTGCAGCTGTTCATGGGCAACCTGAGGAATAAATGTATACAATGGCCTCCCACCAATG
CTTCCTTGGAGGAACATAGTATAGAAAAGAATATAACTGTGAATTATAATGGTACACTTATAAATGAAACTGTCTTTG
AGTTTGACTGGAAGTCATATATTCAAGATTCAAGATATCATTATTTCCTGGAGGGTTTTTTAGATGCACTACTATGTG
GAAATAGCTCTGATGCAGGCCAATGTCCAGAGGGATATATGTGTGTGAAAGCTGGTAGAAATCCCAATTATGGCTA
CACAAGCTTTGATACCTTCAGTTGGGCTTTTTTGTCCTTGTTTCGCCTAATGACTCAGGACTCCTGGGAAAATCTTTAT
CAACTGACATTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGTTGGTCATTTTCcTaGGCTCATTCTACCTAA
TAAATTTGATCCTGGCTGTGGTGGCCATGGCCTACGAGGAACAGAATCAGGCCACCTTGGAAGAAGCAGAACAGAA
AGAGGCCGAATTTCAGCAGATGATTGAACAGCTTAAAAAGCAACAGGAGGCAGCTCAGCAGGCAGCAACGGCAAC
TGCCTCAGAACATTCCAGAGAGCCCAGTGCAGCAGGCAGGCTCTCAGACAGCTCATCTGAAGCCTCTAAGTTGAGTT
CCAAGAGTGCTAAGGAAAGAAGAAATCGGAGGAAGAAAAGAAAACAGAAAGAGCAGTCTGGTGGGGAAGAGAAA
GATGAGGATGAATTCCAAAAATCTGAATCTGAGGACAGCATCAGGAGGAAAGGTTTTCGCTTCTCCATTGAAGGGA
ACCGATTGACATATGAAAAGAGGTACTCCTCCCCACACCAGTCTTTGTTGAGCATCCGTGGCTCCCTATTTTCACCAA
GGCGAAATAGCAGAACAAGCCTTTTCAGCTTTAGAGGGCGAGCAAAGGATGTGGGATCTGAGAACGACTTCGCAG
ATGATGAGCACAGCACCTTTGAGGATAACGAGAGCCGTAGAGATTCCTTGTTTGTGCCCCGACGACACGGAGAGAG
ACGCAACAGCAACCTGAGTCAGACCAGTAGGTCATCCCGGATGCTGGCAGTGTTTCCAGCGAATGGGAAGATGCAC
AGCACTGTGGATTGCAATGGTGAGGTTTCCTTGGTTGGTGGACCTTCAGTTCCTACATCGCCTGTTGGACAGCTTCTG
CCAGAGGGAACAACCACTGAAACTGAAATGAGAAAGAGAAGGTCAAGTTCTTTCCACGTTTCCATGGACTTTCTAGA
AGATCCTTCCCAAAGGCAACGAGCAATGAGTATAGCCAGCATTCTAACAAATACAGTAGAAGAACTTGAAGAATCCA
GGCAGAAATGCCCACCCTGTTGGTATAAATTTTCCAACATATTCTTAATCTGGGACTGTTCTCCATATTGGTTAAAAGT
GAAACATGTTGTCAACCTGGTCGTGATGGACCCATTTGTTGACCTGGCCATCACCATCTGTATTGTCTTAAATACTCTT
TTCATGGCCATGGAGCACTATCCAATGACGGACCATTTCAATAATGTGCTTACAGTAGGAAACTTGGTTTTCACTGGG
ATCTTTACAGCAGAAATGTTTCTGAAAATTATTGCCATGGATCCTTACTATTATTTCCAAGAAGGCTGGAATATCTTTG
ACGGTTTTATTGTGACGCTTAGCCTGGTAGAACTTGGACTCGCCAATGTGGAAGGATTATCTGTTCTCCGTTCATTTC
GATTGCTGCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACGTTAAATATGCTAATAAAGATCATCGGCAATTCCGTG
GGGGCTCTGGGAAATTTAACCCTCGTCTTGGCCATCATCGTCTTCATTTTTGCCGTGGTCGGCATGCAGCTCTTTGGT
AAAAGCTACAAAGATTGTGTCTGCAAGATCGCCAGTGATTGTCAACTCCCACGCTGGCACATGAATGACTTCTTCCAC
TCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGGGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTTGCTGGTCA
AGCCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAACCTAGTGGTCCTGAATCTCTTTCTGGCCTTGCTT
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CTGAGCTCATTTAGTGCAGACAACCTTGCAGCCACTGATGATGATAATGAAATGAATAATCTCCAAATTGCTGTGGAT
AGGATGCACAAAGGAGTAGCTTATGTGAAAAGAAAAATATATGAATTTATTCAACAGTCCTTCATTAGGAAACAAAA
GATTTTAGATGAAATTAAACCACTTGATGATCTAAACAACAAGAAAGACAGTTGTATGTCCAATCATACAGCAGAAA
TTGGGAAAGATCTTGACTATCTTAAAGATGTAAATGGAACTACAAGTGGTATAGGAACTGGCAGCAGTGTTGAAAA
ATACATTATTGATGAAAGTGATTACATGTCATTCATAAACAACCCCAGTCTTACTGTGACTGTACCAATTGCTGTAGG
AGAATCTGACTTTGAAAATTTAAACACGGAAGACTTTAGTAGTGAATCGGATCTGGAAGAAAGCAAAGAGAAACTG
AATGAAAGCAGTAGCTCATCAGAAGGTAGCACTGTGGACATCGGCGCACCTGTAGAAGAACAGCCCGTAGTGGAAC
CTGAAGAAACTCTTGAACCAGAAGCTTGTTTCACTGAAGGCTGTGTACAAAGATTCAAGTGTTGTCAAATCAATGTG
GAAGAAGGCAGAGGAAAACAATGGTGGAACCTGAGAAGGACGTGTTTCCGAATAGTTGAACATAACTGGTTTGAG
ACCTTCATTGTTTTCATGATTCTCCTTAGTAGTGGTGCTCTGGCATTTGAAGATATATATATTGATCAGCGAAAGACG
ATTAAGACGATGTTGGAATATGCTGACAAGGTTTTCACTTACATTTTCATTCTGGAAATGCTTCTAAAATGGGTGGCA
TATGGCTATCAAACATATTTCACCAATGCCTGGTGTTGGCTGGACTTCTTAATTGTTGATGTTTCATTGGTCAGTTTAA
CAGCAAATGCCTTGGGTTACTCAGAACTTGGAGCCATCAAATCTCTCAGGACACTAAGAGCTCTGAGACCTCTAAGA
GCCTTATCTCGATTTGAAGGGATGAGGGTGGTTGTGAATGCCCTTTTAGGAGCAATTCCATCCATCATGAATGTGCTT
CTGGTTTGTCTTATATTCTGGCTAATTTTCAGCATCATGGGCGTAAATTTGTTTGCTGGCAAATTCTACCACTGTATTA
ACACCACAACTGGTGACAGGTTTGACATCGAAGACGTGAATAATCATACTGATTGCCTAAAACTAATAGAAAGAAAT
GAGACTGCTCGATGGAAAAATGTGAAAGTAAACTTTGATAATGTAGGATTTGGGTATCTCTCTTTGCTTCAAGTTGCC
ACATTCAAAGGATGGATGGATATAATGTATGCAGCAGTTGATTCCAGAAATGTGGAACTCCAGCCTAAGTATGAAG
AAAGTCTGTACATGTATCTTTACTTTGTTATTTTCATCATCTTTGGGTCCTTCTTCACCTTGAACCTGTTTATTGGTGTC
ATCATAGATAATTTCAACCAGCAGAAAAAGAAGTTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGAAAT
ACTATAATGCAATGAAAAAATTAGGATCGAAAAAACCGCAAAAGCCTATACCTCGACCAGGAAACAAATTTCAAGG
AATGGTCTTTGACTTCGTAACCAGACAAGTTTTTGACATAAGCATCATGATTCTCATCTGTCTTAACATGGTCACAATG
ATGGTGGAAACAGATGACCAGAGTGAATATGTGACTACCATTTTGTCACGCATCAATCTGGTGTTCATTGTGCTATTT
ACTGGAGAGTGTGTACTGAAACTCATCTCTCTACGCCATTATTATTTTACCATTGGATGGAATATTTTTGATTTTGTGG
TTGTCATTCTCTCCATTGTAGGTATGTTTCTTGCCGAGCTGATAGAAAAGTATTTCGTGTCCCCTACCCTGTTCCGAGT
GATCCGTCTTGCTAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTGCTT
TGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTACTCTTCCTAGTCATGTTCATCTACGCCATCTTTGGGATG
TCCAACTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCATGAT
CTGCCTATTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCCATTCTCAACAGTAAGCCACCCGACTG
TGACCCTAATAAAGTTAACCCTGGAAGCTCAGTTAAGGGAGACTGTGGGAACCCATCTGTTGGAATTTTCTTTTTTGT
CAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGCTAC
TGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCGAT
GCAACTCAGTTCATGGAATTTGAAAAATTATCTCAGTTTGCAGCTGCGCTTGAACCGCCTCTCAATCTGCCACAACCA
AACAAACTCCAGCTCATTGCCATGGATTTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGATATCTTATTTGCT
TTTACAAAGCGGGTTCTAGGAGAGAGTGGAGAGATGGATGCTCTACGAATACAGATGGAAGAGCGATTCATGGCTT
CCAATCCTTCCAAGGTCTCCTATCAGCCAATCACTACTACTTTAAAACGAAAACAAGAGGAAGTATCTGCTGTCATTA
TTCAGCGTGCTTACAGACGCCACCTTTTAAAGCGAACTGTAAAACAAGCTTCCTTTACGTACAATAAAAACAAAATCA
AAGGTGGGGCTAATCTTCTTATAAAAGAAGACATGATAATTGACAGAATAAATGAAAACTCTATTACAGAAAAAACT
GATCTGACCATGTCCACTTCAGCTTGTCCACCTTCCTATGACCGGGTGACAAAGCCAATTGTGGAAAAACATGAGCA
AGAAGGCAAAGATGAAAAAGCCAAAGGGAAATAA 
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SNC1A-5N TTX-Resistant amino acid sequence: 
 
Met E Q T V L V P P G P D S F N F F T R E S L A A I E R R I A E E K A K N P K P D K K D D D E N G P K P N S D L E 
A G K N L P F I Y G D I P P E Met V S E P L E D L D P Y Y I N K K T F I V L N K G K A I F R F S A T S A L Y I L T P F 
N P L R K I A I K I L V H S L F S Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I I A R G F C L E D F T F L R D P W N W L D F T V I T F A F V T E F V N L G N F S A L R T F R V L R A L K T 
I S V I P G L K T I V G A L I Q S V K K L S D VMet I L T V F C L S V F A L I G L Q L F Met G N L R N K C I Q W P P T 
N A S L E E H S I E K N I T V N Y N G T L I N E T V F E F D W K S Y I Q D S R Y H Y F L E G F L D A L L C G N S S D 
A G Q C P E G Y Met C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D S W E N L Y Q L T L R A 
A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q Q Met I 
E Q L K K Q Q E A A Q Q A A T A T A S E H S R E P S A A G R L S D S S S E A S K L S S K S A K E R R N R R K K R K 
Q K E Q S G G E E K D E D E F Q K S E S E D S I R R K G F R F S I E G N R L T Y E K R Y S S P H Q S L L S I R G S L F 
S P R R N S R T S L F S F R G R A K D V G S E N D F A D D E H S T F E D N E S R R D S L F V P R R H G E R R N S N 
L S Q T S R S S R Met L A V F P A N G K Met H S T V D C N G E V S L V G G P S V P T S P V G Q L L P E G T T T E 
T E Met R K R R S S S F H V S Met D F L E D P S Q R Q R A Met S I A S I L T N T V E E L E E S R Q K C P P C W Y 
K F S N I F L I W D C S P Y W L K V K H V V N L V V Met D P F V D L A I T I C I V L N T L F Met A Met E H Y 
P Met T D H F N N V L T V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N I F D G F I V T L S L 
V E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F 
I F A V V G Met Q L F G K S Y K D C V C K I A S D C Q L P R W H Met N D F F H S F L I V F R V L C G E W I E 
T Met W D C Met E V A G Q A Met C L T V F Met Met V Met V I G N L V V L N L F L A L L L S S F S A D N L A A 
T D D D N E Met N N L Q I A V D R Met H K G V A Y V K R K I Y E F I Q Q S F I R K Q K I L D E I K P L D D L N N K 
K D S C Met S N H T A E I G K D L D Y L K D V N G T T S G I G T G S S V E K Y I I D E S D YMet S F I N N P S L T V 
T V P I A V G E S D F E N L N T E D F S S E S D L E E S K E K L N E S S S S S E G S T V D I G A P V E E Q P V V E P E 
E T L E P E A C F T E G C V Q R F K C C Q I N V E E G R G K Q W W N L R R T C F R I V E H N W F E T F I V 
F Met I L L S S G A L A F E D I Y I D Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G Y Q T Y F 
T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E G Met R V V 
V N A L L G A I P S IMet N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N T T T G D R F D I E D V N N 
H T D C L K L I E R N E T A R W K N V K V N F D N V G F G Y L S L L Q V A T F K G W Met D I Met Y A A V D S R 
N V E L Q P K Y E E S L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N Q Q K K K F G G Q D I F Met T E 
E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K F Q G Met V F D F V T R Q V F D I S I Met I L I C L 
N Met V T Met Met V E T D D Q S E Y V T T I L S R I N L V F I V L F T G E C V L K L I S L R H Y Y F T I G W N I F D 
F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I K G A K G I R T L L F A 
L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D D Met F N F E T F G N 
S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P N K V N P G S S V K G D C G N P S V G I F F F V S 
Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W E K F D P D A T Q 
F Met E F E K L S Q F A A A L E P P L N L P Q P N K L Q L I A Met D L P Met V S G D R I H C L D I L F A F T K R V 
L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y Q P I T T T L K R K Q E E V S A V I I Q R A Y R R H 
L L K R T V K Q A S F T Y N K N K I K G G A N L L I K E D Met I I D R I N E N S I T E K T D L T Met S T S A C P P S 
Y D R V T K P I V E K H E Q E G K D E K A K G K Stop 
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SCN2A-6A TTX-Resistant cDNA sequence: 
 
ATGGCACAGTCAGTGCTGGTACCGCCAGGACCTGACAGCTTCCGCTTCTTTACCAGGGAATCCCTTGCTGCTATTGAA
CAACGCATTGCAGAAGAGAAAGCTAAGAGACCCAAACAGGAACGCAAGGATGAGGATGATGAAAATGGCCCAAAG
CCAAACAGTGACTTGGAAGCAGGAAAATCTCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGTGCCC
CTGGAGGATCTGGACCCCTACTATATCAATAAGAAAACGTTTATAGTATTGAATAAAGGGAAAGCAATCTCTCGATT
CAGTGCCACCCCTGCCCTTTACATTTTAACTCCCTTCAACCCTATTAGAAAATTAGCTATTAAGATTTTGGTACATTCTT
TATTCAATATGCTCATTATGTGCACGATTCTTACCAACTGTGTATTTATGACCATGAGTAACCCTCCAGACTGGACAAA
GAATGTGGAGTATACCTTTACAGGAATTTATACTTTTGAATCACTTATTAAAATACTTGCAAGGGGCTTTTGTTTAGA
AGATTTCACATTTTTACGGGATCCATGGAATTGGTTGGATTTCACAGTCATTACTTTTGCATATGTGACAGAGTTTGT
GGACCTGGGCAATGTCTCAGCGTTGAGAACATTCAGAGTTCTCCGAGCATTGAAAACAATTTCAGTCATTCCAGGCC
TGAAGACCATTGTGGGGGCCCTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCTTGACTGTGTTCTGTCTAA
GCGTGTTTGCGCTAATAGGATTGCAGTTGTTCATGGGCAACCTACGAAATAAATGTTTGCAATGGCCTCCAGATAAT
TCTTCCTTTGAAATAAATATCACTTCCTTCTTTAACAATTCATTGGATGGGAATGGTACTACTTTCAATAGGACAGTGA
GCATATTTAACTGGGATGAATATATTGAGGATAAAAGTCACTTTTATTTTTTAGAGGGGCAAAATGATGCTCTGCTTT
GTGGCAACAGCTCAGATGCAGGCCAGTGTCCTGAAGGATACATCTGTGTGAAGGCTGGTAGAAACCCCAACTATGG
CTACACGAGCTTTGACACCTTTAGTTGGGCCTTTTTGTCCTTATTTCGTCTCATGACTCAAGACTCCTGGGAAAACCTT
TATCAACTGACACTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGCTGGTCATTTTCTTGGGCTCATTCTATC
TAATAAATTTGATCTTGGCTGTGGTGGCCATGGCCTATGAGGAACAGAATCAGGCCACATTGGAAGAGGCTGAACA
GAAGGAAGCTGAATTTCAGCAGATGCTCGAACAGTTGAAAAAGCAACAAGAAGAGGCTCAGGCGGCAGCTGCAGC
CGCATCTGCTGAATCAAGAGACTTCAGTGGTGCTGGTGGGATAGGAGTTTTTTCAGAGAGTTCTTCAGTAGCATCTA
AGTTGAGCTCCAAAAGTGAAAAAGAGCTGAAAAACAGAAGAAAGAAAAAGAAACAGAAAGAACAGTCTGGAGAA
GAAGAGAAAAATGACAGAGTCCGAAAATCGGAATCTGAAGACAGCATAAGAAGAAAAGGTTTCCGTTTTTCCTTGG
AAGGAAGTAGGCTGACATATGAAAAGAGATTTTCTTCTCCACACCAGTCCTTACTGAGCATCCGTGGCTCCCTTTTCT
CTCCAAGACGCAACAGTAGGGCGAGCCTTTTCAGCTTCAGAGGTCGAGCAAAGGACATTGGCTCTGAGAATGACTTT
GCTGATGATGAGCACAGCACCTTTGAGGACAATGACAGCCGAAGAGACTCTCTGTTCGTGCCGCACAGACATGGAG
AACGGCGCCACAGCAATGTCAGCCAGGCCAGCCGTGCCTCCAGGGTGCTCCCCATCCTGCCCATGAATGGGAAGAT
GCATAGCGCTGTGGACTGCAATGGTGTGGTCTCCCTGGTCGGGGGCCCTTCTACCCTCACATCTGCTGGGCAGCTCC
TACCAGAGGGCACAACTACTGAAACAGAAATAAGAAAGAGACGGTCCAGTTCTTATCATGTTTCCATGGATTTATTG
GAAGATCCTACATCAAGGCAAAGAGCAATGAGTATAGCCAGTATTTTGACCAACACCATGGAAGAACTTGAAGAAT
CCAGACAGAAATGCCCACCATGCTGGTATAAATTTGCTAATATGTGTTTGATTTGGGACTGTTGTAAACCATGGTTAA
AGGTGAAACACCTTGTCAACCTGGTTGTAATGGACCCATTTGTTGACCTGGCCATCACCATCTGCATTGTCTTAAATA
CACTCTTCATGGCTATGGAGCACTATCCCATGACGGAGCAGTTCAGCAGTGTACTGTCTGTTGGAAACCTGGTCTTCA
CAGGGATCTTCACAGCAGAAATGTTTCTCAAGATAATTGCCATGGATCCATATTATTACTTTCAAGAAGGCTGGAATA
TTTTTGATGGTTTTATTGTGAGCCTTAGTTTAATGGAACTTGGTTTGGCAAATGTGGAAGGATTGTCAGTTCTCCGAT
CATTCCGGCTGCTCCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACTCTAAATATGCTAATTAAGATCATTGGCAATT
CTGTGGGGGCTCTAGGAAACCTCACCTTGGTATTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCT
TTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATTTCCAATGATTGTGAACTCCCACGCTGGCACATGCATGACTTTT
TCCACTCCTTCCTGATCGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTCGCT
GGCCAAACCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAATCTAGTGGTTCTGAACCTCTTCTTGGCC
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TTGCTTTTGAGTTCCTTCAGTTCTGACAATCTTGCTGCCACTGATGATGATAACGAAATGAATAATCTCCAGATTGCTG
TGGGAAGGATGCAGAAAGGAATCGATTTTGTTAAAAGAAAAATACGTGAATTTATTCAGAAAGCCTTTGTTAGGAA
GCAGAAAGCTTTAGATGAAATTAAACCGCTTGAAGATCTAAATAATAAAAAAGACAGCTGTATTTCCAACCATACCA
CCATAGAAATAGGCAAAGACCTCAATTATCTCAAAGACGGAAATGGAACTACTAGTGGCATAGGCAGCAGTGTAGA
AAAATATGTCGTGGATGAAAGTGATTACATGTCATTTATAAACAACCCTAGCCTCACTGTGACAGTACCAATTGCTGT
TGGAGAATCTGACTTTGAAAATTTAAATACTGAAGAATTCAGCAGCGAGTCAGATATGGAGGAAAGCAAAGAGAAG
CTAAATGCAACTAGTTCATCTGAAGGCAGCACGGTTGATATTGGAGCTCCCGCCGAGGGAGAACAGCCTGAGGTTG
AACCTGAGGAATCCCTTGAACCTGAAGCCTGTTTTACAGAAGACTGTGTACGGAAGTTCAAGTGTTGTCAGATAAGC
ATAGAAGAAGGCAAAGGGAAACTCTGGTGGAATTTGAGGAAAACATGCTATAAGATAGTGGAGCACAATTGGTTC
GAAACCTTCATTGTCTTCATGATTCTGCTGAGCAGTGGGGCTCTGGCCTTTGAAGATATATACATTGAGCAGCGAAA
AACCATTAAGACCATGTTAGAATATGCTGACAAGGTTTTCACTTACATATTCATTCTGGAAATGCTGCTAAAGTGGGT
TGCATATGGTTTTCAAGTGTATTTTACCAATGCCTGGTGCTGGCTAGACTTCCTGATTGTTGATGTCTCACTGGTTAGC
TTAACTGCAAATGCCTTGGGTTACTCAGAACTTGGTGCCATCAAATCCCTCAGAACACTAAGAGCTCTGAGGCCACTG
AGAGCTTTGTCCCGGTTTGAAGGAATGAGGGTTGTTGTAAATGCTCTTTTAGGAGCCATTCCATCTATCATGAATGTA
CTTCTGGTTTGTCTGATCTTTTGGCTAATATTCAGTATCATGGGAGTGAATCTCTTTGCTGGCAAGTTTTACCATTGTA
TTAATTACACCACTGGAGAGATGTTTGATGTAAGCGTGGTCAACAACTACAGTGAGTGCAAAGCTCTCATTGAGAGC
AATCAAACTGCCAGGTGGAAAAATGTGAAAGTAAACTTTGATAACGTAGGACTTGGATATCTGTCTCTACTTCAAGT
AGCCACGTTTAAGGGATGGATGGATATTATGTATGCAGCTGTTGATTCACGAAATGTAGAATTACAACCCAAGTATG
AAGACAACCTGTACATGTATCTTTATTTTGTCATCTTTATTATTTTTGGTTCATTCTTTACCTTGAATCTTTTCATTGGTG
TCATCATAGATAACTTCAACCAACAGAAAAAGAAGTTTGGAGGTCAAGACATTTTTATGACAGAAGAACAGAAGAA
ATACTACAATGCAATGAAAAAACTGGGTTCAAAGAAACCACAAAAACCCATACCTCGACCTGCTAACAAATTCCAAG
GAATGGTCTTTGATTTTGTAACCAAACAAGTCTTTGATATCAGCATCATGATCCTCATCTGCCTTAACATGGTCACCAT
GATGGTGGAAACCGATGACCAGAGTCAAGAAATGACAAACATTCTGTACTGGATTAATCTGGTGTTTATTGTTCTGT
TCACTGGAGAATGTGTGCTGAAACTGATCTCTCTTCGTTACTACTATTTCACTATTGGATGGAATATTTTTGATTTTGT
GGTGGTCATTCTCTCCATTGTAGGAATGTTTCTGGCTGAACTGATAGAAAAGTATTTTGTGTCCCCTACCCTGTTCCG
AGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTG
CTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTTCTTTTCCTGGTCATGTTCATCTACGCCATCTTTGGG
ATGTCCAATTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCAT
GATCTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAATAGTGGACCTCCAGA
CTGTGACCCTGACAAAGATCACCCTGGAAGCTCAGTTAAAGGAGACTGTGGGAACCCATCTGTTGGGATTTTCTTTTT
TGTCAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGC
TACTGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCC
GATGCGACCCAGTTTATAGAGTTTGCCAAACTTTCTGATTTTGCAGATGCCCTGGATCCTCCTCTTCTCATAGCAAAAC
CCAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGACATCTTATTTG
CTTTTACAAAGCGTGTTTTGGGTGAGAGTGGAGAGATGGATGCCCTTCGAATACAGATGGAAGAGCGATTCATGGC
ATCAAACCCCTCCAAAGTCTCTTATGAGCCCATTACGACCACGTTGAAACGCAAACAAGAGGAGGTGTCTGCTATTAT
TATCCAGAGGGCTTACAGACGCTACCTCTTGAAGCAAAAAGTTAAAAAGGTATCAAGTATATACAAGAAAGACAAA
GGCAAAGAATGTGATGGAACACCCATCAAAGAAGATACTCTCATTGATAAACTGAATGAGAATTCAACTCCAGAGA
AAACCGATATGACGCCTTCCACCACGTCTCCACCCTCGTATGATAGTGTGACCAAACCAGAAAAAGAAAAATTTGAA
AAAGACAAATCAGAAAAGGAAGACAAAGGGAAAGATATCAGGGAAAGTAAAAAGTAA 
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SCN2A-6A TTX-Resistant amino acid sequence: 
 
Met A Q S V L V P P G P D S F R F F T R E S L A A I E Q R I A E E K A K R P K Q E R K D E D D E N G P K P N S D L 
E A G K S L P F I Y G D I P P E Met V S V P L E D L D P Y Y I N K K T F I V L N K G K A I S R F S A T P A L Y I L T P F 
N P I R K L A I K I L V H S L F N Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I L A R G F C L E D F T F L R D P W N W L D F T V I T F A Y V T E F V D L G N V S A L R T F R V L R A L K 
T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L R N K C L Q W P 
P D N S S F E I N I T S F F N N S L D G N G T T F N R T V S I F N W D E Y I E D K S H F Y F L E G Q N D A L L C G N 
S S D A G Q C P E G Y I C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D S W E N L Y Q L T L R 
A A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q 
Q Met L E Q L K K Q Q E E A Q A A A A A A S A E S R D F S G A G G I G V F S E S S S V A S K L S S K S E K E L K N 
R R K K K K Q K E Q S G E E E K N D R V R K S E S E D S I R R K G F R F S L E G S R L T Y E K R F S S P H Q S L L S I 
R G S L F S P R R N S R A S L F S F R G R A K D I G S E N D F A D D E H S T F E D N D S R R D S L F V P H R H G E 
R R H S N V S Q A S R A S R V L P I L P Met N G K Met H S A V D C N G V V S L V G G P S T L T S A G Q L L P E G 
T T T E T E I R K R R S S S Y H V S Met D L L E D P T S R Q R A Met S I A S I L T N T Met E E L E E S R Q K C P P 
C W Y K F A N Met C L I W D C C K P W L K V K H L V N L V V Met D P F V D L A I T I C I V L N T L 
F Met A Met E H Y P Met T E Q F S S V L S V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N 
I F D G F I V S L S L Met E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A 
L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V C K I S N D C E L P R W H Met H D F F H S F L I V F 
R V L C G E W I E T Met W D C Met E V A G Q T Met C L T V F Met Met VMet V I G N L V V L N L F L A L L L S 
S F S S D N L A A T D D D N E Met N N L Q I A V G R Met Q K G I D F V K R K I R E F I Q K A F V R K Q K A L D E 
I K P L E D L N N K K D S C I S N H T T I E I G K D L N Y L K D G N G T T S G I G S S V E K Y V V D E S D Y Met S F 
I N N P S L T V T V P I A V G E S D F E N L N T E E F S S E S D Met E E S K E K L N A T S S S E G S T V D I G A P A 
E G E Q P E V E P E E S L E P E A C F T E D C V R K F K C C Q I S I E E G K G K L W W N L R K T C Y K I V E H N W 
F E T F I V F Met I L L S S G A L A F E D I Y I E Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G 
F Q V Y F T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E 
G Met R V V V N A L L G A I P S I Met N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N Y T T G 
E Met F D V S V V N N Y S E C K A L I E S N Q T A R W K N V K V N F D N V G L G Y L S L L Q V A T F K G 
W Met D I Met Y A A V D S R N V E L Q P K Y E D N L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N 
Q Q K K K F G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P A N K F Q G Met V F D F V T 
K Q V F D I S I Met I L I C L N Met V T Met Met V E T D D Q S Q E Met T N I L Y W I N L V F I V L F T G E C V L 
K L I S L R Y Y Y F T I G W N I F D F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I 
K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D 
D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S G P P D C D P D K D H P G S S V K G D C 
G N P S V G I F F F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W 
E K F D P D A T Q F I E F A K L S D F A D A L D P P L L I A K P N K V Q L I A Met D L P Met V S G D R I H C L D I L 
F A F T K R V L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y E P I T T T L K R K Q E E V S A I I I Q 
R A Y R R Y L L K Q K V K K V S S I Y K K D K G K E C D G T P I K E D T L I D K L N E N S T P E K T D Met T P S T T 
S P P S Y D S V T K P E K E K F E K D K S E K E D K G K D I R E S K K Stop 
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SCN2A-5N TTX-Resistant cDNA sequence: 
 
ATGGCACAGTCAGTGCTGGTACCGCCAGGACCTGACAGCTTCCGCTTCTTTACCAGGGAATCCCTTGCTGCTATTGAA
CAACGCATTGCAGAAGAGAAAGCTAAGAGACCCAAACAGGAACGCAAGGATGAGGATGATGAAAATGGCCCAAAG
CCAAACAGTGACTTGGAAGCAGGAAAATCTCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGTGCCC
CTGGAGGATCTGGACCCCTACTATATCAATAAGAAAACGTTTATAGTATTGAATAAAGGGAAAGCAATCTCTCGATT
CAGTGCCACCCCTGCCCTTTACATTTTAACTCCCTTCAACCCTATTAGAAAATTAGCTATTAAGATTTTGGTACATTCTT
TATTCAATATGCTCATTATGTGCACGATTCTTACCAACTGTGTATTTATGACCATGAGTAACCCTCCAGACTGGACAAA
GAATGTGGAGTATACCTTTACAGGAATTTATACTTTTGAATCACTTATTAAAATACTTGCAAGGGGCTTTTGTTTAGA
AGATTTCACATTTTTACGGGATCCATGGAATTGGTTGGATTTCACAGTCATTACTTTTGCATATGTGACAGAGTTTGT
GAACCTGGGCAATGTCTCAGCGTTGAGAACATTCAGAGTTCTCCGAGCATTGAAAACAATTTCAGTCATTCCAGGCC
TGAAGACCATTGTGGGGGCCCTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCTTGACTGTGTTCTGTCTAA
GCGTGTTTGCGCTAATAGGATTGCAGTTGTTCATGGGCAACCTACGAAATAAATGTTTGCAATGGCCTCCAGATAAT
TCTTCCTTTGAAATAAATATCACTTCCTTCTTTAACAATTCATTGGATGGGAATGGTACTACTTTCAATAGGACAGTGA
GCATATTTAACTGGGATGAATATATTGAGGATAAAAGTCACTTTTATTTTTTAGAGGGGCAAAATGATGCTCTGCTTT
GTGGCAACAGCTCAGATGCAGGCCAGTGTCCTGAAGGATACATCTGTGTGAAGGCTGGTAGAAACCCCAACTATGG
CTACACGAGCTTTGACACCTTTAGTTGGGCCTTTTTGTCCTTATTTCGTCTCATGACTCAAGACTCCTGGGAAAACCTT
TATCAACTGACACTACGTGCTGCTGGGAAAACGTACATGATATTTTTTGTGCTGGTCATTTTCTTGGGCTCATTCTATC
TAATAAATTTGATCTTGGCTGTGGTGGCCATGGCCTATGAGGAACAGAATCAGGCCACATTGGAAGAGGCTGAACA
GAAGGAAGCTGAATTTCAGCAGATGCTCGAACAGTTGAAAAAGCAACAAGAAGAGGCTCAGGCGGCAGCTGCAGC
CGCATCTGCTGAATCAAGAGACTTCAGTGGTGCTGGTGGGATAGGAGTTTTTTCAGAGAGTTCTTCAGTAGCATCTA
AGTTGAGCTCCAAAAGTGAAAAAGAGCTGAAAAACAGAAGAAAGAAAAAGAAACAGAAAGAACAGTCTGGAGAA
GAAGAGAAAAATGACAGAGTCCGAAAATCGGAATCTGAAGACAGCATAAGAAGAAAAGGTTTCCGTTTTTCCTTGG
AAGGAAGTAGGCTGACATATGAAAAGAGATTTTCTTCTCCACACCAGTCCTTACTGAGCATCCGTGGCTCCCTTTTCT
CTCCAAGACGCAACAGTAGGGCGAGCCTTTTCAGCTTCAGAGGTCGAGCAAAGGACATTGGCTCTGAGAATGACTTT
GCTGATGATGAGCACAGCACCTTTGAGGACAATGACAGCCGAAGAGACTCTCTGTTCGTGCCGCACAGACATGGAG
AACGGCGCCACAGCAATGTCAGCCAGGCCAGCCGTGCCTCCAGGGTGCTCCCCATCCTGCCCATGAATGGGAAGAT
GCATAGCGCTGTGGACTGCAATGGTGTGGTCTCCCTGGTCGGGGGCCCTTCTACCCTCACATCTGCTGGGCAGCTCC
TACCAGAGGGCACAACTACTGAAACAGAAATAAGAAAGAGACGGTCCAGTTCTTATCATGTTTCCATGGATTTATTG
GAAGATCCTACATCAAGGCAAAGAGCAATGAGTATAGCCAGTATTTTGACCAACACCATGGAAGAACTTGAAGAAT
CCAGACAGAAATGCCCACCATGCTGGTATAAATTTGCTAATATGTGTTTGATTTGGGACTGTTGTAAACCATGGTTAA
AGGTGAAACACCTTGTCAACCTGGTTGTAATGGACCCATTTGTTGACCTGGCCATCACCATCTGCATTGTCTTAAATA
CACTCTTCATGGCTATGGAGCACTATCCCATGACGGAGCAGTTCAGCAGTGTACTGTCTGTTGGAAACCTGGTCTTCA
CAGGGATCTTCACAGCAGAAATGTTTCTCAAGATAATTGCCATGGATCCATATTATTACTTTCAAGAAGGCTGGAATA
TTTTTGATGGTTTTATTGTGAGCCTTAGTTTAATGGAACTTGGTTTGGCAAATGTGGAAGGATTGTCAGTTCTCCGAT
CATTCCGGCTGCTCCGAGTTTTCAAGTTGGCAAAATCTTGGCCAACTCTAAATATGCTAATTAAGATCATTGGCAATT
CTGTGGGGGCTCTAGGAAACCTCACCTTGGTATTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCTCT
TTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATTTCCAATGATTGTGAACTCCCACGCTGGCACATGCATGACTTTT
TCCACTCCTTCCTGATCGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTCGCT
GGCCAAACCATGTGCCTTACTGTCTTCATGATGGTCATGGTGATTGGAAATCTAGTGGTTCTGAACCTCTTCTTGGCC
279 
 
TTGCTTTTGAGTTCCTTCAGTTCTGACAATCTTGCTGCCACTGATGATGATAACGAAATGAATAATCTCCAGATTGCTG
TGGGAAGGATGCAGAAAGGAATCGATTTTGTTAAAAGAAAAATACGTGAATTTATTCAGAAAGCCTTTGTTAGGAA
GCAGAAAGCTTTAGATGAAATTAAACCGCTTGAAGATCTAAATAATAAAAAAGACAGCTGTATTTCCAACCATACCA
CCATAGAAATAGGCAAAGACCTCAATTATCTCAAAGACGGAAATGGAACTACTAGTGGCATAGGCAGCAGTGTAGA
AAAATATGTCGTGGATGAAAGTGATTACATGTCATTTATAAACAACCCTAGCCTCACTGTGACAGTACCAATTGCTGT
TGGAGAATCTGACTTTGAAAATTTAAATACTGAAGAATTCAGCAGCGAGTCAGATATGGAGGAAAGCAAAGAGAAG
CTAAATGCAACTAGTTCATCTGAAGGCAGCACGGTTGATATTGGAGCTCCCGCCGAGGGAGAACAGCCTGAGGTTG
AACCTGAGGAATCCCTTGAACCTGAAGCCTGTTTTACAGAAGACTGTGTACGGAAGTTCAAGTGTTGTCAGATAAGC
ATAGAAGAAGGCAAAGGGAAACTCTGGTGGAATTTGAGGAAAACATGCTATAAGATAGTGGAGCACAATTGGTTC
GAAACCTTCATTGTCTTCATGATTCTGCTGAGCAGTGGGGCTCTGGCCTTTGAAGATATATACATTGAGCAGCGAAA
AACCATTAAGACCATGTTAGAATATGCTGACAAGGTTTTCACTTACATATTCATTCTGGAAATGCTGCTAAAGTGGGT
TGCATATGGTTTTCAAGTGTATTTTACCAATGCCTGGTGCTGGCTAGACTTCCTGATTGTTGATGTCTCACTGGTTAGC
TTAACTGCAAATGCCTTGGGTTACTCAGAACTTGGTGCCATCAAATCCCTCAGAACACTAAGAGCTCTGAGGCCACTG
AGAGCTTTGTCCCGGTTTGAAGGAATGAGGGTTGTTGTAAATGCTCTTTTAGGAGCCATTCCATCTATCATGAATGTA
CTTCTGGTTTGTCTGATCTTTTGGCTAATATTCAGTATCATGGGAGTGAATCTCTTTGCTGGCAAGTTTTACCATTGTA
TTAATTACACCACTGGAGAGATGTTTGATGTAAGCGTGGTCAACAACTACAGTGAGTGCAAAGCTCTCATTGAGAGC
AATCAAACTGCCAGGTGGAAAAATGTGAAAGTAAACTTTGATAACGTAGGACTTGGATATCTGTCTCTACTTCAAGT
AGCCACGTTTAAGGGATGGATGGATATTATGTATGCAGCTGTTGATTCACGAAATGTAGAATTACAACCCAAGTATG
AAGACAACCTGTACATGTATCTTTATTTTGTCATCTTTATTATTTTTGGTTCATTCTTTACCTTGAATCTTTTCATTGGTG
TCATCATAGATAACTTCAACCAACAGAAAAAGAAGTTTGGAGGTCAAGACATTTTTATGACAGAAGAACAGAAGAA
ATACTACAATGCAATGAAAAAACTGGGTTCAAAGAAACCACAAAAACCCATACCTCGACCTGCTAACAAATTCCAAG
GAATGGTCTTTGATTTTGTAACCAAACAAGTCTTTGATATCAGCATCATGATCCTCATCTGCCTTAACATGGTCACCAT
GATGGTGGAAACCGATGACCAGAGTCAAGAAATGACAAACATTCTGTACTGGATTAATCTGGTGTTTATTGTTCTGT
TCACTGGAGAATGTGTGCTGAAACTGATCTCTCTTCGTTACTACTATTTCACTATTGGATGGAATATTTTTGATTTTGT
GGTGGTCATTCTCTCCATTGTAGGAATGTTTCTGGCTGAACTGATAGAAAAGTATTTTGTGTCCCCTACCCTGTTCCG
AGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTG
CTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTTCTTTTCCTGGTCATGTTCATCTACGCCATCTTTGGG
ATGTCCAATTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTTGGCAACAGCAT
GATCTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAATAGTGGACCTCCAGA
CTGTGACCCTGACAAAGATCACCCTGGAAGCTCAGTTAAAGGAGACTGTGGGAACCCATCTGTTGGGATTTTCTTTTT
TGTCAGTTACATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGTGTTGC
TACTGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCC
GATGCGACCCAGTTTATAGAGTTTGCCAAACTTTCTGATTTTGCAGATGCCCTGGATCCTCCTCTTCTCATAGCAAAAC
CCAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGACATCTTATTTG
CTTTTACAAAGCGTGTTTTGGGTGAGAGTGGAGAGATGGATGCCCTTCGAATACAGATGGAAGAGCGATTCATGGC
ATCAAACCCCTCCAAAGTCTCTTATGAGCCCATTACGACCACGTTGAAACGCAAACAAGAGGAGGTGTCTGCTATTAT
TATCCAGAGGGCTTACAGACGCTACCTCTTGAAGCAAAAAGTTAAAAAGGTATCAAGTATATACAAGAAAGACAAA
GGCAAAGAATGTGATGGAACACCCATCAAAGAAGATACTCTCATTGATAAACTGAATGAGAATTCAACTCCAGAGA
AAACCGATATGACGCCTTCCACCACGTCTCCACCCTCGTATGATAGTGTGACCAAACCAGAAAAAGAAAAATTTGAA
AAAGACAAATCAGAAAAGGAAGACAAAGGGAAAGATATCAGGGAAAGTAAAAAGTAA 
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SCN2A-5N TTX-Resistant amino acid sequence: 
 
Met A Q S V L V P P G P D S F R F F T R E S L A A I E Q R I A E E K A K R P K Q E R K D E D D E N G P K P N S D L 
E A G K S L P F I Y G D I P P E Met V S V P L E D L D P Y Y I N K K T F I V L N K G K A I S R F S A T P A L Y I L T P F 
N P I R K L A I K I L V H S L F N Met L I Met C T I L T N C V F Met T Met S N P P D W T K N V E Y T F T G I Y T F 
E S L I K I L A R G F C L E D F T F L R D P W N W L D F T V I T F A Y V T E F V N L G N V S A L R T F R V L R A L K 
T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L R N K C L Q W P 
P D N S S F E I N I T S F F N N S L D G N G T T F N R T V S I F N W D E Y I E D K S H F Y F L E G Q N D A L L C G N 
S S D A G Q C P E G Y I C V K A G R N P N Y G Y T S F D T F S W A F L S L F R L Met T Q D S W E N L Y Q L T L R 
A A G K T Y Met I F F V L V I F L G S F Y L I N L I L A V V A Met A Y E E Q N Q A T L E E A E Q K E A E F Q 
Q Met L E Q L K K Q Q E E A Q A A A A A A S A E S R D F S G A G G I G V F S E S S S V A S K L S S K S E K E L K N 
R R K K K K Q K E Q S G E E E K N D R V R K S E S E D S I R R K G F R F S L E G S R L T Y E K R F S S P H Q S L L S I 
R G S L F S P R R N S R A S L F S F R G R A K D I G S E N D F A D D E H S T F E D N D S R R D S L F V P H R H G E 
R R H S N V S Q A S R A S R V L P I L P Met N G K Met H S A V D C N G V V S L V G G P S T L T S A G Q L L P E G 
T T T E T E I R K R R S S S Y H V S Met D L L E D P T S R Q R A Met S I A S I L T N T Met E E L E E S R Q K C P P 
C W Y K F A N Met C L I W D C C K P W L K V K H L V N L V V Met D P F V D L A I T I C I V L N T L 
F Met A Met E H Y P Met T E Q F S S V L S V G N L V F T G I F T A E Met F L K I I A Met D P Y Y Y F Q E G W N 
I F D G F I V S L S L Met E L G L A N V E G L S V L R S F R L L R V F K L A K S W P T L N Met L I K I I G N S V G A 
L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V C K I S N D C E L P R W H Met H D F F H S F L I V F 
R V L C G E W I E T Met W D C Met E V A G Q T Met C L T V F Met Met VMet V I G N L V V L N L F L A L L L S 
S F S S D N L A A T D D D N E Met N N L Q I A V G R Met Q K G I D F V K R K I R E F I Q K A F V R K Q K A L D E 
I K P L E D L N N K K D S C I S N H T T I E I G K D L N Y L K D G N G T T S G I G S S V E K Y V V D E S D Y Met S F 
I N N P S L T V T V P I A V G E S D F E N L N T E E F S S E S D Met E E S K E K L N A T S S S E G S T V D I G A P A 
E G E Q P E V E P E E S L E P E A C F T E D C V R K F K C C Q I S I E E G K G K L W W N L R K T C Y K I V E H N W 
F E T F I V F Met I L L S S G A L A F E D I Y I E Q R K T I K T Met L E Y A D K V F T Y I F I L E Met L L K W V A Y G 
F Q V Y F T N A W C W L D F L I V D V S L V S L T A N A L G Y S E L G A I K S L R T L R A L R P L R A L S R F E 
G Met R V V V N A L L G A I P S I Met N V L L V C L I F W L I F S I Met G V N L F A G K F Y H C I N Y T T G 
E Met F D V S V V N N Y S E C K A L I E S N Q T A R W K N V K V N F D N V G L G Y L S L L Q V A T F K G 
W Met D I Met Y A A V D S R N V E L Q P K Y E D N L Y Met Y L Y F V I F I I F G S F F T L N L F I G V I I D N F N 
Q Q K K K F G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P A N K F Q G Met V F D F V T 
K Q V F D I S I Met I L I C L N Met V T Met Met V E T D D Q S Q E Met T N I L Y W I N L V F I V L F T G E C V L 
K L I S L R Y Y Y F T I G W N I F D F V V V I L S I V G Met F L A E L I E K Y F V S P T L F R V I R L A R I G R I L R L I 
K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y V K R E V G I D 
D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S G P P D C D P D K D H P G S S V K G D C 
G N P S V G I F F F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S A E P L S E D D F E Met F Y E V W 
E K F D P D A T Q F I E F A K L S D F A D A L D P P L L I A K P N K V Q L I A Met D L P Met V S G D R I H C L D I L 
F A F T K R V L G E S G E Met D A L R I Q Met E E R F Met A S N P S K V S Y E P I T T T L K R K Q E E V S A I I I Q 
R A Y R R Y L L K Q K V K K V S S I Y K K D K G K E C D G T P I K E D T L I D K L N E N S T P E K T D Met T P S T T 
S P P S Y D S V T K P E K E K F E K D K S E K E D K G K D I R E S K K Stop 
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SNC9A-5A TTX-Resistant cDNA sequence: 
 
ATGGCAATGTTGCCTCCCCCAGGACCTCAGAGCTTTGTCCATTTCACAAAACAGTCTCTTGCCCTCATTGAACAACGC
ATTGCTGAAAGAAAATCAAAGGAACCCAAAGAAGAAAAGAAAGATGATGATGAAGAAGCCCCAAAGCCAAGCAGT
GACTTGGAAGCTGGCAAACAACTGCCCTTCATCTATGGGGACATTCCTCCCGGCATGGTGTCAGAGCCCCTGGAGGA
CTTGGACCCCTACTATGCAGACAAAAAGACTTTCATAGTATTGAACAAAGGGAAAACAATCTTCCGTTTCAATGCCAC
ACCTGCTTTATATATGCTTTCTCCTTTCAGTCCTCTAAGAAGAATATCTATTAAGATTTTAGTACACTCCTTATTCAGCA
TGCTCATCATGTGCACTATTCTGACAAACTGCATATTTATGACCATGAATAACCCGCCGGACTGGACCAAAAATGTCG
AGTACACTTTTACTGGAATATATACTTTTGAATCACTTGTAAAAATCCTTGCAAGAGGCTTCTGTGTAGGAGAATTCA
CTTTTCTTCGTGACCCGTGGAACTGGCTGGATTTTGTCGTCATTGTTTTTGCGTATGTGACAGAATTTGTAGACCTAG
GCAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGCCTGAAGACAA
TTGTAGGGGCTTTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCCTGACTGTGTTCTGTCTGAGTGTGTTTG
CACTAATTGGACTACAGCTGTTCATGGGAAACCTGAAGCATAAATGTTTTCGAAATTCACTTGAAAATAATGAAACAT
TAGAAAGCATAATGAATACCCTAGAGAGTGAAGAAGACTTTAGAAAATATTTTTATTACTTGGAAGGATCCAAAGAT
GCTCTCCTTTGTGGTTTCAGCACAGATTCAGGTCAGTGTCCAGAGGGGTACACCTGTGTGAAAATTGGCAGAAACCC
TGATTATGGCTACACGAGCTTTGACACTTTCAGCTGGGCCTTCTTAGCCTTGTTTAGGCTAATGACCCAAGATTCCTG
GGAAAACCTTTACCAACAGACGCTGCGTGCTGCTGGCAAAACCTACATGATCTTCTTTGTCGTAGTGATTTTCCTGGG
CTCCTTTTATCTAATAAACTTGATCCTGGCTGTGGTTGCCATGGCATATGAAGAACAGAACCAGGCAAACATTGAAG
AAGCTAAACAGAAAGAATTAGAATTTCAACAGATGTTAGACCGTCTTAAAAAAGAGCAAGAAGAAGCTGAGGCAAT
TGCAGCGGCAGCGGCTGAATATACAAGTATTAGGAGAAGCAGAATTATGGGCCTCTCAGAGAGTTCTTCTGAAACA
TCCAAACTGAGCTCTAAAAGTGCTAAAGAAAGAAGAAACAGAAGAAAGAAAAAGAATCAAAAGAAGCTCTCCAGT
GGAGAGGAAAAGGGAGATGCTGAGAAATTGTCGAAATCAGAATCAGAGGACAGCATCAGAAGAAAAAGTTTCCAC
CTTGGTGTCGAAGGGCATAGGCGAGCACATGAAAAGAGGTTGTCTACCCCCAATCAGTCACCACTCAGCATTCGTGG
CTCCTTGTTTTCTGCAAGGCGAAGCAGCAGAACAAGTCTTTTTAGTTTCAAAGGCAGAGGAAGAGATATAGGATCTG
AGACTGAATTTGCCGATGATGAGCACAGCATTTTTGGAGACAATGAGAGCAGAAGGGGCTCACTGTTTGTGCCCCA
CAGACCCCAGGAGCGACGCAGCAGTAACATCAGCCAAGCCAGTAGGTCCCCACCAATGCTGCCGGTGAACGGGAA
AATGCACAGTGCTGTGGACTGCAACGGTGTGGTCTCCCTGGTTGATGGACGCTCAGCCCTCATGCTCCCCAATGGAC
AGCTTCTGCCAGAGGGCACGACCAATCAAATACACAAGAAAAGGCGTTGTAGTTCCTATCTCCTTTCAGAGGATATG
CTGAATGATCCCAACCTCAGACAGAGAGCAATGAGTAGAGCAAGCATATTAACAAACACTGTGGAAGAACTTGAAG
AGTCCAGACAAAAATGTCCACCTTGGTGGTACAGATTTGCACACAAATTCTTGATCTGGAATTGCTCTCCATATTGGA
TAAAATTCAAAAAGTGTATCTATTTTATTGTAATGGATCCTTTTGTAGATCTTGCAATTACCATTTGCATAGTTTTAAAC
ACATTATTTATGGCTATGGAACACCACCCAATGACTGAGGAATTCAAAAATGTACTTGCTATAGGAAATTTGGTCTTT
ACTGGAATCTTTGCAGCTGAAATGGTATTAAAACTGATTGCCATGGATCCATATGAGTATTTCCAAGTAGGCTGGAA
TATTTTTGACAGCCTTATTGTGACTTTAAGTTTAGTGGAGCTCTTTCTAGCAGATGTGGAAGGATTGTCAGTTCTGCG
ATCATTCAGACTGCTCCGAGTCTTCAAGTTGGCAAAATCCTGGCCAACATTGAACATGCTGATTAAGATCATTGGTAA
CTCAGTAGGGGCTCTAGGTAACCTCACCTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCT
CTTTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACATGAACGACT
TCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTC
GCTGGTCAAGCTATGTGCCTTATTGTTTACATGATGGTCATGGTCATTGGAAACCTGGTGGTCCTAAACCTATTTCTG
GCCTTATTATTGAGCTCATTTAGTTCAGACAATCTTACAGCAATTGAAGAAGACCCTGATGCAAACAACCTCCAGATT
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GCAGTGACTAGAATTAAAAAGGGAATAAATTATGTGAAACAAACCTTACGTGAATTTATTCTAAAAGCATTTTCCAA
AAAGCCAAAGATTTCCAGGGAGATAAGACAAGCAGAAGATCTGAATACTAAGAAGGAAAACTATATTTCTAACCAT
ACACTTGCTGAAATGAGCAAAGGTCACAATTTCCTCAAGGAAAAAGATAAAATCAGTGGTTTTGGAAGCAGCGTGG
ACAAACACTTGATGGAAGACAGTGATGGTCAATCATTTATTCACAATCCCAGCCTCACAGTGACAGTGCCAATTGCA
CCTGGGGAATCCGATTTGGAAAATATGAATGCTGAGGAACTTAGCAGTGATTCGGATAGTGAATACAGCAAAGTGA
GATTAAACCGGTCAAGCTCCTCAGAGTGCAGCACAGTTGATAACCCTTTGCCTGGAGAAGGAGAAGAAGCAGAGGC
TGAACCTATGAATTCCGATGAGCCAGAGGCCTGTTTCACAGATGGTTGTGTACGGAGGTTCTCATGCTGCCAAGTTA
ACATAGAGTCAGGGAAAGGAAAAATCTGGTGGAACATCAGGAAAACCTGCTACAAGATTGTTGAACACAGTTGGTT
TGAAAGCTTCATTGTCCTCATGATCCTGCTCAGCAGTGGTGCCCTGGCTTTTGAAGATATTTATATTGAAAGGAAAAA
GACCATTAAGATTATCCTGGAGTATGCAGACAAGATCTTCACTTACATCTTCATTCTGGAAATGCTTCTAAAATGGAT
AGCATATGGTTATAAAACATATTTCACCAATGCCTGGTGTTGGCTGGATTTCCTAATTGTTGATGTTTCTTTGGTTACT
TTAGTGGCAAACACTCTTGGCTACTCAGATCTTGGCCCCATTAAATCCCTTCGGACACTGAGAGCTTTAAGACCTCTA
AGAGCCTTATCTAGATTTGAAGGAATGAGGGTCGTTGTGAATGCACTCATAGGAGCAATTCCTTCCATCATGAATGT
GCTACTTGTGTGTCTTATATTCTGGCTGATATTCAGCATCATGGGAGTAAATTTGTTTGCTGGCAAGTTCTATGAGTG
TATTAACACCACAGATGGGTCACGGTTTCCTGCAAGTCAAGTTCCAAATCGTTCCGAATGTTTTGCCCTTATGAATGT
TAGTCAAAATGTGCGATGGAAAAACCTGAAAGTGAACTTTGATAATGTCGGACTTGGTTACCTATCTCTGCTTCAAGT
TGCAACTTTTAAGGGATGGACGATTATTATGTATGCAGCAGTGGATTCTGTTAATGTAGACAAGCAGCCCAAATATG
AATATAGCCTCTACATGTATATTTATTTTGTCGTCTTTATCATCTTTGGGTCATTCTTCACTTTGAACTTGTTCATTGGT
GTCATCATAGATAATTTCAACCAACAGAAAAAGAAGCTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGA
AATACTATAATGCAATGAAAAAGCTGGGGTCCAAGAAGCCACAAAAGCCAATTCCTCGACCAGGGAACAAAATCCA
AGGATGTATATTTGACCTAGTGACAAATCAAGCCTTTGATATTAGTATCATGGTTCTTATCTGTCTCAACATGGTAACC
ATGATGGTAGAAAAGGAGGGTCAAAGTCAACATATGACTGAAGTTTTATATTGGATAAATGTGGTTTTTATAATCCT
TTTCACTGGAGAATGTGTGCTAAAACTGATCTCCCTCAGACACTACTACTTCACTGTAGGATGGAATATTTTTGATTTT
GTGGTTGTGATTATCTCCATTGTAGGTATGTTTCTAGCTGATTTGATTGAAACGTATTTTGTGTCCCCTACCCTGTTCC
GAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTT
GCTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGG
AATGTCCAACTTTGCCTATGTTAAAAAGGAAGATGGAATTAATGACATGTTCAATTTTGAGACCTTTGGCAACAGTAT
GATTTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAACAGTAAGCCACCCGA
CTGTGACCCAAAAAAAGTTCATCCTGGAAGTTCAGTTGAAGGAGACTGTGGTAACCCATCTGTTGGAATATTCTACTT
TGTTAGTTATATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATTGCAGTCATACTGGAGAATTTTAGTGTTGCC
ACTGAAGAAAGTACTGAACCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCG
ATGCGACCCAGTTTATAGAGTTCTCTAAACTCTCTGATTTTGCAGCTGCCCTGGATCCTCCTCTTCTCATAGCAAAACC
CAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTTAGTGGTGACCGGATCCATTGTCTTGACATCTTATTTGC
TTTTACAAAGCGTGTTTTGGGTGAGAGTGGGGAGATGGATTCTCTTCGTTCACAGATGGAAGAAAGGTTCATGTCTG
CAAATCCTTCCAAAGTGTCCTATGAACCCATCACAACCACACTAAAACGGAAACAAGAGGATGTGTCTGCTACTGTC
ATTCAGCGTGCTTATAGACGTTACCGCTTAAGGCAAAATGTCAAAAATATATCAAGTATATACATAAAAGATGGAGA
CAGAGATGATGATTTACTCAATAAAAAAGATATGGCTTTTGATAATGTTAATGAGAACTCAAGTCCAGAAAAAACAG
ATGCCACTTCATCCACCACCTCTCCACCTTCATATGATAGTGTAACAAAGCCAGACAAAGAGAAATATGAACAAGACA
GAACAGAAAAGGAAGACAAAGGGAAAGACAGCAAGGAAAGCAAAAAATAG 
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SCN9A-5A TTX-Resistant amino acid sequence: 
 
Met A Met L P P P G P Q S F V H F T K Q S L A L I E Q R I A E R K S K E P K E E K K D D D E E A P K P S S D L E A 
G K Q L P F I Y G D I P P G Met V S E P L E D L D P Y Y A D K K T F I V L N K G K T I F R F N A T P A L Y Met L S P 
F S P L R R I S I K I L V H S L F S Met L I Met C T I L T N C I F Met T Met N N P P D W T K N V E Y T F T G I Y T F 
E S L V K I L A R G F C V G E F T F L R D P W N W L D F V V I V F A Y V T E F V D L G N V S A L R T F R V L R A L 
K T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L K H K C F R N S 
L E N N E T L E S I Met N T L E S E E D F R K Y F Y Y L E G S K D A L L C G F S T D S G Q C P E G Y T C V K I G R N 
P D Y G Y T S F D T F S W A F L A L F R L Met T Q D S W E N L Y Q Q T L R A A G K T Y Met I F F V V V I F L G S 
F Y L I N L I L A V V A Met A Y E E Q N Q A N I E E A K Q K E L E F Q Q Met L D R L K K E Q E E A E A I A A A A A 
E Y T S I R R S R I Met G L S E S S S E T S K L S S K S A K E R R N R R K K K N Q K K L S S G E E K G D A E K L S K S 
E S E D S I R R K S F H L G V E G H R R A H E K R L S T P N Q S P L S I R G S L F S A R R S S R T S L F S F K G R G R 
D I G S E T E F A D D E H S I F G D N E S R R G S L F V P H R P Q E R R S S N I S Q A S R S P PMet L P V N G 
K Met H S A V D C N G V V S L V D G R S A L Met L P N G Q L L P E G T T N Q I H K K R R C S S Y L L S E 
D Met L N D P N L R Q R A Met S R A S I L T N T V E E L E E S R Q K C P P W W Y R F A H K F L I W N C S P Y W 
I K F K K C I Y F I V Met D P F V D L A I T I C I V L N T L F Met A Met E H H P Met T E E F K N V L A I G N L V F T 
G I F A A E Met V L K L I A Met D P Y E Y F Q V G W N I F D S L I V T L S L V E L F L A D V E G L S V L R S F R L L 
R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V 
C K I N D D C T L P R W H Met N D F F H S F L I V F R V L C G E W I E T Met W D C Met E V A G Q A Met C L I 
V Y Met Met V Met V I G N L V V L N L F L A L L L S S F S S D N L T A I E E D P D A N N L Q I A V T R I K K G I N 
Y V K Q T L R E F I L K A F S K K P K I S R E I R Q A E D L N T K K E N Y I S N H T L A E Met S K G H N F L K E K D 
K I S G F G S S V D K H L Met E D S D G Q S F I H N P S L T V T V P I A P G E S D L E N MetN A E E L S S D S D S 
E Y S K V R L N R S S S S E C S T V D N P L P G E G E E A E A E P Met N S D E P E A C F T D G C V R R F S C C Q V 
N I E S G K G K I W W N I R K T C Y K I V E H S W F E S F I V L Met I L L S S G A L A F E D I Y I E R K K T I K I I L E 
Y A D K I F T Y I F I L E Met L L K W I A Y G Y K T Y F T N A W C W L D F L I V D V S L V T L V A N T L G Y S D L G 
P I K S L R T L R A L R P L R A L S R F E G Met R V V V N A L I G A I P S I Met N V L L V C L I F W L I F S I Met G 
V N L F A G K F Y E C I N T T D G S R F P A S Q V P N R S E C F A L Met N V S Q N V R W K N L K V N F D N V G 
L G Y L S L L Q V A T F K G W T I I Met Y A A V D S V N V D K Q P K Y E Y S L Y Met Y I Y F V V F I I F G S F F T L 
N L F I G V I I D N F N Q Q K K K L G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K I 
Q G C I F D L V T N Q A F D I S I Met V L I C L N Met V T Met Met V E K E G Q S Q H Met T E V L Y W I N V V F 
I I L F T G E C V L K L I S L R H Y Y F T V G W N I F D F V V V I I S I V GMet F L A D L I E T Y F V S P T L F R V I R L 
A R I G R I L R L V K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y 
V K K E D G I N D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P K K V H P 
G S S V E G D C G N P S V G I F Y F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S T E P L S E D D F 
E Met F Y E V W E K F D P D A T Q F I E F S K L S D F A A A L D P P L L I A K P N K V Q L I A Met D L P Met V S 
G D R I H C L D I L F A F T K R V L G E S G E Met D S L R S Q Met E E R F Met S A N P S K V S Y E P I T T T L K R 
K Q E D V S A T V I Q R A Y R R Y R L R Q N V K N I S S I Y I K D G D R D D D L L N K K D Met A F D N V N E N S 
S P E K T D A T S S T T S P P S Y D S V T K P D K E K Y E Q D R T E K E D K G K D S K E S K K Stop 
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SNC9A-5N TTX-Resistant cDNA sequence: 
 
ATGGCAATGTTGCCTCCCCCAGGACCTCAGAGCTTTGTCCATTTCACAAAACAGTCTCTTGCCCTCATTGAACAACGC
ATTGCTGAAAGAAAATCAAAGGAACCCAAAGAAGAAAAGAAAGATGATGATGAAGAAGCCCCAAAGCCAAGCAGT
GACTTGGAAGCTGGCAAACAACTGCCCTTCATCTATGGGGACATTCCTCCCGGCATGGTGTCAGAGCCCCTGGAGGA
CTTGGACCCCTACTATGCAGACAAAAAGACTTTCATAGTATTGAACAAAGGGAAAACAATCTTCCGTTTCAATGCCAC
ACCTGCTTTATATATGCTTTCTCCTTTCAGTCCTCTAAGAAGAATATCTATTAAGATTTTAGTACACTCCTTATTCAGCA
TGCTCATCATGTGCACTATTCTGACAAACTGCATATTTATGACCATGAATAACCCGCCGGACTGGACCAAAAATGTCG
AGTACACTTTTACTGGAATATATACTTTTGAATCACTTGTAAAAATCCTTGCAAGAGGCTTCTGTGTAGGAGAATTCA
CTTTTCTTCGTGACCCGTGGAACTGGCTGGATTTTGTCGTCATTGTTTTTGCGTATTTAACAGAATTTGTAAACCTAGG
CAATGTTTCAGCTCTTCGAACTTTCAGAGTATTGAGAGCTTTGAAAACTATTTCTGTAATCCCAGGCCTGAAGACAAT
TGTAGGGGCTTTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCCTGACTGTGTTCTGTCTGAGTGTGTTTGC
ACTAATTGGACTACAGCTGTTCATGGGAAACCTGAAGCATAAATGTTTTCGAAATTCACTTGAAAATAATGAAACATT
AGAAAGCATAATGAATACCCTAGAGAGTGAAGAAGACTTTAGAAAATATTTTTATTACTTGGAAGGATCCAAAGATG
CTCTCCTTTGTGGTTTCAGCACAGATTCAGGTCAGTGTCCAGAGGGGTACACCTGTGTGAAAATTGGCAGAAACCCT
GATTATGGCTACACGAGCTTTGACACTTTCAGCTGGGCCTTCTTAGCCTTGTTTAGGCTAATGACCCAAGATTCCTGG
GAAAACCTTTACCAACAGACGCTGCGTGCTGCTGGCAAAACCTACATGATCTTCTTTGTCGTAGTGATTTTCCTGGGC
TCCTTTTATCTAATAAACTTGATCCTGGCTGTGGTTGCCATGGCATATGAAGAACAGAACCAGGCAAACATTGAAGA
AGCTAAACAGAAAGAATTAGAATTTCAACAGATGTTAGACCGTCTTAAAAAAGAGCAAGAAGAAGCTGAGGCAATT
GCAGCGGCAGCGGCTGAATATACAAGTATTAGGAGAAGCAGAATTATGGGCCTCTCAGAGAGTTCTTCTGAAACAT
CCAAACTGAGCTCTAAAAGTGCTAAAGAAAGAAGAAACAGAAGAAAGAAAAAGAATCAAAAGAAGCTCTCCAGTG
GAGAGGAAAAGGGAGATGCTGAGAAATTGTCGAAATCAGAATCAGAGGACAGCATCAGAAGAAAAAGTTTCCACC
TTGGTGTCGAAGGGCATAGGCGAGCACATGAAAAGAGGTTGTCTACCCCCAATCAGTCACCACTCAGCATTCGTGGC
TCCTTGTTTTCTGCAAGGCGAAGCAGCAGAACAAGTCTTTTTAGTTTCAAAGGCAGAGGAAGAGATATAGGATCTGA
GACTGAATTTGCCGATGATGAGCACAGCATTTTTGGAGACAATGAGAGCAGAAGGGGCTCACTGTTTGTGCCCCAC
AGACCCCAGGAGCGACGCAGCAGTAACATCAGCCAAGCCAGTAGGTCCCCACCAATGCTGCCGGTGAACGGGAAA
ATGCACAGTGCTGTGGACTGCAACGGTGTGGTCTCCCTGGTTGATGGACGCTCAGCCCTCATGCTCCCCAATGGACA
GCTTCTGCCAGAGGGCACGACCAATCAAATACACAAGAAAAGGCGTTGTAGTTCCTATCTCCTTTCAGAGGATATGC
TGAATGATCCCAACCTCAGACAGAGAGCAATGAGTAGAGCAAGCATATTAACAAACACTGTGGAAGAACTTGAAGA
GTCCAGACAAAAATGTCCACCTTGGTGGTACAGATTTGCACACAAATTCTTGATCTGGAATTGCTCTCCATATTGGAT
AAAATTCAAAAAGTGTATCTATTTTATTGTAATGGATCCTTTTGTAGATCTTGCAATTACCATTTGCATAGTTTTAAAC
ACATTATTTATGGCTATGGAACACCACCCAATGACTGAGGAATTCAAAAATGTACTTGCTATAGGAAATTTGGTCTTT
ACTGGAATCTTTGCAGCTGAAATGGTATTAAAACTGATTGCCATGGATCCATATGAGTATTTCCAAGTAGGCTGGAA
TATTTTTGACAGCCTTATTGTGACTTTAAGTTTAGTGGAGCTCTTTCTAGCAGATGTGGAAGGATTGTCAGTTCTGCG
ATCATTCAGACTGCTCCGAGTCTTCAAGTTGGCAAAATCCTGGCCAACATTGAACATGCTGATTAAGATCATTGGTAA
CTCAGTAGGGGCTCTAGGTAACCTCACCTTAGTGTTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATGCAGCT
CTTTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATCAATGATGACTGTACGCTCCCACGGTGGCACATGAACGACT
TCTTCCACTCCTTCCTGATTGTGTTCCGCGTGCTGTGTGGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTC
GCTGGTCAAGCTATGTGCCTTATTGTTTACATGATGGTCATGGTCATTGGAAACCTGGTGGTCCTAAACCTATTTCTG
GCCTTATTATTGAGCTCATTTAGTTCAGACAATCTTACAGCAATTGAAGAAGACCCTGATGCAAACAACCTCCAGATT
285 
 
GCAGTGACTAGAATTAAAAAGGGAATAAATTATGTGAAACAAACCTTACGTGAATTTATTCTAAAAGCATTTTCCAA
AAAGCCAAAGATTTCCAGGGAGATAAGACAAGCAGAAGATCTGAATACTAAGAAGGAAAACTATATTTCTAACCAT
ACACTTGCTGAAATGAGCAAAGGTCACAATTTCCTCAAGGAAAAAGATAAAATCAGTGGTTTTGGAAGCAGCGTGG
ACAAACACTTGATGGAAGACAGTGATGGTCAATCATTTATTCACAATCCCAGCCTCACAGTGACAGTGCCAATTGCA
CCTGGGGAATCCGATTTGGAAAATATGAATGCTGAGGAACTTAGCAGTGATTCGGATAGTGAATACAGCAAAGTGA
GATTAAACCGGTCAAGCTCCTCAGAGTGCAGCACAGTTGATAACCCTTTGCCTGGAGAAGGAGAAGAAGCAGAGGC
TGAACCTATGAATTCCGATGAGCCAGAGGCCTGTTTCACAGATGGTTGTGTACGGAGGTTCTCATGCTGCCAAGTTA
ACATAGAGTCAGGGAAAGGAAAAATCTGGTGGAACATCAGGAAAACCTGCTACAAGATTGTTGAACACAGTTGGTT
TGAAAGCTTCATTGTCCTCATGATCCTGCTCAGCAGTGGTGCCCTGGCTTTTGAAGATATTTATATTGAAAGGAAAAA
GACCATTAAGATTATCCTGGAGTATGCAGACAAGATCTTCACTTACATCTTCATTCTGGAAATGCTTCTAAAATGGAT
AGCATATGGTTATAAAACATATTTCACCAATGCCTGGTGTTGGCTGGATTTCCTAATTGTTGATGTTTCTTTGGTTACT
TTAGTGGCAAACACTCTTGGCTACTCAGATCTTGGCCCCATTAAATCCCTTCGGACACTGAGAGCTTTAAGACCTCTA
AGAGCCTTATCTAGATTTGAAGGAATGAGGGTCGTTGTGAATGCACTCATAGGAGCAATTCCTTCCATCATGAATGT
GCTACTTGTGTGTCTTATATTCTGGCTGATATTCAGCATCATGGGAGTAAATTTGTTTGCTGGCAAGTTCTATGAGTG
TATTAACACCACAGATGGGTCACGGTTTCCTGCAAGTCAAGTTCCAAATCGTTCCGAATGTTTTGCCCTTATGAATGT
TAGTCAAAATGTGCGATGGAAAAACCTGAAAGTGAACTTTGATAATGTCGGACTTGGTTACCTATCTCTGCTTCAAGT
TGCAACTTTTAAGGGATGGACGATTATTATGTATGCAGCAGTGGATTCTGTTAATGTAGACAAGCAGCCCAAATATG
AATATAGCCTCTACATGTATATTTATTTTGTCGTCTTTATCATCTTTGGGTCATTCTTCACTTTGAACTTGTTCATTGGT
GTCATCATAGATAATTTCAACCAACAGAAAAAGAAGCTTGGAGGTCAAGACATCTTTATGACAGAAGAACAGAAGA
AATACTATAATGCAATGAAAAAGCTGGGGTCCAAGAAGCCACAAAAGCCAATTCCTCGACCAGGGAACAAAATCCA
AGGATGTATATTTGACCTAGTGACAAATCAAGCCTTTGATATTAGTATCATGGTTCTTATCTGTCTCAACATGGTAACC
ATGATGGTAGAAAAGGAGGGTCAAAGTCAACATATGACTGAAGTTTTATATTGGATAAATGTGGTTTTTATAATCCT
TTTCACTGGAGAATGTGTGCTAAAACTGATCTCCCTCAGACACTACTACTTCACTGTAGGATGGAATATTTTTGATTTT
GTGGTTGTGATTATCTCCATTGTAGGTATGTTTCTAGCTGATTTGATTGAAACGTATTTTGTGTCCCCTACCCTGTTCC
GAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTAGTCAAAGGAGCAAAGGGGATCCGCACGCTGCTCTTT
GCTTTGATGATGTCCCTTCCTGCGTTGTTTAACATCGGCCTCCTGCTCTTCCTGGTCATGTTCATCTACGCCATCTTTGG
AATGTCCAACTTTGCCTATGTTAAAAAGGAAGATGGAATTAATGACATGTTCAATTTTGAGACCTTTGGCAACAGTAT
GATTTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTAGCACCTATTCTTAACAGTAAGCCACCCGA
CTGTGACCCAAAAAAAGTTCATCCTGGAAGTTCAGTTGAAGGAGACTGTGGTAACCCATCTGTTGGAATATTCTACTT
TGTTAGTTATATCATCATATCCTTCCTGGTTGTGGTGAACATGTACATTGCAGTCATACTGGAGAATTTTAGTGTTGCC
ACTGAAGAAAGTACTGAACCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAGGTTTGGGAGAAGTTTGATCCCG
ATGCGACCCAGTTTATAGAGTTCTCTAAACTCTCTGATTTTGCAGCTGCCCTGGATCCTCCTCTTCTCATAGCAAAACC
CAACAAAGTCCAGCTCATTGCCATGGATCTGCCCATGGTTAGTGGTGACCGGATCCATTGTCTTGACATCTTATTTGC
TTTTACAAAGCGTGTTTTGGGTGAGAGTGGGGAGATGGATTCTCTTCGTTCACAGATGGAAGAAAGGTTCATGTCTG
CAAATCCTTCCAAAGTGTCCTATGAACCCATCACAACCACACTAAAACGGAAACAAGAGGATGTGTCTGCTACTGTC
ATTCAGCGTGCTTATAGACGTTACCGCTTAAGGCAAAATGTCAAAAATATATCAAGTATATACATAAAAGATGGAGA
CAGAGATGATGATTTACTCAATAAAAAAGATATGGCTTTTGATAATGTTAATGAGAACTCAAGTCCAGAAAAAACAG
ATGCCACTTCATCCACCACCTCTCCACCTTCATATGATAGTGTAACAAAGCCAGACAAAGAGAAATATGAACAAGACA
GAACAGAAAAGGAAGACAAAGGGAAAGACAGCAAGGAAAGCAAAAAATAG 
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SCN9A-5N TTX-Resistant amino acid sequence: 
 
Met A Met L P P P G P Q S F V H F T K Q S L A L I E Q R I A E R K S K E P K E E K K D D D E E A P K P S S D L E A 
G K Q L P F I Y G D I P P G Met V S E P L E D L D P Y Y A D K K T F I V L N K G K T I F R F N A T P A L Y Met L S P 
F S P L R R I S I K I L V H S L F S Met L I Met C T I L T N C I F Met T Met N N P P D W T K N V E Y T F T G I Y T F 
E S L V K I L A R G F C V G E F T F L R D P W N W L D F V V I V F A Y L T E F V N L G N V S A L R T F R V L R A L K 
T I S V I P G L K T I V G A L I Q S V K K L S D V Met I L T V F C L S V F A L I G L Q L F Met G N L K H K C F R N S L 
E N N E T L E S I Met N T L E S E E D F R K Y F Y Y L E G S K D A L L C G F S T D S G Q C P E G Y T C V K I G R N P 
D Y G Y T S F D T F S W A F L A L F R L Met T Q D S W E N L Y Q Q T L R A A G K T Y Met I F F V V V I F L G S F 
Y L I N L I L A V V A Met A Y E E Q N Q A N I E E A K Q K E L E F Q Q Met L D R L K K E Q E E A E A I A A A A A E 
Y T S I R R S R I Met G L S E S S S E T S K L S S K S A K E R R N R R K K K N Q K K L S S G E E K G D A E K L S K S E 
S E D S I R R K S F H L G V E G H R R A H E K R L S T P N Q S P L S I R G S L F S A R R S S R T S L F S F K G R G R 
D I G S E T E F A D D E H S I F G D N E S R R G S L F V P H R P Q E R R S S N I S Q A S R S P PMet L P V N G 
K Met H S A V D C N G V V S L V D G R S A L Met L P N G Q L L P E G T T N Q I H K K R R C S S Y L L S E 
D Met L N D P N L R Q R A Met S R A S I L T N T V E E L E E S R Q K C P P W W Y R F A H K F L I W N C S P Y W 
I K F K K C I Y F I V Met D P F V D L A I T I C I V L N T L F Met A Met E H H P Met T E E F K N V L A I G N L V F T 
G I F A A E Met V L K L I A Met D P Y E Y F Q V G W N I F D S L I V T L S L V E L F L A D V E G L S V L R S F R L L 
R V F K L A K S W P T L N Met L I K I I G N S V G A L G N L T L V L A I I V F I F A V V G Met Q L F G K S Y K E C V 
C K I N D D C T L P R W H Met N D F F H S F L I V F R V L C G E W I E T Met W D C Met E V A G Q A Met C L I 
V Y Met Met V Met V I G N L V V L N L F L A L L L S S F S S D N L T A I E E D P D A N N L Q I A V T R I K K G I N 
Y V K Q T L R E F I L K A F S K K P K I S R E I R Q A E D L N T K K E N Y I S N H T L A E Met S K G H N F L K E K D 
K I S G F G S S V D K H L Met E D S D G Q S F I H N P S L T V T V P I A P G E S D L E N MetN A E E L S S D S D S 
E Y S K V R L N R S S S S E C S T V D N P L P G E G E E A E A E P Met N S D E P E A C F T D G C V R R F S C C Q V 
N I E S G K G K I W W N I R K T C Y K I V E H S W F E S F I V L Met I L L S S G A L A F E D I Y I E R K K T I K I I L E 
Y A D K I F T Y I F I L E Met L L K W I A Y G Y K T Y F T N A W C W L D F L I V D V S L V T L V A N T L G Y S D L G 
P I K S L R T L R A L R P L R A L S R F E G Met R V V V N A L I G A I P S I Met N V L L V C L I F W L I F S I Met G 
V N L F A G K F Y E C I N T T D G S R F P A S Q V P N R S E C F A L Met N V S Q N V R W K N L K V N F D N V G 
L G Y L S L L Q V A T F K G W T I I Met Y A A V D S V N V D K Q P K Y E Y S L Y Met Y I Y F V V F I I F G S F F T L 
N L F I G V I I D N F N Q Q K K K L G G Q D I F Met T E E Q K K Y Y N A Met K K L G S K K P Q K P I P R P G N K I 
Q G C I F D L V T N Q A F D I S I Met V L I C L N Met V T Met Met V E K E G Q S Q H Met T E V L Y W I N V V F 
I I L F T G E C V L K L I S L R H Y Y F T V G W N I F D F V V V I I S I V GMet F L A D L I E T Y F V S P T L F R V I R L 
A R I G R I L R L V K G A K G I R T L L F A L Met Met S L P A L F N I G L L L F L V Met F I Y A I F G Met S N F A Y 
V K K E D G I N D Met F N F E T F G N S Met I C L F Q I T T S A G W D G L L A P I L N S K P P D C D P K K V H P 
G S S V E G D C G N P S V G I F Y F V S Y I I I S F L V V V N Met Y I A V I L E N F S V A T E E S T E P L S E D D F 
E Met F Y E V W E K F D P D A T Q F I E F S K L S D F A A A L D P P L L I A K P N K V Q L I A Met D L P Met V S 
G D R I H C L D I L F A F T K R V L G E S G E Met D S L R S Q Met E E R F Met S A N P S K V S Y E P I T T T L K R 
K Q E D V S A T V I Q R A Y R R Y R L R Q N V K N I S S I Y I K D G D R D D D L L N K K D Met A F D N V N E N S 
S P E K T D A T S S T T S P P S Y D S V T K P D K E K Y E Q D R T E K E D K G K D S K E S K K Stop 
 
